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SUMMARY
Microspectrophotometry has been used to evaluate 
the distribution of some selectively inducible species of 
microsomal cytochrome P-450 in the rat liver lobule. 
Centrilobular increases in cytochrome P-450 concentration 
evoked by pretreatment with phenobarbitone or isosafrole 
contrasted markedly with the periportal induction produced 
by 3-methylcholanthren.e. Lobular and lobar variations 
in drug-metabolising enzyme activity were measured, and 
their significance is discussed.
Some oxygen-containing heterocyclic compounds 
were evaluated for their acute toxicity in rats. Several 
furans and methylenedioxyphenyls produced a classical 
hepatotoxic response, with fatty degeneration and 
necrosis. Benzofuran administration resulted in a clinical 
and ultrastructural picture of intrahepatic cholestasis, 
but without demonstrable stagnation of bile flow. Renal 
toxicity followed pretreatment with benzofuran or safrole, 
and diminution of splenic erythropoiesis occurred after 
the injection of various furans or methylenedioxyphenyls.
Benzofuran, dibenzofuran and Via.vi^ -stilbene 
oxide were potent inducers of hepatic microsomal epoxide 
hydrolase activity, corresponding with an increase in a 
polypeptide band of 48000 MW upon SDS gel electrophoresis. 
These compounds also induced a band of about 52000 MW.
Pretreatment with furan or benzofuran caused a 
loss of microsomal cytochrome P-450, the latter with a 
concomitant increase in haem oxygenase activity. 
Dibenzofuran induced haem oxygenase, but did not lower 
cytochrome P-450 concentrations. Many of the effects of 
benzofuran were potentiated by pretreatment with inducers 
of cytochrome P-450. Administration of &iCLnA-stilbene 
oxide or methylenedioxyphenyls increased hepatic cytochrome 
P-450 levels; the latter also increased a polypeptide band
of 53000 MW on gel electrophoresis.
Possible mechanisms of toxicity of some oxygen 
heterocycles, particularly benzofuran, are discussed in 
the light of the interrelationship of these endoplasmic 
reticulum protein changes.
Tritiated benzofuran was excreted by the rat in 
considerable quantities in both urine and faeces. Radio­
activity was detected in several tissues, and was retained 
in the spleen one week after pretreatment. Chromatographic 
analysis suggests that a major route of benzofuran 
metabolism may involve cleavage of the furan ring.
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CHAPTER 1 
INTRODUCTION
1.
1.1
INTRODUCTION .
Microanatomy of the Liver: the Lobule and Acinus
The classical microscopic unit of the liver is 
the static polyhedral lobule described by Kiernan (1833). 
This consists of a centrally positioned afferent vein 
(the central vein), which is a terminal tributary of the 
hepatic vein, surrounded by radially orientated sinusoids 
alternating with anastomosing columns (’cords') of 
hepatocytes (Fig. 1.1). The central vein is thus regarded as 
the morphological axis of the lobule. In three-dimensional 
aspect, the hepatocytes are in fact arranged in the form 
of plates or sheets, one cell in thickness (Elias,
1949a,b; Grisham <Lt 1975, 1976), which branch to form 
the hepatic muralium. Only in a few species is the boundary 
of the lobule well-defined by interlobular septa of 
connective tissue; in the rat connective tissue is sparse 
except in the portal tracts, which lie at the peripheral 
’corners’ of the lobule, and comprise a -bile ductule, 
hepatic artery and afferent terminal portal venule.
Despite the enlargement of the central veins as they 
unite to drain into the hepatic veins, there is no 
agglomeration of units to form a lobular complex, and the 
lobule is thus the basic microanatomical structure of the 
liver.
Kiernan's lobule is still very commonly used as 
a frame of reference. However, there is considerable 
evidence that the functional arrangement of the hepatocytes 
X.n vXvo is along the microcirculatory pathway, whose 
pressure gradient slopes from the hepatic arterioles 
and terminal portal venules towards the terminal hepatic 
venules (Rappaport Q.t at. , 1954a; Rappaport, 1973). The 
classical lobule is thus divided into irregularly shaped 
sectors, termed acini (Fig. 1.2.). A simple liver acinus 
is a parenchymal mass arranged around an axis consisting
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Figure 1.1. Diagrammatic representation of a classical 
lobule of rat liver
Figure 1.2. The hepatic acinus
tpv = terminal portal venule 
thv = terminal hepatic venule 
ha = hepatic arteriole 
bd = bile ductule 
Z1 = zone 1 
Z2 = zone.2 
Z3 = zone 3
o p 0 2 = direction of oxygen concentration gradient
(adapted and redrawn from Rappaport, 1976)
of a terminal hepatic arteriole, a terminal portal venule, 
bile ductule(s), lymph vessels and nerves, the vascular 
and biliary axial channels interdigitating with two or 
more terminal hepatic venules (central veins). The acinus 
is divided into three circulatory zones. Zone 1 is situated 
close to the supplying vessels, and contains all of the 
arteriolar openings (Hase and Brim, 1966; McCuskey, 1966; 
Rappaport dt al. , 1966; Reeves dt at. , 1966). Hepatocytes in 
zone. 3 are the most distant from their own supplying 
vessels, and from those feeding the neighbouring acini, 
and constitute the periphery of the microcirculatory unit. 
Cells of zone 3 of adjacent acini lie close to a terminal 
hepatic venule and form the acra of the acini. Because 
of the direction of blood flow, these cells are the most 
liable to damage from anoxia, ischaemia or nutritional 
deficiency (Rappaport dt a£., 1954b; Rappaport, 1963).
Zone 2 lies between the other zones, and is a less well- 
defined transitional belt of tissue. The acinus is also 
the basic secretory unit of the liver, since bile produced 
is delivered into the axial bile ductule, and the watershed 
of bile flow is the dividing line between two adjacent 
acini (Rappaport, 1976). In contrast to the lobular 
concept, simple acini may be considered to form larger 
units, the complex acini, three or more of which in turn 
constitute the acinar agglomerate (Rappaport, 1976).
Although the acinus, rather than the ’hexagonal 
lobule' appears to be the fundamental structural, 
microcirculatory and secretory hepatic unit, most reported 
toxicological studies have used the lobule as the basis 
for description of liver damage. For comparative purposes, 
the present study employs the same system, except where 
the acinus is markedly better related to the lesions seen 
after the administration of various chemicals.
1.2. Bile Formation and Secretion in the Rat
Bile secretion is a major function of vertebrate 
species, but the mechanisms of bile formation at the level 
of the hepatocyte are difficult to characterise because 
of an inability at present to sample the primary secretion 
with micropuncture techniques. However, a considerable 
amount is now known about the broad aspects of bile 
secretion.
The smallest branch of the biliary tree is the 
bile canaliculus, the lumen of which is located at the 
apical portion of the hepatocyte, where it is formed by a 
small section (13% of the surface membrane) of two adjacent 
hepatocytes (Weibel dt at., 1969). Isolating the canaliculi 
from the rest of the intercellular space and the sinusoidal 
lumen are tight junctions, or zona occludens (Farquhar 
and Palade, 1963), which by morphological criteria seem 
to be intermediate in permeability between classical tight 
and leaky epithelia (Friend and Gilula, 1972).
Canalicular bile formation is generally regarded 
as an osmotic water flow in response to active solute 
transport. Bile flow and bile acid output in bile 
correlate; thus bile acids appear to be solutes generating 
bile flow, and this fraction is known as bile acid- 
dependent flow. The flow occurring when bile acids are 
low in concentration or absent is bile acid-independent 
flow (for reviews, see Erlinger and Dhumeaux, 1974;
Javitt, 1976; Forker, 1977).
The uptake of bile acids by liver is saturable 
and carrier-mediated (Reichen and Paumgartner, 1975), and 
exhibits a strong sodium dependence (Reichen and Paumgartner, 
1976; Ruifrok and Meijer, 1980). Transport of sodium along 
its electrochemical gradient is postulated to be coupled 
to a carrier that takes bile acids into the cell against 
their electrochemical gradient (Schultz and Curran, 1970; 
Crane, 1977). Once in the cell, bile acids move into the
canalicular lumen along their concentration gradient by 
a process which is also carrier-mediated (Accatino and
Simon, 1976; Erlinger, 1981). Although still a matter for
\
debate, there is much evidence that the fluid and electrolyte 
flow following bile acid secretion into the canaliculi 
enter by a paracellular pathway from the intercellular 
space rather than from within cells (Forker, 1970; Layden 
dt at., 1978).
Bile acid (or salt) -independent flow has been 
postulated from plots of bile salt secretion rate against 
canalicular bile flow (Balabaud dt al., 1977), or from 
the action of barbiturates, which increase canalicular 
bile flow without modifying bile salt secretion (Capron 
and Erlinger, 1975). Phenobarbitone is not appreciably 
secreted into bile, nor is there evidence that it alters 
the osmotic activity of the bile acids, or the permeability 
of the biliary system to water or ions. Transport of 
either sodium (for review, see Erlinger and Dhumeaux,
1974), or bicarbonate (Hardison and Wood, 1978; Izutsu 
dt al., 1978; Dumont dt al., 1980), have been implicated 
in the interpretation of bile acid-independent flow.
Microfilaments (Phillips dt al., 1975; Erlinger, 
1978) and microtubules (Erlinger dt al., 1978; Gregory 
dt al., 1978) also appear to have a role in the secretion 
of bile, but their mechanism of action is uncertain.
One of the most important aspects of bile secretion 
from the viewpoint of assessment of toxic damage is the 
difference in the contribution to bile formation of 
hepatocytes from different regions of the hepatic 
microstructure. Bile canaliculi diameters in the acinar 
zone 1 are greater than those in zone 3 (Jones dt al.,
1978; Layden and Boyer, 1978), and during bile acid- 
induced choleresis the cross-sectional areas of zone 3 
canaliculi increase, whereas zone 1 canaliculi dilate only 
at supraphysiological rates of bile acid infusion (see
Blitzer and Boyer, 1982). Under basal conditions, periportal 
hepatocytes transport the major portion of bile acids 
entering the lobule. The rate of hepatic uptake of bile 
acids is proportional to their concentration in sinusoidal 
blood (Glasinovic dt at., 1975; Schwarz dt al., 1975;
Reichen and Paumgartner, 1976), and concentrations of 
bile acids in blood are diminished markedly by the time 
blood .is collected from the hepatic vein. Selective 
damage to periportal or pericentral hepatocytes by allyl 
alcohol or bromobenzene respectively does not prevent 
the maintenance of bile acid transport (Gumucio dt al.,
1978a), implying that the hepatocytes of both regions have 
the capacity to transport bile acids. Bile acid concentration 
rose after treatment with bromobenzene, and fell after 
treatment with allyl alcohol, although bile flow was decreased 
in either case, suggesting that bile production in zone 
3 hepatocytes may be primarily bile acid-independent.
A lobular gradient for bile acid uptake has also been 
demonstrated by autoradiography, using [125I]-cholyl- 
glycylhistamine (Jones dt al., 1980), showing that the 
first 6-9 periportal hepatocytes take up most of the bile 
acids in portal blood. Permeability of the junctional 
complexes may be greater in periportal than in pericentral 
areas (Elias and Boyer, 1978). In addition, lobar perfusion 
patterns may affect the magnitude and composition of 
bile secreted (Tavoloni dt al., 1978). At low perfusate 
flow rate in isolated rat liver, peripheral perfusion of 
the left lobe was diminished, as measured with radiolabelled 
microspheres, correlating with a decrease in bile acid- 
independent flow.
1.3. Cholestasis
1.3.1. Definition
The literal translation of ’cholestasis’ is 
’stagnation of bile flow’, but application of the term 
varies according to the viewpoint of the user (Popper 
dt al., 1976). It is characterised by the clinician as 
the accumulation in blood of substances normally secreted 
in the bile; by the radiologist as a demonstrable bile 
duct obstruction; by the physiologist as disturbed 
secretion of whole bile into canaliculi by the hepatocytes; 
and by the morphologist as the visible accumulation of 
bile-pigmented material in hepatocytes, bile thrombi in 
bile canaliculi, and bile in the Kupffer cells and other 
macrophages. Some bile is always in transit in normal 
hepatocytes, and the morphological picture of milder 
cholestasis is best taken as the characteristic electron 
microscopic lesions of hepatocyte and canaliculus associated 
with the syndrome. This is especially important in 
experimental rodents, where bile thrombi do not form 
even in severe cholestasis, except in neonatal rats, or 
after gross bilirubin overload (Desmet, 1972).
1.3*2. Classification
Mechanical or obstructive cholestasis refers to 
lesions of the extrahepatic biliary tract (extrahepatic 
cholestasis), or to lesions of the large intrahepatic 
bile ducts; in the latter case, jaundice will be observed 
only if the flow is compromised in the majority of the 
intrahepatic biliary passages. Where there is functional 
cholestasis, but no demonstrable mechanical obstruction, 
the term ’intrahepatic cholestasis' has been applied 
(Popper and Schaffner, 1952; Popper dt al., 1976).
Any obstacle to bile flow along an axis extending
from the opening of the common bile duct to its division 
into lesser ducts may produce cholestasis, with dilatation 
of the ducts above the obstacle. In the rat, frank 
jaundice will probably be absent, although marker enzymes 
such as alkaline phosphatase (3-glycerophosphatase) and 
aminotransferase activities are generally raised in serum.
The obstruction may result from the presence of carcinoma 
at one of several sites, inflammatory lesions of the bile 
duct, or diseases of the pancreas (Douglass and Holyoke,
1974; Scott dt al. , 1976; Snape dt al., 1976; Morgan and 
Wormsley, 1977)-
Intrahepatic mechanical obstruction may result 
in focal cholestasis in the parenchyma drained by that 
bile ductule, usually without jaundice, since the 
remaining unaffected part of the liver compensates for 
the local obstruction. Any fibrosing condition, particularly 
cirrhosis, abscesses or granulomas, may produce such focal 
alterations. Biochemical evidence of obstruction may be 
present, depending on the extent of the lesion. Intrahepatic 
cholestasis without demonstrable biliary obstruction may 
arise from a variety of causes, including cardiac failure, 
malignancies, amyloidosis, viral or bacterial infections, 
as a component of hepatitis or cirrhosis, and the 
administration of certain chemicals. The last of these 
is discussed below.
1.3.3. Primary features of cholestasis
The primary features of cholestasis are identical 
in virtually all forms of the condition, and involve 
alterations of the bile canaliculi and of the pericanalicular 
ectoplasm. Initially, the lesion is often centrilobular, 
but, since the centrilobular region is formed by several 
zones 3 of the Rappaport acini, and the severity of 
cholestasis may vary among these acini, the cholestasis is
frequently not concentric around the terminal hepatic 
venules. Hepatocytes in the cholestatic area may exhibit 
eosinophilia, owing to an increased amount of smooth 
endoplasmic reticulum, or they may be hyperplastic or 
hypertrophic (see Popper, 1977). Electron microscopy 
reveals dilatation of bile canaliculi, and blunted, 
deformed or absent microvilli (Schaffner and Popper, 1970; 
Desmet, 1972). However, the microvilli in the vicinity of 
the tight junctions appear to remain intact for much 
longer (Compagno and Grisham, 1974; Motta and Fumagalli, 
1975; Vial dt at., 1976), which indicates that dilatation 
of the canaliculi may not of itself necessarily lead to 
a pulling apart of the tight junctions (Vial dt al .,
1976). Diverticular outpouchings extend from the dilated 
canaliculi into the cytoplasm of the hepatocytes, which 
resemble the developmental stages of the canaliculi in 
the neonatal liver, and suggests that cholestasis may 
be associated with the formation of new canaliculi (De 
Wolf-Peeters dt al. , 1971, 1974). The degree of dilatation 
frequently varies greatly, even in the same canaliculus, 
indicating variation in the extent of cholestasis in 
neighbouring hepatocytes. Canaliculi with a normal lumen 
are not uncommon even in severe cholestasis. Dilated 
canaliculi of cholestatic liver may appear empty, or 
be filled with a variety of materials. Biliary concrements 
may be homogeneous, granular, crystalline, lipid-like, 
lamellar or whorled, and have been interpreted as 
representing bilirubin, membrane fragments, extruded 
pericanalicular ectoplasm, or liquid crystals resulting 
from disturbed micelle formation (Biava, 1964; Schaffner 
and Popper, 1970; see Desmet, 1979). Crystalline 
precipitates seen in lithocholate-induced cholestasis in 
the rat have been described as crystals of lithocholate 
(Miyai dt al., 1975), or of cholesterol (Bonvicini dt al., 
1976).
The pericanalicular ectoplasm is widened and 
homogeneous, and may contain cytoplasmic vacuoles. Golgi 
vesicles and cisternae are generally enlarged in cholestasis 
and the vesicles contain electron-opaque granules. 
Morphometric studies with bile duct-ligated rats have 
given not entirely consistent results (Popper and 
Schaffner, 1952; Jones dt at., 1976; Yamauchi dt at.,
1976; Denk dt at., 1977), but dilatation and hypertrophy 
of the smooth endoplasmic reticulum appears to occur in 
cholestasis. This is reflected in a significant reduction 
of cytochrome P-450 levels, and an increase in liver 
microsome yield, without alteration of the protein: 
phospholipid ratio (Schaffner dt at., 1971; Hutterer 
dt at.-, 1972; Jones dt at., 1976; Roessner dt at., 1976). 
Glucose-6-phosphatase activity is reduced, whereas the 
activities of conjugating enzymes are not markedly 
changed (Jones dt at., 1976).
Several hepatocellular sites must be considered 
in the initiation of cholestasis - the canalicular plasma 
membrane, the cytoskeleton and the tight junction, apart 
from lesions of the portal tracts themselves.
Histochemical techniques show an early disappearanc 
of Mg2+-ATPase activity from the hepatocyte canalicular 
membrane, and a reduction in the activity of 5 ’-nucleotidase 
(Wills and Epstein, 1966; Oda and Phillips, 1975; Popper 
dt at., 1976). Alkaline phosphatase activity is increased 
(Gall and Braunstein, 1955). These enzymes are located 
in the deeper portion of the thin, carbohydrate-rich 
glycocalix covering the outer aspect of the microvilli. 
Disappearance of the glycocalix has also been reported 
(Phillips dt at., 1975). Leucine aminopeptidase and 
y-glutamyltransferase also show cholestasis-dependent 
changes in activity at the biliary pole of the hepatocyte, 
but these changes vary with species (Desmet, 1972; 
Hagestrand, 1973; Ronchi and Desmet, 1973b). Gamma-
glutamyltransferase activity generally increases, and is 
supposed, to rise earlier in metabolically induced cholestasis 
than in obstructive jaundice (Ronchi and Desmet, 1973).
The Na+ ,K+-ATPase activity, located on the sinusoidal 
and lateral areas of the rat hepatocyte plasma membrane 
(Blitzer and Boyer, 1978), is reduced (Reichen dt at.,
1976). Membrane phospholipid and cholesterol levels are 
altered (Nemchausky dt at., 1976; Yousef dt at., 1976), 
and the sialic acid concentration increased (Simon and 
Arias, 1973). There is some evidence that the ion pump 
of the membrane depends on the latter’s lipid constitution 
(Adlercreutz dt at., 1967), and these changes may lead 
to an alteration in membrane permeability.
The rigid microtubules and contractile, myosin- 
associated microfilaments (Oda dt at., 1974; Accatino 
and Simon, 1976; Graf, 1976) of the cytoskeleton may 
maintain the canaliculi in a partly contracted state, 
and favour biliary secretion (Phillips dt at., 1975). 
Cytochalasin B, which disrupts microfilaments in non­
muscle cells, produces canalicular dilatation and a 
reduction in bile flow (Phillips dt at., 1975). Cholestatic 
sex steroids also appear to inhibit microfilament action 
(French, 1976).
Administration of phalloidin to rats causes a 
marked increase in microfilament visibility around bile 
canaliculi in hepatocytes, especially around the tight 
junctions (Agostini dtat., 1975; Gabbiani dt at.,
1975). Bile flow is reduced, the hepatocyte cell membrane 
is weakened, and the control of access of secretory 
products to the canalicular space may be affected 
(Bradley dt at., 1974; Gabbiani dt at., 1975).
1.3.4. Secondary features of cholestasis
The secondary features of cholestasis are those
considered not absolutely essential for a morphological 
diagnosis, and depend on the degree and the duration of 
the condition. Two substances, bilirubin and bile salts, 
are significant by their retention in the hepatocyte.
Bilirubin, in the concentrations generally found 
in cholestasis, decreases the uptake of oxygen by 
hepatic mitochondria, and uncouples oxidative phosphory­
lation (Stakeberg dt al., 1974). Mitochondrial cytochrome 
concentration is decreased (Yamada dt al., 1975), and 
curling of cristae is caused by excess cholate or 
lithocholate (Schaffner and Javitt, 1966; Witzleben,
1972; Miyai dt al., 1975). Swelling of mitochondria 
parallels the increase in serum activity of mitochondrial 
glutamate dehydrogenase (Van Husen dt al., 1976).
Dihydroxy and trihydroxy bile salts bind competitive 
to microsomes and inhibit biotransformation of foreign 
compounds in cholestasis in experimental animals 
(Hutterer dt al., 1970a). At higher concentrations there 
.is dose-dependent detergent action on microsomes, leading 
to their disintegration, with denaturation of cytochrome 
P-450 and inhibition of cytochrome P-450 reductase. 
Cholestasis affects the rough endoplasmic reticulum in 
addition to the smooth form, leading to degranulation 
and a loss of cellular content (Jones dt al., 1976).
In rats, synthesis of lipoproteins is increased, accounting 
for the appearance of the abnormal, cholesterol-rich, 
lipoprotein-X (Seidel dt al., 1970, 1976). Solubilisation 
of canalicular membrane components, especially phospholipids, 
results from the excess of bile salts present (Yousef 
dt al., 1975; Evans dt al., 1976).
Lysosomes, especially secondary lysosomes and 
autophagic vacuoles, increase in number in hepatocytes 
during cholestasis. Hepatocytic inclusions, apparently 
bile pigments, are more specific for cholestasis than 
are autophagic vacuoles and increased lipofuscin deposition
(see Desmet, 1979). Conjugated bilirubin is proposed to 
precipitate in areas of focal cytoplasmic degeneration; 
the precipitates become sequestered and subjected to 
digestion by lysosomal enzymes. Pseudobile inclusions 
also occur. These are lamellar, often whorled, and 
resemble phospholipids (and possibly bile salt) liquid 
crystals.
Alteration of hepatocytic tubulin leads to 
feathery degeneration, which proceeds to single cell 
necrosis, associated with focal reactive inflammation 
(Schaffner and Popper, 1970). Intralobular inflammation 
is accompanied by reactive portal inflammation, which may 
lead to ductular alterations, proliferation and fibrosis 
(Shorter and Baggenstoss, 1959). Portal and periportal 
fibrosis occur eventually in any form of cholestasis, 
the first type of collagen to appear in both man and 
experimental animals being type III (reticulin), followed 
by the formation of hard type I collagen. This may 
interfere with ductular bile flow, producing a secondary 
periportal cholestasis (Kent dt at., 1976).
1.3.5. Pathways of bile regurgitation
Since, in cholestasis, components of bile 
accumulate in the blood, pathways must exist for regurgitation 
from the biliary compartment to the bloodstream. Different 
situations may occur depending upon whether there is 
functional disturbance at the level of the hepatocyte, 
in which case no bile enters the biliary passages, or 
whether a block in the biliary pathway allows reabsorption 
of bile by hepatocytes to occur. Either biliary-venous 
or biliary-lymphatic regurgitation may take place 
(Bergan dt at., 1975).
With small increases in biliary tract pressure, 
bile leaks mainly from small bile ducts into the peripheral
connective tissue, and water and electrolytes are 
absorbed freely into the bloodstream. Colloid concentration 
in the interstitial fluid of the portal spaces increases 
and, as lymph is formed from this interstitial fluid, 
the lymphatic concentration of colloidal or colloid- 
bound substances leaking from the bile ducts attains 
high levels. The lymphatic transport of bile constituents 
is limited (Szabo dt at., 1975a,b) and, as biliary pressure 
rises further, bile leaks from the canaliculi into the 
spaces of Disse (Waldeck, 1970; Bergan dt at., 1975;
Szabo dt al., 1975a,b, 1976).
Changes in the morphology and permeability of 
tight junctions (Metz dt al., 1977; De Vos and Desmet,
1978) indicate that they may become permeable to bile 
water and solutes passing from canaliculi to blood.
There are also two possible transcellular pathways, 
involving either retrograde diacytosis, or a diffuse 
flow through the hepatocyte, based on a reversed secretory 
polarity. Widened intercellular spaces bounded by ATPase- 
and alkaline phosphatase- rich microvilli are seen in 
cholestasis, while similar structures disappear from 
the biliary pole of the hepatocyte (see Desmet, 1979), 
supporting the possibility of reversed polarity.
Hepatic alkaline phosphatase may reach the blood 
in cholestasis by the shedding of membrane fragments at 
the hepatocyte sinusoidal face, caused possibly by an 
increased detergent.concentration near the liver cell 
surface (De Broe and Wieme, 1975; De Broe dt al., 1975). 
These vesicular membrane fragments also contain 5 1- 
nucleotidase, L-leucyl-3-naphthylamidase and y-glutamyl- 
transferase (De Broe dt al., 1975). Loss of these fragments 
may increase the permeability of the membrane and explain 
the appearance of high aminotransferase activities in 
serum.
1.3.6. Drug- and chemical- induced intrahepatic cholestasis
Early references to drug-related jaundice were 
made by Hanger and Gutman (1940), and by Ottenburg and 
Spiegel (1943), when it was observed that some patients 
receiving the therapeutic agents arsphenamine, cinchophen 
and certain sulphonamides developed this syndrome. The 
lesion was described, as cholangiohepatitis by Himsworth 
(1954), but it was not until Popper’s studies (Popper,
1954, 1968;. Popper and Szanto, 1956) that attention 
shifted to the hepatocyte and to hepatocanalicular 
mechanisms of bile formation.
There is now at least a limited understanding 
of the pathogenic mechanisms involved in drug-induced 
cholestasis. However, while it is possible to induce 
cholestasis in experimental animals chemically, no animal 
model has been developed that entirely satisfactorily 
duplicates the features of drug-induced cholestasis 
in man.
Many chemicals are known to produce hepato­
cellular necrosis or ’toxic hepatitis’ (Klatskin, 1969). 
Commonly, these compounds elicit a distinctive histological 
lesion, have a predictable latent period, exhibit a 
dose-related high incidence of effect according to 
exposure conditions, and these effects are reproducible 
in laboratory animals. Compounds that cause cholestasis 
generally fulfil only the first of these criteria, 
and this explains the lack of predictability of the 
cholestatic potential of new drugs. The failure of 
reproducibility in experimental species has been used to 
support the theory that drug-induced cholestasis in man 
is a hypersensitivity reaction. However, although 
positive lymphocyte transformation and macrophage 
migration inhibitory factor production have been shown 
in patients with ’drug-induced allergic intrahepatic
cholestasis' when peripheral blood lymphocytes were 
incubated with the relevant drug (Mizoguchi dt at.,
1981), in most circumstances where hypersensitivity has 
been invoked as an explanation for drug-induced cholestasis, 
it has been arrived at indirectly.
Although several drugs evoke a cholestatic 
response in man, the incidence is low. Erythromycin 
estolate (Brown, 1963; Farmer dt al., 1963; Braun, 1969; 
Lunzer dt al., 1975), norethandrolone (Arias, 1963) and 
triacetyloeandomycin (Ticktin and Zimmerman, 1962) are 
among the most frequent causes of drug-related cholestasis 
in man, but the incidence is probably little greater than.
2% (see Plaa and Priestly, 1977). Chlorpromazine appears 
to produce jaundice in perhaps '\% of patients treated, 
and exhibits very variable reactions in experimental 
species (Popper dt al., 1957; Sharma and Prasad, 1967;
Ros dt al., 1975). Cholestasis due to the administration 
of contraceptive steroids is well-documented in man 
(e.g. Larsson-Cohn and Stenram, 1965, 1967), and these 
agents have been observed to affect bile formation and 
bilirubin clearance in rats (Heikel and Lathe, 1970).
Many other chemicals, including various steroids, 
phenothiazines, tricyclic antidepressants, antibiotics, 
hypoglycaemics and antirheumatics, have been linked with 
drug-induced cholestasis in man (for listings, see 
Zimmerman, 1963, 1974; Klatskin, 1969, 1974; Perez dt al.,
1972). However, none of these chemicals reliably produces 
a cholestatic response in laboratory species. Bile duct 
ligation has been used in experimental cholestasis 
(e.g. De Wolf-Peeters dt al., 1971, 1972, 1974; Kryszewski 
dt al., 1973; De Vos dt al., 1975; Johnstone and Lee,
1976; Vial dt al., 1976), but this is not an ideal model 
for studying the phenomenon of intrahepatic cholestasis, 
because the initiating factor is an extrahepatic obstruction.
However, a-naphthylisothiocyanate (ANIT) has
been observed to induce an acute cholestasis and 
hyperbilirubinaemia in susceptible species such as the 
rat and mouse, in a dose-related and reproducible manner. 
(Becker and Plaa, 1965a,b; Plaa, 1969; Indacochea- 
Redmond and Plaa, 1971). This compound is discussed in 
relation to chemicals examined in the present study 
during later chapters.
1.4. Cytochrome P-450
1.4.1. Historical aspects: discovery and early
characterisation
The importance of oxygen in its role as terminal 
oxygen acceptor of the respiratory chain has been 
recognised for many years. However, another function 
became evident following reports that molecular oxygen 
(^O^) Could be enzymically and directly incorporated into 
substrates (Hayaishi zt aZ. , 1955; Mason zt aZ., 1955).
In the same year (Brodie zt aZ.> 1955), microsomes prepared 
from rabbit liver were shown to be capable of hydroxylating 
various aromatic compounds; the process was enzyme- 
catalysed, and required NADPH and molecular oxygen 
(Brodie zt aZ., 1955; Gillette zt aZ., 1957). This 
enzyme system, which inserts a single oxygen atom into 
the substrate molecule, has been termed a mixed, function 
oxidase (Mason, 1957), or a monooxygenase (Hayaishi, 1962).
Klingenberg (1958) and Garfinkel (1958) subsequently 
described a microsomal pigment which bound carbon monoxide 
to yield a broad absorption maximum in the Soret region 
at 450nm. It was further characterised as a new 6-type 
cytochrome by Omura and Sato (1962, 1964a,b), who 
termed it cytochrome P-450. Evidence supporting the 
participation of cytochrome P-450 in monooxygenation 
was produced by Estabrook and coworkers (1963), and 
during the same decade its involvement in the metabolism 
of both foreign and endogenous compounds became apparent. 
Early attempts to solubilise mammalian cytochrome P-450 
resulted in its conversion to inactive cytochrome P-420 
(Omura and Sato, 1964a), but later experiments achieved 
the resolution of three components - cytochrome P-450, 
cytochrome P-450 reductase and phospholipid, which, 
recombined, catalysed the hydroxylation of lauric acid 
(Lu and Coon, 1968).
1.4.2. Occurrence
Cytochrome P-450 has been described in a wide 
range of mammalian, avian, amphibian, fish and insect 
species, in plants, yeasts, and in bacteria. Within 
mammals, this haemoprotein occurs in liver and in most 
extrahepatic tissues, including kidney, lung, intestinal 
mucosa, spleen, skin, testis, placenta, ovary, adrenal 
gland, brain, heart and aorta wall. In most organs 
cytochrome P-450 is located in the endoplasmic reticulum, 
but mitochondrial forms are important in steroidogenic 
tissues (Harding and Nelson, 1966; Yohro and Horie,
1967), and a nuclear cytochrome P-450 has been reported 
(Rogan and Cavalieri, 1974, 1978). Evolutionary aspects 
of cytochrome P-450-associated drug metabolism have 
been treated by Bridges (1980), and extrahepatic 
distribution and function of cytochrome P-450 is the 
subject of a review by Connelly and Bridges (1980).
1.4.3* Structure of cytochrome P-450
Cytochromes are classified a, 6 or c. on the basis 
of absorption characteristics. In common with other 6-type 
•cytochromes, cytochrome P-450 contains an iron proto­
porphyrin IX prosthetic group, but it differs from these 
others in its ability to react with oxygen, cyanide and 
carbon monoxide, and in the red-shifted 450nm absorption 
maximum of the carbon monoxide-complexed form. Disturbance 
of the lipophilic milieu of cytochrome P-450 haem 
(Imai and Sato, 1967b) by detergents or lipase brings 
about conversion to cytochrome P-420, which has the 
absorption characteristics of a typical 6-type cytochrome. 
The intact apoprotein is apparently also important, 
as proteinases or denaturants generate cytochrome P-420 
(Mason zt at., 1965).
Four planar ligand interactions with proto­
porphyrin nitrogen atoms by the iron of cytochrome P-450 
haem leave two axial ligands available for further 
binding. Electron spin (paramagnetic) resonance spectroscopy 
(ES[P]R), in conjunction with optical spectroscopy, 
indicates that cytochrome P-450 exists in both a high 
spin (5 unpaired electrons) and a low spin state (Jefcoate 
and Gaylor, 1969; Hill zt at., 1970), and that the low 
spin form predominates in its normal oxidised condition 
(Tsai zt aZ., 1970). Loss of low spin character after the 
treatment of microsomes with p-chloromercuribenzoate 
(Mason zt aZ., 1965) suggests that sulphur may be liganded 
to cytochrome P-450 haem. Later studies, employing model 
systems with thiol agents, and haemoglobin or metmyoglobin, 
showed similar EPR spectra (Jefcoate and Gaylor, 1969;
Hill zt aZ., 1970; Blumberg and Peisach, 1971; Collman 
zt aZ., 1975; Tang zt aZ., 1976) to those of cytochrome 
P-450 from mammalian (Peisach zt aZ., 1973; Stern zt aZ. , 
1973) and bacterial (Tsai zt aZ., 1970) sources. Stern 
and Peisach (1974) concluded that a thiolate anion was 
necessary to produce the characteristic spectrum of 
cytochrome P-450. The nature of the sixth ligand remains 
uncertain; water (Peterson and Griffin, 1973; Griffin and 
Peterson, 1975), a hydroxyl group (Nebert zt.aZ,, 1976; 
Kumaki and Nebert, 1978) and the imidazole nitrogen of 
histidine (Jefcoate and Gaylor, 1969; Tang zt aZ., 1976; 
Chevion zt aZ., 1977) have been suggested. Production of 
the low spin Fe2+-carbon monoxide complex has been 
proposed to involve the displacement of the sixth ligand, 
with retention of the mercaptide ligand (Peisach zt a.Z.} 
1973; Chevion zt aZ., 1977).
1.4.4. Cytochrome P-450-dependent spectral changes
Various agents, if added to microsomes, produce
characteristic spectral alterations that may be monitored 
by difference spectroscopy. Early demonstrations of this 
phenomenon were made in both adrenal (Narasimhulu zt at., 
1965) and liver (Imai and Satx>, 1966; Remmer zt at.,
1966; Schenkman zt at., 1967) microsomes.
The spectral changes observed divide into three 
categories: type I, characterised by an absorption 
maximum at 385-390nm and a minimum at 4l5-425nm; type II, 
with an absorption maximum at 425-435nm and a minimum at 
390-400nm; and reverse type I (type RI), which is 
essentially a.mirror image of type I, and has a minimum 
at 385-390nm and a maximum at 4l5-425nm.
Schenkman and coworkers (1967) proposed that
these spectral changes were brought about by interaction
between oxidised cytochrome P-450 and the added compound.
A double reciprocal plot (Lineweaver and Burk, 1934) of
magnitude of spectral displacement ve/t^ u.4 substrate
concentration gives an intercept on the abscissa, termed
the spectral dissociation constant, K , analogous to as
Michaelis constant. It defines the concentration of 
reactant responsible for 50% of the maximum spectral 
change, A . The latter is analogous to the maximal
Ilia. X
velocity of enzyme reactions, Vmax- The spectral magnitude 
is dependent on substrate concentration, and on the 
concentration of cytochrome P-450 in the microsomal 
suspension (Estabrook zt &Z., 1972).
Many endogenous (e.g. fatty acids and steroids) 
and exogenous (e.g. barbiturates and polycyclic aromatic 
hydrocarbons) compounds elicit a type I spectrum.
Schenkman and Sato (1968) considered that type I compounds 
might interact with the apoprotein of cytochrome P-450, 
rather than with the haem. These compounds are generally 
lipophilic, but removal of phospholipid has been variously 
reported to increase (Vore zt at., 1974), or to decrease 
(Chaplin and Mannering, 1970; Eling and Di Augustine, 1971
Leibman and Estabrook, 1971), the binding of type I 
substrates. Some authors (Levin zt aZ.t 1974; Narasimhulu,
1975) have concluded that lipid is not a requisite for 
type I binding at all, but in certain cases K values
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correlate with the lipophilicity of type I ligands 
(Al-Gailany, 1975; Al-Gailany zt at., 1975). EPR studies 
show a shift of haemoprotein iron to high spin upon type I 
interaction (Jefcoate and Gaylor, 1970; Tsai zt at.,
1970; Whysner zt at., 1970; Waterman zt aZ., 1973), 
thought to be due to displacement of the sixth ligand 
of cytochrome P-450 haem.
Type II spectra are produced by the binding to 
cytochrome P-450 of amines (Schenkman zt aZ., 1967;
Jefcoate zt aZ., 1969), or other compounds containing 
nitrogen atoms with a lone electron pair (Temple, 1971). 
Electron transfer between nitrogen and the haem sixth 
ligand, involving ferrihaemochrome formation, is thought 
to be responsible for the spectral change (Schenkman zt clZ., 
1967; Kulkarni zt aZ., 1974; Mailman zt aZ., 1974). Few 
type II compounds are metabolised by cytochrome P-450; 
however, aniline, which competes with carbon monoxide 
for reduced cytochrome P-450 (Schenkman zt aZ., 1967), 
produces a type II spectrum with a type I component 
(Schenkman, 1970), and is metabolised.
Type RI compounds differ from type II in that 
they do not displace carbon monoxide, or alter aniline 
binding to oxidised cytochrome P-450 (Schenkman zt aZ. ,
1973). A diverse group of compounds elicits the type RI 
spectral change, and it has been suggested that displacement 
of bound endogenous substrates causes reversal of the 
type I spectrum (Schenkman zt aZ., 1969, 1972^, .1973;
Diehl zt a,Z. , 1970). In contrast, Vore zt &Z. ( 1974), 
using solvent-extracted microsomes, and Al-Gailany (1975), 
employing fluorescent probes, deduced that type I, type 
II and type RI binding sites were specific, and differed
with respect to their lipophilicity. Many type RI compounds 
contain oxygen, which has been proposed to displace the 
sixth ligand of cytochrome P-450, in the same manner as 
nitrogen (Mailman zt clZ., 1974), the hypsochromic shift 
of the spectral maximum relative to type II compounds 
being due to lower nucleophilicity. Yoshida and Kumaoka 
(1975) and Kumaki zt at. (1978) also concurred that 
interaction between the type RI compound and a cytochrome 
P-4'50 haem ligand produces the characteristic spectrum.
Multiple interactions between compounds and 
various sites of cytochrome P-450 are possible (Yoshida 
and Kumaoka, 1975), and type RI binding may be a result 
of a combination of the above phenomena. It appears that 
type RI interaction involves conversion of high spin 
cytochrome P-450 to a low spin species, and that the 
sixth position becomes occupied by a weak ligand, but 
the nature of that ligand remains uncertain.
1.4.5. Mechanism of monooxygenation by cytochrome P-450
A scheme for the mechanism of cytochrome P-450 
action was proposed by Schenkman and coworkers (1972a).
In this model, substrate and low spin ferric cytochrome 
P-450 react to form a high spin ferric cytochrome P-450- 
substrate complex, accompanied by a type I spectral change 
and an increase in the high spin EPR signal. The shift of 
redox potential of the cytochrome to less negative values 
(Sligar, 1976; Sligar zt aZ., 1979) results in an increased 
flow'of electrons to cytochrome P-450 (Ristau zt a.Z.,
1978; Sligar zt olZ. , 1979). The ferric cytochrome P-450- 
substrate complex undergoes one electron reduction by 
accepting an electron from NADPH via the flavoprotein 
enzyme NADPH:cytochrome P-450 reductase. Subsequent 
reaction with oxygen produces an oxygenated reduced 
cytochrome P-450- substrate ternary complex, associated
with an absorption maximum at 440nm (Estabrook zt at.,
1971; Werringloer and Estabrook, 1975; Guengerich zt at.,
1976).
The oxycytochrome P-450 complex then undergoes 
a further one electron reduction, the electron being 
donated either by NADPH:cytochrome P-450 reductase, or 
by NADH:cytochrome 6  ^ reductase and cytochrome 6^
(Cohen and Estabrook, 1971a,b,c; Estabrook zt a£., 1971; 
Hildebrandt and Estabrook, 1971; Sasame zt at., 1973). 
Cytochrome b^ varies in its degree of involvement in 
the NADPH-dependent reaction according to substrate and 
to the species of cytochrome P-450 present (Lu zt at.,
1974). Imai and Sato (1977) have shown that if NADH, 
cytochrome 6  ^ and NADH:cytochrome 6  ^ reductase are incubated 
in a reconstituted system of cytochrome P-450, NADPH: 
cytochrome P-450 reductase, sodium cholate and NADPH, 
while not obligatory, the second electron in benzphetamine 
or dimethylaniline metabolism is supplied almost exclusively 
by NADH and cytochrome 6 .^
After transfer within the ternary complex of 
one oxygen atom, and the uptake of two protons, the complex 
dissociates into oxidised cytochrome P-450, water and 
hydroxylated product. The nature of the active oxygen 
intermediate is uncertain. An oxygen transfer or oxenoid 
mechanism has been suggested (Hamilton, 1964; Guroff et at., 
1967). Cytochrome P-450 can function as a peroxidase with 
organic hydroperoxides (Hrycay and O ’Brien, 1971a,b), 
and cumene hydroperoxide sustains the cytochrome P-450- 
mediated hydroxylation and 0-dealkylation of a variety 
of substrates in rabbit liver microsomes in the absence 
of NADPH and molecular oxygen (Rahimtula and O ’Brien,
1974, 1975). The hydroxylation of some steroids and fatty 
acids is supported in similar circumstances by other 
’active oxygen’ containing compounds, such as sodium 
periodate and sodium chlorite (Hrycay zt at., 1975a,b, 1976).
Iodosobenzene serves as an oxygen donor in 7-ethoxy- 
coumarin 0-deethylation (Lichtenberger zt aZ., 1976).
EPR and optical spectroscopic evidence of free radical 
production in the cumene hydroperoxide-supported reaction 
caused Rahimtula and colleagues (1974) to propose that 
a ferryl ion complex (in resonance with a ferric oxene 
complex, F e ^ - C T i  Fe3+-0) is the active oxygen species 
involved in cytochrome P-450-mediated reactions.
1.4.6. Induction and purification of multiple forms
of cytochrome P-450
Inducing agents act tn vtvo to increase the 
rate of production and/or to decrease the rate of 
degradation of cytochrome P-450, as distinguished from 
activation tn vttAo (Cinti, 1978). Early observations of 
the inducing effect of an exogenous substance on the 
metabolism of another foreign compound were made by the 
Millers and their associates (Miller zt aZ., 1952;
Brown zt a,Z. , 1954; Conney zt aZ., 1956), who showed that 
aminoazo dye metabolism in rats was increased by 
pretreatment of the animals with 3-methylcholanthrene. 
Selective increases in the activities, of various liver 
microsomal monooxygenases were subsequently found to 
occur after exposure to, or administration of, numerous 
compounds, including barbiturates, polycyclic aromatic 
hydrocarbons, steroids, insecticides, pesticides and 
other environmental contaminants (Conney, 1967; Mannering, 
1971; Remmer, 1972). These results imply that multiple 
forms of cytochrome P-450 exist, and that their levels 
are selectively manipulated by different inducers.
Phenobarbitone and 3-methylcholanthrene are 
generally regarded as the 'classical’ inducing agents.
The former causes an increase in the level of a cytochrome 
with a reduced-carbon monoxide complex absorbance maximum
the same as that in control microsomes. Pretreatment with 
3-methylcholanthrene results in the synthesis of a new 
haemoprotein, cytochrome P-448 (Alvares z t  a t . ,  1967), 
or cytochrome P^-450 (Sladek and Mannering, 1966), which 
has a reduced-carbon monoxide difference spectrum 
absorbance maximum at 446-448nm. Optimum inducing doses 
of 3-methylcholanthrene and phenobarbitone have been 
reported to produce additive induction (Bidleman and 
Mannering, 1970). Other evidence that different forms of 
cytochrome P-450 are induced is that phenobarbitone 
increases the metabolism of a wide range of substrates, 
whereas 3-methylcholanthrene is more specific (Conney,
1967). Some model substrates, including testosterone 
(Kuntzman zt c l Z . , 1968; Conney et clZ., 1973), biphenyl 
(Creaven and Parke, 1966; Burke and Bridges, 1975), 
benzo(a)pyrene (Rasmussen and Wang, 1974) and warfarin 
(Pohl zt a,Z., 1977), form different metabolites in 
microsomal suspensions according to the inducing pretreatment 
used.
Many other agents are known to induce cytochrome 
P-450. Corticosteroids, androgens and some synthetic 
steroids induce hepatic microsomal enzyme activities 
(Selye, 1970), one of the most potent steroids being 
pregnenolone 16a-carbonitrile, which appears to induce 
a form of cytochrome P-450 different from that induced 
by either phenobarbitone or 3-methylcholanthrene (Lu 
z t  c l Z . , 1972; Birnbaum z t  c l Z . , 1976).
Various polyhalogenated compounds act as 
inducing agents. DDT (1,1,1-trichloro-2,2-bis[p-chloro- 
phenylethane]), dieldrin and aldrin resemble phenobarbitone 
as inducers (Hart and Fouts, 1965). Mixtures of poly­
chlorinated biphenyls appear to have mixed properties of 
3-methylcholanthrene and phenobarbitone (Alvares and 
Kappas, 1977; Ryan z t  clZ. , 1977), which can be separately 
ascribed to different isomers (Goldstein z t  a Z ., 1977). 
Commercial mixtures of polybrominated biphenyls yield 
similar results (Dent z t  clZ. , 1976, 1977, 1978).
2,3,?,£-Tetrachlorodibenzo-p-dioxin (TCDD) induces 
cytochrome P-448 in rats and mice, the enzyme profile 
resembling that of 3-methylcholanthrene pretreatment 
(Poland and Glover, 1974; Haugen zt at., 1976), but the 
potency of TCDD is far greater (Poland and Glover, 1974).
Many flavones are inducers of the 3-methyl­
cholanthrene type (Wattenberg zt aZ., 1968), the most 
potent being 5 ,6-benzoflavone, or 3-naphthoflavone 
(Boobis zt clZ. , 1977). Ethanol induces a form of cytochrome 
P-450 of specific spectral, catalytic and electrophoretic 
characteristics (Joly zt aZ., 1973, 1977; Ohnishi and 
Lieber, 1977). The hypolipidaemic drug, clofibrate, 
induces in rats a species of cytochrome P-450 with a 
molecular weight of 52000, and a reduced-carbon monoxide 
difference spectrum absorbance maximum of 452nm (Parker 
and Orton, 1980; Gibson zt clZ.  , 1982). Chemically initiated 
diabetes has also been reported to increase the amount 
of a specific form of rat liver cytochrome P-450 (Past 
and Cook, 1980, 1982a,b).
Treatment of animals with methylenedioxyphenyl 
compounds, including benzodioxole, safrole and isosafrole, 
initially inhibits cytochrome P-450-dependent reactions, 
and after longer periods, enhances them (Jaffe zt aZ.,
1969; Lake zt aZ., 1973; Yu and Terriere, 1974). Safrole 
or isosafrole induces a haemoprotein band visualised upon 
sodium dodecyl sulphate (SDS)-polyacrylamide disc gel 
electrophoresis with a molecular weight intermediate 
between those induced by 3-methylcholanthrene or by 
phenobarbitone (Dickins, 1978; Dickins zt aZ., 1978).
SDS-polyacrylamide disc gel electrophoresis of 
microsomes is a useful approach to estimate the forms of 
cytochrome P-450 present in preparations from different 
sources. Microsomes prepared from rats pretreated with 
phenobarbitone, 3-methylcholanthrene or isosafrole show 
distinct electrophoretic patterns in the 48000-55000 
molecular weight region (Alvares and Siekevitz, 1973;
Welton and Aust, 1974; Dickins zt at., 1978). In microsomes 
from animals pretreated with either saline or corn oil, 
there are four major protein bands in this region. Band 
1 (48000 MW) is increased slightly by treatment with 
phenobarbitone or isosafrole; band 2 (49000 MW) remains 
unchanged; band 3 (50000 MW) is induced by phenobarbitone; 
band 4 (53000 MW), which is scarcely detectable in 
control microsomes, is increased by isosafrole; and band 5 
(55000 MW) is increased by 3-methylcholanthrene, which 
also produces a small induction of band 4 (Fennell, 1980).
Characterising the existence of a population 
of forms of cytochrome P-450 in pither untreated animals, 
or within animals given a single inducer, is more 
difficult. Using cyanide and octylamine ligands, Comai 
and Gaylor (1973) reported that three forms of cytochrome 
P-450 in control microsomes were selectively induced by 
3-methylcholanthrene, phenobarbitone or dietary ethanol. 
Werringloer and Estabrook (1975) described four cytochrome 
pools, which were preferentially inducible. Marked 
heterogeneity of cytochrome proteins from untreated rat 
liver has been demonstrated by electrofocussing in 
polyacrylamide (Warner zt at., 1978). Examination of 
developmental changes in induction in rat, mouse and 
rabbit with 5 ,6-benzoflavone, 3-methylcholanthrene and 
TCDD has shown that two species of cytochrome P-450 
(termed ’P-448’ and P^-450) are induced (Atlas zt at.,
1977; Guenthner and Nebert, 1978).
Purified preparations have provided much of the 
evidence for the multiplicity of cytochrome P-450.
Early results from reconstituted systems established 
that substrate specificity resides in the cytochrome 
P-450 fraction (Lu zt at., 1973; Nebert zt at., 1973). 
Improved purification techniques subsequently allowed 
more than one cytochrome P-450 fraction to be separated 
from a single microsomal preparation. Antibodies raised
against cytochrome P-450 and ’cytochrome P-448’ from 
3-methylcholanthrene-pretreated rats, suggested that the 
purified fractions contained at least six different 
proteins (Thomas zt at., 1976a,b). Generally, there is 
immunological non-identity among forms of cytochrome 
P-450 purified from the liver of one species, or among 
forms from different species (Thomas zt at., 1976b,
1979b; Johnson and Muller-Eberhard, 1977).
The different electrophoretic mobilities of 
purified fractions from control or induced animals of 
several species (Haugen zt at., 1975; Hashimoto and Imai, 
1976; Guengerich, 1977b) when subjected to SDS-polyacrylamide 
disc gel electrophoresis, is one of the most powerful 
arguments for the multiplicity of cytochrome P-450 forms. 
Limited proteolysis ptuA peptide mapping by electrophoresis 
extends this technique to show differences among cytochrome 
P-450 preparations (Guengerich, 1978; Johnson zt at.,
1979; Ryan zt al., 1979).
Notable differences in the amino acid composition 
of three homogeneous forms of rat liver cytochrome P-450 
(Guengerich, 1978), and between rabbit liver cytochromes 
P-450 LMjj and LM^ (Haugen and Coon, 1976), have been 
reported.
Induction of cytochrome P-450 is thought to 
involve dz novo protein synthesis. Inhibition of the 
peptidyl transferase reaction, DNA-dependent RNA synthesis 
or RNA polymerase II, by cycloheximide, actinomycin D 
or a-amanitin respectively, prevents the induction of 
cytochrome P-450 (Gelboin and Blackburn, 1963; Cutroneo 
and Bresnick, 1973; Jacob zt a£., 1974). If a-amanitin is 
given up to eight hours after phenobarbitone, induction is 
prevented, whereas at later time periods it is not, which 
suggests that dz novo synthesis of RNA is an initial event 
in induction (Jacob zt at., 1974). Inducers may stabilise, 
or reduce the rate of degradation of, various components
of the enzyme synthetic process (Louis-Ferdinand and Fuller, 
1970, 1972; Seifert and Vacha, 1970; Black zt 1971;
Pousada and Lechner, 1972). The primary event of induction 
has been proposed to be an interaction of the inducer with 
a receptor protein, notably in the case of polycyclic 
aromatic hydrocarbons (Poland and Kende, 1976), and 
uncoupling of electron flow with release of singlet 
oxygen has been suggested as a mediating process.(Paine,
1978).
1.4.7* Inhibitors of cytochrome P-450
Inhibition of cytochrome P-450-mediated mono­
oxygenation may occur at any one of several sites (Netter,
1973), although the most widely studied inhibitors compete 
for the substrate binding site, or for the site of oxygen 
activation (haem iron).
Carbon monoxide binds to the reduced haemoprotein 
to yield a complex, which is photodissociable with light 
of 450nm wavelength'(Diehl zt at., 1969; Cooper zt at.,
1977). SKF525A (3-diethylaminoethyldiphenylvalerate) 
competes with cytochrome P-450 substrates for their binding 
site. It also forms metabolites that bind to the haem iron, 
and thus compete with oxygen for reduced cytochrome P-450 
(Hildebrandt, 1973), these twin effects being apparently 
responsible for the competitive and non-competitive 
inhibition kinetics reported for SKF525A (Anders and 
Mannering, 1966; Ikeda zt at., 1968). A metabolite- 
cytochrome P-450 complex with an absorbance maximum at 525nm 
appears to be generated In vivo (Buening and Franklin, 1976).
As mentioned above, methylenedioxyphenyl compounds 
are initially inhibitpry to cytochrome P-450. Both competitive 
inhibition, and non-competitive inhibition associated with 
the formation of a metabolite-cytochrome P-450 complex, 
are found. The isosafrole metabolite-cytochrome P-450 
complex is characterised in the reduced form by absorbance 
maxima at 427 and 455nm In vivo and In vlVio (Franklin,
1971, 1972; Philpot and Hodgson, 1972).
Benzphetamine (Werringloer and Estabrook, 1973) 
and phenylalkylamines (Franklin, 1974a, b; Jonsson and 
Lindeke, 1976; Lindeke z t  a t . ,  1978) form metabolite- 
cytochrome P-450 complexes upon metabolism I n  v l t K O  . 
Amphetamines form a metabolite-cytochrome P-450 complex 
I n  v l V i o  , but not I n  v i v o  (Franklin, 1971, 1974b; Hirata 
z t  o i l . , 1977, 1979).
Metyrapone (2-methyl-1,2-bis[pyrid-3-yljpropan-
1-one) gives a type I spectrum with oxidised cytochrome 
P-450, and is an inhibitor (Hildebrandt zt at., 1969).
Although it undergoes oxidative metabolism (De Graeve z t  aZ,,
1979), the mode of inhibition by metyrapone is non-competitive 
Metyrapone binds preferentially to phenobarbitone-induced 
cytochrome P-450 (Ullrich z t  aZ., 1973), whereas 7 ,8- 
benzoflavone (a-naphthoflavone) binds to, and inhibits, the
3-methylcholanthrene-induced haemoprotein (Gelboin z t  aZ., 
1970; Burke z t  c l Z . , 1977). Tetrahydrofuran has been claimed 
to be a specific inhibitor of the ethanol-induced cytochrome 
P-450 (Ullrich z t  aZ., 1975).
Ellipticine, a polyaromatic pyridine, binds via 
the pyridinic nitrogen to cytochrome P-450 to produce 
absorbance maxima at 428nm in the oxidised state, and 455nm 
in the reduced state (Lesca zt aZ-, 1978), and is an 
effective inhibitor of monooxygenation. Alkyl- and aryl- 
substituted imidazoles are also very potent monooxygenase 
inhibitors (Wilkinson zt-aZ., 1974a, b; Dickins and 
Bridges, 1976; Dickins, 1978).
Sulphydryl reagents, including mersalyl (Franklin 
and Estabrook, 1971), p-chloromercuribenzoate (Illing and 
Netter, 1975) and W-ethylmaleimide (Kampffmeyer and Kiese, 
1963, 1964) inhibit cytochrome P-450-dependent mono­
oxygenation. It has been suggested that p-chloromercuri­
benzoate inhibits at various stages of the cytochrome P-450 
reaction cycle (Illing and Netter,’1975), but conversion
of cytochrome P-450 to cytochrome P-420 is a major cause 
of inhibition (Mason zt at., 1965).
1.4.8. Denaturation and destruction of cytochrome P-450
Cytochrome P-450 is converted to the inactive form, 
cytochrome P-420, by a variety of agents. These include 
cholate (Klingenberg, 1958), deoxycholate, phospholipase A 
and steapsin (Omura and Sato, 1964a, b), trypsin, urea and 
sulphydryl reagents (Mason zt at., 1965), and high 
concentrations of neutral salts, for example, potassium 
thiocyanate, sodium iodide and guanidine (Imai and Sato, 
1967a). Generally, these agents act by blocking or oxidising 
the thiolate haem ligand, or by disrupting the membrane 
environment of cytochrome P-450.
A common direction of attack on the cytochrome 
P-450 molecule is degradation of the haem moiety. NADPH- 
dependent lipid peroxidation leads to destruction of 
cytochrome P-450 haem (Jacobson zt at., 1973; Levin zt at., 
1973a, b), and lipid peroxidation has been proposed as the 
cause of haem loss following carbon tetrachloride intoxication 
(reviewed by Plaa and Witschi, 1976; Smuckler, 1976).
De Matteis (1970, 1971) reported that 2-allyl-2- 
isopropylacetamide (AIA) degraded cytochrome P-450 haem, 
with an accompanying production of ’green pigments’, 
apparently after metabolism of the AIA molecule by cytochrome 
P-450 (De Matteis, 1970; Levin zt at., 1973a). Secobarbitone, 
an allyl-containing barbiturate, is also converted to a 
metabolite which destroys cytochrome P-450 haem, with 
formation of green pigments (Levin zt a,Z., 1973a). Suicidal 
7r-bond metabolism by cytochrome P-450 appears to be the key 
to the destruction of cytochrome P-450 haem by olefins 
(Levin zt clZ. , 1972a; Ortiz de Montellano and Mico, 1980), 
acetylenes (White and Muller-Eberhard, 1977; Ortiz de 
Montellano and Kunze, 1980b) and allenes (Ortiz de Montellano
and Kunze, 1980a). Monosubstituted olefins and acetylenes 
cause an approximately equimolar decrease of microsomal 
haem content (De Matteis, 1971; Bradshaw zt at., 1978;
White, 1978), and an appearance of green pigments (White and 
Muller-Eberhard, 1977; Ortiz de Montellano and Kunze,
1980b; Ortiz de Montellano and Mico, 1980). Production of 
these pigments, however, does not accompany the destruction 
of cytochrome P-450 by disubstituted olefins and acetylenes, 
or by allenes (Ortiz de Montellano and Kunze, 1980a, b;
Ortiz de Montellano and Mico, 1980). The anaesthetic, 
fluroxene, converts haem to green pigments (Bradshaw zt at.,
1978), but, in contrast to AIA, fluroxene binds as a type 
I substrate, and is metabolised by a form of cytochrome 
P-450 induced by phenobarbitone (Ivanetich ztaZ., 1976;
Marsh zt at., 1977). However, fluroxene degrades preferentially 
cytochrome P-448 in 3-methylcholanthrene-induced rats 
(Bradshaw zt aZ., 1978). It has been proposed that terminal 
olefins (Ortiz de Montellano zt at., 1979, 1981) and 
acetylenes (Ortiz de Montellano and Kunze, 1980b) are oxidised 
by cytochrome P-450 to intermediates that alkylate the 
prosthetic haem. Epoxides have been suggested as the reactive 
metabolites of various compounds that attack cytochrome 
P-450 haem, but incubation of microsomes with some of these 
epoxides prepared synthetically led to insufficient 
destruction to account for that caused by the parent 
compounds (Guengerich and Strickland, 1977; Ortiz de 
Montellano zt at. , 1979; Ortiz de Montellano and Mico,
1980). Nonetheless, the epoxide of alclofenac, an analgesic 
which destroys cytochrome P-450 in vltKo , is potent in 
causing the loss of cytochrome P-450 in the absence of 
NADPH (Brown and Ford-Hutchinson, 1982).
A model for green pigment production has been 
reported by Callot and Schaeffer (1980), and the porphyrin 
product of propyne administration has been identified as an 
isomer of W-(2-oxopropyl)protoporphyrin IX (Ortiz de
Montellano and Kunze, 1981). The green pigments produced by 
treatment with these unsaturat'ed compounds are distinguishable 
from those resulting from the administration of 3 ,5- 
diethoxycarbonyl-1,4-dihydrocollidine, griseofulvin and 
isogriseofulvin (De Matteis zt at., 1980), these pigments 
being inhibitors of ferrochelatase (De Matteis and Gibbs,
1975).
Other compounds cause the destruction of cytochrome 
P-450 by binding to the apoprotein. These compounds include 
carbon disulphide (Bond and De Matteis, 1969; Freundt and 
Kuttner, 1969) and parathion (Hunter and Neal, 1975), both 
of which appear to be metabolised to an active sulphur 
species (De Matteis and Seawright, 1973; Dalvi zt at., 1974; 
Norman zt at., 1974). Chloramphenicol is also converted to 
an active metabolite which binds to the cytochrome P-450 
protein (Pohl and Krishna, 1978; Pohl zt at., 1978). The 
sulphur-containing steroid, spironolactone, has been reported 
co destroy cytochrome P-450 in steroidogenic organs by 
an undefined mechanism (Menard at., 1974a,b ).
Several heavy metals, including cobalt (Tephly and 
Hibbeln, 1971), nickel and platinum (Maines and Kappas, 1977b) 
and cadmium (Hadley zt at., 1974), elicit a loss of cytochrome 
P-450 upon their administration to animals. These metal 
ions may be in the form of inorganic elements or metallo- 
porphyrins (Drummond and Kappas, 1981), or be bound to 
organic moieties (Rosenberg ei at., 1980). Diminution of 
cytochrome P-450 levels may arise as the result of several 
different mechanisms; direct (Maines and Kappas, 1977c), 
or indirect (Bissell and Hammaker, 1976), induction of haem 
oxygenase, inhibition of A-aminolaevulinate synthetase 
(Igarashi zt at., 1978; Sinclair zt at., 1979), or competition 
of the metal with iron for ferrochelatase, which inserts the 
metal ion into protoporphyrin (Igarashi zt al., 1978;
Watkins zt at., 1980).
Chemical (reviewed by Plaa and Priestly, 1977),
or mechanical (McLuen and Fouts, 1961), cholestasis may 
also lower the hepatic level of cytochrome P-450. This 
topic is considered in section 1.3 and in the discussion 
of chapter 5 of the present work.
1.5. Haem Metabolism
1.5.1. The synthesis and degradation of haem
The constituent carbon atoms of haem are provided 
by succinyl coenzyme A and glycine (Fig. 1.3*). Their 
reaction to form A-aminolaevulinic acid (ALA) is catalysed 
in the presence of pyridoxal phosphate by the mitochondrial 
enzyme, A-aminolaevulinic acid synthetase. ALA is considered 
to be the first compound of the pathway committed to haem 
synthesis, although its metabolism by minor alternative 
routes occurs (Meyer and Schmid, 1978). The formation of 
ALA is rate limiting for the synthesis of haem in liver 
(Marver zt at., 1966), and ALA synthetase has a key role 
in the regulation of the synthetic pathway.
In animal cells, ALA synthetase appears to be 
synthesised in the cytoplasm, and then transported to the 
inner mitochondrial matrix, where succinyl coenzyme A is 
available (Sano and Granick, 1961; Hayashi zt at., 1969, 
1970). The instability of mammalian ALA synthetase to heat, 
extremes of pH, dialysis, and in ion-exchange resins', has 
made the purification of this enzyme difficult, but some 
attempts have provided a certain amount of information 
about the enzyme. When extracted from chick embryo liver 
mitochondria, ALA synthetase has a molecular weight of 
87000±9000, as assessed by gel chromatography (Whiting and 
Granick, 1976). The enzyme extracted from rat liver mito­
chondria, and purified 40-fold, has a molecular weight of 
77000 (Whiting and Elliott, 1972), whereas Hayashi and 
coworkers (1970) have reported this value to be 113000. 
Purified ALA synthetase exhibits marked specificity for 
both glycine'and succinyl coenzyme A (Scholnick zt at.,
1972).
Numerous studies indicate that ALA synthetase is 
fundamental to the homeostatic mechanism for adjusting the 
level of haem synthesis to the needs of the organism (see
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Figure 1.3. Haem synthesis and degradation
Bissell, 1979). A haem pool appears to serve this regulatory 
function; it consists of haem in transit, and is fed by 
endogenous-synthesis, in addition to being in equilibrium 
with cytochrome-associated haem (Schmid, 1973). Exogenously 
administered haem may in part enter the pool, effecting 
a diminution in ALA synthetase activity (Marver, 1969).
New synthesis of apocytochrome, resulting in depletion of 
the haem pool, causes the induction or stimulation of ALA 
synthetase activity. Treatment of rats with phenobarbitone, 
for example, is followed by an increase in ALA synthetase 
activity (Correia and Meyer, 1975; Rajamanickam zt at., 
1975). The precise manner in which haem alters the activity 
of ALA synthetase is not certain; there may be a decrease 
in enzyme synthesis, with haem acting as a corepressor, 
direct inhibition of the enzyme itself, and/or post- 
translational interaction of haem and ALA synthetase, 
preventing the transfer of enzyme to mitochondria from the 
cytoplasm. A combination of these phenomena may operate 
In vivo (Gidari and Levere, 1977).
The remainder of the mammalian synthetic pathway, 
leading from A-aminolaevulinic acid to protoporphyrin IX, 
and hence via the action of ferrochelatase.to haem, is 
summarised in Figure 1.3* In addition to its function in 
the biosynthesis of haem-containing proteins, haem in the 
regulatory pool (and that derived from haemoprotein 
breakdown) is degraded to bile pigments (Fig. 1.3*). This 
process is mediated by a microsomal enzyme, haem oxygenase, 
which is present in both the parenchymal and the sinusoidal 
lining cells of liver (Bissell zt at., 1972).
Haem oxygenase, originally identified in mammals 
in spleen, liver and kidney (Tenhunen zt al., 1968), 
catalyses the conversion of haem to biliverdin IX , and 
consumes NADPH and molecular oxygen. These similarities, and 
others, to the properties of the microsomal cytochrome P-450 
system led to a belief initially that cytochrome P-450
was involved as the terminal oxidase (Tenhunen zt at.,
1969, 1972). However, studies with purified haem oxygenase 
preparations (Yoshida and Kikuchi, 1977, 1978a, 1979) 
reveal that the enzyme is independent of cytochrome P-450, 
and that haem acts as both substrate and coenzyme, with the 
haem oxygenase protein providing a favourable site for 
rapid autocatalytic oxidation of bound haem.
Purified haem oxygenase of either pig spleen or 
rat liver has a unit molecular weight of 32000 (Yoshida and 
Kikuchi, 1979), and binds haem to form a 1:1 complex 
(Yoshida and Kikuchi, 1978a). The microsomal haem oxygenation 
system consists of.haem oxygenase itself, and NADPH-cytochrome 
c reductase, which serves as an electron donor (Yoshida 
zt at., 1980). NADH can also act as an electron donor in 
haem degradation, but appears to be utilised in conjunction 
with NADPH-cytochrome c. reductase, rather than NADH-cytochrome 
6^ reductase (Noguchi zt at., 1979).
The whole process of catabolism of haem to biliverdin 
IXa is catalysed by the single enzyme, haem oxygenase, as 
long as the appropriate reducing equivalents are available. 
Cleavage of the protoporphyrin ring requires the presence 
of a central iron (Brown and Grundy, 1977) or cobalt (Maines 
and Kappas, 1977a) atom, since free porphyrins do not yield 
linear tetrapyrroles, and are excreted unchanged. Haem 
oxygenase is most active with free haem, or with haem 
loosely associated with protein (e.g. methaemalbumin), and 
exhibits a high degree of substrate specificity. Haem 
is dissociated from its parent haemoprotein, and binds to 
haem oxygenase in such a way that oxidation at the 3-, 
y- and 6-carbon bridges is prevented (Brown, 1976). After 
reduction of the enzyme-bound haem by NADPH, oxygen is 
bound and subsequently activated, probably by the ferrous 
iron. The activated oxygen attacks the a-methene bridge of 
the haem to form a-hydroxyhaem, which combines with 
additional molecular oxygen to yield a biliverdin-iron
complex. This is then hydrolysed to biliverdin IXa and 
carbon monoxide. A chemical sequence of haem catabolism 
is shown in Figure 1.3. (based on Kikuchi and Yoshida,
1980). A mechanistic reaction sequence has also been suggested 
by these authors (Yoshida and Kikuchi, 1978b; Kikuchi and 
Yoshida, 1980).
1.5 .2 . Induction of haem oxygenase
After the administration to experimental animals 
of a haem load comprised of either haem or haemoglobin, 
the haem oxygenase activity of liver (Tenhunen zt at., 1970), 
kidney (Pimstone zt at., 1971a) and macrophages (Pimstone 
zt at., 1971b; Shibahara zt at., 1978) is increased. The 
functional mRNA for haem oxygenase is increased in cultured, 
haemin-induced pig alveolar macrophages, and free polysomes 
are the major site of synthesis of haem oxygenase (Shibahara 
zt at., 1979). Various other compounds, including selenium 
(Maines and Kappas, 1976b), carbon disulphide and other 
sulphur-containing chemicals (Jarvisalo zt at., 1978), 
bromobenzene (Guzelian and Elshourbagy, 1979) and cobalt 
chloride (Maines and Kappas, 1975, 1976a,b), also increase 
the activity of hepatic haem oxygenase. Splenic haem 
oxygenase is refractory to these inducing agents (Tenhunen 
zt at., 1970;-Maines and Kappas, 1975).
Haem and haemoglobin appear to increase the 
activity of haem oxygenase via a mechanism that is mediated 
directly by haem (Kikuchi zt at., 1981). It has been suggested 
that the administration of non-haem substances causes a 
shift in intracellular haem distribution, and a resulting 
’endogenous’ haem load is responsible for the induction of 
haem oxygenase (Bissell and Hammaker, 1976). This process, 
or another haem-mediated mechanism, may initiate the 
increase in haem oxygenase activity after the pretreatment 
of rats with carbon disulphide (Kikuchi zt at., 1981),
whereas the characteristics of induction by bromobenzene, 
cobalt or cadmium are very different, and result in a much 
higher hepatic activity of haem oxygenase, without increased 
saturation of tryptophan pyrrolase by haem (Kikuchi zt at.,
1981). Cobalt chloride is also capable of inducing rat 
hepatic haem oxygenase in the absence of significant 
labilisation of the haem moiety of cytochrome P-450 
(Drummond zt at., 1982). These observations indicate that 
the induction of haem oxygenase is able to proceed through 
a mechanism independent of haem, but which is at present 
poorly understood.
1.5.3. Role of cytochrome P-450 in the regulation of
haem metabolism
Cells of all tissues that carry out aerobic 
metabolism probably synthesise haem to supply their need 
for mitochondrial cytochromes. The type of haemoproteins 
needed, their concentration and their half-life determine 
the rate at which haem is synthesised. Most mammalian body 
haem is present as haemoglobin, but the life span of rat 
erythrocytes is some 57 days (see Bissell, 1979), whereas 
the half-life of constitutive hepatic cytochrome P-450 
haem has been reported to be 4-5 hours (Kumar zt at., 1980). 
Thus, the haem requirement for hepatic cytochrome P-450 in 
the rat has been estimated as about 10% of that for 
haemoglobin (Bissell, 1979). Synthesis and degradation of 
cytochrome P-450 account in large part for the high rate 
of turnover of haem in the liver, and changes in cytochrome 
P-450 production would be expected to alter markedly the 
rate of hepatic haem synthesis. Inducers of cytochrome P-450 
cause the synthesis of new protein, which in turn requires 
an increased rate of manufacture of haem; phenobarbitone, 
for example, additionally lengthens the half-life of 
apocytochrome P-450 (Kumar zt at., 1980).
1.6. Epoxides and Epoxide Metabolism
1.6.1 . Epoxides - occurrence and metabolic formation
Epoxides (oxiranes) are three-membered cyclic 
ethers that are not numerous in nature, but are widely 
distributed (Cross, I960), and include several pharmacolo­
gically or toxicologically active species. Coumarin epoxides 
were among the earliest known (Spath and Klager, 1933); 
a-carotene oxide was described in 1945 (Karrer and Jucker, 
1945), and picrotoxinin, twelve years later (Conroy, 1957). 
Epoxides are found among the alkaloids and fungal metabolites 
(Warnhoff and Wildman, 1958). Steroidal oxiranes include 
several toad poisons (Bharucha zt aZ., 1959; Hofer zt aZ., 
1959). Some of the carcinogenic SznzzZo alkaloids are 
epoxides (Bradbury and Masamune, 1959; Geissman, 1959), 
as is scopolamine (see Holmes, 1960). The antibiotic, 
fumagallin, from A-6pzsigZZZtiA iumtgata^ is a naturally 
occurring diepoxide (Landquist, 1956).
Industrial production of epoxides is enormous.
They have widespread applications as cross-linking or 
alkylating agents, and as stabilisers, or as intermediates, 
in various manufacturing processes. Many are toxic or 
carcinogenic, and these have been reviewed by Manson (1980).
A large number of compounds of varying origin are 
susceptible to metabolic conversion to epoxides -in vtvo. 
Several polycyclic aromatic hydrocarbons are metabolised to 
epoxides (see Daly zt aZ., 1972; Sims and Grover, 1974; 
Heidelberger, 1975), and in many cases vicinal diol-epoxides 
are thought to be their ultimate carcinogenic forms (Jerina 
and Daly, 1977). The metabolism of arylhalides, including 
bromobenzene (Baumann and Preusse, 1879), and probably 
halogenated biphenyls (Chen zt aZ., 1976), proceeds 
through intermediate epoxides. Various furan and thiophene 
derivatives (Mitchell zt &Z., 1974, 1975, 1976b; Wirth zt aZ., 
1975; Boyd, 1976; Guengerich, 1977a; McMurtry and Mitchell,
1977) are also considered to form toxic epoxides. Because 
of ring tension and electronic polarisation, epoxides are 
chemically reactive (see Jerina zt &Z., 1973), and may 
bind to tissue macromolecules, including RNA and DNA, 
with apparent selectivity for purine bases (Grover and 
Sims, 1973). Garner (1976) has reviewed the role of epoxides 
in carcinogenesis.
1.6.2. Metabolism of epoxides
The most biologically significant reactions of 
epoxides are those with nucleophiles i.e. electron-rich 
compounds. Some epoxides react spontaneously with water to 
yield iAo.Fi-6-dihydrodiols; others may be hydrated by epoxide 
hydrolase (Oesch, 1973; see below). Unstable aromatic 
epoxides, such as benzo(a)pyrene-7 ,8-oxide, may rearrange 
under physiological conditions to give phenols (Waterfall 
and Sims, 1972).
A common reaction of epoxides is with sulphur- 
containing amino acids, usually the cysteine moiety of 
glutathione, by means of a group of cytosolic enzymes, 
the glutathione S-transferases (see Chasseaud, 1979), or 
by a non-enzymic reaction (Boyland and Chasseaud, 1969).
These enzymes are fairly non-specific, but have partial 
selectivity, and also function as binding proteins (Ketley 
zt aZ., 1975). Various systems of nomenclature have been 
used for the glutathione S-transferases (see Chasseaud,
1979). It is important to note, for example, that ligandin, 
which binds several compounds, including bilirubin (see 
Fleischner and Arias, 1976), and comprises 5% of the extractable 
protein of rat liver (Fleischner zt aZ., 1972), is 
synonymous with Y-protein (Reyes zt aZ., 1971), and with 
rat liver glutathione S-transferase B (Habig zt aZ., 1974).
The properties of the glutathione S-transferases have been 
reviewed by several authors (Jakoby zt &Z., 1976a,b; Grover,
1977; Jakoby, 1978). Many of the substrates for glutathione 
S-transferases are synthetic chemicals, or their phase I 
metabolic products, but some are naturally occurring, or 
endogenous (Boyland and Chasseaud, 1969; Chasseaud, 1976;
Grover, 1977).
The glutathione conjugate has the necessary properties 
for biliary excretion (Chasseaud, 1973a,b), but it may 
also be converted to a W-acetylcysteine conjugate, or 
mercapturic acid (Barnes zt at., 1959; Bray zt at. , 1959), 
which may be excreted in urine or bile:
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1.7. Microsomal Epoxide Hydrolase
1.7.1. Molecular properties
Epoxide hydrolase is located predominantly in 
the endoplasmic reticulum of cells from many animal organs 
and species (Oesch and D a l y 19-71.; Oesch zt at., 1971b). 
Although it lies in close physical association with 
cytochrome P-450, epoxide hydrolase and cytochrome P-450- 
associated monooxygenases appear to be under discrete 
genetic control (Oesch zt at., 1973a,b ). In primary 
foetal rat cell culture, the half-life of microsomal 
epoxide hydrolase has been reported to be 72 hours (Goujon 
zt at., 1980).
Epoxide hydrolase has been identified in a wide 
range of mammalian and non-mammalian vertebrates (Oesch 
zt at., 1978; Walker zt at., 1978), and in 26 organs and 
tissues of the Sprague-Dawley rat (Oesch zt at., 1977).
In addition to the microsomal form, both cytosolic (Gill 
and Hammock, 1980; Ota and Hammock, 1980) and nuclear 
membrane (Jernstrom zt at., 1976; Bornstein zt at., 1978) 
species of epoxide hydrolase have been described. Rat 
microsomal and nuclear enzymes- have been reported to be 
immunologically identical (Thomas zt at., 1979a), whereas 
the cytosolic epoxide hydrolase is immunologically distinct 
(Guenthner zt at., 1981).
Neutral and anionic detergents activate microsomal 
epoxide hydrolase by 30-60% (Burchell zt at., 1976), 
suggesting that the enzyme may lie deep in the microsomal 
membrane. However, antibodies to epoxide hydrolase will 
react with microsom'es in the absence of detergent (Oesch 
and Bentley, 1976; Levin zt at., 1978c), although the 
resulting complex retains most or all of the original 
catalytic activity.
Purification and SDS-polyacrylamide disc gel 
electrophoresis of rat liver epoxide hydrolase indicates
that it is a single polypeptide of molecular weight about 
49000(Bentley and Oesch, 1975; Lu zt at., 1975; Knowles 
and Burchell, 1977). Spectral characteristics suggest that 
it is rich in tryptophan, and that it does not contain a 
prosthetic group (Lu zt at., 1975). Bentley and coworkers 
(1975) have reported that in a purified preparation the 
W-terminal amino acid is blocked, and the C-terminal amino 
acid is asparagine or glutamine, whereas DuBois zt at. 
(1979) claim that leucine and methionine are the C- and.W- 
terminal amino acids respectively.
Both purified and membrane-bound rat liver epoxide 
hydrolase preparations possess wide substrate specificity, 
hydrating various alkene oxides, and the non-K-region 
arene oxides of naphthalene and benzo(a)pyrene (Lu zt at.,
1977). Mutagenic or carcinogenic bay region diol-epoxides 
of several polycyclic aromatic hydrocarbons have been shown 
to be poor substrates for epoxide hydrolase (Wood et at., 
1976, 1977).
1.7.2. Multiple forms of microsomal epoxide hydrolase
The use of chemical inducing agents does not give 
the same picture of multiple forms of rat liver microsomal 
epoxide hydrolase as is seen for the multiple species of 
cytochrome P-450. Phenobarbitone pretreatment of rats has 
been shown to increase the rate of hydration of several 
substrates (Jerina zt at-, 1977), but 3-methylcholanthrene 
appears to have either a small effect or none at all, 
depending on the substrate being hydrated (Bresnick zt at-,
1977). The latter results are not simple to interpret, 
since the extent of induction seen was both weak and 
variable. T/t&j^-stilbene oxide is a potent inducer of rat 
liver microsomal epoxide hydrolase (Schmassmann and Oesch, 
1978; Seidegard zt at., 1979), but there is no evidence 
that the form of the enzyme induced differs from that
induced by phenobarbitone.
Using partially purified epoxide hydrolase,
Oesch and coworkers (1971a) reported that the rate of 
hydration of benzene oxide was increased by a factor 
different from that of several other substrates. Benzene 
oxide also does not inhibit the hydration of styrene
7,8-oxide (Dansette zt at., 197*0. However, benzene oxide 
has a rather high Km value, and its hydration by epoxide 
hydrolase is very sensitive to detergents (Oesch zt at.,
1980), thus the presence of detergent in the enzyme 
preparation, and the low affinity of the enzyme for benzene 
oxide, may explain these observations.
In preparations purified to homogeneity, pH 
optima and purification factors for different substrates 
have been found to vary (Bentley zt at., 1976; Lu zt at.,
1977), and inhibitors of epoxide hydrolase exert differential 
effects (Levin et at., 1978a,c). Even these data are not 
conclusive; different lipophiliclties and susceptibility
to detergent may explain the different purification 
factors, and the inhibition results could be rationalised 
on the basis of multiple catalytic and effector sites on 
the enzyme. Supporting this is the failure to detect more 
than one peptide during amino acid sequencing (DuBois zt at.,
1979).
Guengerich and colleagues (1979a,b), however, 
have reported the separation by column chromatography, 
amino acid composition and immunochemical properties, 
of multiple forms of epoxide hydrolase in individual rat 
and human tissues. These forms had similar molecular 
weights, but were selective for substrate, and underwent 
differential effects when treated with various modifiers of 
enzyme activity.
Species differences in epoxide hydrolase activity 
have been described (Levin zt at., 1978a,c; Oesch zt at.,
1978). In contrast, liver microsomal epoxide hydrolase of
\rats, B6 mice and D2 mice are immunologically identical 
(Levin zt at., 1978a,c).
1.7.3. Mechanism of action
Epoxide hydrolase catalyses the hydration of 
epoxides to VianA-],2-dihydrodiols, in a manner which is 
highly regiospecific, with monosubstituted 1,1- and ctA-
1,2-disubstituted epoxides containing at least one large 
lipophilic group being the most readily hydrated (Oesch 
zt at., 1971c; Oesch, 1973). Hydration occurs at the 
sterically least hindered epoxide carbon atom (Hanzlik 
zt at., 1976). This discrimination appears to hold until 
almost complete symmetry exists around the epoxide ring 
(Thakker zt at., 1977).
Arene oxides and zt*-1,2-disubstituted epoxides 
are hydrated with almost complete inversion of configuration 
at the epoxide carbon attacked, and may result in unique 
isomeric products of high optical purity (Dansette zt at.,
1978). The mechanism of reaction has been proposed to be 
either acid catalysis (Watabe zt at., 1971) or nucleophilic 
attack (Hanzlik zt at., 1976), with the balance of evidence 
favouring the latter (Dansette zt at., 1978). When chemical 
models are constructed, the nucleophilic hydration of 
epoxides mimics the characteristics of the enzyme-catalysed 
reaction (Hanzlik zt at., 1976; Dansette zt at., 1978).
Water may be activated to a nucleophilic species 
by histidine imidazole deprotonation, and specific alkylation 
of one of the histidine residues of epoxide hydrolase has 
been shown to completely inactivate the purified enzyme 
(DuBois zt at., 1978). Thus, it appears that epoxide 
hydrolase functions by nucleophilic attack at the least 
hindered epoxide carbon atom by an incoming hydroxyl ion, 
with ring opening away from this ion, and the generation 
of a i^tcm^-dihydrodiol product.
1.7.4. Modification of activity tn vtVio
Various compounds are capable of stimulating 
epoxide hydrolase tn vttAo. Carbonyl type stimulators 
(metyrapone, 9-fluorenone and chalcone oxide) appear to 
bind at a site distinct from the substrate binding site 
(Ganu and Alworth, 1978)., Aryl carbonyl substituted 
compounds with an additional hydrophobic group are the most 
effective activators as judged by the hydration of styrene
7,8-oxide. Flavones (Alworth zt at., 1980) and ellipticine, 
harman, norharman and isoquinoline (Vaz zt at. , 1981) also 
stimulate epoxide hydrolase activity tn vtVio.
Other compounds, such as 1,1,1-trichloropropene
2 ,3-oxide and cyclohexene oxide, are potent inhibitors of 
styrene oxide conjugation tn vttAo (Oesch zt at., 1973a; 
Oesch, 1979).
However, the effects of certain inhibitors and 
activators of epoxide hydrolase vary with the substrate 
undergoing hydration. Metyrapone, for example, inhibits 
the hydration of benzo(a)pyrene 11,12-oxide and
3-meth.ylcholanthrene 11,12-oxide (Levin et at. , 1978a,c). 
High concentrations of some inhibitors, including 1 , 1 , 1- 
trichloropropene 2,3-oxide, also inhibit cytochrome P-450, 
and may further confuse the interpretation of their effects
1.7.5. Identification of epoxide hydrolase as a pre­
neoplastic antigen
Hyperplastic liver nodules produced by the action 
of ethionine, 2-acetamidofluorene, safrole, aflatoxin , 
nitrosamines or aminoazo dyes have been described as 
possessing a preneoplastic antigen, which is located 
predominantly in the smooth endoplasmic reticulum (Lin 
zt at., 1977), and can be detected in the nodules, or in 
hepatomas (Epstein zt at., 1967b; Farber, 1973; Okita zt at
1975). This preneoplastic antigen is also present in 
normal rat liver microsomes, but at much lower levels 
(Griffin and Kizer, 1978), and has been identified as 
hepatic microsomal epoxide hydrolase (Levin zt at., 1978b) 
on the basis of the following criteria:
i) preneoplastic antigen and purified epoxide hydrolase 
show immunochemical identity upon Ouchterlony double­
diffusion analysis;
ii) preneoplastic antigen purified from hyperplastic 
nodules, and purified epoxide hydrolase from phenobarbitone- 
pretreated rats, show a minimum molecular weight of 49000 
upon SDS-polyacrylamide disc gel electrophoresis;
iii) epoxide hydrolase and preneoplastic antigen both 
convert certain arene oxides to dihydrodiols;
iv) microsomes prepared from hyperplastic nodules from
rats pretreated with 2-acetamidofluorene catalyse the hydration 
of a series of epoxide substrates at rates much greater 
than liver microsomes from untreated rats.
1.8. Furans
1.8.1. Occurrence
Furans are commonly plant products, but a few 
are of fungal origin, dendrolasin is an insect product, 
and castoramine is a constituent of the scent gland of the 
beaver. Many of these compounds are terpenoids, irrespective 
of their source.
Of the simple furans, furfuraldehyde is the most 
widespread, and is found in many essential oils (Masson, 
1909; Takahashi zt at., 1959). Elsholtzione (Asahina and 
Murayama, 1914) is found in the essential oil of Et*hottzta 
z*it*tata, and the isomeric perilla ketone is a constituent 
of the oils of various VzKttta species (Goto, 1937).
The sweet potato (Ipomoza batata*) is liable to 
black rot, caused by any of several fungi, including 
Czkato*tomztta ^tmbxtata and VvL*aA.tam *otanl (Uritani and 
Muramatsu, 1953; Wilson zt at., 1970, 1971). fu*aAtum 
infection is associated with the presence of a group of 
structurally related furans, including 4-ipomeanol, 1-ipo- 
meanol, 1,4-ipomeadiol and ipomeamine (Boyd zt at., 1974).
Many other complex furans of plant or fungal 
origin have been described, of which some possess multiple 
saturated or unsaturated ring systems, or are linked to 
glucose residues. These have been reviewed by Dean (1963).
The benzofuran nucleus is common in natural 
products. Some of the most important benzofurans in nature 
are 5-methoxybenzofuran of S t z A Z u m  * u b p t t z a t u m  (Birkinshaw 
z t  a t . ,  1957), euparin, from the gravel root plant (Von 
Gizychi, 1950), and egonol from S t y x a x  species (Kawai and 
Yamagami, 1938). An antioxidant found in bakers’ yeast,
2-(2-hydroxy-6-methoxy-3,4-methylenedioxypheny1)benzofuran, 
contains both a benzofuran and a methylenedioxyphenyl 
moiety (Forbes zt at., 1958; Meisinger zt at., 1959). 
Dibenzofurans occur in large quantities in lichens (e.g.
Shibata, 1944).
Other important furans and benzofurans are synthetic 
compounds, used industrially (e.g. Schlaepfer and Kabas,
1974; Wehling, 1980; Gardziella, 1981) or therapeutically 
(e.g. Grell zt at., 1980; Langlois zt at., 1980; Hishmat 
zt at., 1982). Benzofuran is found in coal tar and cigarette 
smoke, and is involved in the preparation of coumarene- 
indene resins (Kharchenko and Petrovskaya, 1975). Saunders 
and coworkers (1974) reported that 3-methylfuran, present 
in smog, may be a reaction product of isoprenes and other 
terpenes released into the atmosphere by vegetation.
1.8.2. Toxic and pharmacological properties of furans
Several furans are known to cause pulmonary toxicity 
in laboratory species. These include 4-ipomeanol (1- 
[3-furyl]-4-hydroxypentanone) and other furan products 
of Fu*aAium *olcLYil (Boyd and Wilson, 1972; Boyd zt at.,
1974), 3-methylfuran (Boyd zt at., 1978b; Statham zt at.,
1978), furan carbamates (Seawright and Mattocks, 1973; 
Guengerich, 1977), perilla ketone (Wilson zt at., 1977),
2-methylfuran (Franklin and Boyd, 1978), 2-furamide (Boyd, 
1980a), and the therapeutic agent, 5-nitrofurantoin 
(A/-[5-nitro-2-furfurylidine]-1-aminohydantoin) , which has 
caused lung disease in humans (Rosenow, 1976), as well
as pulmonary damage in rodents (Boyd zt at., 1977, 1979).
In some species tested, 4-ipomeanol damages other 
organs in addition to the lungs. Thus, whereas only 
pulmonary lesions occurred in rats, rabbits and guinea 
pigs, hepatic necrosis was sometimes observed in hamsters 
(Dutcher and Boyd, 1978, 1979). Adult male mice exhibited 
renal cortical necrosis as well as pulmonary damage (Boyd 
and Dutcher, 1978), but young male mice (Jones zt at.,
1979) and female mice (Boyd,.1980b) were resistant to the 
renal toxicity of 4-ipomeanol. Avian species show
hepatotoxicity, but not pulmonary lesions, when given
4-ipomeanol (Buckpitt and Boyd, 1978). In the study of 
McMurtry and Mitchell (1977), benzofuran was shown to exert 
renal toxicity in the mouse, whereas furan caused lesions 
in both kidney and liver. Furosemide (W-[2’-furylmethyl]-
4-chloro-5-sulphamoylanthranilic acid) elicited hepatic 
necrosis in mice, but not in rats.
The furan moiety of 4-ipomeanol is necessary for 
its toxicity (Boyd zt aZ., 1978a), and it has been proposed 
that the lung necrotic action of this compound, and some 
other furans, is mediated via a highly reactive furan 
epoxide (see Boyd, 1980a,b), which is produced by cytochrome 
P-450 of Clara cells (Boyd, 1977). The hepatic necrosis 
caused by furosemide (Mitchell zt aZ., 1974, 1976b; Wirth
zt aZ., 1976) has also been postulated to be caused by a
furan epoxide, and there is a degree of correlation 
between the metabolism and covalent binding of a series 
of furan derivatives and their renal and/or hepatic toxicity
in the rat and mouse (McMurtry and Mitchell, 1977). A.
considerable amount of evidence indicates that rat and 
human hepatic microsomes mediate the production of an 
epoxide of the dihydrofuran moiety of aflatoxin B ^ , a 
carcinogen from A*pzsiglZZu* y l I q z k (Swenson zt aZ. , 1973).
Benzofuran derivatives have been investigated, and 
applied, as hypolipidaemics (Grell zt aZ., 1980), hypotensive 
agents and diuretics (Areschka zt aZ., 1976, 1977; Woyke 
zt aZ., 1981). Benzofuryloxyalkylamidoxamines show properties 
similar to the tricyclic antidepressants (Areschka zt aZ.,
1973). Hishmat and coworkers (1982) have decribed the 
antimicrobial properties of some substituted benzofurans; 
diguanidinodibenzofuran (Puetzer, 1940) and hydroxydibenzo- 
furan (Phatak and Leake, 1936) derivatives are also 
bacteriocidal. Griseofulvin, which is a potent fungicide, 
is a 2,3-substituted benzofuran (Oxford zt aZ., 1939).
1.9. Methylenedioxyphenyl (Benzodioxole) Compounds
1.9.1. Occurrence
The methylenedioxyphenyl group is widely distributed 
among the chemical constituents of dicotyledenous plants 
(Simmonds and Stevens, 1956), generally attached to a 
benzene ring, except in rare compounds such as the alkaloid, 
delpheline (Edwards zt a,Z. , 1958). Various benzodioxole 
compounds, including safrole, are found in nutmeg, cinnamon, 
ginger, black pepper, camphor oil, star anise oil, sesame 
oil, dill, mint, parsley, carrot and turnip (Weil, 1965; 
Fishbein and Falk, 1969; Russell and Jennings, 1969;
Furia and Bellanca, 1971). Safrole is also a constituent 
of root beer, and has been employed as an additive in 
toilet and pharmaceutical preparations (Fishbein and 
Falk, 1969). Schmeltz zt at. (1966) have reported the 
presence of benzodioxole compounds in cigarette smoke.
1.9.2. Toxicity and carcinogenicity of methylenedioxy­
phenyl compounds
The acute toxicity of most methylenedioxyphenyl 
compounds studied is relatively low. Methylenedioxybenzene 
(1,3-benzodioxole) has a fairly high acute toxicity in the 
rat, with an oral of 0.5g/kg, whereas the corresponding
values for safrole, isosafrole or dihydrosafrole fall in 
the range 1.0-2.5g/kg (Jenner zt at., 1964). The LD^q 
values for piperonyl butoxide have been reported to lie 
between 0.6 and 11.5g/kg for the rat and mouse (Sarlis 
zt al., 1949).
Little systematic toxicity data is available 
regarding the methylenedioxyphenyl compounds as a class. 
Severe liver lesions have been reported following the 
administration to rats of safrole, isosafrole or dihydro­
safrole (Taylor zt at., 1964). An examination of the
structural requirements for the production of hepatotoxicity 
showed that, although many allyl compounds were hepato- 
toxic, the appearance of lesions was independent of the 
nature of the 3-carbon side chain, but that such a side 
chain, and a methylenedioxyphenyl group, were obligatory. 
Long term administration of safrole to female rats 
(Crampton a.£. , 1977) produced a centrilobular loss of 
hepatic glucose-6-phosphatase, derangement of lysosome 
distribution, and the appearance of autophagic vacuoles. 
Piperonyl butoxide (reviewed by Haley, 1978), sesamin and - 
sesamolin (Neering zt at., 1975) cause dermatitis in man. 
Much of the toxicity of benzodioxole compounds is I possibly 
due to their ability to inhibit cytochrome P-450-mediated 
metabolism (Epstein zt at., 1967a,c).
Subacute administration of safrole causes liver 
damage (Jacobs, 1958; Leidy, 1958), and chronic exposure 
shows safrole to be a weak hepatocarcinogen in both rats 
and mice (Homburger zt at., 1961, 1962; Long zt at., 1963; 
Hagan zt at., 1965; Borchert zt at., 1973). Isosafrole and 
dihydrosafrole exhibited weaker hepatocarcinogenicity 
(Hagan zt at., 1965), but dihydrosafrole caused benign and 
malignant oesophageal tumours in rats, and has also been 
shown to produce carcinoma of the mouse forestomach (Reuber,
1979). Lymphomas and adenomas of the lung have also been 
described after the treatment of rats with safrole (Taylor 
zt at., 1964).
The metabolite(s ), if any, responsible for the 
acute toxicity of safrole are unknown; however, the 
carcinogenic electrophile produced from safrole appears 
to be a species such as 1’-hydroxysafrole-2',3’-oxide, 
safrole-1’-sulphate or 1'-acetoxysafrole (Wislocki zt at., 
1976, 1977; Swanson zt at., 1979).
The present study represents an attempt to evaluate, 
particularly, the hepatic reactions associated with the 
administration to rats of oxygen heterocycles containing 
a furan or a methylenedioxyphenyl moiety. Structural and 
ultrastructural changes in the liver resulting from either 
a classical hepatotoxic response, or from clinically 
defined cholestasis, are described. These are related to 
changes in serum chemistry, and to the effects on components 
of the endoplasmic reticulum, especially cytochrome P-450 
and epoxide hydrolase.
CHAPTER 2 
MATERIALS AND METHODS
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2.1 .
MATERIALS AND METHODS 
Chemicals
2,3-Benzofuran, furan, dihydrofuran, dibenzofuran, 
dihydrobenzofuran, 2-coumaranone, o-hydroxyphenylacetic 
acid, coumarin, 1 , 3-benzodioxole, indole and tKCLViA-stilbene 
oxide were purchased from the Aldrich Chemical Co. Ltd. 
(Poole, Dorset). Isosafrole was supplied by Merck GmbH 
(Darmstadt, West Germany), and safrole was obtained from 
Hopkin and Williams Ltd. (Essex, England).
NADH, NADPH, glucose-6-phosphate (disodium salt),
glucose-6-phosphate dehydrogenase, 2-oxoglutarate (sodium
salt), L-aspartic acid, L-alanine, adenosine-5'-monophosphate
(monosodium salt), isocitric acid, malate dehydrogenase
(E .C .1.1.1.37, porcine heart), lactate dehydrogenase
(E.C .1.1.1.27, bovine heart), glutamate dehydrogenase
(E.C .1.4.1.2, bovine liver), glucose oxidase (E. C . 1 . 1 . 3 • 4,
vlIqq.k ) , isocitrate dehydrogenase ((E. C . 1 . 1 .1 . 42*
porcine heart), adenosine deaminase (E.C.3.5.4.4, calf
liver), peroxidase (E .C .1.11.1.7, horseradish), urease
(E.C .3.5.1.5, Jack bean), p^nitrophenyl phosphate (disodium
salt), L-y-glutamyl-4-nitroanilide, UDP-glucuronic acid,
1-naphthyl-3,D-glucuronide, 4-nitrophenyl-$,D-glucuronide,
3-methylcholanthrene, anthrone, hemin, rat albumin, human
globulin, bovine serum albumin, cyanmethaemoglobin standard,
bilirubin standard, Coomassie Brilliant Blue R and Tris 
R(Trizma ) were all purchased from the Sigma London Chemical 
Co. Ltd. (Poole, Dorset).
Acrylamide and W,W*-methylenebisacrylamide (both 
specially purified for electrophoresis), sodium dodecyl 
sulphate (specially purified for biochemical research), 
phenobarbitone (sodium salt), Folin-Ciocalteu phenol 
reagent and N ,W ,W ’,W ’-tetramethylethylenediamine were 
supplied by British Drug Houses Ltd. (Poole, Dorset).
Styrene oxide, 1-chloro-2,4-dinitrobenzene,
2-amino-2-methyl-1-propanol, 2-amino-2-methyl-1,3-propanediol 
glycylglycine, glutathione, p-dimethylaminobenzaldehyde,
W-(1-naphthyl)ethylenediamine dihydrochloride, pyridoxal- 
5 ’-phosphate, neotetrazolium chloride, phenazine methosulphat 
£-p-bromotetramisole oxalate, o-dianisidine hydrochloride 
and bromocresol green were all obtained from the Aldrich 
Chemical Co. Ltd. (Poole, Dorset).
Ethoxyresorufin (50yM in methanol) and resorufin 
(10yM in ethanol) were purchased from Pierce and Warriner 
(U.K.) Ltd. (Chester, Cheshire).
Toluidine Blue, .Ehrlich’s acid haematoxylin, 
eosin and Oil Red 0 were supplied by Raymond A. Lamb Ltd. 
(London, England).
Combiteck standard proteins for electrophoresis 
were obtained from the Boehringer Corporation (Lewes,
Sussex).
[7-3H]-styrene oxide, [dimethylamine-1 **C ]- 
aminopyrine and [ 1-14C]-lauric acid were purchased from 
the Radiochemical Centre (Amersham, Bucks.).
[2-3H]-Benzofuran was kindly made by exchange 
tritiation by Dr J.A. Jones of the Department of Chemistry, 
University of Surrey.
Benzo(a)pyrene-4,5-oxide and G[3H]-benzo(a)pyrene-
4,5-oxide (366mCi/mmol) were the generous gifts of Dr G.M. 
Cohen (Department of Biochemistry, University of Surrey).
Antisera to rat Immunoglobulin A and rat 
Immunoglobulin A Free Secretory Component were kindly 
supplied by Dr Eva Orlans and Dr Jane Peppard of the 
Chester Beatty Research Institute, Royal Marsden Hospital, 
Sutton, Surrey.
2.2. Animals
Male and female Wistar Albino rats (170-220g) 
were obtained from the University of Surrey. The rats were 
housed in cages with sawdust bedding (Lee and Co., Chertsey, 
Surrey), and were allowed food (Spratts Animal Diet No.1) 
and water ad Z'Lb'Ltum, except for an experiment in which 
the effects of food deprivation for 48 hours were examined.
A 12-hour light/dark cycle was operated (0700-1900 light), 
at a temperature of 22° and 50% humidity.
2.2.1. Pretreatment - of animals
The identity and purity of compounds for adminis­
tration to rats were routinely checked by infra-red 
spectroscopy, and by thin-layer chromatography pZu.A 
melting point/boiling point determination respectively.
Controls
Control animals received corn oil (2.5ml/kg 
bodyweight) by intraperitoneal (i.p.) injection for 3,5,
6 or 21 days as appropriate. Animals were killed 24 hours 
after the last injection.
Food deprivation
Animals were allowed access to food and water 
ad Z^ibZtam for 24 hours, then deprived of food for the 
following 48 hours, and killed immediately thereafter.
Benzofuran
2,3-Benzofuran was administered to rats as a 
solution in corn oil (2.5ml/kg bodyweight). Animals 
received 0.42, 1.25, 2.50 or 5.00 mmol/kg by i.p. injection 
for 3 consecutive days, or 1.25 mmol/kg by i.p. injection 
for 21 days, and were killed 24 hours after the last 
injection. Alternatively, for time course studies, animals
received a single dose of 1.25mmol/kg, and groups were 
killed at various time intervals.
Furan and related compounds
Furan, and furan derivatives, were administered 
by i.p. injection in corn oil, at dose levels ranging 
from 0.68 to 7.50mmol/kg, as detailed in the relevant 
experimental sections. Each animal received the compound 
in a total of 2.5ml corn oil/kg.
o-Hydroxyphenylacetic acid
Cbti/io-Hydroxyphenylacetic acid was neutralised 
with sodium hydrogen carbonate before administration 
to rats. Each animal received 5.00mmol/kg in 0.9% (w/v) 
saline for 3 consecutive days, and was killed 24 hours 
after the last injection.
Phenobarbitone
Phenobarbitone (sodium salt) was administered 
in 0.9% (w/v) saline. Animals received 80mg/kg (0.3mmol/kg) 
by i.p. injection once daily for 3 consecutive days, 
and were killed 24 hours after the last injection.
3-Methylcholanthrene
3-Methylcholanthrene was administered to rats as 
a solution in corn oil at a dose level of 20mg/kg (0.075 
mmol/kg) by i.p. injection daily for 3 days. Animals were 
killed 24 hours after the final injection.
Benzodioxole and related compounds
Benzodioxole, isosafrole and safrole were 
administered by i.p. injection in corn oil at dose levels 
that were typically either 3.75 or 5.00mmol/kg. In all 
cases, animals received the dose in 2.5ml corn oil/kg, 
and were killed 24 hours after the last injection.
T/can^-Stilbene oxide
Rats received either 1.5mmol/kg once daily for 
5 consecutive days, or 4.Ommol/kg on the first day and 
2.Ommol/kg on each of the two following days. In each case, 
the vehicle was corn oil (2.5ml/kg), and the animals were 
killed 24 hours after the final injection.
Phenobarbitone-benzofurari
Phenobarbitone (0.3mmol/kg) was administered by 
i.p. injection in 0.9% (w/v) saline for either 5 or 6 
consecutive days, and benzofuran (5.Ommol/kg) coadministered 
as a solution in corn oil for the final 2 or 3 days 
respectively.
3-Methylcholanthrene-benzofuran
3-Methylcholanthrene (0.075mmol/kg) was administered 
by i.p. injection in corn oil for 6 consecutive days, 
and benzofuran (5.Ommol/kg) was administered concurrently 
as a solution in corn oil for the last 3 days. Animals 
were killed 24 hours after the last injection.
Tritiated benzofuran
[2-3H]-Benzofuran was diluted with unlabelled 
benzofuran and dissolved in corn oil to give solutions such 
that 2.5ml contained 5.0mmol benzofuran (1.22yCi), and 
5.0mmol benzofuran (13.4yCi), respectively. Animals for 
distribution and excretion experiments, including those 
undergoing jugular vein cannulation, were administered, 
typically, a single dose of [2-3H]-benzofuran in corn
oil, 5.Ommol/kg (1.22yCi/kg) by i.p. injection, and killed 
at the times indicated during Chapter 6. Rats subsequently 
undergoing biliary cannulation received 5.Ommol/kg 
(13.4yCi/kg) by i.p. injection in corn oil, and the bile ducts 
were cannulated either 1 hour or 24 hours after injection.
2.2.2. Surgical procedures for bile and blood collection
For collection of bile samples, rats (200-250g)
Rwere anaesthetised with Sagatal (May and Baker Ltd., 
Dagenham, Essex), using 1.0ml/kg bodyweight, the abdomen 
opened, and plastic cannula tubing inserted into an opening 
made in the common bile duct. After tying the cannula in 
place, the operation incision was closed, and the animals 
were maintained under anaesthesia for periods of up to 
3.5 hours. Body temperature was monitored via a rectal 
thermometer, and regulated using an insulated heat pad.
Bile samples were collected over timed periods. At the 
termination of the experiment the rats were killed by 
cervical dislocation, before recovery from anaesthesia.
In certain studies of distribution and excretion 
of radiolabelled benzofuran, cannulae were implanted into 
the right external jugular vein of rats (about 400g 
bodyweight), and the animals were allowed to recover.
These animals were maintained in metabolism cages for 
periods of up to 30 hours, while blood samples were 
obtained via the cannulae at timed intervals. At the end 
of the experiment the rats were killed by cervical 
dislocation, and tissues removed and digested for liquid 
scintillation counting as described below.
2.2.3. Metabolism cages
Studies of distribution and excretion of 
radiolabelled material were carried out in plastic and 
stainless steel metabolism cages (manufactured in the 
workshops of the University of Surrey), with facilities 
for the collection of urine and faeces. These products 
were collected and measured over 24-hour periods, and 
treated for scintillation counting as described below.
2.2.4. Pre- and post-mortem procedures
Animals were weighed daily during the pretreatment 
period, and, in certain experiments, food and water intake 
were measured. Rats were observed for changes in appearance 
and behaviour, or for any other toxic symptoms produced 
by the compounds used. This was carried out with particular 
care in the hour immediately following i.p. injection. 
Occasionally, urine and saliva samples were collected during 
the dosing period.
At the termination of the experiments rats were 
routinely anaesthetised with Sagatal (1.0ml/kg bodyweight), 
and blood was obtained from the vena cava, using a 5ml. 
Gillette plastic- syringe fitted with a 20swg needle.
Blood samples were taken into both plain glass bottles, 
and plastic tubes containing disodium EDTA (1mg/ml blood). 
Where possible, bladder urine samples were obtained, 
using a 1ml plastic syringe fitted with a 23swg needle.
The rats were killed by cervical dislocation.
For cytochrome P-450 distribution studies, the liver 
was excised, and whole or portions of lobes were removed 
and treated as detailed below, and in Chapter 3.
In other, typical, studies, the liver, kidneys, 
lungs and spleen were excised and weighed. Samples of liver 
were removed and treated for subsequent glycogen estimation, 
and for histological, histochemical and electron micro­
scopic examination respectively. Pieces of kidney, lung 
and spleen were fixed for histological processing.
For studies of distribution of radiolabelled 
benzofuran, small pieces of liver, lung, kidney and spleen 
were digested for scintillation counting, as described 
below.
2.3* Methods of Tissue Protein Preparation and Estimation
2.3.1. Preparation of subcellular fractions from liver
Livers excised at post-mortem were placed in
ice-cold 20mM Tris-HCl buffer, pH 7.4, containing 1.15%
(w/v) KC1. The livers were washed, blotted dry, and weighed.
Subsequent operations were carried out at 0-4°. After
scissor mincing of either the entire organ or of individual
lobes, the livers were homogenised in 3 volumes of ice-cold
20mM Tris-HCl buffer, pH 7.4, containing 1.15% (w/v) KC1,
using a motor-driven Potter-Elvehjem glass-Teflon homogeniser
(3 return strokes). A sample of the homogenate was retained,
and the remainder was centrifuged in polycarbonate tubes
at 10000gav for 20 minutes, using an aluminium head rotor
in an MSE ’High Speed 18’ refrigerated centrifuge. The
supernatant was decanted, and a sample was retained for
further analysis (10000g supernatant1. The remainder was
recentrifuged at 105000g (40000rpm) for 1 hour, usinga v
an 8 x 25ml aluminium angle head rotor in an MSE ’Super­
speed 50’ refrigerated centrifuge, or at 155000gav
(50000rpm) for 40 minutes, using an 8 x 35ml titanium
angle head rotor in a Beckman L5-65 refrigerated centrifuge.
The supernatant obtained was discarded, and the pellet
was resuspended in ice-cold 20mM Tris-HCl buffer, pH 7.4,
containing 1.15% (w/v) KC1, using a Potter-Elvehjem
glass-Teflon homogeniser. The resulting suspension was
recentrifuged at either 105000g for 1 hour, at at 155000gav av
for 40 minutes. The washed microsomal pellet was finally 
resuspended in 20mM Tris-HCl, pH 7.4, containing sucrose 
(250mM) and EDTA (5.4mM), to a concentration equivalent 
to 1.Og wet weight of liver per ml. The microsomal suspension 
was stored in 1.0ml aliquots in polycarbonate sample cups 
at -40°.
When small volumes of homogenate were obtained, 
e.g. in the preparation of microsomes from individual
liver lobes, the post-10000g .centrifugations were carried
3. V
out at 210000g for 30 minutes, using a 10 x 10ml titanium av
angle head rotor in a Beckman L5-65 refrigerated centrifuge.
2.3.2. Protein assay in tissue subfractions
The protein concentration in microsomal suspensions, 
10000g supernatants and crude tissue homogenates was 
determined by a modification of the method of Lowry e.t aZ. 
(1951), standardised against bovine serum albumin.
Reagents
0.05M NaOH
1 % (w/v) copper sulphate pentahydrate
2% (w/v) sodium potassium tartrate
0.05M NaOH, containing 2% (w/v) sodium carbonate
Folin-Ciocalteu phenol reagent, diluted with water
( 1 : 2 , v / v )
Bovine serum albumin in 0.05M NaOH (250yg/ml)
Method
The protein standard was diluted with 0.05M NaOH 
to give a range of concentrations of 50, 100, 150, 200 
and 250yg/ml. Microsomal samples were diluted to an 
appropriate protein concentration with 0.05M NaOH.
Copper sulphate, sodium potassium tartrate and sodium 
carbonate in NaOH were mixed in a ratio of 1:1:100 (v/v) 
immediately before use. Sodium carbonate reagent (5.0ml) 
was added to the protein standards, samples and blanks 
(0.5ml), mixed, and allowed to stand at room temperature 
for 10 minutes. Diluted Folin-Ciocalteu reagent (0.5ml) 
was added, and the solution mixed immediately. After 
standing for a minimum of 30 minutes at room temperature, 
the absorbance at 715nm was recorded using a Pye Unicam 
SP500 spectrophotometer.
Proteins were also measured by the adaptation to
the Autoanalyser of the Lowry method (Schuel and Schuel, 
1967).
Reagents
0.66M NaOH
0.1 % (w/v) CuSO^.^H^O, containing 0.2% (w/v) sodium
potassium tartrate
1.0M NaHCO^, containing 0.625M NaOH
Folin-Ciocalteu phenol reagent, diluted with water
(1:2, v/v)
Stock bovine serum albumin standard, 2mg/ml
Method
The Autoanalyser manifold flow diagram is shown 
in Figure 2.1.
Sampling time was 1 minute, and wash (0.66M 
NaOH) time was 36 seconds.
The stock protein solution was diluted with 
NaOH (0.66M) to give a range of concentrations of 0.2,
0.^, 0.6, 0.8, 1.0, 1.5 and 2.0mg/ml bovine serum albumin. 
Transmission {%) was recorded at 721nm, and converted to 
absorbance. Protein concentrations were calculated from 
the standard curve.
Microsomal protein concentrations estimated by 
both the manual and Autoanalyser methods for protein 
were plotted as a scatter diagram (n=34), shown in Figure
2.2. The line of best fit is represented by the equation:
y = 1.0236x + 0.048,
where the ’y* values are results from the manual method, 
and the ’ x ’ values are results from the Autoanalyser method.
The coefficient of correlation for results from, 
the two methods is 0.989.
Figure 2.1.
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The protein concentration in 3^ microsomal suspensions was determined . 
by both manual and Autoanalyser adaptations of the method of Lowry 
at at. (1951) as described in section 2.3.2.
The line of best fit (y = 1.0236x + 0.048) was calculated by regression 
analysis. A = 0.989.
2.4. Spectrophotometry
Routine absorbance measurements were made using 
a Pye Unicam SP500 spectrophotometer. Spectral determinations 
were carried out using a Pye Unicam SP1800 spectrophotometer, 
or a Varian Cary 219 split beam spectrophotometer. The 
latter two instruments were equipped with thermostatted 
cuvette holders, and measurements were made in the split 
beam mode (using 2 cuvettes, sample wavelength, X-j = 
reference wavelength, X2K
2.4.1. Cytochrome P-450
The cytochrome P-450 content of microsomal 
suspensions was measured by the method of Omura and Sato 
(1964a).
Reagents
66mM Tris-HCl buffer, pH 7.4 
Sodium dithionite, solid
Method
Microsomes (5ml of a suspension of 1mg protein/ml
in 66mM Tris-HCl, pH 7.4) were divided equally between
two cuvettes. Following the establishment of a baseline
of equal light absorbance between 400 and 500nm, the
contents of both cuvettes were reduced by the addition of
solid sodium dithionite- (1-2mg). Carbon monoxide was
bubbled through the sample cuvette for 30 seconds, and
the resulting difference spectrum was recorded. The
absorbance at the wavelength of maximum light absorption
(around 450nm) was measured relative to that at 490nm,
and the concentration of cytochrome P-450 was calculated,
-1 -1using an extinction coefficient of 91mM cm . When the
X of the reduced-carbon monoxide spectrum was determined, max
a narrow slit width (1.0nm), slow scan speed (0.1nm/sec) 
and slow response (2.5sec) were used.
2.4.2. Cytochrome
Microsomal cytochrome 6^ content was measured by 
reduction with NADH.
Reagents
66mM Tris-HCl buffer, pH 7.4
11.5mM NADH in 66mM Tris-HCl, pH 7.4 -
Method
Microsomal suspension was diluted with 66mM 
Tris-HCl, pH 7.4, to give a final concentration of 
1mg protein/ml, and a baseline of equal light absorbance 
was established between 400 and 440nm. The contents of 
the sample cuvette were reduced with NADH (0.45mM), and 
the spectrum was recorded. Cytochrome b^ concentration 
was calculated from the difference in absorption between 
424 and 409nm, employing an extinction coefficient of 
185mM”1 cm”1.
2.4._3. Ligand-induced binding spectra
Binding spectra were elicited as described by 
Schenkman Q.t at, ( 1967). Microsomes (5ml of a suspension 
containing 1mg protein/ml, in 66mM Tris-HCl, pH 7.4) 
were divided equally between two cuvettes housed in a 
thermostatted cuvette holder maintained at. 37°, or 25°.
A baseline of equal light absorbance was established 
between 350 and 500nm. Ligands were added to the sample 
cuvette in microlitre quantities of a concentrated solution, 
either in buffer, or in W ,W-dimethylformamide (not 
exceeding 2yl/ml sample), using a Terumo microlitre 
syringe (Shandon Southern Co. Ltd., Camberley, Surrey).
An equal volume of solvent was added to the reference 
cuvette, and the contents of both cuvettes were mixed 
by gentle inversion. Series of difference spectra were 
recorded between 350 and 500nm.
The addition of increasing amounts of ligand
produced a corresponding increase in the magnitude of
the binding spectrum elicited. Measurement of the peak-to-
trough absorbance changes at different ligand.concentrations
enabled apparent K and apparent AA values to be ^  s max
calculated from a double reciprocal plot (Schenkman <Lt at, , 
1967).
2.4.4. Determination of methylenedioxyphenyl metabolite- 
cytochrome P-450 complexes
Following the administration of substituted 
methylenedioxyphenyl and related compounds to rats, the 
presence of a metabolite-cytochrome P-450 complex isolated 
in the microsomal fraction was determined by measuring 
the dithionite-reduced minuA oxidised spectrum between 
400 and 500nm. Microsomal suspension (5ml of 1mg protein/ml, 
in 66mM Tris-HCl, pH 7.4) was divided equally between 
cuvettes, and a baseline of equal light absorbance was 
established between 400 and 500nm. Solid sodium dithionite 
(1-2mg) was added to the sample cuvette to reduce the 
contents, and the reduced mtnuA oxidised spectrum was 
recorded. The presence of a peak at 455nm was interpreted 
as being indicative of a metabolite-cytochrome P-450 
complex, and was expressed in terms of absorbance at 
455nm mZnuA absorbance at 490nm per mg of microsomal 
protein. Formation of the complex, in at least some cases, 
also seems to increase the absorbance at 427nm, although 
it is difficult to distinguish this component from the 
large absorbance at 427nm due to cytochrome 6^.
2.4.5. Regeneration of NADPH
When NADPH was required over long periods for 
enzyme assays, metabolic studies and spectral determinations,
an NADPH-generating system was used. This comprised 4.0mM 
glucose-6-phosphate and 2 units/ml glucose-6-phosphate 
dehydrogenase (E.C.1.1.1.4 9 ) . The addition of 250-500yM 
NADPH allowed the maintenance of constant NADPH concentrations 
over long periods of time.
2.5. Assays of Monooxygenase Activities In ViVio
2.5.1. 7-Ethoxycoumarin fl-deethylation
7-Ethoxycoumarin is metabolised by hepatic 
microsomes to a single fluorescent product, 7-hydroxy- 
coumarin (umbelliferone). The rate of reaction may be 
measured by monitoring the linear increase in fluorescence 
with time. An adaptation of the method of Ullrich and 
Weber (1972) was used.
Reagents
1.OmM 7-ethoxycoumarin in 66mM Tris-HCl, pH 7.4 
1.OmM 7-hydroxycoumarin in 66mM Tris-HCl, pH 7.4 
6.2mM NADPH in 66mM Tris-HCl, pH 7.4 
66mM Tris-HCl, pH 7.4
Method
Microsomes (200-800yg protein/ml) and 7-ethoxy- 
coumarin (100yM) were mixed in a fluorescence cuvette, 
and allowed to equilibrate to 37° for 5 minutes in the 
thermostatted cuvette holder of a Perkin-ETmer MPF-3' 
fluorescence spectrophotometer. NADPH (50yM) was added 
to the cuvette, and the initial increase in fluorescence 
at 450nm was monitored, using an excitation wavelength 
of 370nm. Standards of 7-hydroxycoumarin (0.5 and 1.0yM) 
were added to calibrate the reaction.
2.5.2. 7-Ethoxyresorufin fl-deethylation
Hepatic microsomes metabolise 7-ethoxyresorufin 
to the single fluorescent product, resorufin. Continuous 
measurement of the reaction can be achieved by monitoring 
the increasing fluorescence as resorufin is formed. The 
method used is adapted from Burke and Mayer (1975).
Reagents
50yM^7-ethoxyresorufin in methanol 
1OyM resorufin in ethanol 
66mM Tris-HCl, pH 7.4
31.12mM NADPH in 66mM Tris-HCl, pH 7.4
Method
Microsomal suspension (40-400yg protein/ml), 
7-ethoxyresorufin (0.2yM) and 66mM Tris-HCl, pH 7.4, 
were mixed in a fluorescence cuvette and allowed to 
equilibrate at 37° for 5 minutes in a thermostatted cell 
holder. The reaction was initiated by the addition of 
NADPH (250yM), and the time-dependent increase in fluorescence 
at 586nm was monitored, using an excitation wavelength of 
510nm. At the end of the reaction resorufin was added in 
increasing concentrations, to calibrate the rate of 
7-ethoxyresorufin 0-deethylation.
2.5.3. Aminopyrine M-demethylation
Microsomal aminopyrine W-demethylase activity 
was determined by the method of Poland and Nebert ( 1973) , 
using [dimethylamine-14C]-aminopyrine as substrate.
Reagents
4.OmM, [dimethylamine-1^CJ-aminopyrine (1OOyCi/mmol) 
in 66mM Tris-HCl, pH 7.4, containing 10mM 
semicarbazide hydrochloride
5OmM MgCl2
66mM Tris-HCl buffer, pH 7.4
40mM glucose-6-phosphate, containing 20 units/ml
glucose-6-phosphate dehydrogenase
6.2mM NADPH 
0.1M NaOH
Method
Microsomal suspension (0.8mg protein/ml),
[dimethylamine-1 **C]-aminopyrine (2. OmM, TOOnCi), MgCl2 
(5.OmM), glueose-6-phosphate (4.OmM), glucose-6-phosphate 
dehydrogenase (2 units/ml) and 66mM Tris-HCl buffer, 
pH 7.4, were mixed in a total volume of 480yl in Soveril 
tubes, placed on an ice bath. The tubes were preincubated 
at 37° for 3 minutes, and the reaction was then initiated 
by the addition of NADPH (250yM) After incubation for a 
further 5 minutes, the reaction was terminated by placing 
the tubes in ice-water, and adding cold chloroform (8ml).
NaOH (0.1M, 1.0ml) was added, and the capped tubes were 
mixed on a rotary mixer for 10 minutes before centrifugation 
(1000g for 5 minutes).
An aliquot (1.0ml) of the aqueous phase was 
reextracted with a further 8ml.of chloroform, and re­
centrifuged (1000g for 5 minutes). Aliquots of the aqueous 
phase (0.5ml) were removed, mixed with 4.5ml of a toluene/ 
metapol (2:1) scintillant, containing 0.02% (w/v) dimethyl 
P0P0P and 0.5% (w/v) PPO, and counted on an LKB. RackBeta 
scintillation counter.
Blanks, containing protein and cofactors, but with 
[dimethylamine-1^CJ-aminopyrine added after the chloroform, 
were also run.
2.5.4. Laurate hydroxylase
The method is due to Prough and coworkers (1978), 
and measures total hydroxylated products (11- 12-
hydroxylaurate).
■ Reagents
0.5mM [1-14C]-lauric acid (500yCi/mmol) in 0.1M
Tris-HCl buffer, pH 7.5, containing 1OmM MgCl^
1OmM isocitric acid, >1600U/1 isocitrate dehydrogenase 
(E.C.1.1.1.42, porcine heart) and 2.OmM NADP, in 
0.1M Tris-HCl buffer, pH 7.5, containing 10mM MgCl^
10% (v/v) H2S04
Method
Tris-HCl buffer, pH 7.5 (75mM), [ 1-1‘Cl-lauric 
acid (0.1mM, 100nCi/incubate), MgCl^ (7mM), isocitrate 
(5mM), isocitrate dehydrogenase (>800U/1) and NADP (1..OmM)' 
were mixed together in a Soveril test tube, and preincubated 
for 3 minutes at 37°. Microsomal suspension (about 0.75 
mg protein/ml) was added in a final incubation volume of 
2.0ml, and the incubation was continued for a further 5 
minutes. The reaction was terminated by the addition of 
H^SO^ (2.86%, v/v), and the mixture extracted 3 times with 
diethyl ether .(3 x 5ml). The ether layers were combined 
and washed twice with water (2 x 5ml). After evaporation 
to dryness, the residue was taken up in methanol, and 
aliquots were subjected to thin-layer chromatography on 
Silica Gel G-coated aluminium plates (Merck GmbH, Darmstadt, 
West Germany), developed in hexane:ether:glacial acetic 
acid (70:28.5:1.5, v/v). The positions of unmetabolised 
[1-14C]-lauric acid and labelled hydroxylated products 
were determined by autoradiography. The relevant zones of 
the plate were cut into small pieces, placed in counting 
vials,, and 4.0ml of Picofluor-30 (Packard Instrument Co. 
Inc., Downers Grove, 111., 60515, USA) were added. Counting 
was carried out on an LKB 1216 RackBeta scintillation 
counter, using a preexisting quench curve. Blanks, in 
which cofactors were absent, were also taken through the 
entire procedure.
2.6. Assays of Other Microsomal and Soluble Enzymes
In VttAo
2.6.1. Epoxide hydrolase (E.C .4.2.1.63)
Hepatic microsomal epoxide hydrolase converts 
epoxides to the corresponding t^arc^-dihydrodiols. Epoxide 
hydrolase activity was measured using two substrates, 
[7-3H]-styrene oxide and G[3H]-benzo(a)pyrene-4,5-oxide.
The conversion of [7-3H]-styrene oxide to 
[7-3H]-styrene dihydrodiol was measured using the method 
of Oesch o.t at, (1971b).
Reagents
40mM [7-3H]-styrene oxide (156.7yCi/mmol) in aceto-
nitrile
0.5M Tris-HCl buffer, pH 9.0
Method
Microsomal suspension (about 5mg microsomal 
protein/ml), 131•5mM Tris-HCl, pH 9.0, and distilled water 
were mixed in Soveril test tubes to give a final volume 
of 380yl. The tubes were preincubated in a shaking water 
bath (120 cycles/min) at 37° for 5 minutes, and the reaction 
was initiated by the addition of [7-3H]-styrene oxide 
(2.OmM, 125.5nCi). After 5 minutes’ further incubation at 
37° the reaction was stopped by the addition of petroleum 
ether (b.p. 40-60°, 9.0ml). The incubates were extracted 
for 10 minutes on a rotary mixer, then centrifuged for 10 
minutes at 400g, and the upper (petroleum ether) layer was 
removed by aspiration. The process was repeated twice, 
and the reaction product, [7-3H]-styrene dihydrodiol, was 
extracted into ethyl acetate (2.0ml). Aqueous and organic 
phases were separated by centrifugation at 400g for 5 
minutes, and an aliquot (0.5 or 1.0ml) of the ethyl acetate 
layer was removed for scintillation counting. Blanks 
containing boiled microsomes, and [7-3H]-styrene oxide
standards were also prepared. Scintillation counting was 
carried out in a toluene/metapol (2:1) scintillant, 
containing 0.02% (w/v) dimethyl P0P0P and 0.5% (w/v) PPO. 
Samples were counted on an LKB 1216 RackBeta scintillation 
counter, with standardisation by an external standard 
channels ratio method. Counting efficiencies were calculated 
by computer, using a quench curve prepared with [3H]- 
toluene as standard.
The hydration of G[3H]-benzo(a)pyrene-4,5-oxide 
to [3H]-benzo(a)pyrene-4,5-dihydrodiol was measured by 
the method of Schmassmann dt at, (1976).
Reagents
3.OmM [3H]-benzo(a)pyrene-4,5-oxide (0.96mCi/mmol)
500mM Tris-HCl buffer, pH 9.0
Method
Soveril test tubes were prepared containing 
microsomal suspension (0.2mg protein/ml), 100mM Tris-HCl 
buffer, pH 9-0, and distilled water, to a final volume of 
0.5ml. The tubes were preincubated for 5 minutes at 37°, 
and the reaction was initiated by the addition of [3H ] — 
benzo(a)pyrene-4,5-oxide (150yM, 72nCi). After 10 minutes’ 
further incubation, the reaction was terminated by the 
addition of petroleum ether (b.p. 40-60°, 3.5ml) and the 
tubes were cooled on ice. Dimethyl sulphoxide (0.5ml) 
was added, and the tubes were mixed for 3 minutes on a 
rotary mixer. After centrifugation at 400g for 2 minutes, 
the upper (petroleum ether) layer was removed by aspiration, 
and the process was repeated twice. [3H]-Benzo(a)pyrene-
4,5-dihydrodiol was extracted into ethyl acetate (1.0ml,
10 minutes), the phases separated by centrifugation at 
400g for 5 minutes, and an aliquot of the ethyl acetate 
layer removed for scintillation counting. Standards of
[3H]-benzo(a)pyrene-4,5-oxide, and blanks containing boiled 
microsomes were also prepared. Samples were counted on 
an LKB 1216 RackBeta scintillation counter, using a toluene/ 
metapol (2:1) scintillant, containing 0.02% (w/v) dirnethyl 
P0P0P and 0.5% (w/v) PPO. Standardisation was by an 
external standard channels ratio method. A quench correction 
curve prepared with [3H]-toluene was used to estimate 
counting efficiencies..
2.6.2. NADPH:Cytochrome c reductase
This enzyme is considered to reflect the activity 
of NADPH:cytochrome P-450 reductase. Direct measurement 
of cytochrome P-450 reduction is difficult to perform 
routinely, thus cytochrome c is used as an alternative 
electron acceptor. The reduction of cytochrome c. is 
monitored here by the spectrophotometric technique of 
Williams and Kamin (1962).
Reagents
0.1M Potassium phosphate buffer, pH 7.4, containing
1.OmM potassium cyanide
0.1mM cytochrome c
3.OmM NADPH in 0.1M potassium phosphate buffer, pH 7.4
Method
Microsomal suspension (0.1mg protein/ml), cytochrome
C- (33yM) and 0.1M potassium phosphate buffer, pH 7.4,
containing 1.OmM KCN, were placed in each of two cuvettes
to give a final volume of 2.9ml in the sample, and 3.0ml
in the reference cuvette. The cuvettes were preincubated
at 25° for 5 minutes, and the reaction was initiated by
the addition of NADPH (0.1mM) to the sample cuvette. The
reduction of cytochrome c was measured by monitoring the
absorbance change at 550nm, and the rate of reduction
-1 -1calculated using an extinction coefficient of l8.5mM cm
2.6.3. UDP-Glucuronyltransferase (E.C .2.4.1.17)
UDP-Glucuronyltransferase activity was measured 
with respect to two different aglycone substrates,
1-naphthol and 4-nitrophenol.
The glucuronidation of 1-naphthol was measured 
by the method of Bock (1974).
Reagents
2.OmM 1-naphthol, containing 25mM MgCl^
0.2M Tris-HCl buffer, pH 7.6, containing 0.2% (v/v)
Brij-35
5OmM' UDP-glucuronic acid
0.5M glycine-trichloroacetic acid buffer. pH 2.2
1.0M glycine-NaOH buffer, pH 10.6
Method
UDP-Glucuronic acid (5mM), 1-naphthol (0.4mM), 
Tris-HCl buffer, pH 7.6 (0.1M), MgCl^ (5mM) and Brij-35 
(0.1%, v/v) were mixed together and preincubated at 37 
for 5 minutes. The reaction was initiated by the addition 
of'microsomal suspension (0.1mg protein/ml) in a final 
reaction volume of 0.5ml. After incubation at 37° for 4 
minutes, the reaction was terminated by the addition of 
ice-cold 0.5M glycine-trichloroacetic acid buffer, pH 2.2 
(1.0ml). The incubates were extracted with chloroform 
(6.0ml) for 10 minutes on a rotary mixer, and centrifuged 
at 2000g for 5 minutes. Aliquots of the aqueous layer 
(0.5ml) were removed, and adjusted to a final volume of 
2.0ml with 1.0M glycine-NaOH buffer, pH 10.6. The 
fluorescent product was estimated using an excitation 
wavelength of 344nm. Appropriate blanks, and standards 
containing 1-naphthyl-$,D-glucuronide (40yM), were run 
in parallel.
The glucuronidation of 4-nitrophenol was measured 
by an adaptation of the method of Hanninen (1968).
Reagents
3.5mM 4-nitrophenol
0.2M Tris-HCl buffer, pH 7.6, containing 10mM
MgClg and 0.2% (v/v) Brij-35
7OmM UDP-glucuronic acid
170mM Trichloroacetic acid
5.0M NaOH
Method
UDP-glucuronic acid (3.OmM), 4-nitrophenol 
(0.35mM), Tris-HCl buffer, pH 7.6 (0.1M), Brij-35 (0.1% 
v/v) and MgCl^ (5.OmM) were mixed together to give a final 
volume of 60yl. After preincubation at 37 for 5 minutes, 
the reaction was started by the addition of microsomal 
suspension (0.25mg protein/ml), in a final reaction 
volume of 100yl. Incubation was continued for 10 minutes, 
and the reaction was then terminated by the addition of 
170mM trichloroacetic acid (0.9ml). After centrifugation, 
5.0M NaOH (0.1ml) was added to the supernatant, and the 
absorbance was measured at 400nm. Appropriate blanks, 
containing either no 4-nitrophenol or no UDP-glucuronic 
acid, were run in parallel. Standardisation was carried out 
using solutions of 4-nitrophenyl-$,D-glucuronide.
2.6.4. Glutathione S-transferase (E.C.4.4.1.7)
Glutathione S-transferase activity was measured 
by the method of Habig zt at. (1974), using 1-chloro-
2,4-dinitrobenzene as substrate.
Reagents
50mM 1-chloro-2,4-dinitrobenzene in ethanol
0.1M potassium phosphate buffer, pH 6.5
50mM glutathione in 0.1M potassium phosphate buffer,
pH 6.5
Method
Glutathione (1.0mM), 1 -chloro-2,4-dinitrobenzene
(1.0mM) and 0.1M potassium phosphate buffer, pH 6.5, were
mixed in two cuvettes to give a final volume of 2.5ml
in the reference cuvette and 2.4ml in the sample cuvette.
Both cuvettes were preincubated for 4 minutes at 25°,
and the reaction was initiated by the addition of soluble
fraction (5-1Oyg protein in 100yl) to the sample cuvette.
The change in absorbance was monitored at 340nm, and the
activity of glutathione S-transferase was calculated,
- 1  —  1using an extinction coefficient of 9.6mM cm .
2.6.5. Glucose-6-phosphatase (E.C.3.1.3.9)
Glucose-6-phosphate is metabolised by glucose-6- 
phosphatase to yield glucose and inorganic phosphate.
The inorganic phosphate so released may be estimated by 
any standard procedure. This glucose-6-phosphatase method 
is based on Hinton zt at. (1970), as modified by Prospero 
and Hinton (1973).
Reagents
0.3M 3,3-dimethylglutaric acid buffer, pH 6.5,
containing 0.025M EDTA and 0.03M Na(+)tartrate 
3.5mM D-glucose-6-phosphate, monosodium salt 
0.37M trichloroacetic acid
Method
Liver homogenate (0.1mg protein/ml), 3,3-dimethyl­
glutaric acid buffer, pH 6.5 (130mM), EDTA* (10mM) and 
sodium tartrate (13mM) were mixed in small test tubes on 
an ice bath. D-glucose-6-phosphate (350yM) was added 
rapidly to all tubes, and these were incubated for 20 
minutes at 37° in a shaking water bath (120 cycles/min).
A tissue blank was set up for each sample, in which
substrate was replaced by. distilled water. Substrate 
blanks (tissue replaced by distilled water) and reagent 
blanks (tissue and substrate replaced by distilled water) 
were also run. The reaction was stopped by the addition 
to all tubes of ice-cold trichloroacetic acid (0.22M), 
and the temperature was maintained at 4° for at least 15 
minutes. Protein was centrifuged out (20Q0g for 5 minutes) 
and the inorganic phosphate content of the supernatant 
was estimated by the procedure of Lowry and Lopez (1946), 
as adapted to the Autoanalyser by Marzban and Hinton 
(1970).
The phosphate is estimated by reaction with 
ammonium molybdate, followed by reduction of the resulting 
phosphomolybdate complex with ascorbic acid to yield 
’molybdenum blue’. The absorbance of this complex is 
measured at 721nm.
Reagents
0.03M ammonium molybdate containing 0.32M perchloric
acid
11.4mM ascorbic acid
245mM trichloroacetic acid (sample wash)
367mM trichloroacetic acid
0.1M potassium dihydrogen phosphate (stock standard)
Method
The Autoanalyser flow diagram is shown in Figure
2.3.
Sampling time was 48 seconds, with a wash of 
36 seconds.
Working standards of 0.25, 0.5, 0.75, 1.0, 1.5 
and 2.Oymoles/2.5ml were prepared from the stock phosphate 
solution, by dilution initially to 2.0ml, followed by 
the addition of trichloroacetic acid (220mM, 3.0ml). The 
absorbance of standards and samples was read at 721nm, and
Figure 2.3.
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the phosphate content of the samples was subsequently 
estimated from the standard curve.
From this, the glucose-6-phosphatase activity in 
liver may be calculated from:
Glucose-6-phosphatase (Exp-TB)-(SB-RB) x D
.... = x— c— — 7— :— r-— 7T~F umol/min/g liveractivity Inc. time(min) x 0.5 K
where: Exp is the amount of phosphate in the experimental
tube (ymol).
TB is the amount of phosphate in the tissue blank
(ymol).
SB is the amount of phosphate in the substrate blank
(ymol).
RB is the amount of phosphate in the reagent blank
(ymol).
D is the dilution factor for the liver homogenate
used in the assay.
2.6.6. A-Aminolaevulinic acid synthetase (ALA synthetase, 
E.C.2.3.1.37)
The method is essentially that of Gross and 
Hutton (1971), as modified by Marks zt at. (1973).
Reagents
0.1M Tris-HCl buffer, pH 7.2, containing 133mM glycine 
13.3mM EDTA and 0.265mM pyridoxal phosphate
1.5M trichloroacetic acid
1.0M potassium phosphate buffer, pH 6.8
5.0M NaOH
13.33M acetic acid, containing 1.27M perchloric acid,
122mM p-dimethylaminobenzaldehyde and 11.7mM 
HgCl^ (modified Ehrlich’s reagent)
Method
Supernatant protein (10000g fraction, 2-2.5mg 
protein/ml), 75mM Tris-HCl buffer, pH 7.2, glycine (99.8mM),
EDTA (9.98mM) and pyridoxal phosphate (0.2mM) were mixed 
together in each of two Soveril test tubes, and trichloro­
acetic acid (0.3M) was added to the blank. All tubes were 
incubated at 37° for 30 minutes in a shaking water bath 
(120 cycles/min), and trichloroacetic acid (0.3M) was then 
added to the test sample. The precipitated protein was 
pelleted by centrifugation (2000g for 5 minutes), and an 
aliquot of supernatant (2.0ml) was mixed with potassium 
phosphate buffer, pH 6.8 (313mM). Sodium hydroxide (l60mM) 
and ethyl acetoacetate (245mM) were added to each tube, 
and the tubes were stoppered and heated at 100° for 7 
minutes. After cooling, the contents were extracted with 
diethyl ether (3.0ml), which had previously been equilibrated 
with 1.0M potassium phosphate buffer, pH 6.8. The aqueous 
(lower) phase was removed, and the ether washed with 
1.0M NaOH (1.0ml). Modified Ehrlich’s reagent (4.0ml) 
was added to the combined aqueous solutions, and the 
mixture was allowed to stand for 20 minutes. The sample 
was scanned against the blank from 490 to 660nm, and the 
absorbance at 650nm subtracted from the' absorbance at
553nm. ALA synthetase activity was calculated using an
—  1 —  1extinction coefficient of 58mM cm 
2.6.7. Haem oxygenase
The method used was that of Tenhunen zt at.
(1970).
Reagents
0.1M potassium phosphate buffer, pH 7.4 
1.7mM haemin in 1.0M NaOH
27mM NADPH in 0.1M potassium phosphate buffer, pH 7.4
Method
Supernatant protein (10000g fraction, about
3mg protein/ml), 100mM phosphate buffer, pH 7.4 and
haemin (17yM), in a final incubation volume of 3*Oml,
were placed in each of two cuvettes maintained at 37°.
After preincubation for 5 minutes, NADPH (l80yM) was added
to the sample cuvette to initiate the reaction. Bilirubin
production was monitored at 468nm, and the rate of reaction
- 1  _ 1
calculated using an extinction coefficient of 30mM cm 
The 10000g supernatant served as a source of biliverdin 
reductase.
2.7. Other Non-Enzymic Components of Liver
2.7.1. Glycogen
Small pieces of liver are digested in potassium 
hydroxide solution; subsequent analysis of the amount of 
glucose derived from glycogen gives the liver glycogen 
conterrt in glucose equivalents/g tissue.
Reagents
5.36M KOH
12.9mM anthrone in 13.5M H^SO^
0.1M and 0.2M standard glucose solutions
Method
Small pieces of liver (about 0.5g) were placed 
in preweighed tubes containing 5.36M KOH (3.0ml), and the 
tubes reweighed to calculate the exact amount of liver 
taken. The tubes were heated on a boiling water bath for 
30 minutes, cooled, and the contents made to a volume 
of 10.0ml with distilled water. Further dilutions were 
carried out to bring the glucose concentrations into an 
appropriate range. Aliquots of water, standards or tests 
(1.0ml) were placed in tubes cooled in ice-water, and 
anthrone (10.3niM) in sulphuric acid (10.8M) was added.
The tubes were covered and boiled for exactly 10 minutes 
on a water bath. After rapid cooling, tests and standards 
were read at 620nm against the water blank, and tissue 
glycogen concentrations were calculated as ymol glucose 
equivalents/g liver.
2.7.2. Glutathione
The method is based on that of Saville (1958), 
and actually measures total non-protein thiol groups vZa 
the production of an azo dye complex.
Reagents
0..27M H^SO^, containing 1. OmM NaN02
44mM ammonium sulphamate
0.4M HC1, containing 7.4mM HgCl^ and 158mM
sulphanilamide
0.4M HC1, containing 3.9mM A/-1 -naphthylethylene-
diamine hydrochloride (freshly prepared)
0,61M trichloroacetic acid
0.325mM stock glutathione standard in 400mM trichloro­
acetic acid
Method
Liver homogenate (5mg protein/ml) was mixed with 
trichloroacetic acid (0.4M), and protein allowed to 
precipitate at 4° for 15 minutes before centrifugation 
(2000g for 5 minutes). Aliquots of supernatant (0.1ml) 
were mixed with NaNO^ (0.83mM) and H^SO^ (0.225mM), and 
allowed to stand for 5‘ minutes. A range of standard 
glutathione solutions (0.065, 0.130, 0.195, 0.260, 0.325mM) 
was prepared from the stock glutathione, and aliquots 
(0.1ml) treated in the same manner as the samples. Ammonium 
sulphamate (11mM) was added, and the mixtures left for 
a further 5 minutes. Sulphanilamide (6lmM), HgCl^ (2.85mM), 
A/-1-naphthylethylenediamine (1.2mM) and HC1 (0.277M) were 
added, and the resulting solutions were allowed to stand 
for 10 minutes. The absorbance of standards and tests 
was recorded at 546nm against a reagent blank, and homo­
genate glutathione concentrations were derived from the 
standard curve.
2.8. Sodium Dodecyl Sulphate-Polyacrylamide Disc Gel
Electrophoresis of Microsomal Proteins
Microsomal proteins were separated and analysed 
by the method of Laemmli (1970). Microsomal suspensions 
are initially solubilised with sodium dodecyl sulphate, 
and subsequently resolved on a polyacrylamide gel, using 
a discontinuous buffer system.
Reagents
Gel stock: 30% (w/v) acrylamide, containing 0.8%
(w/v) N,N’-methylenebisacrylamide
Buffer 1: 1.5M Tris-HCl, pH 8.8, containing 0.4%
(w/v) sodium dodecyl sulphate
Buffer 2: 0.5M Tris-HCl, pH 6.8, containing 0.4%
(w/v) sodium dodecyl sulphate
Buffer 3: 25mM Tris-HCl, pH 8.3, containing 192mM
glycine and 0.1% (w/v) sodium dodecyl 
sulphate
Buffer 4: 62.5mM Tris-HCl, pH 6.8, containing 2.3%
(w/v) sodium dodecyl sulphate, 15% (v/v) 
glycerol, 5% (v/v) 2-mercaptoethanol and 
0.001% (w/v) bromophenol blue
10% (w/v) ammonium persulphate
Method
A vertical slab gel apparatus made in the workshop 
of the Biochemistry Department, University of Surrey, was 
used. The gel was poured in a glass and perspex cuvette 
of internal dimensions 120mm x 100mm x 1.5mm. Electrophoresis 
was performed at room temperature.
The glass plates forming the faces of the gel 
cuvette were washed in detergent, rinsed with tap water, 
distilled water, methanol and acetone, and allowed to dry. 
After dry assembly, the cuvette was sealed with 1.5% (w/v) 
molten agar, and clamped in a vertical position. The lower 
(running) gel was prepared by mixing buffer 1 (10ml),
gel stock (13.3ml) and distilled water (16.6ml), and 
polymerisation was initiated by the addition of N,N'- 
tetramethylethylenediamine (20yl) and freshly prepared 
ammonium persulphate solution (240yl). This solution was 
poured into the cuvette to form a gel of height 8.0cm.
A layer of distilled water was introduced above the gel 
mixture to ensure a flat interface between the separating 
gel and stacking gel after polymerisation. The upper 
(stacking) gel was prepared by mixing buffer 2 (2.5ml), 
gel stock (1.0ml), distilled water (6.5ml), ammonium 
persulphate solution (60yl) and W,W’-tetramethylethylene- 
diamine (20yl). When polymerisation of the running gel 
was complete, the water layer was removed and the stacking 
gel mixture added to the cuvette. A perspex comb was 
introduced into the stacking gel before polymerisation to 
form the sample wells. After complete polymerisation, the 
comb was removed, and a small amount of buffer 3 was 
introduced into the sample wells to maintain their shape. 
The lower perspex spacer was removed from the cuvette, 
and the assembly placed in the electrophoresis tank.
Buffer 3 was added to both upper and lower reservoirs, 
and air bubbles trapped underneath the gel were removed, 
using a syringe.
Microsomal suspensions were diluted with buffer 4 
to a final concentration of 1.Omg protein/ml, and the 
diluted samples were boiled on a water bath for 3 minutes. 
After cooling, the samples were applied to the stacking 
gel, typically at a level of 15yg protein per 3mm linear 
width of sample well. A constant current of 20mA was 
applied until the bromophenol blue entered the running gel, 
and the current was then increased to 40mA until the 
bromophenol blue was within 5mm of the end of the gel.
The cuvette was removed from the tank after completion 
of electrophoresis, the glass plates and stacking gel 
were separated from the running gel, and the latter was
stained as described below.
Measurement of molecular weight was carried out 
by plotting a graph of log^ Q(molecular weight) vzsiAu* 
mobility for standard proteins, and employing interpolation 
to derive the molecular weights of unknown proteins. A 
typical standard curve is shown in Figure 2.4.
Detection of proteins on polyacrylamide gels
Staining of the protein bands was carried out 
by immersing gels overnight in propan-2-ol/acetic acid/water 
(5:2:13, v/v), containing 0.5$ (w/v) Coomassie Blue R-250. 
The gel background was destained by immersion in progressive 
changes of propan-2-ol/acetic acid/water (1:1:8, v/v) over 
a period of 48 hours. Gels were stored in 3% (v/v) glycerol, 
containing sodium azide (1.0mM) at 4° after clearing.
Figure 2.4.
SDS-Polyacrylamide gel electrophoresis of standard molecular weight 
proteins .
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Mobility
A series of standard molecular weight proteins were dissolved in 62.5mM 
Tris-HCl, pH 6.8, containing 2.3$ (w/v) SDS, 15$ (v/v) glycerol, 5$
(v/v) mercaptoethanol and 0.001$ (w/v) bromophenol blue. Proteins (1.5mg 
each) were applied to the gel in parallel with the solubilised microsomal 
samples. The standard proteins were: phosphorylase a (92500), bovine 
serum albumin (68000), catalase (60000), glutamate dehydrogenase 
(53000), chick egg albumin (43000), creatine phosphokinase (40000) and 
lactate dehydrogenase (36000). Molecular weights of microsomal proteins 
were determined by interpolation from a plot of l°g-|Q molecular weight 
veAAuA mobility of the standard proteins.
2.9. Preparation of Serum
Blood obtained from the vena cava of rats under
RSagatal anaesthesia was taken into plain glass tubes and 
allowed to coagulate at 37° for 30 minutes. Clots were 
rimmed gently with a sealed Pasteur pipette, and then 
centrifuged (2000g for 10 minutes). Serum was removed, 
using a drawn-out Pasteur pipette, and stored at 4° in 
clean containers until required.
2.10. Serum Enzyme Activity Estimations
Serum enzyme activity assays were controlled by 
the use of Sigma enzyme control sera 2-N and 2-E (Sigma 
London Chemical Co. Ltd., Poole, Dorset). Interference 
with the assays by the compounds administered was monitored 
by the addition of those compounds in increasing amounts 
to control sera, with subsequent reassay of the enzyme 
activity. Generally, no interference was noted, except at 
high concentrations of the added compound.
2.10.1. Serum alanine aminotransferase (A1AT, E.C.2.6.1.2)
The method is adapted from the optimised conditions
described by the Scandinavian Society for Clinical Chemistry 
(1974).
A1AT
L-alanine + 2-oxoglutarate------•►pyruvate + L-glutamate
rr+ Lactate dehydrogenase T , , , ' TT ^pyruvate + NADH + H ------------ - ------->• L-lactate + NAD + H^O
Oxidation of NADH is monitored at 340nm, and is
directly proportional to A1AT activity.
Reagents
86mM Tris-HCl, pH 7.4, containing 444mM L-alanine,
200yM NADH, 2222U/1 lactate dehydrogenase 
(E.C.1.1.1.27, bovine heart) and 5.55mM EDTA
364mM 2-oxoglutarate in 86mM Tris-HCl, pH 7.4
Method
Buffered substrate (0.9ml) and serum (67yl) were
placed in a cuvette maintained at 30°. After 5 minutes’
preincubation the reaction was initiated by the addition
of 2-oxoglutarate (33yl, 12mM) and the rate of change of
absorbance at 340nm was monitored. Serum A1AT activity was
- i - 1estimated, using an extinction coefficient of 6.22mM cm
2.10.2. Serum aspartate aminotransferase (AsAT, E.C.2.6.1.1)
AsATL-aspartate + 2-oxoglutarate------ ►oxaloacetate + L-glutamate
oxaloacetate + NADH + H+ -Mal^.-?..j.ehydrogenase »L-malate + NAD+ + H20
The rate of decrease of absorbance at 340nm due 
to the formation of NAD+ is directly proportional to the 
rate of production of oxaloacetate, and, hence, to AsAT 
activity. The method is based on that of the Expert Panel 
on Enzymes of the International Federation of Clinical 
Chemistry (1977).
Reagents
86mM Tris-HCl, pH 7.8, containing 222mM L-aspartate, 
200yM NADH, 667U/1 lactate dehydrogenase 
(E.C.1.1.1.27, bovine heart) and 667U/1 malate 
dehydrogenase (E.C.1.1.1.37, porcine heart)
364mM 2-oxoglutarate in 86mM Tris-HCl, pH 7.8
Method
Buffered substrate (0.9ml) and serum (67yl) were 
mixed in a cuvette and preincubated for 5 minutes at 30° 
in a thermostatted cuvette holder. The reaction was
started by adding 2-oxoglutarate (33yl), and the resulting 
decrease in absorbance at 340nm was monitored. AsAT 
activity was calculated by use of an extinction coefficient 
for NADH of 6.22mM” 1 cm” 1.
2.10.3* Serum alkaline1 phosphatase (E.C.3.1.3.1)
The hydrolysis of p-nitrophenyl phosphate by 
alkaline phosphatase yields p-nitrophenol and inorganic 
phosphate. At pH 10.3, the p-nitrophenol exists as a 
yellow phenoxide, with an absorbance maximum at 402.5nm.
The method is based on that of Bowers and McComb (1975). ,
Reagents
1.5mM MgCl2 .6H20
225mM p-nitrophenylphosphate in 1.5mM MgClp.6HpO, 
freshly prepared
890mM 2-amino-2-methyl-1-propanol buffer, pH 10.3
Method
Serum (33yl) and 2-amino-2-methyl-1-propanol
buffer, pH 10.3 (800mM) were placed in a cuvette and
preincubated for 5 minutes at 30°. The reaction was
initiated by adding p-nitrophenyl phosphate (l4.67mM), and
the production of p-nitrophenol was monitored at 402.5nm.
Alkaline phosphatase activity was calculated using an
-1 -1extinction coefficient of l8.8mM cm .
2.10.4. Serum y-glutamyl transferase (yGT, E.C.2.3.2.2)
The assay is based on the method of Szasz (1969), 
in which the rate of production of 4-nitroanilide is 
considered to be proportional to the rate of transfer of 
the glutamyl group from L-y-glutamyl-4-nitroanilide to 
glycylglycine by yGT.
Reagents
0.2M 2-amino-2-methyl-1,3-propanediol, pH 8.5,
containing 44mM glycylglycine
120mM L-y-glutamyl-4-nitroanilide in 150mM HC1
Method
Serum (67yl) and 0.2M 2-amino-2-methyl-1 , 3- 
propanediol buffer, pH 8.5, containing 44mM glycylglycine 
(0.9ml) were mixed in a cuvette and allowed to reach a 
temperature of 30°. L-y-glutamyl-4-nitroanilide (3.96mM) 
was added, and the rate of increase of absorbance at 405nm
was monitored. yGT activity was calculated using an
-1 -1 '
extinction coefficient of 9.9mM cm
2.10.5. Serum 5 1-nucleotidase (5TN T , E .C .3.1.3.5)
5’NTAdenosine monophosphate----- ► adenosine + inorganic phosphate
. , . Adenosine deaminase . , „TT +.Adenosine---------------------- - m o s m e  + ammonia (as NH^ )
0 n , . .T.nn tt+ L-Glutamate dehydrogenase _ , ,NH^ + 2-oxoglutarate + NADH + H ------------------------- - L-glutamate
+ NAD+ + H20
The rate of oxidation of NADH is directly 
proportional to the rate of adenosine formation (and, 
hence, 5 ’NT activity), and may be measured by monitoring 
the decrease in absorbance at 340nm. The method used is 
adapted from that of Arkesteijn (1976).
Reagents
44.4mM barbitone buffer, pH 7.5, containing 2.22mM
NADH, 4mM 2-oxoglutarate, >10000U/1. L-glutamate 
dehydrogenase (E.C .1.4.1.2, bovine liver),
>400U/1 adenosine deaminase (E.C .3•5.4.4, 
calf intestine) and 2.75mM sodium 3-glycero­
phosphate
91mM adenosine monophosphate in 42.9mM barbitone
buffer, pH 7,5
Method
Serum (67yl), 40mM barbitone buffer, pH 7.5,
NADH (2.0mM), 2-oxoglutarate (3.6mM), L-glutamate de­
hydrogenase (>9000U/1), adenosine deaminase (>360U/1) 
and sodium 3-glycerophosphate (2.48mM) were mixed, and 
allowed to equilibrate at 30° for 5 minutes in a thermo- 
statted cuvette holder. The reaction was initiated by the 
addition of adenosine monophosphate (3.0mM) and the
decrease in absorbance at 340nm was monitored. An extinction
- 1 -1coefficient of 6.22mM cm was used to calculate the 
5 ’NT activity.
2.10.6. Serum sorbitol dehydrogenase (E.C .1.1.1.14)
Sorbitol dehydrogenase catalyses the following
reaction:
D(-)fructose + NADH + H+ :----  D-sorbitol + NAD+
The rate of oxidation of NADH, monitored at 
340nm, is a measure of the sorbitol dehydrogenase activity. 
The method is an adaptation of that of Wiesner dt at,
(1965).
Reagents
150mM Tris-HCl buffer, pH 7.5, containing 150yM
NADH, freshly prepared
4.0M 3-D(-)fructose
Method
Serum (250yl), Tris-HCl buffer, pH 7.5 (100mM) 
and NADH (100yM) were mixed in a cuvette maintained at 25 
in a thermostatted cuvette holder. After preincubation for 
15 minutes, the reaction was initiated with 3-D(-)fructose 
(0.67M), and the absorbance at 340nm was read at one minute 
intervals for 5 minutes. Serum sorbitol dehydrogenase 
activity was subsequently calculated, using an extinction 
coefficient for NADH o f -6.22mM“1 cm” 1.
2.11. Non-Enzymic Constituents of Serum
2.11.1,, Serum bilirubin
Two forms of serum bilirubin may be distinguished 
by a diazo reaction. Water-soluble bilirubin conjugates 
are diazotised in the absence of an ’accelerator’ (direct 
bilirubin), whereas the unconjugated, albumin-bound form 
reacts in the presence of an accelerator (indirect bilirubin). 
The method used is based on Michaelsson’s (1961) modification 
of the approach of Jendrassik and Grof (1938).
Reagents
Diazo reagent, freshly prepared by mixing 28.9mM 
sulphanilic acid (10ml) with 72.5mM sodium 
nitrite (0.25ml)
2.5M sodium hydroxide, containing 1.88M sodium
potassium tartrate
227mM ascorbic acid, freshly prepared
0.92M sodium acetate trihydrate, containing 520mM
sodium benzoate, 258mM caffeine and 3.42mM EDTA
Bilirubin reference serum (Sigma London Chemical Co.
Ltd., Poole, Dorset)
Method
For each test, and the reference serum, 0.1ml 
of serum was placed into each of three test tubes. These 
were treated as follows:
Total bilirubin. Diazo reagent (0.25ml) was added and
mixed with the serum, followed by caffeine-benzoate- 
acetate solution (1.0ml). After standing for 10 
minutes, ascorbic acid (50yl) was added, followed at 
once by alkaline tartrate (0.75ml)
Conjugated (direct) bilirubin. Diazo reagent (0.25ml) 
was added and mixed with the serum, and the tube 
was allowed to stand for 10 minutes. Ascorbic acid 
(50yl) was then added, followed at once by caffeine- 
benzoate-acetate solution (1.0ml) and alkaline 
tartrate (0.75ml).
Blank. The following reagents were added, with mixing, 
in the given order: ascorbic acid (50yl), diazo 
reagent (0.25ml), caffeine-benzoate-acetate solution 
(1.0ml) and alkaline tartrate (0.75ml).
The absorbance at 600nm was read as soon as 
possible after the addition of alkaline tartrate solution. 
Bilirubin concentrations were determined by assuming the 
extinction coefficient of alkaline azobilirubin to be 
73mM” 1 cm” 1.
Note: biliary bilirubin concentrations were determined 
by essentially the same method.
2.11.2. Serum total protein
Cupric sulphate in alkaline solution (Biuret 
reagent), stabilised with tartrate, reacts with protein to 
yield purple copper/protein complexes, with an absorption 
maximum at 545nm. The colour intensity is proportional 
to the serum total protein concentration. The Biuret 
reagent used here is based on that of Gornall dt at. (1949).
Reagents
0.75M NaOH, containing 6mM CuSO^. 51^0, 20mM sodium 
potassium tartrate and 20mM potassium iodide
(Biuret reagent)
Protein standard solution, containing 5g/dl rat
serum albumin and 3g/dl human serum globulin
Method
Serum (20yl), or total protein standard (20yl) , 
was mixed with Biuret reagent (1.0ml), and allowed to 
stand for 15 minutes at room temperature, before reading 
against a reagent blank at 540nm. Serum total protein 
concentration was calculated from the ratio of absorbance 
of the sample to that of the standard.
2.11.3* Serum albumin
At acidic pH, albumin binds bromocresol green to 
yield an intense blue albumin-bromocresol green complex, 
with an absorbance at 632nm that is proportional to the 
concentration of albumin present. The method is adapted 
from that of Doumas and coworkers (1971), as modified by 
Spencer and Price (1977).
Reagents
80yM bromocresol green in 50mM succinate buffer, 
pH 4.1, containing 1.54mM sodium azide
5g/dl bovine serum albumin in distilled water
Method
Serum (20yl) was added to bromocresol green 
solution (4.0ml), and allowed to stand for at least 10 
minutes at room temperature, before reading against a 
blank of dye solution at 632nm. A standard solution of 
bovine serum albumin was treated identically, and the 
serum albumin concentration was calculated from the ratio 
of absorbances at 632nm.
2.11.4. Serum glucose
^ „ Glucose oxidase , . • OTT ~Glucose + 2H20 + 0^ ------------------ ►gluconic acid +
Peroxidase
^2^2 + c'_d^an^s^dine ------------ ►•oxidised O-dianisidine
The absorbance due to oxidised o-dianisidine 
is measured at 450nm, and is proportional to the glucose 
concentration. The method is an adaptation of those of 
Huggett and Nixon (1957) and Raabo and Terkildsen (1960).
Reagents
250mM sodium phosphate buffer, pH 6.8, containing
>5000U/1 glucose oxidase (E.C .1.1.3.4, A^pe*.- 
gilluA ntgdsi), >1000 purpurogallin units/1 
horseradish peroxidase (E.C .1.11.1.7) and 1.55mM 
o-dianisidine HC1, freshly prepared (glucose 
colour reagent)
5.55mM glucose in 0.1% benzoic acid
Method
Serum (10yl) was added to glucose colour reagent 
(2.0ml) and‘incubated for 30 minutes at 37°. A series of 
glucose standard solutions (1.11, 2.22, 3-33, 4.44, 5.55mM 
glucose) and a reagent blank were treated in the same 
manner. The absorbance at 450nm of standards and tests 
was read against the reagent blank, and serum glucose 
concentrations were calculated from the standard curve.
2.11.5. Serum total cholesterol and high-density lipo­
protein (HDL) cholesterol
The method is based on that of Allain zt at.
(1974). Low-density lipoprotein (LDL), very low-density 
lipoprotein (VLDL) and chylomicrons are precipitated with 
a phosphotungstate/Mg + reagent (Burstein zt al., 1970), 
leaving HDL in solution. HDL cholesterol and total cholesterol 
may each then be separately estimated by the same method.
r. 4. a  u  i ■> Cholesterol ester , , _ _ ^Estenfied cholesterol----- — -—  -------- ► cholesterol + fatty acidshydrolase J
n u  n *. n o  Cholesterol oxidase TT «Cholesterol + 0^----------- :-----------^cholest-4-en-3-one +
Peroxidase
^2^2 + 4-aminophenazone + phenol  quinoneimine dye
Reagents
50mM Tris-HCl buffer, pH 7.0, containing 1.OmM 
4-aminophenazone, 6.8mM phenol, >4000U/1 
peroxidase, >125U/1 cholesterol oxidase, >100U/1 
cholesterol ester hydrolase and 25mM sodium 
cholate (enzymic colour reagent)
15.6mM phosphotungstic acid, containing l60mM NaOH
1.8MMgCl2
Cholesterol stock standard, 250mg/dl in 225mM NaCl
Method
For the estimation of HDL cholesterol, serum 
(0.4ml), phosphotungstic acid (1'.42mM) and NaOH (l4.5mM) 
were mixed in centrifuge tubes, and then MgCl^ (40mM) was 
added. The tubes were centrifuged at 10000g for 10 minutes, 
and aliquots of supernatant (50yl) were removed and added 
to enzymic colour reagent (1.0ml). Aliquots (50yl) of 
water, and of cholesterol standards, were treated in the 
same manner. All tubes were incubated at 37° for 15 
minutes, and the absorbance at 500nm was read. Serum 
HDL cholesterol concentrations were calculated by comparison 
with the standards, making allowance for the dilution 
due to the initial precipitation of lipoprotein.
For the estimation of serum total cholesterol, 
aliquots (100yl) of serum/ water or cholesterol standards 
(150, 200 and 250mg/dl) were added to enzymic colour reagent 
(1.0ml) in cuvettes, and incubated at 37° for 15 minutes.
The absorbance at 500nm was recorded, and the serum total 
cholesterol concentrations thus calculated.
HDL Cholesterol Control-L and HDL Cholesterol 
Control-H sera (Sigma London Chemical Co. Ltd., Poole, 
Dorset) were assayed as a quality control procedure.
2.11.6. Serum urea nitrogen
tt tt n Urease .TtJ +Urea + H ^ O --------► NH^ + CO^
2-Oxoglutarate + NH„+ + NADH Glutamate— ---►glutamate + NAD+
& 4 dehydrogenase
The reaction is allowed to go to completion; 
thus the amount of NAD+ formed is directly proportional 
to the amount of urea nitrogen present in the sample. The 
method is adapted from that of Hallett and Cook (1971).
Reagents
66mM potassium phosphate buffer, pH 7.6, containing 
200yM NADH, 1.OmM 2-oxoglutarate, >1500U/1 
urease (E.C .3.5.1.5, Jack bean), >10000U/1 
glutamate dehydrogenase (E.C.1.4.1.2, bovine 
liver), freshly prepared
10mM urea nitrogen reference solution in 0.1% benzoic
acid
Method
Potassium phosphate buffer, pH 7.6 (66mM, 3•0ml),
containing 200yM NADH, 1 .OmM 2-oxoglutarate, >1500U/1
urease and >10000U/1 glutamate dehydrogenase was placed in
a cuvette, and the absorbance was read at 340nm. Serum
(5yl) was added, and the solution was mixed. The urea
nitrogen reference solution was treated similarly. After
a 5 minute incubation period at 37°, the final absorbance
was recorded at 340nm. Serum urea nitrogen concentration
was calculated from the difference in absorbance readings
at the beginning and the end of the incubation, employing
-1 -1an extinction coefficient for NADH of 6.22mM cm
2.12. Serum and Bile Immunoelectrophoresis
Serum was subjected to immunoelectrophoresis by 
a standard rocket technique (Axelsen zt at., 1973), using 
antisera raised in rabbits against rat Immunoglobulin A 
(IgA), and against IgA Free Secretory Component (FSC). 
Duplicate glass plates were coated with 1.0% agarose in 
barbitone-acetate buffer, pH 8.6 (0.1M), containing either 
the anti-IgA or the anti-FSC antibody. Serum (5yl) was 
placed in wells cut in the agarose. A constant voltage of 
40V was applied for 24 hours, and the plates were then 
washed, dried and stained with Coomassie Brilliant Blue 
R-250 (5g/l, w/v, in ethanol/water/glacial acetic acid,
4 . 5 : 4 . 5 : 1 ,  v / v ) .
Occasionally, bile collected by cannulation of 
the common bile duct was investigated, using Laurell 
immunoelectrophoresis (Axelsen zt at., 1973), and employing 
an antiserum raised in rabbits against whole rat bile 
(used by the kind- permission of Dr B.M. Mullock and 
Dr R.H. Hinton). Samples (5yl) were electrophoresed 
initially on glass plates coated with plain 1.0% agarose . 
in barbitone-acetate buffer, pH 7.5 (0.1M) at about 200V 
and 20mA per plate. The excess agar was removed, and replaced 
with 1.0% agarose in barbitone-acetate buffer, pH 7.5 
(0.1M), containing the rabbit anti-(rat bile) antiserum. 
Electrophoresis was carried out in the second dimension 
(45V, 16 hours), and the plates were then stained with 
Coomassie Brilliant Blue R-250, as described above.
2.13. Haematology
2.13.1. Preparation of blood samples
RVena caval blood, obtained under Sagatal 
anaesthesia, was taken into tubes containing disodium EDTA 
(1.Omg/ml blood) and mixed thoroughly. Haematological 
parameters were measured during the day on which the blood 
was taken.
2.13.2. White blood cell and red blood cell counts
For white blood cell counts, whole blood was
Rdiluted 1 in 500 with Isoton (Coulter Electronics Ltd.,
Harpenden, Hertfordshire), and 3 drops per 10ml of
ZAPonin (Coulter Electronics Ltd.) were added. The diluted
sample was mixed by gentle inversion, and left for 8
minutes to ensure the complete lysis of red blood cells
and platelets. White cell counts were carried out within
R30 minutes, typically in a Coulter Dn counter (Coulter
Electronics Ltd.), with the aperture control set at ’2 ’,
and a threshold level of 14.
For red blood cell counts, whole blood was diluted' 
R1 in 50000 with Isoton and counted within 30 minutes,
Rusually in the Coulter model Dn counter. Aperture current
was set at ’2', and the threshold level at ’11’.
ROccasionally, a Coulter model S counter (Coulter 
Electronics Ltd.) was used for both red and white blood 
cell counts. In either case, coincidence corrections were 
made to the counts where appropriate.
2.13.3. Packed cell volume
Whole, anticoagulated blood was taken into plain 
glass capillary tubes, and one end was sealed by gentle 
heating in a Bunsen burner flame. The tubes were centrifuged
at 12000g for 5 minutes in a Microhaematocrit centrifuge 
(MSE Ltd., Crawley, Sussex), and the packed cell volume 
was read by means of a Microhaematocrit reader (MSE Ltd.). 
When the packed cell volume was greater than 50%, the blood 
was recentrifuged for 5 minutes, and the reading repeated.
2.13.4. Haemoglobin
At alkaline pH, potassium ferricyanide oxidises 
haemoglobin and its derivatives, except sulphaemoglobin, 
to methaemoglobin. Methaemoglobin reacts with potassium 
cyanide to form cyanmethaemoglobin. The absorbance, at 
540nm is proportional to the total haemoglobin concentration 
in blood. The method is based upon that of Drabkin and 
Austin (1935).
Reagents
1.04mM potassium dihydrogen phosphate, containing
6l0yM potassium ferricyanide, 770yM potassium 
cyanide and 0.05% (v/v) Brij-35 (Drabkin’s
solution)
Methaemoglobin standard, reconstituted with Drabkin’s 
solution to give an absorbance at 540nm 
equivalent to that of a whole blood sample 
containing l8g/dl haemoglobin (Sigma London 
Chemical Co. Ltd., Poole, Dorset)
Method
RVenous blood, obtained under Sagatal anaesthesia, 
and taken into EDTA anticoagulant, was thoroughly mixed. 
Aliquots (20yl) were added to Drabkin’s solution (5.0ml), 
and allowed to stand for at least 15 minutes at room 
temperature. A range of standards (equivalent to whole 
blood samples containing 6.0, 12.0 and l8.0g/dl haemoglobin) 
was prepared by diluting the cyanmethaemoglobin stock 
solution with Drabkin’s reagent. Standards and samples were 
read against a Drabkin’s solution blank at 540nm.
2.13.5. Mean cell volume (MCV)
The mean volume of one red blood cell was calculated 
by the following formula:
mr\r - volume of red cells in 1 litre of blood 
red cell count (cells/litre")
The final volume is expressed in femtolitres (fl).
2.13.6. ' Mean cell haemoglobin (MCH)
The mean cell haemoglobin was calculated as
follows:
Mptt _ haemoglobin concentration (g/dl) 
red cell count (cells/litre)
and expressed in picograms (pg).
2.13-7. Mean cell haemoglobin concentration (MCHC)
The average concentration of haemoglobin in 
red blood cells was calculated thus:
Mr*un haemoglobin concentration (g/dl)
MCHC =  - ~ T c TTJ1----------- -------
and expressed as a percentage.
2.14. Urinalysis
Fresh urine samples obtained from the bladder at 
post-mortem, or by 24-hour collection from animals in 
metabolism cages, were screened routinely for pH, and for 
the presence of protein, glucose, ketones, bilirubin and 
blood, using Bili-Labstix reagent test strips (Ames Co., 
Stoke Poges, Slough, Berks.).
In certain cases, the absence, or presence and 
identity, of urinary sugars was confirmed by employing 
thin-layer chromatography on Silica Gel, G (Merck GmbH, 
Darmstadt, West Germany). Aliquots (5yl) of undiluted 
urine were used, and the plates were developed in n-butanol/ 
acetic acid/water (75:25:6, v/v). Monosaccharide sugars 
were visualised with aniline-diphenylamine reagent (10 
volumes of 11OmM aniline and 59mM diphenylamine in acetone 
pluA 1 volume o^tAophosphoric acid, s.g. = 1.75), and 
heating at 110° for 5 minutes.
Occasionally, the osmolality of urine samples 
was measured, using a Wescor 5100C Vapor Pressure Osmometer 
(Wescor Inc., Main Street, Logan, Utah, 84321, USA).
2.15. Salivary Amylase
Salivary amylase activity was measured by employing 
a dye release method (Phadebas Amylase Test, Pharmacia 
Diagnostics AB, Uppsala, Sweden). The substrate is a 
water-insoluble, cross-linked starch polymer, carrying 
a blue dye. It is hydrolysed by a-amylase to water-soluble 
blue fragments, the absorbance of which at 620nm is 
proportional to the amylase activity.
Method
Saliva was diluted 4-fold, and aliquots (50yl) 
were added to distilled water (4.0ml) and preincubated at 
3.7° for 5 minutes. One 'tablet* of substrate was added 
to each tube, rapidly vortex-mixed, and the samples were 
incubated at 37° for a further 15 minutes. The reaction 
was stopped with NaOH (0.5M, 1.0ml), and the mixture 
was filtered through the filter paper supplied with the 
test kit. The filtrate was read at 620nm against a distilled 
water, blank that had been taken through the same procedure. 
Amylase activities were read from the matched standard 
curve included with the kit.
2.16. Histological Procedures
2.16.1. Preparation of samples
Pieces of tissue obtained at post-mortem were 
taken into 10% neutral buffered formalin (NBF), Bouin’s 
fixative and Rossman’s fixative respectively. In the last 
case, slices of 1.5mm or less in thickness were used, to 
ensure the rapid penetration of the fluid. Tissue treated 
with NBF was allowed to remain in the fixative for at 
least 2 weeks. Bouin’s fluid was decanted after 36-48 
hours, and the tissue blocks washed in progressive changes 
of 70% ethanol. Liver slices in Rossman’s fluid were fixed 
for only 12-18 hours before the fluid was decanted and 
replaced with progressive changes of 100% ethanol, until 
most of the yellow colour had been removed from the 
tissue.
Tissue for haematoxylin and eosin staining 
(NBF- or Bouin’s fluid-fixed), or periodic acid-Schiff 
-treatment (Rossman’s fluid-fixed) was dehydrated"in 
increasing concentrations of ethanol, cleared in toluene 
and impregnated with paraffin wax. Sections (7ym) were 
cut, taken on to glass slides, and allowed to dry at 37°.
2.16.2. Haematoxylin and eosin
Sections were brought to water, stained in 
Ehrlich’s acid haematoxylin (15 minutes), and blued in 
tap water (5 minutes). Following differentiation with 
acid alcohol (5 seconds), they were returned to tap water, 
and counterstained with 1% aqueous eosin (2 minutes).
The sections were rinsed in tap water (30 seconds), 
dehydrated in 85% ethanol (30 seconds) and 100% ethanol 
(2 x 30 seconds), cleared in xylene, and mounted in 
D.P.X. (British Drug Houses Ltd., Poole, Dorset).
2.16.3* Periodic acid-Schiff (PAS) stain for glycogen
(after Culling, 197-4)
Sections were brought to water and oxidised in 
1 % aqueous periodic acid (5-10 minutes). After washing in 
tap water (5 minutes) and distilled water, sections were 
treated with Schiff reagent (10-30 minutes), washed again 
in tap water (10 minutes), dehydrated, cleared, and mounted 
in D.P.X. PAS-positive substances stain red. Further 
sections treated with diastase were stained to check the 
specificity of the reaction for glycogen.
2.16.4. Oil Red 0 (PRO) stain for lipids
(after Culling, 1974)
Reagents
Stock Oil Red 0, 0.5% in isopropanol
Diluted 0R0 for use: stock 0R0 (6ml) added to 
distilled water (4ml), allowed to stand for 10 
minutes, and then filtered
Method
Tissue dehydrated, cleared and embedded in 
paraffin wax in the normal manner cannot be used, since 
the organic solvents employed remove lipids. Accordingly, 
blocks of liver fixed in NBF were frozen, and sections 
(7ym) cut on a cryostatted microtome. The sections were 
washed in water, and placed in the diluted 0R0 solution 
for 10-15 minutes. After differentiation in 60% ethanol, 
the sections were washed in water, counterstained with 
haematoxylin, blued in tap water, and mounted in glycerin 
jelly. Lipids stain bright red, and nuclei blue.
2.17. Histochemical Procedures
2.17.1. Preparation of tissue for histochemistry
A chilling bath was prepared according to the 
method of Chayen <it at. (1973). The bath consisted of an 
enclosed polythene box, contained in a block of expanded 
polystyrene. Ethanol (100%) or methylated spirits were 
placed in the polythene box, and small chips of solid 
carbon dioxide were added until a saturated solution was 
obtained. This was determined by the increased viscosity 
of the alcohol-CO^ mixture, the cessation of bubbling 
upon adding more CO^, and the recording of a temperature 
lower than -67 .
A beaker containing hexane (about 30ml) was 
inserted into the bath through a close-fitting aperture 
cut in the lid. More solid CO^ was added to maintain the 
temperature.
Liver obtained immediately post-mortem was cut 
into blocks approximately 4mm on a side, and dropped into 
the hexane at a temperature below -67°, ensuring that 
the tissue was plunged directly into the hexane without 
touching the sides of the beaker. The rapidly frozen tissue 
was removed after about one minute, and transferred with 
pre-cooled forceps to a dry tube, for storage at -70°.
A metal microtome chuck was cooled in the alcohol- 
CO^ bath, and allowed to equilibrate. The chuck face was 
coated with a dilute solution of toluidine blue, and this was 
allowed to freeze until only a thin film of liquid water 
remained. At this point, the frozen tissue was transferred 
to the chuck with chilled forceps. After the tissue had 
frozen to the chuck, the latter was wiped dry, and removed 
to a cryostat cabinet maintained at -30°, until ready for 
section cutting.
For routine work, sections of 10ym thickness were 
cut on a cryostatted microtome (Bright Instrument Co. Ltd.,
Huntingdon, Cambs.) at -30°, with the knife cooled to 
-70° by means of solid CO^ packed around the handle.
Sections were transferred to glass microscope slides,
and carried through the histochemical procedures described
below.
2.17.2. Preparation of Z5 mounting medium
(Method by permission of Dr J. Chayen, division 
of Cellular Biology, Mathilda and Terence Kennedy Institute 
of Rheumatology, Hammersmith, London)
Polyvinyl alcohol (Wacker-Chemie, Burghausen/Obb, 
West Germany), grade G18/140 (12.Og) was stirred into 
0.4M acetate buffer, pH 6.5 (50ml), and allowed to dissolve 
at 60° for a period of 24 hours. Glycerol (20ml) and 0.1M 
lactic acid (20ml) were added, and the mixture was made to 
a total volume of 100ml. One crystal of thymol was added 
as a preservative.
2.17-3- Toluidine blue staining
Frozen sections were stained routinely with 
toluidine blue, to permit the recognition of liver morphology 
during studies of the distribution within the lobule of 
cytochrome P-450 and other enzymes.
Reagent
0.1% (w/v) toluidine blue in 0.1M acetate buffer,
pH 6.5
Method
Fresh, frozen sections were immersed in 0.1%
(w/v) toluidine blue solution for one minute, rinsed in 
tap water, and allowed to dry before mounting in Z5 medium.
2.17.4. Glucose-6-phosphatase (E.C.3.1.3.9)
Phosphate is split specifically from glucose-6- 
phosphate at pH 6.5. The released phosphate is trapped by 
lead, and the precipitated lead phosphate visualised by 
conversion to lead sulphide (Wachstein and Meisel, 1956), 
adapted by Chayen and coworkers (1973).
Reagents
0.1M acetate buffer, pH 6.5, containing 2.OmM
glucose-6-phosphate monosodium salt, freshly
prepared
0.1M lead nitrate
0.5% (v/v) ammonium sulphide
Method
Sections were incubated at 37° in 0.1M acetate 
buffer, pH 6.5, containing 2.OmM glucose-6-phosphate, 
routinely for 10 minutes. The sections were washed in 
running tap water, followed by distilled water, then 
immersed in 0.5% (v/v) ammonium sulphide solution for 
one minute. After washing in distilled water, the stained 
sections were mounted in Z5 medium. Control incubates, 
containing sodium ^-glycerophosphate (2.OmM), were set up 
to test the specificity of the reaction.
2.17.5. 5 1-Nucleotidase (5'NT, E.C. 3.1.3.5)
There are two practical problems with histochemical 
methods for measuring 5'NT activity: the reaction must 
be specific for the phosphate ester on C-5 of a nucleoside, 
and the sites of activity of 5 ’NT must be distinguished 
from those of the non-specific alkaline phosphatases. The 
reaction is thus usually carried out at a lower pH, to 
reduce the interference from these latter enzymes. At pH 8.3 
(calcium method), the 5 1-nucleotidases with alkaline 
optima are at maximum activity, whereas alkaline phosphatase
may be reduced to one-third of its maximum activity. 
£-p-Bromotetramisole oxalate is also added as a potent 
inhibitor of non-specific alkaline phosphatases.
The reaction may also be performed at pH 6.5, 
or at pH 7.0, using lead as the trapping agent, but 5 ’NT 
activity must then be differentiated from that of the 
non-specific acid phosphatases of the tissue.
The calcium method for 5 'NT is due to Chayen 
at al. (1973), after Gomori (1952).
Reagents
0.2M Tris-HCl buffer, pH 8.3, containing 6.4mM
adenosine-5’-monophosphate, 445mM CaCl^, 10.3mM 
MgSO^ and 0.1mM £-p-bromotetramisole oxalate,
freshly prepared
109mM cobalt nitrate
0.5% (v/v) ammonium sulphide
Method
Frozen sections were incubated at 37° in 0.2M 
Tris-HCl, pH 8.3, containing adenosine-5’-monophosphate, 
CaCl^, MgSO^ and £-p-bromotetramisole oxalate, typically 
for 30 minutes. The sections were washed in running tap 
water for 5 minutes, and then immersed in cobalt nitrate 
(109mM) for 5 minutes. After rinsing in distilled water, 
the sections were immersed in ammonium sulphide solution 
(0.5%, v/v) for one minute, rinsed again in distilled 
water, and mounted in Z5 medium. Enzyme activity was shown 
by a black precipitate of cobalt sulphide. Control 
incubations, in which the adenosine-5'-monophosphate in 
the medium was replaced by sodium 3-glycerophosphate 
(6.4mM), were also carried out.
The lead method for 5 ’NT is from Chayen zt al. 
(1973), after Wachstein and Meisel (1952, 1957).
Reagents
0.1M acetate buffer, pH 6.5, containing 2.0mM
adenosine-5'-monophosphate and 2.44mM lead 
nitrate, freshly prepared
0.5% (v/v) ammonium sulphide
Method
Fresh, frozen sections were incubated at 37° in 
0.1M acetate buffer, pH 6.5, containing adenosine-5’- 
monophosphate and lead nitrate, typically for 20 minutes. 
The sections were washed in running tap water and distilled 
water, and then immersed in ammonium sulphide solution 
(0.5%, v/v) for one minute. After rinsing in distilled 
water, the stained sections were mounted in Z5 medium.
Sites of 5 ’NT activity were indicated by a brown deposit 
of lead sulphide. Control incubations were run, using 
medium containing sodium 3-glycerophosphate (2.0mM) 
in place of adenosine-5’-monophosphate, to demonstrate 
sites of non-specific acid phosphatase activity.
2.17.6. y-Glutamyl transferase (yGT, E.C.2.3.2.2)
Glutamic acid derived from the enzymic hydrolysis 
of the y-linkage of Y-glutamyl-4-methoxy-2-naphthylamide 
is passed to glycylglycine, as an amine acceptor. The 
4-methoxy-2-naphthylamine is coupled with a diazonium 
salt (after Pearse, 1972).
Reagents
25mM Tris-HCl buffer, pH 7.4, containing 9•13mM
Y-glutamyl-4-methoxy-2-naphthylamide, 0.1M NaCl, 
3.78mM glycylglycine and 0.5g/dl Fast Blue
BBN salt
0. 1M Cu S01|.5H20 
l43mM NaCl
Method
Fresh, frozen sections were incubated at 25° in
25mM Tris-HCl buffer, pH 7.4, containing y-glutamyl-4- 
methoxy-2-naphthylamide, sodium chloride, glycylglycine 
and Fast Blue BBN salt, usually for 20 minutes. After - 
rinsing in saline (l43mM), the sections were immersed in 
copper sulphate (0.1M) for 2 minutes. The sections were 
rinsed again in saline and mounted in Z5 medium. Sites of 
•yGT activity were indicated by the bright red copper 
chelate of the azo dye final product.
2.17.7. Glucose-6-phosphate dehydrogenase (E.C.1.1.1.49)
The method is that of Chayen and coworkers (1973), 
after Altman (1972). Glucose-6-phosphate dehydrogenase 
catalyses the oxidation of glucose-6-phosphate by NADP+ . 
Phenazine methosulphate is included, to transfer hydrogen 
rapidly and quantitatively from the NADPH generated to 
neotetrazolium chloride. Polyvinyl alcohol is employed 
to prevent diffusion of the soluble enzyme into the medium; 
there, it may act upon glucose-6-phosphate to form NADPH, 
which may in turn act as a substrate for'NADPH^-diaphorase, 
and thus precipitate reduced tetrazolium on to the section.
Reagent
50mM glycylglycine-NaOH buffer, pH 8.0, containing 
5mM neotetrazolium chloride, 100g/dl polyvinyl 
alcohol (M05/140), 3mM NADP, 5mM glucose-6- 
phosphate and 0.65mM phenazine methosulphate, 
freshly prepared (incubation medium)
Method
Nitrogen was bubbled through the incubation medium 
for 2 minutes at 37° before use. Fresh, frozen sections, 
placed on microscope slides, were surrounded by perspex 
rings, into which was poured the prewarmed medium. The 
sections were incubated for 10 minutes at 37° in an 
atmosphere of nitrogen, then rinsed with distilled water 
and mounted in Z5 medium.
2.18 Electron Microscopy
Tissue (typically, liver), obtained at post­
mortem, was cut into cubes of 0.5-1.Omm side, and fixed 
in glutaraldehyde (4.0%, w/v) in 0.1M cacodylate buffer, 
pH 7.4 (1-18 hours), and counterfixed in osmic acid 
(2.0%, w/v) in 0.1M cacodylate buffer, pH 7.4, for 2 
hours, at room temperature. Dehydration was achieved by 
immersing the fixed material in progressively increasing 
concentrations of ethanol (25, 50, 75, 90 and 100%, v/v;
2 x 10 minute changes of each concentration). The tissue 
was transferred to a propylene oxide/absolute alcohol 
(1:1) solution, to propylene oxide (2 changes), and, 
finally, to a propylene oxide/Epon 812 (1:1) resin mixture 
(20 minutes). Plastic capsules were filled with Epon 812 
resin, and 2 or 3 blocks of tissue were placed in each 
capsule. The resin was polymerised for 48 hours at 60°, 
and sections were subsequently cut, using a Reichert 
Orn U3 Ultramicrotome, for examination under the electron 
microscope (Joel 100B, Japan).
2.19. Measurement of Cytochrome P-450 Concentration in
Hepatocytes, using Microspectrophotometry. 
Distribution of Cytochrome P-450 in Liver Lobules
This work was carried out in the Division of 
Cellular Biology, The Mathilda and Terence Kennedy Institute 
of Rheumatology, Bute Gardens, Hammersmith, London, W6 7DW, 
by the courtesy of Dr J. Chayen.
Mounting medium
Polyvinyl alcohol (grade M05/140, supplied by 
Wacker-Chemie, Burghausen/Obb, West Germany) was dissolved 
in 0.1M potassium phosphate buffer, pH 7.4, containing 
50mM KC1, by standing it overnight in a water bath at 
60°. The medium was cooled, and the volume adjusted with 
the same buffer to give a final polyvinyl alcohol concen­
tration of 20% (w/v).
Immediately before use, sodium dithionite (5mg/ml 
final concentration) was added to the polyvinyl alcohol 
solution (5.0ml) as 125yl of a freshly prepared solution 
of dithionite (200mg/ml) in distilled water.
Generally, carbon monoxide was then bubbled 
vigorously through the medium for 5 minutes (using a 
Pasteur pipette with the edges rounded in a Bunsen burner 
flame) to give a saturated solution. This medium was used 
as soon as possible after preparation.
Preparation and incubation of samples
Blocks of liver (about 4mm on a side), obtained 
at post-mortem, were chilled rapdily, as described in
2.17-1. In certain instances, livers were perfused under 
low pressure with either NaCl (151mM) or polyvinyl alcohol 
(grade M05/140, 5.0%, w/v) before cutting and freezing. 
Unperfused, saline- and colloid-perfused material was 
sectioned (7ym sections), and stained with haematoxylin . 
and eosin to determine whether the perfusion technique
incurred damage to the tissue. A section (10ym) was cut 
on a cryostatted microtome, and stained with toluidine 
blue for preliminary examination, and identification of 
satisfactory lobular configurations for measurement.
The criteria used for identification of the required area 
were the endothelium of the central vein, and the radial 
pattern of hepatocytes emanating from it; and the clear 
presence of a bile duct in the normal arrangement of the 
portal triad. A second section (40ym), adjacent to the 
first, was subsequently ■ cut, taken on to a microscope 
slide, and allowed to warm to room temperature, before 
mounting in the medium described above. A third section 
(10ym) was cut and stained with toluidine blue, and 
examined for continuity of the lobular architecture noted 
in the first two sections.
The section of 40ym thickness was surrounded by 
a perspex ring, which was filled with mounting medium 
(containing sodium dithionite and carbon monoxide) until 
the meniscus was seen to dome above the rim. A coverslip 
was placed on top of the ring to form a hermetic seal.
The section was incubated for 20 minutes at room temperature, 
then the excess medium.was decanted, and the ring replaced 
by a glass coverslip. (In early experiments, the medium 
was centrifuged at low speed before use, but it was later 
found that bubbles dispersed readily during the incubation 
period).
The slide was placed on the sample stage of a 
UMSP I microspectrophotometer (Zeiss, West Germany), and 
the chosen central vein and portal tract were located under 
phase contrast conditions by comparison of the section 
with its toluidine blue-stained counterpart. The section 
was orientated by means of the rotating stage such that a 
straight line could be traversed between central vein 
and portal tract by movement in an ’E-W’ direction only.
A drop of M05/140 medium was placed on a blank
slide mounted in the reference microscope, and a 32ym
mask was centred on each of the sample and reference sides.
One cell was located at the edge of the central vein,
and its absorbance spectrum was scanned between 400 and
650nm, using transmitted light. Wavelength calibration
was achieved by placing a narrow bandpass interference
filter (transmission X =625.5nm) in the path of themax r
sample beam.
Similar measurements were carried out over
successive 32ym diameter areas by driving the section in
the apparent direction of the portal tract by means of
the manual positioning mechanisms of the stage. The
divided graticule of the UMSP I served as a datum line
for accurate repositioning after each scan.
•Normally, measurements were made with the. eyepiece
slide set at ?x10’, with a 12.5x eyepiece, and a 32x/0.40
glycerin immersion objective. Damping was set at the
maximum possible (’3 ’). For routine scanning, a wavelength
drive: chart paper ratio of 1:1 was used. When it was
desired to establish X of the cytochrome P-450'trace,max . ’
the chart paper speed was increased by a factor of 3, 
thus permitting the more accurate measurement of the 
required wavelength.
Transmission readings were converted to absorbance 
readings by the relationship:
A = 2 - log10T,
and cytochrome P-450 concentrations were calculated,
-  1 -  1using an extinction coefficient of 91mM cm
The distance across the lobule was measured on 
both the 40ym section, and on the corresponding toluidine 
blue-stained section, by means of calibrated graticules.
A photographic record was made of the toluidine blue- 
stained material.
2.20. [3H]-Benzofuran Distribution and Excretion
2.20.1. Thin-layer chromatography of radiolabelled material
Silica Gel, G-coated glass plates (Merck GmbH), 
generally incorporating a fluorescent indicator, were 
used throughout.
Serum, urine and bile were applied to the plates 
without further treatment.
Tissue homogenates prepared from liver, kidney, 
spleen and brain were treated, typically, as follows:
Homogenates (tissue diluted 1 in 3 with 20mM 
Tris-HCl buffer, pH 7.4, containing 1.15% KC1, w/v) were 
extracted with 3 tlmo.* 2 volumes of petroleum ether 
(b.p. 40-60°) or ethyl acetate (3 x 30 minutes), and the 
pooled organic layers were evaporated to a very small 
volume. The residues were dissolved in ethanol, and 
aliquots were applied to the chromatography plates.
Further samples of homogenate were treated with one volume 
of HG1 (5.0M), and boiled for two hours on a water, bath 
in capped tubes. These hydrolysates were divided into two 
equal portions. One portion was taken through the extraction 
procedure described, whereas the other was made to pH 
10-11 with NaOH (10.0M) before extraction. Aliquots of the 
ethanolic solutions were spotted on to the thin-layer 
chromatography plates.
Duplicate plates were developed in pre-equilibrated 
tanks, using two different solvent systems - butanol/ 
acetic acid/ water (4:1:2, v/v), and chloroform.
Spots were located by quenching of the fluorescent 
indicator, and radioactive zones were identified by scanning 
the plates with a Diinnschict Scanner II (Berthold, D-7547, 
Wildbad, West Germany).
Measured areas of Silica Gel, G were scraped from 
the plates and transferred to glass or plastic scintillation 
vials. The samples were counted, after the addition of
Cab-o-Sil scintillant (5.0ml, Packard Instrument Co.,
A preexisting quench curve verified for selected samples, 
using [3H]-toluene as standard, was employed.
methanol (1.0ml), and counted in 4.0ml toluene/metapol 
(2:1, v/v) scintillant, containing 0.02% (w/v) dimethyl 
P0P0P and 0.5% (w/v) PP0, on an LKB 1216 RackBeta scintill­
ation counter. Counts were corrected using an existing 
quench curve, verified with [3H]-toluene as above. A 
background count was established by counting areas of 
untreated silica gel.
2.20.2. Solubilisation of tissues and excretion products,
(Packard Instrument Co., Inc.). Soluene-350 (1.0ml) was 
added to the following quantities of material, contained 
in glass scintillation vials of 20ml volume:
Whole tissue (liver, spleen,
muscle) 80-120mg
(kidney, lung) 80-100mg 
After gentle swirling, the vials were allowed to 
stand at 37° for 48 hours. Hydrogen peroxide (0.5ml) and 
propan-2-ol (0.5ml) were added to each vial, and the 
samples were left for a further 48 hours at 37°. HC1 (1.5ml)
Inc.), on an LKB 1210 UltroBeta scintillation counter.
Alternatively, the silica gel was treated with
and scintillation counting
Samples were treated initially with Soluene-350
Serum and bile 
Urine (bladder)
20-1OOyl 
1 OOyl
(24h collection, made 
to 25ml) 1 OOyl
<20mg, homogenised in 
200yl water
Homogenates (liver, kidney, 
lung or brain, 1 in 4 in 
20mM Tris-HCl, pH 7.4, 
containing 1.15% KC1, w/v) 100yl
was added, and the vials agitated occasionally during a 
final period of 24 hours. Counting was carried out in 
a toluene/Synperonic NX (1:2, v/v) scintillant, containing 
0.02% (w/v) dimethyl P0P0P and 0.5% (w/v) PPO. All samples 
were swirled gently, and allowed to stand for at least 
2 hours, before counting on an LKB 1210 UltroBeta liquid 
scintillation counter. Standardisation was by means of 
a tritiated water internal standard (56924±821dpm/1Oyl), 
which was added to the samples before recounting. The 
stability and inherent efficiency of the scintillation 
counter was monitored by means of a [3H]-toluene standard 
of known activity, corrected for change of count with 
respect to the rate of radioactive decay of tritium. 
[2-3H]-Benzofuran, dissolved in corn oil as prepared for 
dosing, was also treated and counted in the manner described 
above.
2.21. Statistics
Data obtained from all of the foregoing 
quantitative assays was expressed statistically, where 
appropriate, as mean plu* or mlnuA standard deviation, 
using a denominator of n-1 . Student’s t-test was employed 
to assess the significance of differences in results 
between treatment groups.
CHAPTER 3 
EFFECTS'OF SOME MODIFIERS OF 
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3. EFFECTS OF SOME MODIFIERS .OF CYTOCHROME P-450
LEVELS UPON ITS DISTRIBUTION IN LIVER LOBULES
3.1. Introduction
The mammalian liver is frequently regarded as a 
homogeneous tissue; nonetheless, it not only possesses a 
clearly definable microanatomical structure, but hepatocytes, 
which probably contain all of the hepatic cytochrome P-450, 
generally represent only 60-80% of the cells present.
Thus, homogenisation of liver, while possessing certain 
advantages, suffers from the twin disadvantages of disruption 
of the integrated functioning of subcellular organelles 
and membranes, and the ’averaging out’ of enzyme activity,
-or concentration of intracellular components, of different 
cell types within_ the tissue. In cytochemistry, however, 
the biochemical functions of cell subpopulations may be 
studied with the cells remaining in a normal structural 
and functional relationship with one another. Also, 
retention of the architecture of a tissue is vital in 
determining those functional differences related to the 
localisation of cells within an organ.
Most cytochemical techniques rely on the binding 
or precipitation of an artificial chromophore (see 
Pattison zt at. , 1979), but, where appropriate, natural 
chromophores within cells may be utilised. Because of the 
ability of reduced cytochrome P-450 to form with carbon 
monoxide a complex that has an absorbance maximum at 
450nm, this cytochrome constitutes a useful natural 
chromophore for cytochemical study. Quantitation may be 
carried out by microdensitometry, generally employing the 
Vickers M85/M85A/M86 series of machines (e.g. Altman zt at., 
1975; Smith and Wills, 1981), or by microspectrophotometry 
(Gooding zt at., 1978), which was used in the present study.
The Zeiss Universal Microspectrophotometer I 
(UMSP I, Plate 3*1.) is an ultraviolet-to-visible double
beam recording microspectrophotometer based \on the design 
of Caspersson (1950). Monochromatic light is passed through 
a reference microscope and a sample microscope, the 
magnification achieved allowing a cell, or part of a cell, 
to replace the cuvette of a conventional spectrophotometer. 
The monochromator is driven, permitting the difference in 
absorbance between sample and reference specimens to be 
measured over a range of wavelengths from 240 to 600nm.
A circular area of the sample specimen is chosen for 
measurement by means of a series of masks of diameter 
0.32ym to 32ym.. A s , in this case, a small absorbance is 
to be recorded, a mask of 32ym is employed, which provides 
the maximum possible signal-to-noise ratio for the resulting 
spectra. Under these conditions the bandwidth between 
400 and 500nm remains less than 2nm, and is 1.6nm at 450nm. 
The principle of measurement is similar to that applied 
to conventional spectrophotometry; however, the techniques 
would be strictly comparable only if two identical cells 
could be located within the masks of the two microscopes. 
This is impossible to achieve in practice, as each cell 
has different subcellular component concentrations and 
different light scattering characteristics, thus, a blank 
slide (pZuA mounting medium and coverslip) is placed in 
the beam of the reference microscope to eliminate variables 
due inherently to the machine. Optical scatter is minimised 
by immersing the section in a polyvinyl alcohol-based 
medium of a refractive index comparable with that of 
hepatocytes. It may be shown (Gooding zt at., 1978; this 
chapter) that a single dithionite-reduced, carbon monoxide- 
complexed spectrum provides all of the data required to 
estimate the cytochrome P-450 concentration in the relevant 
area of the section. In the medium employed, the carbon 
monoxide spectrum is stable for up to about 2 hours.
Accordingly, this microspectrophotometric 
technique was used to reveal the distribution, with respect
to the lobular architecture of the liver, of the species 
of cytochrome P-450 inducible by 3-methylcholanthrene, 
phenobarbitone and isosafrole. Possible differences in 
distribution among lobes of the rat liver (see Figure 3.1 
were examined, and compared with the relative content of 
cytochrome P-450, and the activity of some associated 
monooxygenases, measured in hepatic microsomes prepared 
from similarly pretreated rats.
Plate 3-1. The Zeiss UMSP I at the Mathilda and
Terence Kennedy Institute of Rheumatology, 
Hammersmith, London.
Figure 3-1•
Appearance of rat liver lobe?/ at dissection (arranged to display right
and caudate lobes)
ML
LL
CL
RL
BD
ML = median lobe
LL = left lobe
RL = right lobe
CL = caudate (spigelian) lobe
BD = bile duct
P = pancreas
D = duodenum
S = stomach
0 = oesophagus
3.2. Results
3.2.1. Validation of spectral interpretation
Sections (40ym thick), cut from fresh, frozen 
median lobe of liver from a phenobarbitone-pretreated 
rat, if reduced with sodium dithionite, showed a rather 
wide Soret band, with maximum absorbance at 424nm (line 1, 
Figure 3-2.). The major contributor to this spectrum is 
probably cytochrome 6^, with a component due to contamination 
with haemoglobin. Haemoglobin is largely prevented from 
diffusing from the major blood vessels by the presence of 
a high concentration of polyvinyl alcohol. However, it was 
found that careful perfusion of the liver <ln Aitu. with 
either isotonic saline, or a 5% polyvinyl alcohol solution, 
reduced the height of the Soret band, resulting in less 
distortion of the carbon monoxide-complexed spectrum and 
easier measurement of cytochrome P-450 concentration, 
without significantly affecting the numerical values 
obtained.
The addition of carbon monoxide produced a second 
spectrum, with an absorbance peak at 450nm (line 2,
Figure 3.2.). Extrapolation of the continuous curve from 
424 to 490nm in this spectrum gives a baseline that 
intersects the reduced-only spectrum at 450nm. Thus, the 
concentration of cytochrome P-450 can be calculated from 
the difference in absorbance between peak and extrapolated 
baseline at 450nm, using an extinction coefficient of 
9 1mM"1 cm"1.
3.2.2. Spectral resolution of the UMSP I in the
measurement of cytochrome P-450
Because of the relatively wide bandwidth of the 
UMSP I when using a 32pm mask size, low speed scans of 
reduced-carbon monoxide spectra of median lobe hepatocytes
Figure 3.2.
Reduced and reduced ptuA carbon monoxide spectra derived from 
the same hepatocyte in a fresh frozen section of liver prepared 
from a rat pretreated with phenobarbitone, 0.3mmol/kg i.p. 
daily for 3 days
0.0?-,
0.08-
0.07-
0.06
JQ
JD
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0.01-
0.00
490450 470410 430
nm
Extrapolation (-- ) of the continuous curve of spectrum 2 (dithionite
ptuA carbon monoxide complexed) intersects with spectrum 1 (dithionite 
only) at 450nm. Hence, spectrum 2 contains the information required 
to calculate the absorbance due to cytochrome P-450 under these 
conditions.
from phenobarbitone- and 3-niethylcholanthrene-induced 
male rats, and a reduced-only spectrum of an hepatocyte 
from an isosafrole-pretreated male rat, were generated on 
an expanded wavelength axis (Figure 3.3.). Absorbance 
maxima were distinct, and obtained at 450, 448 and 455nm 
for phenobarbitone-, 3-methylcholanthrene- and isosafrole- 
pretreated animals respectively.
3.2.3. Distribution of cytochrome P-450 in liver of 
phenobarbitone-pretreated rats
Cytochrome P-450 content was measured in successive 
32ym areas across lobules identified in sections from’ the 
median liver lobe of phenobarbitone-pretreated male rats.
The cytochrome P-450 concentration was much higher in 
the centrilobular hepatocytes than in periportal cells 
(Figure 3-4.). Sections cut from different blocks of tissue 
from the same lobe, or obtained from the median lobes of 
livers from various individuals, showed a cytochrome P-450 
concentration of about 100-150yM in the centrilobular 
area, falling fairly sharply and steadily to the edge of 
the portal vessels (20-50yM). Measurements performed 
similarly upon rats pretreated with saline alone revealed 
that the concentration of cytochrome P-450 diminished in 
approximately constant proportion to that in the induced 
animals, but the concentrations were about 40-50yM 
centrilobularly and 10-20yM periportally. The path followed 
between central vein and portal tract in the phenobarbitone- 
pretreated rat is shown superimposed on a toluidine blue- 
stained serial section in Plate 3.2.
3.2.4. Distribution of cytochrome P-450 in liver of 
isosafrole-pretreated rats
It was found that the dithionite-reduced spectra
Figure 3.3.
Dithionite reduced, carbon monoxide-complexed spectra of 
sections of liver from rats pretreated with various 
inducing agents
0.06
0.05
0.04
430 450440 460 470
nm
Fresh frozen liver sections prepared from rats pretreated with
phenobarbitone (--- ), 0.3mmol/kg daily for 3 days,
3-methylcholanthrene (--- ), 0.075mmol/kg daily for 3
days, or isosafrole (-------- ), O.93nimol/kg daily for 3
days, were treated with dithionite and carbon monoxide 
as described in section 2.19. Spectra were recorded between 
430 and 460nm, using a slow scan speed and wavelength 
axis expansion.
Figure 3.4.
Distribution of cytochrome P-450 across a lobule of the hepatic median
lobe of a male rat pretreated with phenobarbitone
120-1
110-
1 0 0 -
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tractedge of 
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(edge of pm '
central vein)
Male rats were treated with saline, 2.5ml/kg daily by i.p. injection
for 3 days ( O  O'), -or with phenobarbitone sodium, 0.3mmol/kg in
saline daily by i.p. injection for 3 days ( v v), and killed on
the 4th day. The concentration of cytochrome P-450 was determined 
at the points indicated in lobules visualised in fresh, frozen 
sections of liver median lobe by the microspectrophotometric method 
described in section 2.19.
Plate 3.2. Path of measurement of cytochrome P-450
distribution across a lobule from the liver 
median lobe of a male rat pretreated with 
phenobarbitone. Same lobule as Figure 3.-4. 
Fresh, frozen tissue, 10ym, toluidine blue 
(x80).
of fresh, frozen liver sections prepared from rats pretreated
with isosafrole exhibited a peak with X =455nm, in the ^ max 7
same manner as the isosafrole metabolite-cytochrome P-450 
complex generated In vZvo, or in microsomes 'in V'itAo. 
Accordingly, the sample spectrum m'LnuA baseline absorbance 
at 455nm was used as an index of the concentration of 
cytochrome P-450 at intervals along a straight line 
traversed between a selected central vein and a portal 
tract. The distribution abtained was qualitatively very 
similar to that seen after the administration of pheno­
barbitone (Figure 3.5.). The line of measurement is 
superimposed upon Plate 3-3.
3.2.5. Interlobar comparison of cytochrome P-450
distribution in livers of 3-methylcholanthrene- 
pretreated rats
The result of successive measurements of cytochrome 
P-450 (^max = i^ 8nm) concentration along a straight line 
between a central vein and a portal tract of a median 
lobe section from a 3-methylcholanthrene-pretreated male 
rat is shown in Figure 3.6. Generally, different tracks 
traversed on one section of median lobe liver, and on 
sections cut from the median lobes of livers from different 
animals, showed much more variation in distribution and 
centrilobular concentration of cytochrome P-450 than did 
sections from phenobarbitone-pretreated rats. Typically, 
the cytochrome P-450 concentration centrilobularly was 
60-80yM and, in contrast to the phenobarbitone-dependent 
distribution, it remained at a similar level across most 
of the width of the lobule (Figure 3.6.). However, 
occasionally very little induction occurred, except that 
the periportal cytochrome P-450 concentration was elevated 
to about the same level as that in the centrilobular region. 
In other readings, a distinctly biphasic distribution was
Figure 3.5.
Distribution of amplitude of absorbance due to an isosafrole metabolite
cytochrome P-450 complex across a lobule of the hepatic median lobe of
a male rat pretreated with isosafrole
0.015-
o.oio-
0.005-
I edge of portal tract
0.000-
400200 600 8000
pm
central vein)
Male rats were pretreated with isosafrole, 0.93 mmol/kg in corn oil 
daily by i.p. injection for 3 days. The distribution of cytochrome 
P-450 was measured in a fresh, frozen section of liver median lobe, 
essentially by the method described in section 2.19., except that 
dithionite alone was added to the section, and the concentration 
of cytochrome P-450 was expressed as the absorbance (A-ucc nQn) due 
to an isosafrole metabolite:reduced cytochrome P-450 
complex.
>/-**&■ r ♦Jty-'i*u^ siw#* • ■■*• j>* ^ i.k >" 4&3?^%3t5?f•: **• *t . • m v »1 .•^ >'r><wV* .<*\ •v w -h S^eSS^*. t
S 8 ^ w £ * r -
Plate 3.3- Direction of measurement of cytochrome P-450 
distribution across a lobule from the liver 
median lobe of a male rat pretreated with 
isosafrole. Same lobule as Figure 3-5. Fresh, 
frozen tissue, 10ym, toluidine blue (x80).
Figure 3.6.
Distribution of cytochrome P-450 (P-448) across a lobule of the
hepatic median lobe of a male rat pretreated with 3-methylcholanthrene
70-,
60-
^  50-
5  40-
| edge of portal tract
tL 20-
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| edge of portal tract
0 200 400 600 800
(edge of 
central vein)
Male rats were treated with corn oil, 2.5ml/kg daily by i.p. injection
for 3 days ( O  o), or with 3-methylcholanthrene, 0.075mmol/kg in
corn oil daily by i.p: injection for 3 days ( v  v ), and killed on
the 4th day. The concentration of cytochrome P-450 (P-448) was 
determined at the points indicated in lobules visualised in fresh, 
frozen sections of liver median lobe by the microspectrophotometric 
method described in section 2.19.
Plate 3-4
**;+. *Iff- ' *  S '  -  V. < 4-.* * .  •- * * *■ ' i ' v  ;  ^  v *
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. . Direction of measurement of cytochromerome P-450 distribution 
across a lobule from the liver median lobe of a male rat 
pretreated with corn oil. Same lobule as Figure 3-6. Fresh, 
frozen tissue, 10ym, toluidine blue (x80).
Plate 3.5. Path of measurement of cytochrome P-450 (P-448) distribution 
across a lobule from the liver median lobe of a male rat 
pretreated with 3-methylcholanthrene. Same lobule as 
Figure 3.6. Fresh, frozen tissue, 10pm, toluidine blue (x80).
obtained, with a midzonal depression in cytochrome P-450 
concentration; sometimes, a pattern indistinguishable from 
that induced by phenobarbitone was found. Corn oil- 
pretreated rats showed no differences in distribution of. 
cytochrome P-450 from rats injected with saline. The lines 
superimposed on Plates 3-^. and 3.5. correspond to the 
lobular radii of median liver lobes from corn oil- and 
3-methylcholanthrene-pretreated male rats for which the 
cytochrome P-450 distribution is shown in Figure 3.6.
Similar analysis of median lobe liver sections 
from 3-methylcholanthrene-pretreated female rats produced 
patterns of distribution broadly comparable to those of 
males (Figure 3-7., Plate 3*6.), although cytochrome P-450 
concentrations appeared to be more consistent across the 
hepatocytes of a given lobule. The biphasic distribution 
was occasionally seen. Less variation in level was also 
observed across liver lobules of corn oil-pretreated 
female rats (Figure 3.7., Plate 3.7.) than in males.
The distribution of cytochrome P-450 in 
3-methylcholanthrene-induced left and right liver lobes 
of male rats was not qualitatively different; nor did the 
distribution vary markedly from that found in median lobe 
lobules (Figures 3-8. and 3.9., Plates 3-8., 3.9., 3.10. 
and 3.11.). Usually, overall levels of cytochrome P-450 
appeared to be slightly higher in median lobe measurements 
than in others, although a high degree of interindividual 
variation was seen in all lobes. However, the major 
difference lay in the markedly lower concentrations of 
cytochrome P-450 in lobules of right lobes of control 
animal liver, compared with, particularly, median lobes. 
This value fell rapidly from the central vein in right 
liver lobe lobules, and was frequently only 10-15yM over 
much of the lobular radius.
Figure 3.7.
Distribution of cytochrome P-450 (P-448) across a lobule of the
hepatic median lobe of a female rat pretreated with 3-methylcholanthrene
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Female rats were treated with corn oil, 2.5ml/kg daily by i.p. injection
for 3 days (O O), or with 3-methylcholanthrene, 0.075mmol/kg in
corn oil daily by i.p. injection for 3 days (v  v ), and killed on
the 4th day. The concentration of cytochrome P-450 (P-448) was 
determined at the points indicated in lobules visualised in fresh, 
frozen sections of liver median lobe by the microspectrophotometric 
method described in section 2.19.
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Plate 3-6. Direction of measurement of cytochrome P-450 distribution 
across a lobule from the liver median lobe of a female 
rat pretreated with corn oil. Same lobule as Figure 3.7. 
Fresh, frozen tissue, 10pm, toluidine blue (x80).
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Plate 3*7. Path of measurement of cytochrome P-450 (P-448) distribution 
across a lobule from the liver median lobe of a female rat 
pretreated with 3-methylcholanthrene. Same lobule as Figure
3.7. Fresh, frozen tissue, 10ym, toluidine blue (x80).
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Figure 3.8.
Distribution of cytochrome P-450 (P-4^8) across a lobule of the
hepatic left lobe of a male rat pretreated with 3-methylcholanthrene
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Male rats were treated with corn oil, 2.5ml/kg daily by i.p. injection 
for 3 days ( O — —  O), or with 3-methylcholanthrene, 0.075mmol/kg in
corn oil daily by i.p. injection for 3 days (v v), and killed on
the 4th day. The concentration of cytochrome P-450 (P-448) was 
determined at the points indicated in lobules visualised in fresh, 
frozen sections of liver left lobe by the microspectrophotometric 
method described in section 2.19.
Plate 3.8. Path of measurement of cytochrome P-450 distribution across 
a lobule from the liver left lobe of a male rat pretreated 
with corn oil. Same lobule as Figure 3-8. Fresh, frozen 
tissue, 10ym, toluidine blue (x80).
Plate 3-9. Path of measurement of cytochrome P-450 (P-448) distribution 
across a lobule from the liver left lobe of a male rat 
pretreated with 3-methylcholanthrene. Same lobule as Figure
3.8. Fresh, frozen tissue, 10ym, toluidine blue (x80).
Figure 3.9.
Distribution of cytochrome P-450 (P-448) across a lobule of the
hepatic right lobe of a male rat pretreated with 3-methylcholanthrene
60-,
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Male rats were treated with corn oil, 2.5ml/kg daily by i.p. injection 
for 3 days ( O — -O), or with 3-methylcholanthrene, 0.075mmol/kg in
corn oil daily by i.p. injection for 3 days (v v), and killed on
the 4th day. The concentration of cytochrome P-450 (P-448) was 
determined at the points indicated in lobules visualised in fresh, 
frozen sections of liver right lobe by the microspectrophotometric 
method described in section 2.19.
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Plate 3.10. Path of measurement of cytochrome P-450 distribution
across a lobule from the right liver lobe of a male rat 
pretreated with corn oil. Same lobule as Figure 3-9. 
Fresh, frozen tissue, 10ym, toluidine blue (x80).
Plate 3-11. Path of measurement of cytochrome P-450 (P-448) distribution 
across a lobule from the liver right lobe of a male rat 
pretreated with 3-methylcholanthrene. Same lobule as Figure 
3.9. Fresh, frozen tissue, 10ym, toluidine blue (x80).
3.2.6. Interlobar comparison of microsomal cytochrome
P-450 concentration and.. monooxygenase activities
SDS-polyacrylamide disc gel electrophoresis 
reveals few differences in the interlobar pattern of 
polypeptide distribution in liver microsomes from rats 
pretreated with either corn oil or 3-methylcholanthrene 
(Figure 3.10.). In all lobes, band 5 (55000 MW) is 
considerably increased, and band 4 (53000 MW) is slightly 
increased, by induction with 3-methylcholanthrene. However, 
band 3 (50000 MW) may be rather less intense in right lobe 
microsomes from control animals, when compared with either 
median or left lobe microsomes. Also, the most pronounced 
induction of band 4 by 3-methylcholanthrene appears to be 
in the right lobe.
Spectral estimations demonstrated that the 
concentrations of cytochrome P-450 were generally lowest, 
and most variable, in the right lobe of corn oil-pretreated 
rat liver (Table 3.1.), correlating with the results described 
above, but that pretreatment of rats with 3-methylcholanthrene 
removed much of this difference between lobes. Hence, the 
fold induction of cytochrome P-450 was greatest for the 
right lobe (Table 3-2.). This lobe was also the most 
deficient in cytochrome 6^. The concentration of the latter 
protein was equal in left and median lobes, but the left 
lobe was more refractory to induction than the median.
Control ethoxycoumarin 0-deethylase activities 
were comparable in right and median lobe microsomes, 
and higher in those prepared from the left lobe; again, 
the smallest degree of induction was in the left lobe, 
and induced activities were similar in magnitude in all 
three lobes (Tables 3.1. and 3.2.). Little variation in 
ethoxyresorufin 0-deethylase activity was observed among 
control rat liver lobes. The fold increase in left lobe 
ethoxyresorufin 0-deethylation after pretreatment with
Figure 3-10.
SDS-Poiyacrylamide disc gel electrophoresis of microsomes 
prepared from individual lobes of livers from rats 
pretreated with corn oil and with 3-methylcholanthrene
1 3 5 7 9 11 13 15 17 19
Solubilisation and SDS-polyacrylamide disc gel electrophor 
of microsomal proteins were carried out as described in
2.8. Samples (15yg protein) were applied in the following 
order:
Wells 2,3,4 median lobe, corn oil-pretreated
5,6,7 median lobe, 3-MC-pretreated
8,9,10 left lobe, corn oil-pretreated
12,13,14 left lobe, 3-MC-pretreated
15,16 right lobe, corn oil-pretreated
17,18 right lobe, 3-MC-pretreated
Wells 1,11,19 contained molecular weight standards
3-methylcholanthrene was only about half of that measured 
in right or median lobe microsomes (Table 3.2.), therefore, 
in contrast to the other parameters considered, the induced 
activity was much lower in one lobe (left) than in the 
others.
A feature of all of the microsomal measurements 
was that the degree of interindividual variation among 
rats when separate lobes were considered was much more 
marked than that normally seen when entire liver preparations 
are used.
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3.3. Discussion
Hepatocytes of the liver acinus (Rappaport, 1958,
1976) lying closer to the incoming supply of portal blood 
will be supplied with higher concentrations of solutes, 
including oxygen, than cells located in the vicinity of 
the acinar outlet. Such non-uniformity of perfusion by 
blood creates conditions leading to heterogeneity among 
hepatocytes, which has resulted in the division of the 
acinus into zones 1 (periportal region), 2 (midzonal 
region) and 3 (centrilobular region), and is reflected 
in the distribution of liver damage inflicted by the 
administration of hepatotoxic chemicals, many of which 
require activation by cytochrome P-450 (Mitchell dt aZ., 
1976a; Hunter dt aZ., 1977; James dt aZ., 1981).
The data obtained from microspectrophotometry of 
frozen, unfixed tissue sections suggest that, even in the 
untreated rat, the distribution of cytochrome P-450 in 
the hepatocytes of a liver lobule is not uniform, and 
that pretreatment of the animals with inducing agents 
results in changes in distribution which vary with the 
agent used. Median liver lobe sections from rats pretreated 
with corn oil or with saline alone exhibit an approximately
2-fold increase in cytochrome P-450 concentration in 
proceeding from periportal to centrilobular hepatocytes. 
This is in agreement with other findings obtained by 
microspectrophotometry (Gooding dt aZ., 1978) or by an 
unlabelled antibody peroxidase-antiperoxidase technique 
(Baron dt aZ., 1978b, 1981). The elevated level of 
cytochrome P-450 centrilobularly seems to be due to the 
presence of a ’phenobarbitone type’ cytochrome, rather 
than a ’3-methylcholanthrene type’, as an antibody to 
purified cytochrome P-448 reveals a uniform distribution 
of cytochrome across the untreated lobule (Baron dt aZ. , 
1978b). Sweeney and coworkers (1978a) also reported that
cells isolated from untreated rat liver were separable 
into two populations, ’large cells' and 1 small cells1 , - 
by centrifugal sedimentation velocity analysis, and that 
the large cells possessed greater benzo(a)pyrene hydroxylase 
activity, but the authors were unable to assign these 
cells to any particular zone of the hepatic lobule.
Phenobarbitone pretreatment resulted in an 
increase of cytochrome P-450 concentration across the 
lobular radius, but with a rather steeper gradient from 
central vein to portal tract than that seen in untreated 
animals. This indicates a preferential induction of 
cytochrome P-450 in centrilobular hepatocytes, but, in 
contrast to the results of Gooding and colleagues (1978), 
no discontinuity dividing lobular cells into two distinct 
subpopulations was found. Following pretreatment with 
phenobarbitone, the division of rat hepatocytes into 
12 subpopulations by sedimentation velocity analysis 
(Sweeney dt at., 1978b) produced continuous density-volume 
characteristics. The volumes of centrilobular hepatocytes 
appeared to be greater than those of periportal cells, 
and the difference seen in control animals was exaggerated 
by pretreatment with phenobarbitone (Sweeney dt at.,
1978a,b). This observation correlates with the proliferation, 
preferentially in centrilobular hepatocytes, of smooth 
endoplasmic reticulum (Gumucio dt aZ., 1978b), and with 
the overall increase observed in liver size.
Pretreatment of rats with isosafrole resulted in 
a median lobe lobular distribution of cytochrome P-450 
that was qualitatively similar to the distribution seen 
after the injection of phenobarbitone. Despite the 
relatively wide bandwidth of the UMSP I, it proved 
possible to clearly distinguish the shift to 455nm of the 
isosafrole metabolite-cytochrome P-450 complex, previously 
observed tn vtvo and Zvi vZVio (see Dickins, 1978; Fennell, 
1980). This is the first time that the characteristic
peak of the complex has been shown in fresh, frozen liver 
sections. The absorbance difference at 455nm was used as 
an expression of relative concentration of cytochrome P-450 
because of the uncertainty of the effects of incubation 
in these circumstances with agents (Elcombe dt at.,
1977) capable of displacing the metabolite complex.
When 3-methylcholanthrene was administered to 
rats, considerable variation of response was seen, whether 
among individual animals, or among lobules located in 
a single section of median, left or right lobe of liver. 
However, the most commonly observed pattern of cytochrome 
P-448 increase, resulting in a similar cytochrome concen­
tration across the lobular radius, agrees broadly with the 
findings of Baron and coworkers (1982), although these 
authors reported that the induction of cytochrome P-448 
was rather more pronounced in the midzonal and periportal 
regions of median lobe lobules. The antisera of Baron and 
colleagues (1982) allowed them to distinguish between
3-methylcholanthrene- and phenobarbitone-inducible 
cytochromes P-448 and P-450. Microspectrophotometry does 
not permit the separation of the cytochrome P-450 peak 
into separate components; nonetheless, it may be inferred 
that less induction occurs centrilobularly after pretreatment 
with 3-methylcholanthrene, by comparison of the shapes- 
and heights of distributions obtained in induced and 
untreated rats.
Preliminary experiments with tissue from female 
rats suggests that there is no difference in the median 
lobe lobular distribution of cytochrome P-448 between 
sexes; nor is there a recognisable variation of pattern 
seen among the 3-methylcholanthrene-induced levels of 
cytochrome P-448 in median, left and right liver lobes of 
male rats. The higher degree of interindividual variation 
found is to be expected as one progresses from the 
estimation of the thoroughly averaged cytochrome P-450
content of microsomal preparations to liver lobes or 
lobules, and then to single cells.
However, one consistent, and potentially 
important, finding was the lower concentration of cytochrome 
P-450 in hepatic right lobe lobules of untreated male 
rats. These microspectrophotometric results are borne 
out tentatively by SDS-polyacrylamide disc gel electro­
phoresis of microsomes and, clearly, by the spectral 
estimation of cytochrome P-450 concentrations in such 
microsomes. The former technique also suggests that a 
polypeptide band of molecular weight 53000, associated 
with the pretreatment of rats with methylenedioxyphenyl 
compounds (Fennell, 1980), is more induced in liver 
right lobe microsomes by 3-methylcholanthrene than in 
those from left or median lobes. Most of the interlobar 
difference in cytochrome P-450 concentration is abolished 
by pretreatment of the rats with 3-methylcholanthrene, 
which indicates that the right lobe possesses the same 
inherent capacity for induction as the other lobes. This 
argues against differences in blood supply to individual 
lobes being linked with the lower cytochrome P-450 
concentration in the right lobe, unless maximal induction 
requires only a relatively small amount of the inducing 
agent to be present at the site of induction. Cytochrome 
bp. concentration in microsomes prepared from the liver 
right lobe was also only two-thirds of the concentration 
in microsomes from left or median lobes of untreated 
rats.
In contrast, the right lobe was not markedly 
deficient in its ability to d-deethylate ethoxycoumarin 
or ethoxyresorufin. However, the left lobe appeared to be 
relatively refractory to the induction of ethoxyresorufin 
0-deethylase by 3-methylcholanthrene, resulting in a 
considerably lower capacity of the induced left lobe to 
metabolise this substrate, when compared with the median
lobe. This is significant insofar as ethoxyresorufin 
0-deethylation is supported specifically by cytochrome 
P-448 (Burke and Mayer, 1974, 1975), and the induction 
of cytochrome P-448 by 3-methylcholanthrene does not 
reveal interlobar differences when measured by micro- 
spectrophotometry. Further investigations are required, 
using statistically larger samples, but such observations 
suggest that it may be important to distinguish between 
amount of cytochrome P-448 (or P-450) and its activity.
The reasons for the differential distribution 
of inducible species of cytochrome P-450 are unclear. 
Possibly they are related to different subpopulations 
of hepatocytes, containing proteins specific to the 
induction processes following the administration to rats 
of various agents. The differences in acinar response 
to 3-methylcholanthrene and to phenobarbitone favour this 
explanation more than a fortuitous association of induction 
with the accessibility of hepatocytes to the inducing 
agents. However, the effects of direction of blood flow 
within acini must be considered. Since the central area 
will be relatively poor in blood-borne metabolites and 
oxygen, any increased utilisation of oxygen, including 
an accelerated rate of cytochrome P-450-mediated 
monooxygenation, in the region of the portal venule, 
may render the former area practically anoxic. Hypoxia 
in isolated, perfused rat liver may lead to centrilobular 
anoxia and necrosis, while periportal cells remain 
normoxic (LeMasters dt at., 1981). If favourable metabolic 
conditions in the periportal hepatocytes are a major 
factor in the differential distribution of phenobarbitone- 
inducible cytochrome P-450, it might be expected that, 
if centrilobular cells were destroyed by a selective toxin 
and replaced by regenerated cells derived from the 
periportal/midzonal region, subsequent administration of 
phenobarbitone would still induce the same distribution 
of cytochrome P-450.
Interlobar differences in cytochrome P-450 
concentration may be related to a non-uniform blood supply 
to the lobes; although many studies have been performed 
on blood flow in whole liver (e.g. McDevitt dt &Z., 1977; 
Rice dt aZ., 1977), little information is available 
regarding the regulation of the supply to individual 
lobes. 3-Methylcholanthrene does not increase rat hepatic 
blood flow, whereas the increase mediated by phenobarbitone 
remains only in proportion to the increased liver mass 
(McDevitt dt aZ., 1977). However, rather than variations 
in gross blood supply to different lobes being important, 
what may be found to be of significance is a non-uniform 
perfusion of the peripheral and central regions of each 
lobe. Peripheral areas of rat liver lobes may not be 
well-perfused under normal circumstances (Daniel and 
Prichard, 1951), and it has been demonstrated that 
factors increasing hepatic blood flow enhance the peripheral 
perfusion of the left lobe, and decrease peripheral 
perfusion in the pyramidal portion of the right lobe 
(Tavoloni dt aZ., 1978).
Differential distribution of cytochrome P-450 
within liver lobules obviously has profound implications 
in reactive metabolite-mediated toxicity. Some compounds 
e.g. allyl alcohol, are activated periportally and exert 
their hepatotoxicity there (James dt aZ., 1981). Most 
area-selective hepatotoxins cause centrilobular damage 
e.g. thioacetamide (Hunter dt aZ., 1977), bromobenzene 
(Mitchell and Jollow, 1975; Mitchell dt clZ . ,  1975) or 
carbon tetrachloride (Sipes dt clZ . , 1977; Villarruel dt clZ .,
1977), and their potency may be modulated by inducers or 
inhibitors of cytochrome P-450 (Gillette dt aZ., 1974;
Hunter dt aZ., 1977).
Furthermore, several other enzymes potentially 
involved in foreign compound metabolism have been reported 
to be non-uniformly distributed in liver. NADPH-cytochrome
P-450 reductase (Baron dt at,, 1978a; Taira dt aZ., 1981) 
and cytochrome 6^ (Redick dt at., 1980) are predominantly 
centrilobular. Of phase II enzymes, epoxide hydrolase 
activity is highest in the centrilobular hepatocytes 
(Bentley dt aZ., 1979; Baron dt aZ., 1980; Waechter dt aZ., 
1982), whereas UDP-glucuronyltransferase is largely 
concentrated in the periportal/midzonal area (James 
dt &Z., 1981). Glutathione appears to be primarily 
periportal in location, at least in the rat liver lobule 
(Smith dt clZ .  , 1979). The relative deficiency of glutathione 
in centrilobular hepatocytes may in part explain their 
susceptibility to attack by reactive species. Also, if 
activation of hepatotoxic agents occurs mainly in the 
centrilobular hepatocytes, and conjugative mechanisms 
are most important in the periportal cells, then because 
of the direction of acinar blood flow there is an increased 
danger of active metabolites passing into the j  extrahepatic; 
circulation.
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4. TOXICOLOGICAL AND CLINICAL STUDIES OF SOME
0- AND N-CONTAINING KETEROCYCLES: STRUCTURE-
ACTIVITY RELATIONSHIPS
4.1. Introduction
Many oxygen-containing heterocyclic compounds of 
both synthetic and natural origin are known, and a considerable 
proportion of these chemicals exert toxic, pharmacological 
or physiological actions in man, or in other mammals 
(for general reviews, see Elderfield, 1951; Dean, 1963).
Among these compounds, furan, and several substituted 
furans, have been reported to show species- and organ- 
selective toxicity (McMurtry and Mitchell, 1977; Boyd,
1980a,b), while 1,3-benzodioxole and many of its side 
chain-substituted derivatives are acutely toxic and, 
several, carcinogenic (Borchert dt at., 1973; Hodgson 
and Philpot, 1974; Crampton dt aZ., 1977). Oxiranes 
(1,2-epoxides) are widespread in nature, and are now 
accepted as a class of heterocycles, rather than as 
substituents'(Cross, 1960). Metabolism to 1,2-epoxides 
is implicated in the toxicity and carcinogenicity of 
numerous organic species, including various 0-heterocycles 
(Garner,1976).
The administration of some 0-heterocycles to 
animals has been shown to affect the concentrations 
of various protein components of the hepatic endoplasmic 
reticulum. T^a.^4-Stilbene oxide has been reported to 
induce epoxide hydrolase in rat liver microsomes 
(Schmassmann and Oesch,•1978), and was thought to be 
relatively specific for this enzyme. However, a broad 
spectrum of enzyme activities, including those of 
cytochrome P-450-associated monooxygenases, UDP-glucuronyl- 
transferase and the cytosolic glutathione S-transferases, 
has since been shown to be increased by the administration 
to rats of f^t&fi^-stilbene oxide (Elmamlouk and Mukhtar,
1979; Seidegard at at. , 1979). Preliminary studies 
(Fennell, 1980; Fennell at at., 1980) have indicated that
2,3-benzofuran increases the staining intensity of band 1 
(48000 MW) upon SDS-polyacrylamide disc gel electro­
phoresis. This band is increased by VianA-stilbene oxide, 
and is proposed to represent epoxide hydrolase. The effect 
of pretreatment of rats with benzofuran was investigated 
further, to characterise more fully the identity of band 1, 
and to compare the effects of benzofuran on other hepatic 
drug-metabolising enzymes with those of VianA-stllbene 
oxide. Various other heterocyclic compounds (Table 4.1.) 
possessing a saturated or unsaturated ring containing 
1 or 2 oxygen atoms were also studied, to determine more 
about the structural requirements for the induction of 
epoxide hydrolase, and the relation of structure to 
toxicity. The nitrogen analogue of benzofuran, indole, 
and a possible metabolite of benzofuran, o-hydroxyphenyl- 
acetic acid, were investigated. Characterisation of the 
effects of these compounds was approached vta a broadly 
based analysis of serum and microsomal parameters, ptuA 
histological and histochemical staining of liver and 
other tissues.
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4.2. Results
4.2.1. Observations on animals during dosing, and at 
post-mortem
Controls
Control rats, pretreated with corn oil only, 
maintained a constant rate of weight gain, and a consistent 
food and water intake, during the period of dosing 
(Table 4.2.). They remained alert and in good general 
health. About 10% of these animals entered the handling 
facilities with infections of one or both eyes, characterised 
by slight inflammation and an appearance of black 
’surgical stitches’ in the flesh immediately adjacent to 
the eye. Occasionally this condition arose during dosing. 
Complete closure of the eyes occurs usually only after a 
prolonged period.
At post-mortem, control animals were well-- 
fleshed, possessed a normal amount of fat and muscle 
bulk, and gross pathological changes were absent from all 
organs examined. However, small, thin ’sheets’ of fat 
were frequently observed adhering to the surface of, 
particularly, the median lobe of the liver. These sheets 
were easily lifted away, and appeared to be a result of 
the administration of corn oil, since they were absent 
from completely untreated rats.
Furan (I)
Rats pretreated with furan (1.5mmol/kg for 3
consecutive days) did not differ in behaviour from controls,
*
although they were evidently undernourished. Their rate 
of weight gain was reduced to about 25% of that of the 
controls, whereas food consumption fell to 72% of the 
control values (see Table 4.2.). The higher dose, level 
(3.7mmol/kg per day for 3 days) caused a loss of weight, 
and food consumption fell to 47% of the control value.
In both cases, water intake was maintained normally. Furan 
administered at 5.0mmol/kg proved to be acutely very 
toxic, and uniformly lethal.
At post-mortem, rats showed a reduction in their 
amount of body fat, which was apparently dose-related. 
Livers appeared pale, and the mean relative liver weights 
were increased by factors of 1.14 and 1.35 for low- and 
high-dose groups respectively (Table 4.3.).
Dihydrofuran (II)
This compound caused no apparent gross effects 
when administered to rats at 3.6mmol/kg for 3 days, 
either during dosing or at post-mortem, except for a 
slight increase in mesenteric fat deposition.
2,3-Benzofuran (III)
Rats receiving benzofuran (5.0mmol/kg for 3 
days) rapidly exhibited tremors, weakness and loss of 
balance, which persisted for about one hour after the 
first i.p. administration. Occasionally, profuse salivation 
occurred shortly after dosing. Animals usually entered a 
recovery phase after this. The same pattern was repeated 
on the second and third days, although recovery was 
progressively delayed. A small number of rats died, 
generally on the third day, and within an hour of dosing. 
Almost all of the rats given benzofuran developed eye 
infections as described above, many severely, sometimes 
proceeding to complete closure of the eyes within 3 
days. Animals appeared emaciated and dehydrated, irritable, 
and with staring fur, although remaining mobile and 
reasonably alert. The rate of weight loss accelerated 
as dosing progressed, but, typically, an animal weighing 
200g lost 1Og in the first 24 hours. Overall weight 
reduction attained 16% of the initial weight in an 
extreme example.
Diminished and yellowed body fat was noted at
post-mortem, with some muscle wastage. Livers were friable 
and soft, and exhibited variable degrees of fat deposition. 
Mean relative liver weight was increased by a factor of 
1.57 relative to controls (Table 4.3*). Urinary bladders 
were distended, and contained discoloured urine.
Dihydrobenzofuran (IV)
When administered i.p at a level of 5.0mmol/kg 
per day for 3 consecutive days, dihydrobenzofuran provoked 
no apparent changes in the behaviour and appearance of 
rats. A higher dose level (7.5mmol/kg for 3 days) caused 
initial loss of balance, followed by prostration. The 
animals had largely recovered by 12 hours after dosing, 
and the righting reflex remained unimpaired. Cloudiness 
and ’pitting' of the cornea was noted. Food consumption 
and rate of bodyweight gain exhibited a dose-related 
reduction relative to controls (Table 4.2.). Water intake 
was also lowered significantly in the higher dose group.
At post-mortem, animals from both groups showed 
variable amounts of fat deposition on liver, kidney and 
spleen. Deposits on the liver were superficial, and 
easily lifted away. Relative liver weights were increased 
significantly in both groups in a dose-related manner. 
Animals given 7.5mmol/kg of dihydrobenzofuran appeared to 
retain less body fat than controls.
Dibenzofuran (V)
Animals receiving dibenzofuran (5.0mmol/kg for 
3 days) remained alert, and normal in appearance. Rates of 
weight gain and food consumption were lowered, but displayed
high interindividual variation, and means were not signifi­
cantly different from control means (Table 4.2.). No 
gross pathological indications were noted at post-mortem, 
except for a marked increase in liver weight (mean relative
liver weight = 1.35 x control).
2-Coumaranone (VI)
When administered to rats at a level of 5.0mmol/kg 
per day for 3 consecutive days, 2-coumaranone produced no 
notable changes in behaviour, weight gain or food and 
water intake. At post-mortem, superficial fat deposits on 
the liver median lobe were seen, with numerous, more 
deeply embedded, deposits on the spleen.
1,3-Benzodioxole (VII)
Benzodioxole (5.0mmol/kg for 3 days) proved to 
be acutely very toxic. Animals died rapidly and were found 
to have extensively fatty livers, and inflamed large and 
small intestines at post-mortem. At 3.75mmol/kg per day 
for 3 consecutive days, benzodioxole caused tremors and 
loss of balance for short periods, with impairment of 
the righting reflex. Mean body weight fell during the 
first two days, but much of this loss was regained over 
the last 24-hour period. Food and water consumption were 
significantly reduced, with no later increase to coincide 
with the change in weight gain characteristics.
At post-mortem, livers were friable and mottled, 
the intestines were distended, and in two animals the 
caecal contents were liquid and foul-smelling. Relative 
liver weight was slightly, but significantly, increased.
Safrole (VIII)
Animals receiving safrole i.p. (5.0mmol/kg for 
3 days) exhibited lethargy and uncertain balance. One 
animal developed exophthalmia., and pitted corneas. An 
overall reduction in bodyweight (Table 4.2.) was noted, 
although one rat gained weight during the first 24 hours, 
and another during the first 48 hours, before rapid and 
severe losses. Food consumption paralleled bodyweight 
changes, whereas water intake was lowered throughout the 
.dosing period.
At post-mortem, livers were mottled, soft and
friable. Mean relative liver weight was increased, but not 
to statistical significance, because of rather high 
individual variations. One rat exhibited splenic enlargement.
Isosafrole (IX)
High doses of isosafrole (5.0mmol/kg) were 
acutely extremely toxic, and rats had to be killed when 
observed to be moribund, following two doses. These 
animals had fatty livers, bloody caeca, and urine heavily 
contaminated with blood.
The administration of 3.75mmol/kg isosafrole for 
3 days invoked a pattern of response similar to that seen 
after the administration of benzodioxole, although food 
consumption was much more drastically reduced (Table 4.2.).
A sharp rise in water consumption during the third 24-hour 
period paralleled a stabilisation of bodyweight after an 
initial loss, but food intake did not increase at the same 
time.
Body fat at post-mortem was reduced in amount.
Liver surfaces were mottled and pale, and mean relative 
liver weight was increased by a factor of 1.37 when 
compared with controls.
T4afl/£-Stilbene oxide (X)
Of three rats dosed with 4.0mmol/kg of tACLnA- 
stilbene oxide, two died within 12 hours. The survivor, 
given 2.Ommol/kg on each of the two following days, exhibited 
loss of balance, followed by a short period of unconsciousness, 
after each injection. Food intake was low (Table 4.2.), 
and weight loss per day erratic during the 3 days. By 
contrast, rats receiving 1.5mmol ^an4-stilbene oxide/kg 
per day for 5 days showed very little evidence of toxicity 
during dosing.
At post-mortem, the livers of rats from both 
groups were pale, hard in texture, and increased in weight 
relative to those excised from control animals.
D/L^Ao-Hydroxyphenylacetic acid (XI)
When administered to rats at a dose level of 
5.0mmol/kg per day for 3 consecutive days, o-hydroxyphenyl- 
acetic acid caused no major behavioural changes and had 
no significant effect on food intake or weight gain.
Water consumption was raised significantly. The abdominal 
region of the rats also became sensitive to pressure. At 
post-mortem, the only notable effect observed was that of 
mild inflammation of the small intestine.
Coumarin (XII)
A single dose of 5.0mmol coumarin/kg administered 
i.p. was rapidly lethal. The regimen used (0.68mmol/kg 
for 3 consecutive days) produced lethargic animals with 
’puffy' faces and staring fur. The rate of weight gain 
was reduced severely (Table 4.2.), although food intake 
was much higher during the second and third days of dosing 
than during the first. The high standard deviation caused 
by this is the sole reason for the mean food intake being 
not significantly low. Water consumption followed the 
same pattern. Reduced amounts of body fat, and superficial 
fat deposits on the liver, were seen at post-mortem.
Indole (XIII)
When administered to rats at 5.0mmol/kg i.p., 
a single dose of indole caused severe tremors and convulsions, 
culminating in death within 15 minutes. If 1.25mmol indole/kg 
was given per day for 3 days, considerable tremors occurred 
during the 20 minutes following each injection, but a 
few hours afterwards.the rats were indistinguishable from 
control animals. Food consumption declined slightly, 
although weight gain remained within normal limits.
Post-mortem examination revealed no significant pathological 
lesions.
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4.2.2. Protein yields
Protein yields in both whole liver homogenates 
and in resuspended microsomes are shown in Table 4.3.
Compounds that increased the specific content of protein 
in whole liver homogenate are also listed in Table 4.4., 
with both whole homogenate and microsomal protein yields 
expressed as percentage of control. Dihydrofuran and 
dihydrobenzofuran pretreatment of rats preferentially 
increased the yield of non-microsomal protein, whereas 
safrole, isosafrole and tAan*-stilbene oxide pretreatment 
increased microsomal protein recovery by a greater proportion. 
Pretreatment of the rats with either benzofuran or benzodioxole 
increased the protein yields of both preparations by a 
similar factor.
4.2.3. Microsomal components
SDS-polyacrylamide disc gel electrophoresis
The results of SDS-polyacrylamide disc gel electro­
phoresis of microsomes obtained from rats pretreated with 
furan or one of several substituted furans are shown in 
Figure 4.1. Furan (both dose levels), dihydrobenzofuran 
(low and high dose levels), dibenzofuran and benzofuran 
pretreatment of rats all increase the staining intensity 
of band 1 (48000 MW), with the most pronounced effect 
being elicited by benzofuran or dibenzofuran. Furan appears 
to produce a dose-related increase in band 1, which is less 
evident in the case of dihydrobenzofuran. Benzofuran and 
furan (dose-related) cause a decrease in the intensity of 
band 3 (50000 MW). Benzofuran also provokes the appearance 
of a protein band of MW about 51500, which is not evident 
in microsomes prepared from corn oil-pretreated animals. 
Microsomes prepared from animals receiving dibenzofuran 
also show this band, but to a lesser extent, and it appears
Table 4.4. Whole homogenate and microsomal protein yields, expressed 
as percentage of control values, for liver preparations 
from rats pretreated with some 0-heterocycles
Pretreatment Protein yield {% control)
Whole homogenate Microsomes
Corn oil (control) 100 100
Dihydrofuran 119 94
Benzofuran 120 120
Dihydrobenzofuran
(7.5mmol/kg x 3 days) 120 98
Benzodioxole 120 121
Safrole 116 158
Isosafrole 114 126
PtaH'i-Stilbene oxide
(1.5mmol/kg x 5 days) 117 126
Protein yields were originally calculated as mg protein/g 
wet weight liver.
Figure 4.1.
SDS-Polyacrylamide disc gel electrophoresis of liver 
microsomes prepared from rats pretreated with furan or 
one of several substituted furans
2 4 6 8 10 12 14 16 18
Solubilisation and electrophoresis of microsomal proteins 
were achieved as described in 2.8. The gel was stained with 
Coomassie Blue R-250. Samples (15yg protein) were applied in 
the following order:
2,3 corn oil
4,5 benzofuran 5.Ommol/kg
6,7 furan 1.5mmol/kg
8,9 f uran 3.7mmol/kg
11,12 dihydrobenzofuran 5.Ommol/kg
13,14 dihydrobenzofuran 7.5mmol/kg
15,16 dihydrofuran 3.6mmol/kg
17,18 dibenzofuran 5.Ommol/kg
1,10,19 contained molecular weight standards
less intensely still in those from animals pretreated with 
dihydrobenzofuran. This band may similarly be present 
in microsomes prepared from one of the rats receiving furan 
at 3.7mmol/kg (Figure 4.1., track 8). Electrophoretic 
patterns of microsomes from rats pretreated with furans 
that cause the appearance of the 51500-52000 MW band are 
shown with greater resolution in Figure 4.2. Benzofuran also 
appears to increase the staining intensity of several 
unidentified low molecular weight protein bands.
Figure 4.3. illustrates the increase in band 1 
when hepatic microsomal epoxide hydrolase purified from 
male University of Surrey Wistar rats is added to microsomes 
prepared from control and benzofuran-pretreated rats.
The purified protein runs coincidentally with the 48000 MW 
band (band 1) in both instances.
Safrole, isosafrole and benzodioxole all increase 
the 53000 MW band (Figure 4.4.) in order of potency 
isosafrole > safrole > benzodioxole. Safrole and isosafrole 
pretreatment also increase slightly the staining intensity of 
band 1, and the latter compound may also increase band 3 
to a small degree. There is, furthermore, some apparent 
induction of the 51500-52000 MW band in microsomes obtained 
from rats injected with benzodioxole.
Pretreatment of rats with coumarin, indole, 
2-coumaranone or o-hydroxyphenylacetic acid do not increase 
or decrease the staining intensity of any of the major bands 
in the 48000-55000 MW region (Figure 4.5.), although 
o-hydroxyphenylacetic acid may induce a very small amount 
of the 51500-52000 MW protein.
‘Ptan^-Stilbene oxide pretreatment induces band 1 
(Figure 4.6. ). When a dosing regimen of 4.0mmol VianA- 
stilbene oxide/kg i.p. followed by two successive daily doses 
of 2.Ommol/kg is employed, there appears to be a diminution 
in band 3 (although underloading of the relevant sample well 
might also account for this), whereas pretreatment with 
1.5mmol VianA-stilbene oxide/kg for 5 consecutive days
Figure 4.2.
SDS-Polyacrylamide disc gel electrophoresis of liver 
microsomes prepared from rats pretreated with furan, 
dihydrobenzofuran or dibenzofuran
Solubilisation and SDS-polyacrylamide disc gel electrophoresis 
of microsomal proteins were achieved as described’ in 2.8. 
Samples (70pg protein) were applied in the following order: 
Well 2 furan 3*7mmol/kg
3 dihydrobenzofuran 7.5mmol/kg
4 benzofuran 5.Ommol/kg
5 dibenzofuran 5.Ommol/kg
Well 1 contained molecular weight standards
Figure 4.3*
SDS-Polyacrylamide disc gel electrophoresis of liver 
microsomes prepared from rats pretreated with benzofuran. 
Comparison with purified rat liver microsomal epoxide 
hydrolase
Sample pretreatment and SDS-polyacrylamide disc gel 
electrophoresis were carried out as described in 2.8. 
Samples (80yg protein) were applied as follows:
Well 2 corn oil
3 corn oil + 4.6pg purified rat liver microsomal
epoxide hydrolase added to well
4 benzofuran
5 benzofuran + 4.6pg purified rat liver microsomal
epoxide hydrolase added to well
6 epoxide hydrolase, 11.5yg, purified from rat
liver microsomes
Well 1 contained molecular weight standards
Figure 4.4.
SDS-Polyacrylamide disc gel electrophoresis of liver 
microsomes prepared from rats pretreated with benzodioxole, 
safrole or isosafrole
2 " 4 6 8 10 12 14 16 18
Sample pretreatment and SDS-polyacrylamide disc gel 
electrophoresis were carried out as described in 2.8. 
Samples (15yg protein) were applied as follows:
Wells 2,3,17,18 corn oil
4,5,6 safrole 5.Ommol/kg
7,9 benzofuran 5.Ommol/kg
10,11,12 isosafrole 3-75mmol/kg
14,15,16 benzodioxole 3.75mmol/kg
Wells 1,8,13,19 contained molecular weight standards
Figure 4.5.
SDS-Polyacrylamide disc gel electrophoresis of liver 
microsomes prepared from rats pretreated with 2-coumaranone, 
o-hydroxyphenylacetic acid, indole and coumarin
• t l t a l M f i t l l M i l i
2 4 6 8 10 12 14 16 18
Sample pretreatment and SDS-polyacrylamide disc gel 
electrophoresis were carried out as described in 2.8. 
Samples (15pig protein) were applied in the following order: 
Wells 2,11 corn oil
2-coumaranone 
benzofuran
3,4,5 
6, 15 
7,8,9
5.Ommol/kg 
5.Ommol/kg
o-hydroxyphenylacetic
acid
12,13,14 indole 
16,17,18 coumarin
5.Ommol/kg 
1.25mmol/kg 
0.68mmol/kg
Wells 1,10,19 contained molecular weight standards
Figure 4.6.
SDS-Polyacrylamide disc gel electrophoresis of liver 
microsomes prepared from rats pretreated with benzofuran 
or tSLanA-stilbene oxide
10
Sample pretreatment and SDS-polyacrylamide disc gel 
electrophoresis were carried out as described in 2.8. 
Samples (40yg protein) were applied as follows:
Wells
Wells
2.9 
3
4,6,8
5,7
1.10
corn oil
tsicinA-stilbene oxide 4.Ommol/kg x 1 
+ 2.Ommol/kg x 2
benzofuran 5.Ommol/kg
tA.anA-stilbene oxide 1.5mmol/kg x 5
contained molecular weight standards
day
days
days
apparently induces band 3. In both cases, a band of 
51500-52000 MW is induced.
Generation of 455nm peak
Reduced mZna^ oxidised spectra measured on liver 
microsomal fractions obtained from rats pretreated with 
benzodioxole, safrole or isosafrole exhibited a peak with 
= ^55n:n, which is not evident in similarly treatedmax
microsomes obtained from control animals (Figures 4.7. and 
4.8.). The 427nm component of the spectrum is also increased 
compared with that of the control. None of the other 
compounds used in this study elicited the presence of the 
455nm peak (Table 4.5.).
Cytochrome P-450
Of the furan-like series of compounds, pretreatment
with furan itself greatly reduced the specific content of
hepatic microsomal cytochrome P-450, although in a non-
dose-related manner (Table 4.6.). Benzofuran caused a lesser,
although still highly significant, decrease. Pretreatment
of the rats with safrole, isosafrole or benzodioxole all
elicited an increase in cytochrome P-450 levels, when the
amount of the. cytochrome present was measured after the
displacement of the metabolite complex with 2-n-heptyl-
benzimidazole. Isosafrole invoked the largest increase in
cytochrome P-450 levels, correlating with the largest
455nm complex produced In v l^ v o , and the greatest increase
in the 53000 MW band upon SDS-polyacrylamide disc gel
electrophoresis.
The carbon monoxide reduced mZnu^ reduced spectra
of microsomes prepared from rats pretreated with the
chemicals used in this study all showed a peak with Xmax =
450nm, except that benzofuran shifted the to 451-452nm,max
and ViCLviA - stilbene oxide (4. Ommol/kg x 1 day, 2. Ommol/kg 
x 2 days) caused a smaller shift to 450.5-451nm. No conclusive 
evidence of a peak wavelength change was noted when using
Figure 4.7.
Reduced ntinuA oxidised spectrum of hepatic microsomes prepared from 
rats pretreated with safrole
0.01A
I I I I  I I I I I I I 
400 420 440 460 480 500
nm
Microsomes prepared from rats pretreated with safrole (5.Ommol/kg i.p. 
in corn oil x 3 days) were diluted with 66mM Tris-HCl, pH 7.4, to 
give a protein concentration of .1 mg/ml. The suspension was divided 
equally between two cuvettes, and a baseline of equal light absorbance 
was established. Solid sodium dithionite (1mg) was added to the 
sample cuvette, and the spectrum recorded.
Figure 4.8.
Reduced mcnuA oxidised spectrum of hepatic microsomes prepared from 
rats pretreated with corn oil (controls)
0.01A
I
- 4 00
I
4 20
I
440
I
4 60
I
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I
5 00
nm
Microsomes prepared from rats pretreated with corn oil (2.5ml/kg i.p. 
x 3 days) were diluted with 66mM Tris-HCl, pH 7.4, to give a protein 
concentration of 1mg/ml. The suspension was divided equally between 
two cuvettes, and a baseline of equal, light absorbance was established. 
Solid sodium dithionite (1mg) was added to the sample cuvette, and 
the spectrum was recorded.
Table 4.5. . Spectral properties of liver microsomes prepared from rats 
pretreated with 0- and W-containing heterocycles
Treatment Dose level A, nor/m& Pr°tein
(mmol/kg)
Corn oil 0.002 + 0.001
Furan 1.5 0.001 + 0.001
3.7 0.002 + 0.001
Dihydrofuran 3.6 0.001 + 0.001
Benzofuran 5.0 0.002 + 0.002
Dihydrobenzofuran 5.0 0.000 + 0.000
7.5 0.002 + 0.001
Dibenzofuran 5.0 0.002 + 0.002
2-Coumaranone 5.0 0.001 + 0.001
Benzodioxole ' 3.75 0.005 + 0.002
Safrole 5.0 0.015 + 0.002
Isosafrole' 3.75 0.031 + 0.007
o-Hydroxyphenylacetic acid 5.0 0.000 + 0.000
Coumarin 0.68 0.001 + 0.001
Indole 1.25 0.001 + 0.001
PtcutS-Stilbene oxide ^
6
4.0 x 1 day 
+2.0 x 2 days 0.001 + 0.001
1 . 5 x 5  days 0.001 + 0.001
Rats received corn oil or the compounds indicated by injection i ., p . for
3 days, except for ^/caw^-stilbene oxide, for which the dosing levels, and 
periods were as shown.
All values are mean ± standard deviation of data from at least 3 
experiments, except
animal, ^2 animals
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microsomes from rats pretreated with an*-stilbene oxide
at a level of 1.5mmol/kg for 5 days.
Cytochrome 6,- ------------- o
Microsomal cytochrome b^ levels were decreased by 
pretreatment of rats with benzofuran, and in a non-dose- 
related manner by furan (Table 4.6.). Benzodioxole, safrole 
and isosafrole all increased the specific content of 
hepatic microsomal cytochrome 6^, to a degree not correlated 
with the increase in cytochrome P-450 concentration elicited 
by these compounds, whether the latter parameter was 
expressed pre- or post-displacement with 2n-heptylbenz- 
imidazole.
Ethoxycoumarin O-deethylase and ethoxyresorufin fl-deethylase
Ethoxycoumarin 0-deethylase was decreased in a 
non-dose-related manner by the pretreatment of rats with 
furan (Table 4.6.), whereas ethoxyresorufin 0-deethylase 
activity was, anomalously, reduced severely only at the 
lower dose level. Benzofuran decreased the activity of 
ethoxycoumarin 0-deethylase to 45% of the control value, 
and lowered ethoxyresorufin 0-deethylase activity to a 
greater extent (to 16% of control). Pretreatment with 
dihydrobenzofuran caused a dose-dependent increase in both 
activities, whereas pretreatment with dibenzofuran enhanced 
significantly only ethoxycoumarin 0-deethylase activity. 
Benzodioxole, safrole and isosafrole all elevated both 
activities to a degree correlating with their order of 
induction potency for cytochrome P-450. Pretreatment with 
Vi&viA-stilbene oxide induced or activated ethoxycoumarin 
0-deethylase activity alone, up to 3.2 time.* control 
activity (Table 4.6.).
Epoxide hydrolase
Several of the compounds studied caused an increase 
in hepatic microsomal epoxide hydrolase activity ([7— 3H] —
styrene oxide substrate) when administered to rats by 
i.p. injection. Of furan and the substituted furans, benzofuran 
and dibenzofuran produced the maximum enhancement of activity 
(fold increase of means 3.09 and 2.91 respectively). 
Benzodioxole, safrole and isosafrole all caused a moderate 
increase in activity. 7><zn4-Stilbene oxide pretreatment 
resulted in an activity of 2.4 tZme.* control activity.
These observations correlate broadly with the ability of 
the compounds to increase band 1 upon SDS-polyacrylamide 
disc gel electrophoresis (see above).
Glucose-6-phosphatase
Glucose-6-phosphatase activity in whole liver 
homogenate was depressed by pretreatment of rats with any one 
of several furans, including benzofuran (to 36.5% of 
control), whereas the methylenedioxyphenyl compounds 
exhibited a trend towards increased activity (Table 4.7.).
The single animal dosed with tk&viA-stilbene oxide at a 
level of 4.0mmol/kg x 1 day p£u4 2.0mmol/kg x 2 days also 
exhibited a markedly diminished activity.
Haem oxygenase
Haem oxygenase activity was elevated considerably 
by pretreatment with benzofuran (27.8-fold), and in a 
dose-related way by dihydrobenzofuran (Table 4.7.). TJianA- 
Stilbene oxide pretreatment also increased haem oxygenase 
activity in rat liver, particularly in the animal given 
4.0mmol tAan^-stllbene oxide/kg on the first day, followed 
by two injections of 2.0mmol/kg (26.5-fold increase).
4.2.4. Soluble liver components
Glycogen
Several compounds, particularly benzofuran and 
safrole, elicited a decrease in the.glycogen content of 
digested rat liver (Table 4.8.). However, pretreatment with
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Table 4.8. Effects of pretreatment with 0- and W-containing
heterocycles upon rat liver glycogen and glutathione levels
Treatment Dose level Glycogen Glutathione
(mmol/kg) (ymol glucose (ymol/g
equivalents/ liver)
g liver)
Corn oil 415 + 21 4.82 + 0.613
Furan 1.5 239 + 186 8.09 + 4.295
3.7 295 + 43C 7.91 + 0.629C
Dihydrofuran 3.6 413 + 17 4.21 + 0.733
Benzofuran 5.0 113 + 69d 10.35 + 2.492C
Dihydrobenzofuran 5.0 449 + 91 7.87 + 0.548C1
7.5 337 + 49 8.67 + 0.453d
Dibenzofuran 5.0 1428 +
A _ d 
213 9.23 + 1.498C
2-Coumaranone 5.0 458 + 69 5.36 + 0.427
Benzodioxole 3.75 362 + 60 7.25 + 1.309
Safrole 5.0 40 + 36e 5.87 + 1.518
Isosafrole 3.75 297 + 2 d 6.80 + 1.235
o-Hydroxyphenylacetic
acid 5.0 379 + 178 4.99 + 1.463
Coumarin 0.68 361 ± 47 8.07 + 0.823C
Indole 1.25 251 + 55C 5.98 + 0.594
Pt£lft6-Stilbene oxide*1
6
4.0 x 1 day 
+2.0 x 2 days
293 6 .54
1 . 5 x 5  days 297 + 49 5.32 i 0.31
Rats received corn oil (2.5ml/kg) or the compounds indicated by injection
i.p. for 3 days, except for £/iclvi6 - stilbene oxide, for which dosing levels
and periods were as shown. All values are mean ± standard deviation of data
a  b
from at least 3 animals, except 1 animal, 2 animals.
CP<0.05 dP<0.005 eP<0.0005
dibenzofuran caused a B.^-fold increase in hepatic 
glycogen levels with respect to controls.
Glutathione
Several furans, particularly benzofuran, increased 
hepatic glutathione levels after 3 days1 of pretreatment 
(Table 4.8.). Coumarin was the only other compound to 
produce a significant change.
4.2.5. Serum parameters
Serum enzymes
Pretreatment of rats with benzofuran or furan 
(3.7mmol/kg x 3 days) caused the broadest spectrum of 
elevated activity among the six serum enzymes considered 
(Tables 4.9. and 4.10.). Benzofuran had a more pronounced 
effect on the aminotransferases, and on y-glutamyltransferase, 
whereas furan elicited a more marked, and dose-related, 
effect on sorbitol dehydrogenase activity. Aspartate 
aminotransferase activity was increased by pretreatment 
with several other substituted furans, but decreased by 
pretreatment with dihydrobenzofuran (7.5'mm'ol/kg x 3 days).
None of the methylenedioxyphenyl compounds studied produced 
a significant change in serum enzyme activities. TAanA- 
stilbene oxide increased some activities in the single 
high-dose rat (Tables-4.9.■■and.-4.10,)-...
Serum bilirubin
Furan (3.7mmol/kg x 3 days) elevated serum total 
bilirubin levels almost 4-fold, but the increase remained 
statistically insignificant because of high interindividual 
variation (Table 4.11.). This variability did not correlate 
with the marked individual differences also observed in 
alanine aminotransferase activity. Pretreatment with 
benzofuran increased serum total bilirubin concentration 
9.8-fold, and conjugated bilirubin 13•1-fold, while
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Table 4.11. Effects of pretreatment with 0- and W-containing 
heterocycles upon rat serum bilirubin levels
Treatment Dose level 
(mmol/kg)
Total
bilirubin
(yM)
Conjugated
bilirubin
(yM)
Corn oil 
Furan
Dihydrofuran 
Benzofuran 
Dihydrobenzofuran
Dibenzofuran 
2-Coumaranone 
Benzodioxole 
Safrole 
Isosafrole
O-Hydroxyphenylacetic 
acid
Coumarin 
Indole
TA.an6-Stilbene oxide*1 4.0 x 1 day
+2,0 x 2 days
^ 1.5 x 5 days
1.5 
3.7
3.6
5.0
5.0 
7.5
5.0
5.0 
3.75
5.0 
3-75
5.0 
0.68 
1.25
2.23 ± 1.52
2.30 ± 0.35 
8.89 ± 4.70
3.98 ± 1.53
21.9 ± 11.50*
4.17 ± 2.06 
2.76 ± 0.16
2.53 ± 0.25
4.67 ± 1.61
NE
2.41 ± 1.48 
2=68 ± 0,26
1.79 ± 0.70 
2.50 ± 0.19 
2.63 ± 0.18
6.91 
2.56 ± 0.06
1.13 ± 0.71
0.88 ± 0.25 
1.44 ± 0.54
0.15 ± 0.05
14.80 ± 9.96*
1.28 ± 0.57 
1.72 ± 0.18
0.40 ± 0.51
1.87 ± 0.74
NE
0.03 ± 0.05
1 v n  j- n  1 )i
I • | -i. • I "T
0 .1 2 ± 0 .10  
1.32 ± 0.09 
0.50 ± 0.07
4.58 
1.04 ± 0.19
Rats received corn oil (2.5ml/kg) or the compounds indicated by injection
i.p. for 3 days, except for t/ian6-stilbene oxide, for which dosing levels
and periods were as shown. All values are mean ± standard deviation of data
cl b
from at least 3 animals, except 1 animal, 2 animals. NE = not estimated. 
CP<0.05
VianA-stllbene oxide elicited a lesser increase, but the 
same relative distribution of conjugated and unconjugated 
bilirubin (Table 4.12.).
Serum cholesterol
None of the furans studied produced a pronounced 
change in either total or high-density lipoprotein 
cholesterol levels, except for a 1.8-fold increase in 
total cholesterol in animals pretreated with furan (3-7 
mmol/kg x 3 days), and a 1.7-fold increase in HDL cholesterol 
in rats given 5.0mmol dihydrobenzofuran/kg per day for 3 
days (Table 4.13.). Safrole and isosafrole caused an 
increase in both parameters such that the ratio of HDL 
cholesterol to total cholesterol remained not significantly 
different from control values. T/La*i4-stilbene oxide 
administered under both regimens increased the serum 
total cholesterol concentration, but only as a result of 
the 5-day dosing period was the HDL cholesterol concentration 
elevated concomitantly.
Serum glucose
Pretreatment of rats with furan lowered serum 
glucose levels in a manner unrelated to dose= Benzofuran 
was the only other compound to elicit a similar depression 
in glucose concentration (Table 4.13.)• Despite the increase 
in hepatic glycogen concentration elicited by the adminis­
tration of dibenzofuran, this compound had no significant 
effect on serum glucose content.
Serum total protein and albumin
Pretreatment with benzofuran, dibenzofuran or 
one of the VicLvu>-stilbene oxide regimens employed (4.0 
mmol/kg x 1 day, 2.0mmol/kg x 2 days) lowered both serum 
total protein and serum albumin levels (Table 4.14.).
However, whereas benzofuran and V iclvl^6-stilbene oxide caused 
comparable relative decreases in albumin and globulin 
concentrations when expressed as percentages of control
Table 4.12. Alterations in conjugated and unconjugated bilirubin 
concentrations in serum samples obtained from rats 
pretreated with some 0-heterocycles
Pretreatment Conjugated bilirubin Unconjugated bilirubin
(yM) ($ control) (yM) {% control)
Corn oil 1.13 100 1.10 100
Furan 1.44 127 7.45 677
Benzofuran 14.80 1310 7.10 645
T-tcui^ -Stilbene oxide 4.58 405 2.33 212
Controls were dosed with corn oil (2.5ml/kg) i.p. for 3 consecutive
days.
Benzofuran (5.Ommol/kg) and furan (3.7mmol/kg) were administered i.p. 
in corn oil for 3 days.
Pum^-Stilbene oxide was administered i.p. in corn oil at a level 
of 4.Ommol/kg on the first day, and 2.Ommol/kg on each of 2 succeeding 
days.
Values are means of data obtained from at least 3 rats, except for 
piCLH6-stilbene oxide data, which are from a single animal.
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values, dibenzofuran appeared to produce a selective loss 
of globulin (Table 4.15.).
Serum IgA and IgA Free Secretory Component
Pretreatment with furan invoked a dose-related 
increase in the heights of the rockets obtained when serum 
was electrophoresed against antibodies to either IgA 
or IgA Free Secretory Component (Table 4.14.). Benzofuran 
elicited a marked increase in the serum concentration of 
both proteins, whereas VianA-stilbene oxide had a less 
pronounced effect. None of the other compounds used 
affected serum IgA or IgA Free Secretory Component levels.
4.2.6. Urinalysis
Urine obtained at post-mortem from the bladders 
of rats pretreated with benzofuran was usually coloured 
deep orange-gold, darkening on standing to red-brown, 
than to a cloudy dark brown. Occasional samples were 
cloudy and viscous when first removed. Bilirubin, and 
high concentrations of protein, were consistently present 
(Table 4.16.). Glucose, however, was absent, and this was 
confirmed using thin-layer chromatography in n-butanol/ 
acetic acid/water, with visualisation by aniline-diphenylamine 
reagent. Urine obtained from animals after pretreatment 
with one of several other furans-also showed traces of 
protein, which is not an unusual finding even in untreated 
Wistar rats. Isosafrole pretreatment alone elicited the 
consistent presence of urinary glucose. Some compounds 
(notably dihydrobenzofuran, dibenzofuran and 2-coumaranone) 
caused a rise in urinary pH. Osmolality values measured on 
urine from either corn oil- or test compound-pretreated 
rats were very variable (Table 4.16.).
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Table 4.15. Changes in albumin and globulin concentrations in serum 
samples obtained from rats pretreated with some 
O-heterocycles
Pretreatment Albumin Globulin
(g/dl) (% control) (g/dl) (% control)
Corn oil 3.70 100 1.86 100
Benzofuran 3.01 81.4 1.52 81.7
Dibenzofuran 3.40 91.9 1.50 80.6
TAOJt'6-Stilbene oxide 2.65 71.6 1.29 69.4
Controls were dosed with corn oil (2.5ml/kg) i.p. for 3 consecutive days.
Benzofuran (5.Ommol/kg) and dibenzofuran (5.Ommol/kg) were administered 
i.p. in corn oil for 3 days.
T-tCM/5-Stilbene oxide was administered i.p. in corn oil at a level of 
4.Ommol/kg on the first day, and 2.Ommol/kg on each of the 2 succeeding 
days.
Values are means of data obtained from at least 3 rats, except for 
-tt<m6-stilbene oxide data, which are from a single animal.
Table 4.16. Analysis of bladder urine samples obtained at post-mortem 
from rats pretreated with 0- and W-containing heterocyeles
Pretreatment Bilirubin^ Protein^ Glucose*1 pH Osmolality 
(mmol/kg)
Corn oil - - - 6.0-6.5 1520-2200
Furan (1.5 
mmol/kg) 5.5 620-1425
(3.7mmol/kg) - - - 5.5-6.0 NE
Dihydrofuran - . - - 5.5-6.0 NE
Benzofuran ++ ++++ - 5.2-5.5 1500-2500
Dihydrobenzofuran 
(5.Ommol/kg) 7.5 930-1755
(7.5mmol/kg) - - 7.0-8.0 1050-1925
Dibenzofuran - - 7.5-8.2 855-1625
2-Coumaranone - - 7.5 970-1520
Benzodioxole . _ 5.0-6.0 365-690
Safrole - trace - 5.3-6.5 270-1535
Isosafrole - - ++ 6.0-7.0 675-1475
o-Hydroxyphenyl- 
acetic acid - - 6.0-6.9 520-2115
Coumarin' - - 6.5-7.0 855-1560
Indole - - - 7.0 480-1950
TAa.i^6-Stilbene 
oxide (4mmol/kg 
x 1 day + 2mmol/kg 
x 2 days) - trace
'
5.5 NE
(1.5mmol/kg x 
5 days) trace 5.5 NE
^Bilirubin, protein and glucose were detected using Labstix reagent test 
strips (Ames Co., Stoke Poges, Slough, Berks.).
NE = not estimated.
4.2.7., Haematology
None of the haematological parameters examined 
showed any marked evidence of derangement (Tables 4.17. 
and 4.18.). In a few cases, white blood cell counts were 
significantly, although slightly, elevated, as were some 
values of parameters derived by calculation (mean cell 
volume and mean cell haemoglobin concentration).
4.2.8. Hepatic histology and histochemistry
Morphology and necrosis
Several of the compounds studied produced 
disturbances of liver structure and necrosis, although 
the pattern of effects varied (Table 4.19.). Furan caused 
the highest degree of necrosis, which was centrilobular 
and related to dose (Plates 4.2. and 4.3.). A section of 
liver from a control animal, also stained with haematoxylin 
and eosin, is shown in Plate 4.1. for comparison. Pretreatment 
with benzofuran resulted in scattered focal and single 
cell necrosis (Plate 4.4.), whereas ^(X/a^-stilbene oxide 
elicited centrilobular necrosis (Plate 4.5.), but to a 
lesser extent than did furan. Vacuolation of periportal 
hepatocytes was observed following the administration of 
either safrole or isosafrole. Hypertrophy of hepatocytes 
was noted after treatment with benzofuran, safrole or 
isosafrole.
Glycogen distribution
The pattern of glycogen distribution in a liver 
section from a corn oil-pretreated rat is shown in Plate
4.6. Pretreatment with furan caused a highly specific 
loss of centrilobular glycogen, with little or no effect 
on periportal glycogen content (Plate 4.7.). Benzofuran 
elicited a severe centrilobular decrease in glycogen
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Plate 4.1. Morphology of liver section from a rat pretreated 
with corn oil (2.5ml/kg x 3 days). Fixed tissue 
(Bouin’s fluid), 7ym, stained H+E (x80).
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Plate 4.2. Centrilobular eosinophilia and necrosis in section of liver 
from a rat pretreated with furan (1.5mmol/kg x 3 days). 
Fixed (Bouin’s fluid), 7pm, stained H+E (x312)
'Vvte.
Plate 4.3. Small focus of necrosis in section of liver from a rat
pretreated with furan (1.5mmol/kg x 3 days). Fixed
(Bouin’s fluid), 7pm, stained H+E (x790)
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Plate 4.4. Area of necrosis in section of liver from a rat pretreated 
with benzofuran (5.Ommol/kg x 3 days). Fixed (Bouin’s 
fluid), 7ym, stained H+E (x312)
Plate 4.5. Centrilobular necrosis in section of liver from a rat
pretreated with ;tim6-stilbene oxide (4.Ommol/kg x 1 day, 
2.Ommol/kg x 2 days). Fixed (Bouin’s fluid), 7|im, stained 
H+E (x312)
Plate 4.6. Glycogen distribution in section of liver from a rat 
pretreated with corn oil (2.5ml/kg x 3 days). Fixed 
(Rossman’s fluid), 7ym, stained PAS (x80)
Plate 4.7. Centrilobular loss of glycogen in section of liver from
a rat pretreated with furan (1.5mmol/kg x 3 days). Fixed
(Rossman’s fluid), 7ym, stained PAS (x80)
concentration, whereas the effect of ^/can^-stilbene oxide 
was less marked. Pretreatment with dibenzofuran provoked 
an apparent increase in glycogen content throughout the 
liver sections examined. The safrole-dependent loss of 
glycogen was primarily centrilobular, but that due to 
isosafrole was frequently most extensive in periportal 
hepatocytes (Table 4.19.). In general, the histologically 
determined changes in liver glycogen content correlated 
satisfactorily with those estimated chemically.
Lipid distribution
The distribution of lipid in a section of liver 
from a rat pretreated with corn oil is shown in Plate 
4.8. Pretreatment with benzodioxole, safrole (Plate 4.9.) 
or isosafrole (Plate 4.10.) provoked fatty infiltration, 
generally in periportal hepatocytes. Pretreatment with 
furan resulted in, primarily, centrilobular fatty infil­
tration, which was also seen, more intensely, in sections 
of liver from rats administered i^ciKU-stilbene oxide 
(Plate 4.11.).
Glucose-6-phosphatase
In corn oil-pretreated rats, the distribution of 
glucose-6-phosphatase activity in liver sections was 
fairly even throughout, except for a slightly less intense 
reaction in centrilobular areas - ( Plate 4.12. ). A pronounced 
centrilobular diminution of activity was noted in rats 
receiving benzofuran (Plate 4.13.). Several other compounds 
studied caused varying degrees of loss of glucose-6- 
phosphatase activity, usually centrilobularly (Table 4.20.)
5 1-Nucleotidase
The appearance of a section from control rat 
liver stained for 5 ’-nucleotidase activity by the calcium- 
trapping method described in 2.17.5. is shown in Plate 
4.14. Pretreatment with furan elicited a dose-related
intensification of activity in the hepatocytes adjacent 
to the central vein (Plate 4.15.). Ptan^-stilbene oxide 
produced a similar effect; a section of liver stained 
for 5 ’-nucleotidase by the lead-trapping method (section 
2.17.5.) is illustrated in comparison with an identically 
treated section from a control animal in Plates 4.16. 
and 4.17.
4.2.9. Histology of other organs
Of the tissues other than liver that were examined 
routinely, several changes were observed in renal sections 
stained with naematoxylin and eosin, after pretreatment 
of rats with one of several compounds. Numerous small 
vacuoles formed in the epithelium of the proximal convoluted 
tubules in kidneys from animals treated with safrole 
(Plate 4.18.). Benzofuran-pretreated rats showed vacuolation 
and necrosis of proximal convoluted tubules, and scattered 
foci of necrosis were noted in sections of kidney from 
animals given 3.7nimol furan/kg per day for 3 days (Plate 
4.19.). Mild dilatation of distal tubules occurred after 
the administration of o-hydroxyphenylacetic acid.
Several of the compounds studied resulted in 
loss of erythropoietic activity in spleen. The most 
pronounced effects occurred after the pretreatment of 
rats with methylenedioxyphenyl compounds, VianA-stilbene 
oxide, dibenzofuran or benzofuran.
No pathological changes were seen in sections 
of lung tissue in any instance.
Plate 4.8. Lipid distribution in section of liver from a rat pretreated 
with corn oil (2.5ml/kg x 3 days). Fixed (Bouin’s fluid), 
7ym, stained Oil Red 0 (x80)
H C K s $ i
mm.
Plate 4.9. Periportal fatty infiltration in section of liver from
a rat pretreated with safrole (5.Ommol/kg x 3 days). Fixed
(Bouin’s fluid), 7ym, stained Oil Red 0 (x80)
Plate 4.
Plate 4.
10. Periportal and diffuse fatty infiltration in section of 
liver from a rat pretreated with isosafrole (3•75mmol/kg 
x 3 days). Fixed (Bouin’s fluid), 7ym, stained Oil Red 0 
(x80)
; u' + <" » ■ .
'•V v -  V
M
■ 'V
11. Intense fatty infiltration of centrilobular area in section 
of liver from a rat pretreated with t/icuvS-stilbene oxide 
(4.Ommol/kg x 1 day, 2.Ommol/kg x 2 days). Fixed (Bouin’s 
fluid), 7ym, stained Oil Red 0 (x80)
Plate 4.12. Glucose-6-phosphatase activity in section of liver from 
a rat pretreated with corn oil (2.5ml/kg x 3 days). 
Fresh, frozen tissue, 10ym (x80)
Plate 4.13. Loss of centrilobular glucose-6-phosphatase activity in 
section of liver from a rat pretreated with benzofuran 
(5.Ommol/kg x 3 days). Fresh, frozen tissue, 10ym (x80)
Table 4.20. Administration of 0- and W-containing heteroeyles to rats 
Effects on hepatic distribution of glucose-6-phosphatase 
and 5’-nucleotidase
Pretreatment Glucose-6-phosphatase 5’-Nucleotidase
Corn oil Distributed throughout, 
more intense PP and MZ
Furan
Dihydrofuran
Benzofuran
Dihydrobenzofuran
Dibenzofuran
2-Coumaranone
Benzodioxole
Safrole
Isosafrole
O-Hydroxyphenyl- 
acetic acid
Coumarin
Indole
Pt<m6-Stilbene oxide
Variable, apparently dose- 
related, slight to moderate 
CL loss
As corn oil
Pronounced CL loss
Slight, non-dose-related 
CL loss
Moderate CL loss 
As corn oil 
As corn oil 
As corn oil 
Moderate CL loss 
As corn oil
Moderate CL loss 
As corn oil 
As corn oil
Relatively intense 
reaction in immediate 
PP and CL regions; 
throughout plasma 
membranes of hepatocytes
Dose-related increase 
CL hepatocytes
Slight increase CL
Possibly small decrease 
in canalicular membrane 
reaction
As corn oil
As corn oil 
As corn oil 
As corn oil 
As corn oil 
As corn oil 
As corn oil
As corn oil
As corn oil
Considerable intensi­
fication of CL reaction
’As corn oil' indicates that the reaction did not differ significantly 
from that in sections of liver from corn oil-pretreated rats.
Staining methods were as described in 2.17.4. and 2.17.5. 
Abbreviations: PP = periportal(ly) MZ = midzonal CL = centri­
lobular
Plate 4.14. 5 ’-Nucleotidase activity in section of liver from a rat
pretreated with corn oil (2.5ml/kg x 3 days). Fresh, 
frozen tissue, 10ym, 5'-AMP substrate, trapping agent 
calcium (x80)
Plate 4.15. Intensification of staining for 5 ’-nucleotidase activity 
in section of liver from a rat pretreated with furan 
(3.7mmol/kg x 3 days). Fresh, frozen tissue, 10ym, 5 ’-AMP 
substrate, trapping agent calcium (x80)
w&r**
Plate 4.16. 5 ’-Nucleotidase activity in section of liver from a rat
pretreated with corn oil (2.5ml/kg x 3 days). Fresh, 
frozen tissue, 10ym, 5 '-AMP substrate, trapping agent 
lead (x80)
Plate 4.17. Intensification of centrilobular staining for 5 '-nucleo­
tidase in section of liver from a rat pretreated with 
tAanA-stilbene oxide (1.5mmol/kg x 5 days). Fresh, frozen 
tissue, 10ym, 5 '-AMP substrate, trapping agent lead (x80)
Plate 4.18. Section of kidney from a rat pretreated with safrole 
(5.Ommol/kg x 3 days) showing numerous small vacuoles 
in proximal convoluted tubule. Fixed (Bouin’s fluid), 
7ym, stained H+E (x312)
Plate 4.19. Section of kidney from a rat pretreated with furan
(3.7mmol/kg x 3 days) showing small necrotic foci.
Fixed (Bouin’s fluid), 7ym, stained H+E (x312)
4.3. Discussion
The effects of the compounds used in the present 
study are considered in relation to the nature of the 
chemicals producing them, together with additional data 
presented in Chapter 5, in the discussion following that 
chapter. However, the salient responses of the rat to 
each compound examined are summarised below.
Furan
Histological and histochemical examination of 
the liver after the administration to rats of furan 
shows a picture characteristic of a classical hepatotoxic 
response, in which accumulation of lipids within hepatocytes 
results in a fatty liver, and the subsequent degeneration 
of the cells leads to zonal or massive necrosis (Drill,
1952; Plaa, 1975). Increased serum IgA and IgA FSC 
concentrations indicate that there may be a cholestatic 
component to the liver damage (see Woolley dt at.,- 1979), 
but this is not an unusual consequence of hepatitis of 
almost any origin (see Schaffner and Popper, 1979).
Serum enzyme markers of hepatic damage are elevated 
without a marked change in serum bilirubin concentration, 
which further supports a diagnosis of a typical, primarily 
hepatocellular, toxic reaction. One unusual finding is 
the-relatively small increase in serum alanine amino­
transferase activity; the possibility that residual 
furan interferes with the assay may require further 
investigation in this respect. A ’toxic response’ is also 
indicated by the reduced food intake and associated weight 
loss in the rats given 3.7mmol furan/kg for 3 days.
These animals had a significantly increased relative liver 
weight, and a decreased hepatic concentration of cytochrome 
P-450 and cytochrome 6^, too marked to be accounted for 
by simple dilution with an increased hepatie mass containing 
primarily non-cytochrome components.
SDS-polyacrylamide disc gel electrophoresis 
suggests that the fall in cytochrome P-450 concentration 
is accompanied by reduced staining intensity of a polypeptide 
band identified with a phenobarbitone-inducible species 
of cytochrome P-450. Curiously, ethoxyresorufin 0-deethylase 
activity was reduced more severely, and haem oxygenase 
activity elevated higher, by the lower dose of furan; 
the explanation for this is unclear. Cytochrome P-450, 
cytochrome 6^, ethoxycoumarin 0-deethylase activity and 
epoxide hydrolase were affected to approximately the same 
extent by either dosing regimen, whereas some other 
parameters, including hepatic glucose-6-phosphatase, some 
serum enzymes and serum bilirubin concentration did appear 
to be altered in a dose-related manner. The significance 
of these observations is difficult to assess, as only 
two different dose levels were used e.g. residual furan 
may be a problem common to several of the estimations.
Of organs other than the liver, the kidneys of rats given
3..7mmol furan/kg for 3 days exhibited focal necrotic 
lesions not associated with changes in the urinary 
constituents measured.
Dihydrofuran
Reduction of one of the double bonds of furan 
(yielding dihydrofuran) appears to greatly lessen the
toxicity^ of the- compound-.-- No- evidence- of- hepatic damage
was observed by light microscopy, except for a very small 
degree of fatty infiltration, when dihydrofuran (3-6 
mmol/kg x 3 days) was administered to rats. The protein 
content of whole liver homogenate was increased significantly, 
and microsomal epoxide hydrolase activity was slightly 
elevated. Serum aspartate aminotransferase and y-glutamyl- 
transferase activities were both increased approximately 
2-fold; the former may possibly be due to mild haemolysis 
(a common problem because of the mechanical fragility of 
rat erythrocytes), but y-glutamyltransferase activity is
very low in red blood cells (Szasz, 1976). While an elevated 
y-glutamyltransferase activity may reflect damage to 
bile duct lining cells (Rosalki, 1975; Moss, 1977), 
there is neither a sufficient increase, nor sufficient 
additional evidence, to reach a conclusive diagnosis.
.Benzofuran
This compound appears to act shortly after dosing 
as a stimulant to the central nervous system, resulting 
in tremors and, frequently, profuse salivation. Histological 
and histochemical studies suggest that benzofuran causes 
hepatic damage in rats, but the picture of centrilobular 
eosinophilia, focal or single cell necrosis, minimal 
fatty infiltration and slight loss of 5 ’-nucleotidase 
activity is more typical of cholestasis than of a classical 
hepatotoxic response (see Desmet, 1979; Schaffner and 
Popper, 1979). The severe loss of liver glycogen is 
probably due to a markedly reduced food intake with 
accompanying weight loss. A cholestatic mechanism is 
supported by the very increased serum IgA and IgA FSC 
and conjugated bilirubin concentrations. Other indicators, 
such as an increased serum sorbitol dehydrogenase activity 
and depressed hepatic centrilobular reaction for glucose-6- 
phosphatase, reflect the presence of some generalised 
hepatic damage, and the diminished serum protein concentration 
may denote a compromised.synthetic.capability.of the liver.
A significantly increased liver~weight is coincident 
with elevated protein yields from both whole homogenate 
and microsomes. Loss of cytochrome P-450, and a markedly 
elevated liver microsomal epoxide hydrolase activity, are 
paralleled in SDS-polyacrylamide disc gel electrophoresis 
by a diminished 50000 MW band, and an increased 48000 MW 
band, respectively. A new polypeptide of 51500-52000 MW 
is also evident, and its significance is discussed during 
the following chapter, as is the shift of the spectral 
absorbance maximum of carbon monoxide-complexed cytochrome
P-450 from 450 to 451-452nm.
Microsomal haem oxygenase underwent a 28-fold 
increase in activity after the administration of benzofuran 
to rats, and may be associated with the decreased cytochrome 
P-450 content. Hepatic glutathione concentration was 
considerably elevated after 3 days; however, it is not 
known at present whether this represents an overcompensation 
for an initial decrease.
The significant proteinuria observed in the 
absence of glycosuria may be the result of impaired 
glomerular function. However, most histologically identifiabl 
renal effects involved the proximal convoluted tubules, 
and the urinary protein may in this case be derived from 
the kidneys themselves. Bilirubinuria is a diagnostic 
feature of cholestasis (see Schaffner and Popper, 1979), 
and was seen in this study in rats treated with benzofuran. 
Erythropoiesis was also noted to be severely reduced or 
absent in sections cut from the spleen of benzofuran- 
pretreated animals. The reason for this is uncertain at 
present.
Dihydrobenzofuran
This compound caused less hepatic degeneration 
and necrosis than did benzofuran, even at doses higher 
than the latter, but a more pronounced degree of fatty 
infiltration -suggests’ the..onset ..of a classical hepatotoxic 
response. Unchanged serum enzyme activities, and bilirubin, 
glucose and protein concentrations correlate with the 
histological observations, but depressed aminotransferase 
activities indicate that, at high doses, dihydrobenzofuran 
may possibly interfere with the enzyme assays. The 
higher dose also resulted in a reduction in the rate of 
bodyweight gain, and in an enlarged liver. Microsomal 
cytochrome P-450 concentration was unchanged, whereas 
the rates of oxidative metabolism of ethoxycoumarin and 
ethoxyresorufin were elevated slightly; possibly residual
chemical behaves as an activator of these reactions, 
although this seems unlikely, since ethoxycoumarin 
0-deethylation in particular is very susceptible to 
inhibition in the presence of solvents. Epoxide hydrolase 
and haem oxygenase activities were increased, but to a 
far lesser extent than that seen after the administration 
of equimolar doses of benzofuran, suggesting that the 
presence of the furan double bond may be important in 
producing these effects.
Dibenzofuran
Dibenzofuran administration elicited little 
histologically or histochemically observable change in 
rat liver sections. A slight increase in staining intensity 
for glycogen did not correlate well with the large increase 
found by chemical assay, and it is possible that dibenzo­
furan (or metabolites) remaining in the liver interferes 
with the colour reaction in the latter instance.
Serum chemistry reveals little, except for a 
slight, but. statistically significant, fall in protein 
concentration. Microsomal epoxide hydrolase activity in 
liver was markedly elevated, which indicates that, say, 
molecular planarity rather than accessibility of the furan 
double bond for metabolism may be significant in the 
induction of this enzyme. Compounds increasing epoxide 
hydrolase activity are discussed in more detail in the 
following chapter. As seen with dihydrobenzofuran, 
dibenzofuran administration caused minor elevations of 
ethoxycoumarin and ethoxyresorufin 0-deethylase activities, 
without increasing the cytochrome P-450 concentration.
No renal damage was observed after the pretreatment of 
rats with dibenzofuran, but splenic erythropoiesis was 
severely diminished.
2-Coumaranone
No histological, histochemical or serological
signs of hepatic or renal change were observed, except 
for a slightly reduced hepatic microsomal protein yield. 
2-Coumaranone lacks a free furan double bond, and the 
2-position is occupied by an oxo group that renders this 
compound more water soluble than dihydrobenzofuran; 
hence, it may be less accessible to microsomal enzymes.
Benzodioxole
High doses (5.Ommol/kg/day for 3 days) of 
benzodioxole were acutely extremely toxic to rats. After 
3.75mmol benzodioxole/kg for 3 days, signs of fatty 
degeneration and necrosis of hepatocytes were present, 
but without the loss of centrilobular glucose-6-phosphatase 
activity. Histological and serological parameters for 
these animals cannot be compared, since either fortuitously, 
or because of the initiation of clotting, or other, 
defects, blood samples were impossible to obtain.
The rats appeared to adapt after initially severe
toxic symptoms during dosing, and some parameters measured
after post-mortem were very variable among different
animals. The mean microsomal protein yield increased,
but with too high a standard deviation to be statistically
elevated above the control mean, and cytochrome b^ and
cytochrome P-450 concentrations, and monooxygenase
activities, were raised. This increase in microsomal
cytochrome P-450 content was paralleled during SDS-
polyacrylamide disc gel electrophoresis by an increase in
the staining intensity of a polypeptide of 53000 MW.
Spectral examination of dithionite-reduced microsomes
showed an absorbance peak of X = 455nm, due to a ^ max 7
benzodioxole metabolite complexed with cytochrome P-450 
(Franklin, 1971; Philpot and Hodgson, 1971b). Administration 
of benzodioxole caused no renal toxic changes, but did 
diminish splenic erythropoiesis, as did pretreatment of 
rats with safrole or isosafrole.
Safrole
' Rats pretreated with safrole showed a greater
degree of hepatic fatty degeneration than those pretreated 
with benzodioxole. However, serum enzyme estimations 
revealed only minimal evidence of liver damage, except for 
elevated, and very variable, sorbitol dehydrogenase 
activities. Glucose-6-phosphatase activity was considerably 
increased, but the cause of this is not apparent. No 
indications of cholestasis were noted.
A marked reduction in food intake, and a loss 
of bodyweight, occurred during dosing, but, whereas the 
hepatic microsomal protein yield was increased by a factor 
larger than that following isosafrole pretreatment, the 
gain in liver weight was less. Even when corrected for 
the difference in dose used, the height of the 455nm 
peak and the increase in cytochrome P-450 content of the 
hepatic microsomes were greater following the administration 
of safrole, than after benzodioxole. These observations 
agree with those of Fennell (1980).
Vacuolation of proximal convoluted tubules, of 
unknown significance, occurred in the kidney.
Isosafrole
The histologically, histochemically and 
serologically definable consequences of the administration 
of isosafrole to rats broadly paralleled those of safrole, 
except that the latter produced a marked increase in serum 
sorbitol dehydrogenase activity, whereas the former did 
not. This is difficult to explain, since the histological 
parameters of hepatic damage were similar in value.
Isosafrole elicited the greatest increase in 
the 455nm peak absorbance height, and the greatest 
elevation of cytochrome P-450 content and associated 
monooxygenase activities in the liver. This increase was 
accompanied by the intense staining of a 53000 MW 
polypeptide band upon SDS-polyacrylamide disc gel
electrophoresis. Rats pretreated with isosafrole consistently 
exhibited glycosuria, the reasons for which are unclear 
at present in the absence of a demonstrable renal tubular 
lesion.
A comparison of the results of some significant 
investigations following the administration to rats of 
either furans or methylenedioxyphenyl compounds is shown 
in Table 4.21 .
o-Hydroxyphenylacetic acid
This compound, a possible ring-opened metabolite 
of benzofuran, produced no significant serologically or 
histologically demonstrable liver damage, except for a 
small degree of fatty infiltration that may have been 
largely artefactual. An increased water intake during 
dosing may have been compensation for changes in fluid 
distribution caused by the administration of a water- 
soluble, ionised molecule, despite the neutralisation of 
the o-hydroxyphenylacetic acid with sodium hydrogen 
carbonate. This may also account for the mild dilatation 
of renal proximal convoluted tubules observed.
Coumarin
High doses (5.0mmol coumarin/kg single injection) 
were rapidly lethal to rats. The dose used (0.68mmol/kg 
per day for 3 days) caused little alteration in liver 
histology, and had no effects of consequence on measured 
serum or endoplasmic reticulum parameters.
Bile duct proliferation and cholangiofibrosis 
have been described following the administration of coumarin 
to rats, but only after long term feeding at high dietary 
concentrations (Hagan dt at., 1967). In view of the 
markedly different effects of the pretreatment of rats 
with benzofuran or 2-coumaranone, it would be of interest 
to compare the toxicity of coumarin and the corresponding
Table 4.21. Some differences in the effects of administration of furans or 
methylenedioxyphenyl compounds to rats
Parameter Furans Methylenedioxyphenyls
Hepatic histology Little change, -to frank 
necrosis, to cholestatic 
features
Periportal fatty degeneration, 
little necrosis, non- 
cholestatic
Glucose-6-phosphatase Normal or depressed 
staining
Normal or elevated
Relative liver weight Slight to marked increase Slight to moderate increase
Serum liver function 
enzymes
Slight to marked increase Slight to moderate increase
Serum cholestatic 
parameters (IgA, FSC, 
bilirubin)
No change to large increase 
(benzofuran)
No change
Microsomal [cytochrome 
P-450]
Normal or decreased Elevated
Production of 455nm 
complex
Negative Positive
SDS-Polyacrylamide disc Little change to marked:
gel electrophoresis loss of 50000 MW band
elevated 48000 MW band 
new 51500-52000 MW band
Increased 53000 MW band 
Moderately increased 48000 
MW band. (Benzodioxole may 
induce some 51500-52000 MW 
polypeptide
Microsomal epoxide 
hydrolase
Moderate to marked elevation Moderately elevated
Microsomal haem 
oxygenase
No change to large increase No change
Hepatic glutathione Frequently elevated at 3 days No significant change
Haematology Normal Normal
Extrahepatic tissue 
changes
Depressed splenic erythropoiesis 
in some cases
Furan and benzofuran cause renal 
proximal convoluted tubule 
vacuolation and necrosis
Splenic erythropoiesis 
depressed
Proximal convoluted tubule 
vacuolation with safrole. 
Glycosuria with isosafrole
compound lacking the 2-oxo group (benzopyran), and this 
experiment will be carried out when possible.
Indole
This compound is the nitrogen-containing analogue 
of benzofuran, and has some physical and chemical properties 
in common with the latter compound. However, a single 
injection of 5.Ommol indole/kg proved rapidly lethal to 
rats, apparently because of acute toxicity to the central 
nervous system. A dose of 1.25mmol indole/kg/day for 3 
days caused slight fatty degeneration of the liver, but 
other histological, and serological, parameters were 
unchanged from control values. Among the most striking 
differences between the effects of indole and of benzofuran 
was the complete failure of the former chemical to increase 
microsomal epoxide hydrolase activity, which suggests 
that the oxygen atom is important for the induction of 
this enzyme, or else that the requirements for spatial 
orientation within the inducing molecule are very strict.
TuanA-Stllbene oxide
The administration of tAanA-stilbene oxide to 
rats caused hepatocellular changes generally more typical 
of a classical hepatotoxic response than of cholestasis, 
although serum IgA and IgA FSC levels were raised in 
both dose groups, and the serum conjugated bilirubin 
concentration was elevated in the higher-dosed animal. 
Centrilobular staining for 5 T-nucleotidase was intensified 
in a manner similar to that following furan pretreatment, 
but in neither case was this accompanied by a large increase 
in serum 5'-nucleotidase activity. Serum enzyme changes 
were equivocal; aspartate aminotransferase and alkaline 
phosphatase activities were elevated, whereas sorbitol 
dehydrogenase activity, often a sensitive indicator of 
hepatic damage (Asada and Galambos, 1963), was not. This 
may reflect the tendency of a raised sorbitol dehydrogenase
level to fall again more rapidly than some other indicators 
of deranged liver function (Wiesner at at., 1965), although 
the lack of an elevated alanine aminotransferase activity 
is inconsistent with severe hepatotoxicity. Another 
possibility is that haemolysis, which artefactually increases 
serum aspartate aminotransferase and alkaline phosphatase 
activities, but has less effect on alanine aminotransferase 
and sorbitol dehydrogenase activities, is at least partly 
responsible for the changes seen. Again, a constant 
problem with interpreting serum enzyme patterns is that 
much of the available data base is for man, and not for 
experimental animals.
T4a.tt4-Stilbene oxide pretreatment of rats 
elevated the activities of various enzymes of the endo­
plasmic reticulum, including cytochrome P-450 and its 
associated monooxygenases, and, particularly, epoxide 
hydrolase activity. These changes are broadly similar to 
those described by Seidegard and coworkers (1979). Haem 
oxygenase activity was also markedly increased, especially 
following the administration of the higher dose of tAanA- 
stilbene oxide; this effect has not previously been 
reported. An increase in haem oxygenase activity without 
the concurrent loss of cytochrome P-450 is in sharp contrast 
to the effects of the pretreatment of rats with benzofuran, 
but has previously been described following the administration 
to rats of cobalt chloride ptuA SKF525A (Drummond at at.,
1982). Again, both -t/LO.n-4-stilbene oxide and benzofuran 
diminish the erythropoietic activity of spleen. These 
two compounds are contrasted further during the course of 
Chapter 5.
Some salient results of the administration 
to rats of o-hydroxyphenylacetic acid, coumarin, indole 
or ^an^-stilbene oxide are summarised in Table 4.22.
(cf. Table 4.21.).
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CHAPTER 5 
FURTHER STUDIES ON THE 
TOXICITY OF BENZOFURAN
5. FURTHER STUDIES ON THE TOXICITY OF BENZOFURAN
5.1. Introduction
Several investigators have indicated that the 
hepatotoxicity of certain compounds is mediated through 
the formation of active metabolites, which subsequently 
become bound to tissue macromolecules (e.g. Miller, 1970; 
Gillette <Lt al. , 1974; Blumberg, 1978). The ’classical’ 
inducing agents, phenobarbitone and 3-methylcholanthrene, 
and others, modulate the intrahepatic concentrations of 
species of cytochrome P-450 of markedly differing properties. 
Evidence in part for the role of cytochrome P-450 in the 
generation of active metabolites is provided by the abilities 
of such inducers, and inhibitors, to modify the toxic 
potential of foreign compounds (Conney, 1967; Gillette,
1979). In addition, a requirement for NADPH and undenatured 
protein during the activation of these compounds by 
microsomes Zn vIV lo may be demonstrable. Preliminary 
observations of benzofuran’s toxicity suggest that benzofuran 
and/or a metabolite(s ) may evoke a cholestatic response 
in the liver of rats. Various other drugs and chemicals 
are now known to induce intrahepatic cholestasis in man 
or in experimental species, the pattern of hepatic damage 
being distinguishable from that of the characteristic 
'hepatotoxic’ response.
This chapter describes further investigations 
into the mechanism of toxicity of benzofuran, using 
biochemical, structural and ultrastructural studies of 
liver following the administration to rats of benzofuran, 
either alone or after the pre-induction of cytochrome P-450. 
Because substituted furan-elicited renal and hepatic 
damage has been reported to vary in degree with compound 
and species (McMurtry and Mitchell, 1977), the response of 
the rat kidney to benzofuran administration was evaluated
concurrently in the present study. .
The polypeptide bands whose staining was inten­
sified upon SDS-polyacrylamide disc gel electrophoresis of 
microsomes prepared from benzofuran- and stilbene
oxide-pretreated rats were further characterised, and the 
spectral interactions of benzofuran with pre-induced 
microsomes were examined. Certain features that might 
confuse the interpretation of the toxicity data obtained 
were noted during early studies of the administration of 
benzofuran to rats, the major one of which was the severely 
reduced food and water intake of the animals. Fasting 
influences several components of the microsomal 
monooxygenase system (Kato at at., 1970; Bock zt aZ.,
1973), and an attempt was made to ’blank out’ these effects 
as far as possible.
5.2. Results
5.2.1. Comparison of the effects of the administration 
of benzofuran and of food deprivation
The administration of benzofuran (5.0mmol/kg
bodyweight) i.p. daily for 3 days caused a marked loss
of weight in rats, which was comparable with the daily
weight loss resulting from deprivation of food for 48
hours (Table 5.1.). Daily water consumption was also
comparable. However, an increase in relative liver weight
occurred in rats receiving benzofuran, whereas the mean
relative liver weight in fasted rats was reduced. Whole
homogenate protein yields were similar; microsomal
protein yields were higher in benzofuran-pretreated
animals. Starvation resulted in an elevated specific
concentration of cytochrome P-450 (A = 450nm) in hepaticmax
microsomes, in contrast to the loss produced by benzofuran. 
Other hepatic components measured in fasted rats were 
normal (Table 5.1. ), except that glycogen levels were 
depressed to an extent similar to that seen after dosing with 
benzofuran under the indicated regimen.
Serum enzyme activities in fasted animals were 
generally not significantly different from the corresponding 
control activities, whereas several were elevated following 
the administration of benzofuran. Most other serum parameters 
in fasted rats were also normal, although the serum glucose 
concentration was depressed to a much greater extent than 
that seen after pretreatment with benzofuran.
Both food deprivation and administration of 
benzofuran increased the hepatic A-aminolaevulinic acid 
synthetase activity in relation to control rats (Table 5.2.), 
but by factors of 1.4 and 4.2 respectively, when expressed 
per mg homogenate protein.
SDS-polyacrylamide disc gel electrophoresis of 
solubilised hepatic microsomes from fasted rats showed a
Table 5.1. Comparison of effects of starvation or of benzofuran 
administration upon rat hepatic and serum parameters
Fasted*1'C Benzofuran^,C"
Food consumption - 16.4 ± 5.1
Water consumption 39.8 ±1.6 37.0 ± 18.7
Relative liver weight 67.4 ±2.2 167.4 ± 15.2
Whole homogenate protein 118.7 ± 10.7 119.4 ± 3.4
yield
Microsomal protein yield 103.8 ± 4.6 121.9 ± 6.9
Cytochrome P-450 134.2 ± 12.7 70.9 ± 5.1
Cytochrome 6 81.7+8.3  73-3 ±1.7b
Epoxide hydrolase 150.4 ± 37.8 407.9 ± 114.8
Glucose-6-phosphatase 99.9 ± 33.8 32.5 ± 3.1
Haem oxygenase 66.7 ± 6.7 2966.7 ± 666.7
Glycogen 5.4 ± 0.7 7.9 ± 1.1
Glutathione 112.7 ±10.1 198.0 ±41.6
Serum aspartate 107.8 ± 55.9 339.2 ±54.9
aminotransferase
Serum alanine 100.0 ±40.7 514.0 ± 31.4
aminotransferase
Serum 5’-nucleotidase 82.8±40.8  110.3 ± 26.4
Serum alkaline phosphatase 91.0 ± 10.9 170.6±4.9
Serum y-glutamyltransferase 140.0 ± 31.2 592.0 ± 17.2
Table 5.1. (continued)
Fasted*1'^  Benzofuran^'C
Serum sorbitol dehydrogenase 89.4 ± 80.2 323.5 ± 9.2
Serum total protein 115.5 ± 5.5 83.4 ± 8.8
Serum albumin 114.3 ± 6.3 ' 75.9 ± 1.5
T A
Serum IgA ± +++
Z
Serum IgA Free Secretory ± +++
Component
Serum total bilirubin 118.1 ± 23.2 779.5 ± 248.8
Serum conjugated bilirubin 105.3 ± 7.9 1193.0 ± 428.1
Serum total cholesterol 91.6 ± 4.4 93.0 ±3.4
Serum high-density 94.5±4.2 87.1 ± 8.1
lipoprotein cholesterol
Serum glucose 22.0 ± 14.7 70.8 ± 2.0
^Rats were deprived of food for 48 hours prior to killing. 
b
Rats were pretreated with benzofuran, 5.0mmol/kg i.p. in corn oil 
daily for 3 consecutive days, and killed on the 4th day.
C
The mean ± standard deviation for groups of at least 3 rats are 
expressed as percentages of the corresponding mean value for a 
group of 3 control rats given 2.5ml corn oil/kg daily by i.p. injection 
for 3 days (mean value for this group = 100%).
Ranking based on rocket height resulting from electrophoresis 
against rabbit (anti-rat) IgA.
e.
Ranking based on rocket height resulting from electrophoresis 
against rabbit (anti-rat) IgA Free Secretory Component.
!±’ indicates no significant difference from control rocket height.
Table 5.2. Effects of pretreatment with benzofuran on the activity
of A-aminolaevulinic acid synthetase in rat liver
Pretreatment
A-Aminolaevulinic acid synthetase activity
(nmol/min/mg whole 
homogenate protein)
a (nmol/min/^ g liver)
Corn oil 0.005 ± 0.0009 0.65 ± 0.134
Benzofuran
Fasted
0.021 ± 0.0019 
0.007 ± 0.0021
3.38 ± 0.307
1.03 ± 0.155
Rats received corn oil (2.5ml/kg), benzofuran (5.0mmol/kg in corn oil) 
by injection i.p. for 3 days, or were deprived of food for 48 hours 
immediately prior to being killed.
All values are mean ± standard deviation of data from at least 3 animals
a
Activity measured as nmol AALA formed/min/mg whole homogenate protein.
6
Activity measured as nmol AALA formed/min/g wet weight liver.
c d
P<0.05 P<0.0005
broadening of the 50000 MW band (Figure 5.1.). There was 
no increase in band 1 (48000 MW).
5.2.2. Laurate hydroxylase
Hepatic microsomal laurate hydroxylase activity 
was decreased following the administration of benzofuran 
(5.0mmol/kg i.p. daily for 3 days) to 22.1% and 38.9% of 
fed control activity when expressed per mg protein and per 
nmol cytochrome P-450 respectively (Table 5.3.).
5.2.3* Further comparison of the effects of administration
of benzofuran and of V iclyiA-stilbene oxide
At the dose levels used in this experiment 
(benzofuran, 1.25mmol/kg; ^an4-stilbene oxide, 2.0mmol/kg, 
each administered i.p. daily for 3 days), the activity of 
hepatic microsomal epoxide hydrolase towards a styrene oxide 
substrate was higher than that observed when benzo(a)pyrene- 
4,5-oxide was employed as the substrate (Table 5.4.). 
Pretreatment with ^t<x^4-stilbene oxide produced the greater 
increase in activity with either substrate. However, it 
should be noted that in some other experiments (e.g. see 
Table 5.8.), the pretreatment of rats with 1.25mmol benzofuran/ 
kg/day for 3 days induced an hepatic microsomal epoxide 
hydrolase activity, using styrene oxide as substrate, 
approximately equal to that reported in Table 5.4. following 
pretreatment with 2.0mmol ^'to.f'U-stilbene oxide/kg/day for 
3 days.
Pretreatment with benzofuran produced a significant 
increase in hepatic glucuronidation of both 1-naphthol and 
4-nitrophenol, whereas VianA-stilbene oxide did not have 
any effect on either of these activities (Table 5.5.). 
Pretreatment with either benzofuran or Vian^-stllbene 
oxide increased soluble glutathione S-transferase activity
Figure 5.1.
SDS-Polyacrylamide disc gel electrophoresis of liver 
microsomes prepared from rats pretreated with benzofuran, 
or deprived of food for 48 hours
1 3 5 7 9 11
Solubilisation and SDS-polyacrylamide disc gel electrophoresis 
of microsomal proteins were carried out as described in 2.8. 
Samples (15yg protein) were applied as follows:
Wells 2,3,10 corn oil
4,5,7 benzofuran 5.0mmol/kg x 3 days 
8,9 food deprivation for 48 hours
Wells 1,6,11 contained molecular weight standards
Table 5.3. Effects of pretreatment with benzofuran on the activity
of laurate hydroxylase in rat liver microsomes
Laurate hydroxylase^
Pretreatment (nmol/min/mg (nmol/min/nmol
microsomal protein) cytochrome P-450)
Corn oil 4.76 ±1.95 6.35 ± 1.63
Benzofuran 1.08 ± 0.58^ .2.47 ± 1.38^
Rats received corn oil (2.5ml/kg) or benzofuran (5.0mmol/kg) by 
injection i.p. for 3 days.
All values are mean ± standard deviation of data from at least 3 rats 
d
Activity measured as nmol total hydroxylated products formed/min/ 
mg microsomal protein or as nmol total hydroxylated products formed/ 
min/nmol cytochrome P-450.
kp<0.05
Table 5.4. Effects of pretreatment with either t/ianA-stilbene oxide 
or benzofuran on the activity of rat liver microsomal 
epoxide hydrolase towards two different substrates
Epoxide hydrolase activity 
(nmol/min/mg microsomal protein) 
towards
Pretreatment Styrene oxide^ Benzo(a)pyrene
-4,5-oxide
b
Corn oil 8.5 ± 1.4 7.9 ± 2.3
Benzofuran 20.5 ± 0.7
,e 14.0 ± 2.2
T>fccut4-Stilbene oxide 27.6 ± 2.9
d 21.0 ±4.1 c
Rats received corn oil (2.5ml/kg), benzofuran (1.25mmol/kg in corn oil) 
or -tfom^-stilbene oxide (2.0mmol/kg in corn oil) by injection i.p. 
for 3 days.
All values represent mean ± standard deviation of data from at least 
3 animals.
^Activity measured as nmol styrene glycol formed/min/mg protein.
bActivity measured as nmol 4,5-dihydroxybenzo(a)pyrene formed/min/mg 
protein.
CP<0.05 rfP<0.005 eP<0.0005
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at the dose levels employed.
Hepatic microsomes prepared from rats pretreated
with benzofuran or V iqlyi&-stilbene oxide showed an increased
intensity of staining of band 1 upon SDS-polyacrylamide
disc gel electrophoresis (Figure 5.2.), and an apparently
new polypeptide band corresponding to a molecular weight of
51500-52000. Microsomes obtained from a rat pretreated with
the hypolipidaemic drug, Clofibrate, are also included in
this gel, since Clofibrate induces a protein band (probably
of a haemoprotein nature) of 51500-52000 MW. In the gel
shown (Figure 5.2.) this band appears to be of a slightly
higher molecular weight than the band induced by benzofuran
or ^aft^-stilbene oxide, and Clofibrate also increases the
staining of a band of about 75000 MW. However, reduced,
carbon monoxide-complexed cytochrome P-450 from benzofuran-
or Clofibrate-pretreated rats has A = 452nm, whereas  ^ max 1
that from tA&vi'5-stilbene oxide-pretreated rats has A =^ max
450nm. Benzofuran causes a decrease in spectrally measurable 
cytochrome P-450 levels without the formation of cytochrome 
P-420, while f^af'U-stilbene oxide and Clofibrate are 
inducers of cytochrome P-450.
5.2.4. Further histochemical characterisation of the 
effects of administration of benzofuran
In sections of liver from rats pretreated with 
corn oil (2.5ml/kg x 3 days), y-glutamyltransferase activity 
was located almost entirely in the lining of the periportal 
bile ducts (Plates 5.1. and 5.3.). Pretreatment of rats 
with benzofuran (5.0mmol/kg x 3 days) caused an increase 
in the intensity of this staining, and diffuse staining for 
y-glutamyltransferase activity in the hepatocytes surrounding 
the portal tract (Plates 5.2. and 5.4.). T/can4-stilbene 
oxide pretreatment exerted a similar effect.
Glucose-6-phosphate dehydrogenase activity in
Figure 5.2.
SDS-Polyacrylamide disc gel electrophoresis of liver 
microsomes prepared from rats pretreated with benzofuran, 
t^cm^-stilbene oxide or Clofibrate, administered for 
3 consecutive days i.p. in corn oil
Solubilisation and SDS-polyacrylamide disc gel electrophoresis 
were achieved as described in 2.8. Samples (80yg protein) 
were applied as follows:
Well 1 benzofuran (5.0mmol/kg)
2 VianA-stilbene oxide (4.0mmol/kg x 1 day +
2.0mmol/kg x 2 days)
3 Clofibrate (400mg/kg, sodium salt)
4 corn oil (2.5ml/kg) + 4.6pg purified rat
microsomal epoxide hydrolase added to well
5 phenobarbitone (0.3mmol/kg)
Well 6 contained molecular weight standards
Plate 5.1. Distribution of y-glutamyltransferase activity in section of
liver from a rat pretreated with corn oil (2.5ml/kg x 3 days). 
Fresh, frozen tissue, 10pm, y-glutamyl-4-methoxy-2-naphthyl- 
amide substrate, counterstained methyl green (x80)
Plate 5.2. Diffuse hepatocyte staining for y-glutamyltransferase
activity in section of liver from a rat pretreated with 
benzofuran (5.0mmol/kg x 3 days). Fresh, frozen tissue, 10ym, 
y-glutamyl-4-methoxy-2-naphthylamide substrate, counter­
stained methyl green (x80)
tf *  m
Plate 5-3. Periportal distribution of y-glutamyltransferase activity, 
with staining of bile duct, in section of liver from a rat 
pretreated with corn oil (2.5ml/kg x 3 days). Fresh, frozen 
tissue, 10ym, y-glutamyl-4-methoxy-2-naphthylamide substrate, 
counterstained methyl green (x312)
. V
L *
J
- o
Plate 5.4. Periportal distribution of y-glutamyltransferase activity,
with diffuse hepatocyte reaction, in section of liver from a 
rat pretreated with benzofuran (5.0mmol/kg x 3 days). Fresh, 
frozen tissue, 10ym, y-glutamyl-4-methoxy-2-naphthylamide 
substrate, counterstained methyl green (x312)
sections of control liver was moderate, and diffusely 
distributed (Plate 5.5.), whereas in animals pretreated 
with benzofuran there was a massive increase in staining 
intensity across the entire lobule (Plate 5.6.).
5.2.5. Effects of benzofuran on biliary parameters
Bile collected by cannulation of the common bile 
duct of rats pretreated with benzofuran (5.0mmol/kg i.p. 
daily for 3 days) exhibited a marked increase in total and 
conjugated bilirubin concentrations (respectively 5.1- 
and 5.5-t'ime.A the levels of these materials in bile from 
rats pretreated with corn oil), with a concomitant slight 
increase in the percentage of bilirubin present as the 
conjugated form (Table 5.6.). Total protein levels were 
also markedly increased (1. control), as was the
biliary pH, but the osmolality of bile from both test and 
control animals was comparable (Table 5.6.).
5.2.6. Benzofuran dose-response studies
Animals were dosed i.p. for 3 days with various 
levels of benzofuran, and the results are summarised in 
Tables 5.7. and 5.8. Relative liver weights increased in 
a dose-related manner with increasing dose of benzofuran. 
Specific content of cytochrome (Table 5.7.) was rather 
variable, and showed no consistent elevation or depression. 
Hepatic microsomal cytochrome c reductase activity (Table 
5.8.) fell slightly after low levels of benzofuran adminis­
tration (0.42mmol/kg daily for 3 days), and thereafter 
increased in a dose-related manner to an activity significantly 
higher than that of. the control.
Epoxide hydrolase activity was increased 3-fold 
at 0.42mmol benzofuran/kg, but plateaued after that point 
to an activity about 4.1 -time.* control. Although ethoxycoumarin
Plate 5.5. Moderate glucose-6-phosphate dehydrogenase activity in 
section of liver from a rat pretreated with corn oil 
(2.5ml/kg x 3 days). Fresh, frozen tissue, 10ym, coupled 
neotetrazolium chloride (x80)
Plate 5.6. Massive diffuse increase in glucose-6-phosphate dehydro­
genase activity in section of liver from a rat pretreated 
with benzofuran (5.0mmol/kg x 3 days). Fresh, frozen 
tissue, 10ym, coupled neotetrazolium chloride (x80)
Ta
bl
e 
5.
6.
 
Pr
op
er
ti
es
 
of 
bi
le
 
co
ll
ec
te
d 
by 
bi
li
ar
y 
ca
nn
ul
at
io
n 
fr
om
 
ra
ts
 
af
te
r 
pr
et
re
at
me
nt
 
wi
th
 
be
nz
of
ur
an
EGCu
CM
O
+1
in
CM
o
+1
o
co
0(—i •HCQ
Q<
>>
•H
O£nO
60
\ 
r—(o££
co
+1
in
CM
r^
+1
C—r*-
CM
Go•H
XO0•O
G
•rH
>>
X
•HcdX
cdxo
E->
G•H0
P>O
G
CU
i—I
X\
60
OO
X
xa-pcd60
G•<->
coo
X0
-Pcd60
G•<->
CJO
o
c•Hx
g
G
•Hi—I 
•rH XI
G•HXI
GG
•Hi—I•HXI
cd
XoH
cd41oH
S
G-
*3 1-1
T— in •H
T- T- o
o o GG
+1 +1 oO
•=r 6-in cr> G
. . •H .o O WW X>> Gcd 0
X £
•H
CO G
0
X CL
CT\ CO X
. . 60 0
CM CO
\ CO
+1 +1 rHO Xin in g w
. . g 0
CO in O 0VO r- . rHm__ • X>> 0
c 0
0 O £
CO G O
CO co G X G
Cm 4 1 Cm
+1 +1 O G
N G 0
T--- 6 - G O X
■=r „ CM 0 Cm 0
CM X TO
0
G X Cm
O X O
G GW O O
>» •H
0 G X
X O 0
•H •H
CO X >
0 0
X r—I
G
TO
CMT-
VO T-
s + ! +1
G -— CT. T-in O
CO
-P
G0£
-Pcd0
G
-P0
GO.
60.X
£in
CM
C
Gcdo
>>
Gcd•H
•a
Gcd
XGcd41n
i—1 +1
>H •H
•H X Go 0
G 0
G 0 £
G X
O Cm X
0 0 G
G 0
1—1 0 TO X W
•H G 0 0 0
O G > X G
Cm •H 0 CL
G O 0 0 0
G N 0 .—1 G
O G 0 i—1 in
O 0 G O W o
CQ 0 0 .
W G o
X w i—1 V
0 0 0 cuK 5 > <3
Ta
bl
e 
5.
7.
 
Ef
fe
ct
s 
of 
do
se
 
le
ve
l 
of 
be
nz
of
ur
an
 
on 
re
la
ti
ve
 
li
ve
r 
we
ig
ht
 
an
d 
mi
cr
os
om
al
 
cy
to
ch
ro
me
G
in •H
c HO 0o +3•H 0 o4-3 s Gcd O Q.
G G
4-3 s: bO
G o E
CD o S
O •P rH
G >> O
O o EO G
on
o
o
+i
o
VO
CMO
o
+1
CTi
•=r
in
o
o
+i
in
o
VO
o
o
+i
oo
in
o
in
•=ri
CL.
0
Eo
g-Goo
>>o
CD 
>  (D .—I
a)woQ
G•Ha)+3o
ga
bOs
CP.
o
o
+1
r-t--
o
-ot—
o
o
+1
VO
■=r
o
in
o
o
+i
VO
on
-Q
oo
o
o
+i
in
-=r
>.
cd
XJ
x:4-3
G
G
O
Cm
CM
O 0
• x:O 4-3
+1 G
Oin
in XJ
. 0
o
rH
•H
X
0
G
0
£
W
•P
cd
G
0
x:4-3
XJ
i G
CP. cd
o
+1
in
o
bO
\rHOB
B
bO
\ t—\
B
in
CM
iH
•HO
G
GOo
CM
-=r
in
CM
o
in
CM
o
o
in
rH0>0
rH
XJa)
-p
cd
o
•H
XJ
G
•H
0 s: -p
-p
cd
co>>
o,
XJ0)
G0
-P
CO
•H
G
•H
B
XJ
cd
w
cd£
G
cd
G
GCmON
G
CDPQ
Wi—i
cd
B
•H
C
cd
- P
co
cda)i—I 
4->
cd
G u -Q cd O
0 on vb VO in CO XJ G
> o o o o O Cm
•H o o o o O on
.—1 4-3 . . . • . cd
X o o o o o G 4->
0 bO o cd
> •H +i +1 +1 +1 +1 Cm XJ
•H 0
CO4-3 5 oo CO on • rH Cm
cd -=r in in t '- t- •H O
rH o o o o O o
0 • . . ■. . G
PC o o o o o G O
•H
- P
cd
•H>
CD
XJ
X J
G
cd
X JG
cd
- P
co
+1
G
cd
a)
B
' 4-3
G
CDW
CD
GO,
CD
G
CO
CD
Gi—I
cd>
in
o
o
o
v
cu
in
o
o
vCu
Ta
bl
e 
5.
8.
 
Ef
fe
ct
s 
of
 
do
se
 
le
ve
l 
of
 
be
nz
of
ur
an
 
on 
mi
cr
os
om
al
 
en
zy
me
 
ac
ti
vi
ti
es
0-deethylase activity decreased in a dose-related manner, 
and ethoxyresorufin 0-deethylase activity remained constant 
until a sharp depression occurred at the highest dose used, 
the content of hepatic microsomal cytochrome P-450 fell in 
a dose-related way after lower concentrations of administered 
benzofuran, and at higher concentrations underwent a dose- 
related rise (Table 5.7.). The lowest level (46.6% of 
control) occurred in animals receiving T.25mmol benzofuran/ 
kg daily for 3 days; 5.0mmol benzofuran/kg for the same 
period invoked an increase to 65.1% of control levels.
SDS-Polyacrylamide disc gel electrophoresis of 
microsomal proteins confirms the plateau effect described 
for epoxide hydrolase induction (band 1, Figure 5.3.).
Band 3 is reduced in microsomes obtained from animals 
pretreated with all levels of benzofuran from 0.42 to 
5.0mmol/kg. A band of molecular weight 51500-52000 appears 
in microsomes from rats receiving 2.5 or 5.Ommol benzofuran/ 
kg, and its intensity is apparently dose-related. Only 
after administration of the latter regimen is the wavelength 
of maximum absorbance of the carbon monoxide complex of 
reduced cytochrome P-450 shifted unequivocally to 452nm.
5.2.7. Benzofuran time-response studies
Rats receiving a single injection of benzofuran 
i.p. (1.25mmol/kg) were killed at predetermined time 
intervals, and the results of certain estimations of 
hepatic microsomal parameters are summarised in Figure 
5.4. All values had returned to near control levels after 
7 days, except for those for epoxide hydrolase, which 
remained at 1.4-£'Cme<6 control activity. The maximum increase 
occurred by 48 hours after injection of benzofuran (230% 
of control). Ethoxycoumarin 0-deethylase (lowest at 24h,
37% of control), ethoxyresorufin 0-deethylase (24h, 58% 
of control), cytochrome 6^ (24h, 70% of control), cytochrome
Figure 5.3.
SDS-Polyacrylamide disc gel electrophoresis of liver 
microsomes prepared from rats pretreated with increasing 
amounts of benzofuran, administered for 3 consecutive 
days in corn oil
2 4 6 8 10 12 14 16 18
Solubilisation and SDS-polyacrylamide disc gel electro­
phoresis of microsomal proteins were carried out as 
described in 2.8. Samples (15yg protein) were applied 
as follows:
Wells 2,3,4 corn oil 2.5ml/kg
5,6,7 benzofuran 0.42mmol/kg
9,10,11 benzofuran 1.25mmol/kg
13,14,15 benzofuran 2.50mmol/kg
16,17,18 benzofuran 5.00mmol/kg
Wells 1,8,12,19 contained molecular weight standards
Figure 5.4.
Response of some microsomal components and relative liver weight with 
time following a single intraperitoneal dose of benzofuran
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Male rats received a single i.p. injection of benzofuran (1.25nunol/kg in corn oil), or corn oil alone 
(2.5ml/kg), and groups of both benzofuran- and corn oil-pretreated animals were killed at the times 
indicated. Liver weight:bodyweight ratio, and the concentration or activity of several microsomal 
components, were determined, and the values of these parameters in benzofuran-pretreated rats were 
expressed as percentages of the corresponding values from corn oil-pretreated rats at the same time point.
c reductase (24h, 76% of control) and aminopyrine N- 
demethylase (24h, 32% of control) activities all fell. ,
The last named underwent a sharp depression to 55% of the 
corresponding control value after only 2 hours. Cytochrome 
P-450 levels also declined, but the lowest point (49% of 
control) occurred 48 hours after injection of benzofuran.
The relative liver weight increased, reaching a peak of 
129% of the control value after 48 hours.
SDS-Polyacrylamide disc gel electrophoresis 
confirms both the increase and the peak induction time for 
epoxide hydrolase activity (Figure 5.5. ). The 50000 MW 
band (band 3) is lowered in microsomes obtained from rats 
killed 24 hours and 48 hours after dosing, and returns to 
normal after 96 hours. There is some evidence for the 
presence of a 51500-52000 MW band in microsomes prepared 
from rats killed 24 hours and 48 hours after dosing.
5.2.8. Longer term administration of benzofuran
Benzofuran (1.25mmol/kg in corn oil) was administered 
i.p. to rats daily for 21 days. Control animals were given 
2.5ml corn oil/kg daily for the same period. The results 
of investigations made after dosing are summarised in 
Table 5.9.
During the dosing period, profuse production of 
saliva occurred from the tenth day. onwards for about 20 
minutes immediately after the administration of benzofuran.
The identity of the fluid was confirmed as saliva, rather 
than a pleural effusate, by measurement of the pH and of 
amylase activity. The rats were irritable and unsteady for 
a short period after dosing, and also exhibited a tendency 
to rapidly dig furrows in their bedding from one end of 
their cage to the other. There was an increase in the 
incidence of eye infections among animals in the test 
group, and the rate of bodyweight increase diminished.
Figure 5.5.
SDS-Polyacrylamide disc gel electrophoresis of liver 
microsomes prepared from rats killed at different time 
periods after pretreatment with a single dose of 
benzofuran, 1.25mmol/kg i.p. in corn oil
•»
16 18
Solubilisation and SDS-polyacrylamide disc gel electro­
phoresis of microsomal proteins were achieved as described 
in 2.8. Samples (17yg protein) were applied in the 
following order:
Wells 2,3 immediately after dosing
4,5 2 hours after dosing
6,7 8 hours after dosing
8,9 24 hours after dosing
11,12 48 hours after dosing
13,14 72 hours after dosing
15,16 96 hours after dosing
17,18 168 hours after dosing
Wells 1,10,19 contained molecular weight standards
Table 5.9. Effects of 21-day administration of benzofuran on several
liver and blood parameters in rats
Change in body weight (g/rat/24h)
Relative liver weight
Serum total bilirubin (yM)
Serum conjugated bilirubin (yM)
Conjugated bilirubin . .
Total bilirubin X
Aspartate aminotransferase (U/l)
White cell count (x109/l)
Red cell count (x10l2/l)
Haemoglobin (g/dl)
a . b
Corn oil Benzofuran
5.26 ± 0.37 3.69 ± 0.26
0.041 ± 0.003 0.052 ± 0.003
4.16 ± 1.17 6.28 ± 1.41
1.36 ± 0.64 2.54 ± 0.69
31.50 ± 10.2 42.70 ± 15.6
40.4 ± 3.12 51.4 ± 2.60
11.0 ± 3.27 8.7 ± 4.14
7.8 ± 0.35 7.7 ± 0.42
15.0 ± 0.74 14.1 ± 0.44
CL
Rats were pretreated with corn oil (2.5ml/kg) daily by injection i.p. 
for 21 days, and killed on the 22nd day.
b
Rats were pretreated with benzofuran (1.25mmol/kg) in corn oil daily by 
injection i.p. for 21 days, and killed on the 22nd day.
Values represent mean ± standard deviation of data from 6 animals.
Relative liver weight, and some serum components 
measured, showed a tendency to increase in value, but the 
results were not significantly different from the 
corresponding control determinations (Table 5.9.). Haem- 
atological parameters showed no alteration.
5.2.9. Coadministration of benzofuran and phenobarbitone 
or 3-niethylcholanthrene
The effects of preinduction of rats with either 
phenobarbitone or 3-methylcholanthrene, followed by the 
coadministration of these compounds with benzofuran, were 
compared with the effects of administration of corn oil, 
benzofuran, phenobarbitone or 3-methylcholanthrene alone.
Observations during dosing and at post-mortem
Rats pretreated with phenobarbitone (0.3mmol/kg 
i.p. in saline daily for 6 consecutive days)' showed little 
change in behaviour or appearance relative to control 
animals, except for a period of lethargy immediately 
following dosing. Their rate of weight gain was slightly 
reduced (Table 5.10.). Food and water consumption remained 
within normal limits. At post-mortem, the appearance of 
the animals was normal macroscopically, although there 
was a significant increase in relative liver weight (Table 
5.10.).
Animals receiving phenobarbitone (0.3mmol/kg in 
saline i.p. daily for 5 consecutive days) with coadministration 
of benzofuran (5.0mmol/kg in corn oil i.p. on the 4th and 
5th days) were practically immobile for about an hour after 
injection, with laboured breathing, puffy faces and staring 
fur. After initial recovery, all were lethargic and unsteady, 
but by 6 hours after dosing their appearance was little 
different from that of control animals. Severe eye infections 
were noted in each member of this group. The rate of
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weight gain decreased markedly from the commencement of 
administration of benzofuran (Table 5.10.), and both food 
and water consumption declined after this point.
Very large, mottled and friable livers were 
observed at post-mortem, although there were no superficial 
fat deposits. Relative liver weights were increased by a 
factor of 1.7 compared with controls (Table 5.10.). Ureters 
and urinary bladders were distended, the latter containing 
large amounts of grossly discoloured urine.
Rats pretreated with 3-methylcholanthrene (0.075 
mmol/kg i.p. in corn oil daily for 6 days) showed no 
aberrance of appearance or behaviour, but rate of bodyweight 
gain, food consumption and water intake were all decreased 
(Table 5.10.). No changes were recorded at post-mortem. 
Relative liver weight was not increased.
Administration of 3-methylcholanthrene (0.075 
mmol/kg i.p. in corn oil daily for 6 days) with 
coadministration of benzofuran (5.0mmol/kg i.p. in corn oil 
on the 4th, 5th and 6th days) caused lethargy, loss of 
balance and, occasionally, prostration. Eye infections 
occurred in all members of this group. Loss of bodyweight 
became severe after the commencement of benzofuran 
administration, and both food and water intake fell to levels 
lower than those for animals pretreated with benzofuran 
alone (Table 5.10.). Livers were enlarged, pale and fatty 
at post-mortem, with an increase in relative liver weight 
to 1 .85-£'tme.'6 control. The large intestines were inflamed 
and blood-streaked. Ureters and urinary bladders were 
grossly distended, and the latter contained thick, dark, 
smoky urine.
Protein yield
Pretreatment with either phenobarbitone or 
3-methylcholanthrene alone increased the hepatic microsomal 
yield, relative to the corresponding whole homogenate
protein yield, whereas pretreatment with benzofuran increased 
the yields of both to virtually the same extent (Table
5.11.). Although administration of phenobarbitone pluA 
benzofuran elevated both whole homogenate and microsomal 
total protein yields (by 6% and 20% respectively, compared 
with corn oil-pretreated animals), coadministration of 
3-methylchoIanthrene and benzofuran decreased these parameters 
to 95% and 89% of control levels respectively (Table 5.11.).
SDS-Polyacrylamide disc gel electrophoresis
Benzofuran pretreatment increased the intensity 
of staining of band 1 (48000 MW), decreased band 3 (50000 
MW), and caused the appearance of a band of molecular 
weight 51500-52000 (Figure 5.6.). Pretreatment with 
phenobarbitone increased band 3 (which may contain more 
than one polypeptide component) and also increased band 1 
slightly. Microsomes prepared from the livers of rats 
pretreated with phenobarbitone ptixA benzofuran exhibited 
an increased staining intensity of band 1, and a less 
intense band 3, the latter being especially obvious in 
track 7 (Figure 5.6.). A considerable amount of the 
51500-52000 MW protein became evident, particularly in 
track 6. Administration of 3-methylcholanthrene produced 
no evident change in band 1, but markedly increased band 
5 (55000 MW), and elevated band 4 (53000 MW) to a lesser 
extent. When administered with benzofuran, the
3-methylcholanthrene-mediated increase in band 5 was abolished, 
and the band appeared similar in intensity to band 5 of 
control microsomes. A large decrease in band 3, relative 
to microsomes obtained from animals pretreated with either 
corn oil or benzofuran alone, was seen. Band 4 appeared to 
remain higher than band 4 of control microsomes, but it 
was difficult to resolve clearly this band from one of 
51500-52000 MW.
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Figure 5.6.
SDS-Polyacrylamide disc gel electrophoresis of liver microsomes 
prepared from rats pretreated with phenobarbitone, 
3-methylcholanthrene, phenobarbitone pluL& benzofuran or 
3-methylcholanthrene pluA benzofuran
“7-*-
10 16 18
Solubilisation and SDS-polyacrylamide disc gel electrophoresis of 
microsomal proteins were carried out as described in 2.8. Samples (15yg 
protein) were applied in the following order:
Wells 2,3,4 phenobarbitone, 0.3mmol/kg x 6 days
benzofuran, 5.0mmol/kg x 3 days5,15
6,7
8,9,11
12,13,14
16,17,18
Wells 1,10,19
phenobarbitone, 0.3mmol/kg x 5 days + benzofuran, 
5.0mmol/kg coadministered last 2 days
corn oil, 2.5ml/kg x 3 days
3-methylcholanthrene, 0.075mmol/kg x 6 days
3-methylcholanthrene, 0.075mmol/kg x 6 days + 
benzofuran, 5.0mmol/kg coadministered last 
3 days
contained molecular weight standards
Hepatic microsomal cytochromes
Phenobarbitone administered at the level indicated
induced an hepatic microsomal protein that formed a reduced-
carbon monoxide complex with = 450nm, whereas X* max ’ max
for the 3-methylcholanthrene-induced protein was 448nm.
Induced levels of cytochrome P-450 were 2.4- and 2.1-^tk.me^
the control value after pretreatment with phenobarbitone
or 3-methylcholanthrene respectively (Table 5.12.).
Administration of benzofuran alone, or benzofuran pZtiA
phenobarbitone, resulted in similarly decreased hepatic
levels of cytochrome P-450, with X shifted to 452nm ■ ’ max
and 451nm respectively. Coadministration of benzofuran and 
3-methylcholanthrene altered the Amax of the reduced- 
carbon monoxide complexed cytochrome P-450 from 448nm to 
450.2nm, and caused a very marked decrease in the microsomal 
concentration of the cytochrome.
Phenobarbitone or 3-methylcholanthrene given alone 
caused a significant increase in cytochrome 6^ levels in 
hepatic microsomes, whereas benzofuran alone, or administered 
with either inducer, resulted in a decreased concentration . 
of this cytochrome (Table- 5.12.).
Microsomal enzymes
Phenobarbitone or 3-methylcholanthrene pretreatment 
increased hepatic microsomal ethoxycoumarin 0-deethylase 
activity by factors of 4.4 and 7.6 respectively (Table
5.12.). Despite this, coadministration of phenobarbitone 
and benzofuran resulted in a lower final activity of 
ethoxycoumarin 0-deethylase than did the administration of 
benzofuran alone, and pretreatment with 3-methylcholanthrene 
pZuA benzofuran resulted in an activity only 8.8% of that 
produced by the injection of 3-methylcholanthrene alone 
(Table 5.12.).
Ethoxyresorufin 0-deethylase activity was induced 
by 3-methylcholanthrene only (Table 5.12.). Benzofuran,
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given alone or with phenobarbitone, caused a marked reduction 
in activity, whereas the coadministration of benzofuran 
and 3-methylcholanthrene produced an activity comparable 
with the control value.
Hepatic microsomal epoxide hydrolase activity 
was increased 3.1-fold by pretreatment with phenobarbitone, 
and to a greater extent by pretreatment with benzofuran 
alone or in conjunction with either inducing agent, although 
the induction resulting from benzofuran ptuA phenobarbitone 
was less than that calculated by addition of their separate 
effects (Table 5.13.).
Glucose-6-phosphatase activity was lowered to the 
greatest extent by coadministration of 3-methylcholanthrene 
and benzofuran. Neither phenobarbitone nor 3-methylcholan­
threne given alone had a significant effect on haem 
oxygenase, but benzofuran, with or without coadministration 
of inducer, increased this activity 24.9- to 32.1-fold 
(Table 5.13.).
Soluble liver components
Benzofuran, benzofuran p-tuA phenobarbitone and 
benzofuran plaA 3-methylcholanthrene pretreatment reduced 
glycogen levels in rat liver homogenate to 28%, 11% and 
8% of fed control levels respectively (Table 5.14.), but 
did not exceed the depression of glycogen concentration 
caused by deprivation of food for 48 hours.Benzofuran 
alone or in conjunction with 3-methylcholanthrene increased 
hepatic glutathione levels significantly, but results obtained 
from animals pretreated with benzofuran pluA phenobarbitone 
were markedly disparate (Table 5.14.).
Serum enzymes
Neither phenobarbitone nor 3-methylcholanthrene 
pretreatment had any great effect on serum enzyme activities, 
except for a slight increase in 5 1-nucleotidase activity,
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Table 5.14. Coadministration of benzofuran and inducing agents.
Effects upon rat liver glycogen and glutathione levels
Pretreatment Glycogen
(ymol glucose 
equivalents/ 
g liver)
Glutathione
(ymol/g
liver)
Corn oil 378 ± 85 6.04 ± 0.122
Benzofuran
Phenobarbitone
Phenobarbitone a.
benzofuran
3-Methylcholanthrene
105 ± 22 
337 ± 28
42 ± 18( 
333 ± 15
11.96 ± 2.505 
6.52 ± 0.718
6
11.55, 2.06 
4.30 ± 0.570°
3-Methylcholanthrene +
benzofuran 30 ± 6 10.67 ± 2.016
Rats were pretreated with corn oil (2.5ml/kg i.p. for 6 days) OK 
benzofuran (5.0mmol/kg i.p. in corn oil for 3 days) OK phenobarbitone 
sodium (0.3mmol/kg i.p. in saline for 6 days) OK phenobarbitone sodium 
(0.3mmol/kg i.p. in saline for 5 days with coadministration of benzofuran, 
5.0mmol/kg in corn oil for the last 2 days) OK 3-methylcholanthrene
(0.075ramol/kg i.p. in corn oil for 6 days) OK 3-methylcholanthrene
(0.075mmol/kg i.p. in corn oil for 6 days with coadministration of
benzofuran, 5.0mmol/kg for the last 3 days)
All values are mean ±-standard deviation of,data from at least 3 rats, 
except 2 rats.
bIndividual glutathione levels for 2 rats.
CP<0.05
and a minor elevation of aminotransferase activity in the 
case of the former inducer (Table 5.15.^. Benzofuran in 
concert with either phenobarbitone or 3-methylcholanthrene 
exerted a synergistic effect on several serum enzyme 
activities (Tables 5.15. and 5.16.). Considerable variability 
of results was shown among animals receiving two compounds 
together, especially with respect to aminotransferase 
activities.
Serum bilirubin
Phenobarbitone or 3-methylcholanthrene alone 
exerted no effect on rat serum bilirubin levels (Table 
5.17.). However, pretreatment with benzofuran caused a 
marked elevation of total and conjugated bilirubin 
concentrations, which were increased still further when 
benzofuran was administered in conjunction with either 
inducer. In particular, 3-methylcholanthrene pZuA benzofuran 
resulted in 63- and 121-fold increases in serum total and 
conjugated bilirubin concentrations respectively, and a 
rise in the percentage of conjugated bilirubin from 45 to 
85% of total.
Serum cholesterol
Benzofuran coadministered with either inducer 
elevated serum total cholesterol levels (Table 5.18.).
However, whereas administration of phenobarbitone pZu* 
benzofuran resulted in variable high-density lipoprotein 
cholesterol concentrations, the administration of 
3-methylcholanthrene with benzofuran lowered the value 
of this parameter relative to control levels.
Serum glucose
Serum glucose concentration was reduced significantly, 
in comparison with fed controls, only after administration 
of benzofuran pZuA 3-methylcholanthrene or benzofuran alone 
(Table 5.18.). No marked fall was seen after pretreatment
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Table 5.17. Coadministration of benzofuran and inducing agents.
Effects upon rat serum bilirubin levels
Pretreatment Total
bilirubin
(yM)
Conjugated
bilirubin
(yM)
Corn oil
Benzofuran
Phenobarbitone
Phenobarbitone + abenzofuran
3-Methylcholanthrene
3-Methylcholanthrene +
benzofuran
2.54 ±0.59 
21.90 ± 11.50* 
1.80 ± 0.23
L
43.04 ± 6.53
2.17 ± 0.68
160.91 ± 45.66*
1.14 ± 0.36
L
14.80 ±9.96 
1.03 ± 0.39
L
25.97 ± 6.31 
0.76 ± 0.39
137.50 ± 46.15*
Rats were pretreated with corn oil (2.5ml/kg i.p. for 6 days) OX 
benzofuran (5.0mmol/kg i.p. in corn oil for 3 days) OX phenobarbitone 
sodium (0.3mmol/kg i.p. in saline for 6 days) OX phenobarbitone sodium 
(0.3mmol/kg i.p. in saline for 5 days with coadministration of 
benzofuran, 5.0mmol/kg in corn oil for the last 2 days) OX
3-methylcholanthrene (0.075mmol/kg i.p. in corn oil for 6 days) OX
3-methylcholanthrene (0.075mmol/kg i.p. in corn oil for 6 days with
coadministration of benzofuran, 5.0mmol/kg for the last 3 days)
All values are mean ± standard- deviation of-data from at least 3 .rats, 
except 2 rats.
L
P<0.05
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with phenobarbitone ptuA benzofuran, and hence the results 
do not entirely correlate with those described for the 
measurement of hepatic glycogen content.
Serum total protein and albumin
Either phenobarbitone or 3-methylcholanthrene 
administered alone to rats resulted in depressed serum 
total protein levels, the effect of the latter being 
comparable in this respect with benzofuran. Phenobarbitone 
pZu* benzofuran- pretreatment invoked no greater reduction 
in serum protein concentration than did phenobarbitone 
separately (Table 5.19.). Coadministration of benzofuran 
and 3-methylcholanthrene had the most pronounced effect.
None of the pretreatments appeared to result in a marked 
selective loss of albumin.
Serum Immunoglobulin A and IgA Free Secretory Component 
Preinduction with either phenobarbitone or 
3-methylcholanthrene, followed by coadministration of 
benzofuran, produced a greater increase in serum IgA and 
IgA Free Secretory Component levels than that described 
for benzofuran alone (Table 5.19.). Phenobarbitone or 
3-methylcholanthrene given separately had no effect on 
these parameters.
Haematology
White cell count, red cell count, haemoglobin 
concentration, packed cell volume, mean cell volume, mean 
cell haemoglobin and mean cell haemoglobin concentration 
were estimated, and the results are shown in Tables 5.20. 
and 5.21. No significant pathological changes were observed.
Blood urea nitrogen
Benzofuran and 3-methylcholanthrene together 
resulted in an approximately 2-fold increase in serum 
(blood) urea nitrogen levels (Table 5.22.). None of the
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Table 5.22. Coadministration of benzofuran and inducing
agents. Effects on serum urea nitrogen levels
Pretreatment Serum urea N (mM)
Corn oil 8.8 ± 0.28
Benzofuran 9.5 ± 0.64
Phenobarbitone 7.9 ± 0.78
Phenobarbitone +
benzofuran 8.0 ± 5.43
3-Methylcholanthrene 6.9 ± 0.55
3-Methylcholanthrene + ,
benzofuran 16.0 ± 2.09
Rats were pretreated with corn oil (2.5ml/kg i.p. for 6 days) OK 
benzofuran (5.0mmol/kg i.p. in corn oil for 3 days) OK 
phenobarbitone sodium (0.3mmol/kg i.p. in saline for 6 days) OK 
phenobarbitone sodium (0.3mmol/kg i.p. in saline for 5 days with 
coadministration of benzofuran, 5.0mmol/kg in corn oil for the last
2 days) OK 3-methylcholanthrene (0.075mmol/kg i.p. in corn oil for
6 days) OK 3-methylcholanthrene (0.075mmol/kg i.p. in corn oil for
6 days with coadministration of benzofuran, 5.0mmol/kg for the last
3 days)
All values ar<| mean ± standard deviation of data from at least 3 
rats, except 2 rats. '
L
P<0.05
other treatments employed exerted a significant effect.
Urinalysis
Urine obtained at post-mortem from the bladders 
of rats pretreated with benzofuran was usually a golden 
orange colour, darkening ultimately to black on standing. 
Benzofuran administered with phenobarbitone or with 
3-methylcholanthrene produced an oligouria, with viscous, 
cloudy urine, which was frequently brown-black in colour. 
Bilirubin, and high concentrations of protein, were 
consistently present (Table 5.23.), although urinary 
osmolality exhibited the same variability as did control 
urine samples. Glucose was not present in any sample, 
and its absence was confirmed using thin-layer chromatography. 
Neither of the classical inducers administered separately 
produced any notable effect on measured urinary parameters.
Renal morphology
In contrast to the results obtained during the 
structure-activity study reported in Chapter 4, more 
marked pathological changes were noted occasionally in 
kidneys removed from rats pretreated with benzofuran.
Swelling of.proximal convoluted tubules, causing compression 
of the Bowman’s capsules, was the most frequently observed 
phenomenon, but it was not common to all kidneys, or to 
all tubules within one kidney (Plates 5.7. and 5.8.).
Sections of kidney obtained from rats given benzofuran 
p£iu phenobarbitone or benzofuran p£u4 3-methylcholanthrene 
showed these effects to a much greater degree (Plates 5.9. 
and 5.10.). All kidneys examined from either of these 
groups showed the same changes, and more glomerular areas 
were affected within any one kidney. Benzofuran given 
with 3-methylcholanthrene exerted a greater effect than 
when given with phenobarbitone, exhibiting compression of 
most of the Bowman’s capsules, loss of brush borders and
Table 5.23. Coadministration of benzofuran and inducing agents.
Analysis of bladder urine samples obtained at post-mortem
a cl
Pretreatment Bilirubin Protein Glucose
CL
pH Osmolality
(mmol/kg)
Corn oil 6 .0-6 .8 1500-2250
Benzofuran ++ +++ 5.0-5.5 1380-2120
Phenobarbitone trace 6.1-6.8 1400-2200
Phenobarbitone
+ benzofuran ++ ++++ 5.2-5.9 925-1850
-MC 6.0-6.5 450-1950
-MC + benzofuran +++ ++++ 5.0-5.5 925-2060
ats were pretreated with corn oil (2.5ml/kg i.p. for 6 days) OK 
enzofuran (5.0mmol/kg i.p. in corn oil for 3 days) OK phenobarbitone 
odium (0.3rnmol/kg i.p. in saline for 6 days) OK phenobarbitone- sodium 
(0.3mmol/kg i.p. in saline for 5 days with coadministration of 
enzofuran, 5.0mmol/kg in corn oil for the last 2 days) OK 
-methylcholanthrene (3-MC, 0.075mmol/kg i.p. in corn oil for 6 days) OK 
-methylcholanthrene (0.075mmol/kg i.p. in corn oil for 6 days with 
oadministration of benzofuran, 5.0mmol/kg for the last 3 days)
Bilirubin, protein and glucose were detected using Labstix reagent 
est strips (Ames Co, Stoke Poges, Slough, Berks.).
Plate 5.7. Morphology of renal cortical area showing normal tubular 
structure and Bowman’s capsules, in section of kidney 
from a rat pretreated with corn oil (2.5ml/kg x 3 days). 
Fixed (Bouin’s fluid), 7ym, stained H + E (x312)
Plate 5.8. Swelling of proximal convoluted tubules and compression 
of Bowman's capsules in section of kidney from a rat 
pretreated with benzofuran (5.0mmol/kg x 3 days).
Fixed (Bouin's fluid), 7ym, stained H + E (x312)
Plate 5.9. Marked swelling of proximal convoluted tubules with
compression of Bowman’s capsules in section of kidney 
from a rat pretreated with phenobarbitone (0.3mmol/kg 
x 5 days) with coadministration of benzofuran (5.0 
mmol/kg) for the last two days. Fixed (Bouin’s fluid), 
7ym, stained H + E (x312)
Plate 5.10. Severe compression of Bowman’s capsules, with swelling
of proximal convoluted tubules and loss of brush borders, 
in section of kidney from a rat pretreated with 
3-methylcholanthrene (0.075mmol/kg x 6 days) with 
coadministration of benzofuran (5.0mmol/kg) for the last 
3 days. Fixed (Bouin’s fluid), 7ym, stained H + E (x312)
closure of the lumen of the proximal convoluted tubules.
Renal sections obtained from animals pretreated with either 
benzofuran alone or benzofuran ptuA inducer contained 
occasional necrotic cells, and, in the latter case, an 
increased number of mitotic figures.
Hepatic histology and histochemistry
Several of the pretreatments employed produced 
degenerative or necrotic changes in liver (Table. -5.24. ) .
A section of liver from a rat pretreated with corn oil is 
shown in Plate 5.11., and the eosinophilia produced by 
administration of benzofuran is demonstrated in Plate 5.12. 
Either phenobarbitone or 3-methylcholanthrene caused 
centrilobular swelling and vacuolation of hepatocytes 
(Plates 5.13. and 5.15.). Coadministration of benzofuran 
and phenobarbitone resulted in the appearance of basophilic 
hepatocytes, and scattered focal and single cell necrosis 
(Plate 5.14.), whereas 3-methylcholanthrene ptuA benzofuran 
produced a more widespread necrosis, with a ’ring* of 
damaged tissue around the portal tract, passing through 
centrilobular areas (Plate 5.16.).
Electron microscopic examination of liver sections 
from rats pretreated with benzofuran showed hepatocyte 
disorganisation; proliferation, degranulation and dilatation 
of rough endoplasmic reticulum; proliferation of smooth
endoplasmic reticulum; proliferation .of .peroxisomes; slight
hypertrophy of the Golgi apparatus and of the bile canalicular 
region; deposition of myelin; and a depression of glycogen 
content, relative to control sections (Plates 5.17., 5.18. 
and 5.19.).
Hepatic sections from animals pretreated with 
phenobarbitone alone also exhibited several of these 
changes, particularly disorganisation of orgenelles and 
proliferation of smooth endoplasmic reticulum (Plates
5.20..and 5.21.). Occasionally, loss of bile canalicular
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.11. Morphology of section of liver from a rat pretreated 
with corn oil (2.5ml/kg i.p. daily x 3 days). Fixed 
(Bouin’s fluid), 7ym, stained H + E (x80)
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12. Loss of basophilia and vacuolation of periportal
hepatocytes in section of liver from a rat pretreated 
with benzofuran (5.0mmol/kg x 3 days). Fixed (Bouin’s 
fluid), 7ym, stained H + E (x80)
Plate 5.
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13- Appearance of section of liver from a rat pretreated 
with phenobarbitone (0.3mmol/kg x 6 days). Fixed 
(Bouin’s fluid), 7pm, stained H + E (x80)
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14. Extensive centrilobular degeneration and necrosis in
section of liver from a rat pretreated with phenobarbitone 
(0.3mmol/kg x 5 days), with coadministration of 
benzofuran (5.0mmol/kg) for the last 2 days. Fixed 
(Bouin’s fluid), 7ym, stained H + E (x80)
Plate 5.15. Appearance of section of liver from a rat pretreated 
with 3-methylcholanthrene (0.075mmol/kg x 6 days). 
Fixed (Bouin's fluid), 7ym, stained H + E (x80)
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Plate 5.16. 'Ring* of degeneration and necrosis in section of liver 
from a rat pretreated with 3-methylcholanthrene (0.075 
mmol/kg x 6 days) with coadministration of benzofuran 
(5.Ommol/kg) for the last 3 days. Fixed (Bouin's fluid), 
7ym, stained H + E (x80)
microvilli was noted. Animals given phenobarbitone p£u4 
benzofuran showed the greatest degree of internal dis­
organisation of hepatocytes, and the most pronounced 
hypertrophy of Golgi apparatus and bile canalicular 
microvilli (Plates 5.22. and 5.23.). Generally, these 
cellular changes were approximately equal in extent 
following pretreatment with either benzofuran or phenobarb­
itone (except for derangement of the rough endoplasmic 
reticulum, which was more marked in the former), and the 
most severe effects were seen after coadministration 
of benzofuran and phenobarbitone. Electron microscopic 
examination of liver sections from rats pretreated with 
3-methylcholanthrene pfu.4 benzofuran was not performed.
The pattern of glycogen distribution in a section 
of liver from a rat pretreated with corn oil is shown in 
Plate 5.24. No change in glycogen distribution was observed 
after pretreatment with 3-methylcholanthrene, and only 
a slight centrilobular loss after the administration of 
phenobarbitone. Very extensive losses of glycogen were 
observed after pretreatment with benzofuran pZuA either 
inducer (Plate 5.25.).
A section of liver from a rat pretreated with 
corn oil is shown stained for lipid distribution in Plate
5.26., in contrast with the minimal fatty infiltration 
observed after administration of benzofuran (Plate 5.27.). 
Marked centrilobular fatty infiltration was noted following 
the administration of phenobarbitone (Plate 5.28.), whereas 
phenobarbitone pfu.4 benzofuran produced a diffuse fatty 
infiltration that was more severe periportally (Plate 5.29.). 
The fatty infiltration caused by pretreatment with 
3-methylcholanthrene was diffuse, and less severe than that 
produced by phenobarbitone (Plate 5.30.), but coadministration 
of 3-methylcholanthrene and benzofuran resulted in a fatty 
infiltration that was centrilobular in the least affected 
animal, and extended to the midzonal and periportal regions
Legends to Plates 5.17. to 5.23.
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Plate
Plate
Plate
Plate
Plate
Plate
'.17. Electron micrograph of hepatocyte from a rat pretreated 
with corn oil (2.5ml/kg x 3 days), showing normal 
organisation of cell organelles. (x8000)
.18. Electron micrograph of hepatocyte from a rat pretreated
with benzofuran (5.0mmol/kg x 3 days), showing disorganisation 
of internal structure, proliferation, dilatation and 
degranulation of rough endoplasmic reticulum and slight 
degree of peroxisome proliferation. (x12000)
.19. Electron micrograph of hepatocyte from a rat pretreated 
with benzofuran (5.Ommol/kg x 3 days), showing bile 
canalicular region. (x10000)
.20. Electron micrograph of hepatocyte from a rat pretreated
with phenobarbitone sodium (0.3mmol/kg x 5 days), showing
disorganisation of structure, derangement of rough 
endoplasmic reticulum and proliferation of smooth 
endoplasmic reticulum. (x10000)
.21. Electron micrograph of hepatocyte from a rat pretreated
with phenobarbitone sodium (0.3mmol/kg x 3 days), showing
organelle disorganisation and increase in density of 
inner mitochondrial matrix. (x8000)
.22. Electron micrograph of hepatocyte from a rat pretreated
with phenobarbitone (0.3mmol/kg x 5 days) with
coadministration of benzofuran (5.Ommol/kg) for the last
2 days, showing internal disorganisation, and hypertrophy 
of bile canalicular microvilli. (x8000)
.23. Electron micrograph of hepatocyte from a rat pretreated
with phenobarbitone (0.3mmol/kg x 5 days), with
coadministration of benzofuran (5.Ommol/kg) for the last
2 days, showing myelin deposition. (x8000)
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Plate 5.23.
Plate 5.24. Glycogen distribution in section of liver from a rat 
pretreated with corn oil (2.5ml/kg x 3 days). Fixed 
(Rossman’s fluid), 7ym, stained PAS (x80)
Plate 5-25. Near total loss of glycogen in section of liver from 
a rat pretreated with phenobarbitone (0.3mmol/kg x 5 
days) with coadministration of benzofuran (5.Ommol/kg) 
for the last 2 days. Fixed (Rossman’s fluid), 7ym, 
stained PAS (x80)
; : 1
Plate 5.26. Lipid distribution in section of liver from a rat
pretreated with corn oil (2.5ml/kg x 3 days). Fixed 
(Bouin's fluid), 7ym, stained Oil Red 0 (x80)
Plate 5.27. Minimal diffuse increase in lipid deposition in
section of liver from a rat pretreated with benzofuran 
(5.Ommol/kg x 3 days). Fixed (Bouin's fluid), 7ym, 
stained Oil Red 0 (x80)
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Plate 5.28. Marked fatty infiltration in section of liver from a 
rat pretreated with phenobarbitone (0.3mmol/kg x 6 
days). Fixed (Bouin’s fluid), 7ym, stained Oil Red 0 
(x80)
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Plate 5.29. Intense staining for lipid deposition in section of 
liver from a rat pretreated with phenobarbitone (0.3 
mmol/kg x 5 days), with coadministration of benzofuran 
(5.Ommol/kg) for the last 2 days. Fixed (Bouin’s fluid), 
7ym, stained Oil Red 0 (x80)
of the more severely affected (Plate 5.31.).
All test pretreatments caused a centrilobular 
loss of glucose-6-phosphatase activity, the most marked 
effects being seen with inducer pZu* benzofuran (Table 
5.25.).
The distribution of 5 ’-nucleotidase activity 
in a section of liver from a rat pretreated with corn oil 
is illustrated in Plate 5.32., and the corresponding 
distribution in a section of liver from a rat pretreated 
with benzofuran in Plate 5.33. The administration of 
phenobarbitone caused no alteration in the hepatic 
distribution of 5'-nucleotidase, whereas phenobarbitone 
pZuA benzofuran, or 3-methylcholanthrene alone, produced 
a slight increase in staining intensity in the immediate 
centrilobular region (Plate 5.3^.). Coadministration of 
3-methylcholanthrene and benzofuran resulted in a marked 
increase in activity in the centrilobular area (Plate 
5.35.).
Histology of other tissues
Pathological changes observed in sections of 
kidney prepared from rats pretreated with benzofuran, or 
benzofuran pZuA inducer, have been described above.
Erythropoietic activity appeared to be normal in 
the spleens of animals pretreated with phenobarbitone, 
but was diminished in sections of this tissue.prepared 
from rats given 3-methylcholanthrene alone. In sections 
of spleen obtained from rats pretreated with benzofuran 
pZuA either phenobarbitone or 3-methylcholanthrene, 
erythropoiesis was almost, or entirely, absent.
No pathological changes were noted in sections 
of lung tissue cut from rats pretreated with any of the 
dosing regimens described during the course of this 
section.
Plate 5.30. Fatty infiltration in section of liver from a rat 
pretreated with 3-methylcholanthrene (0.075mmol/kg 
x 6 days). Fixed (Bouin’s fluid), 7ym, stained Oil 
Red 0 (x80)
Plate 5.31. Pronounced fatty infiltration in section of liver from 
a rat pretreated with 3-methylcholanthrene (0.075mmol/ 
kg x 6 days), with coadministration of benzofuran (5.0 
mmol/kg) for the last 3 days. Fixed (Bouin's fluid), 
7pm, stained Oil Red 0 (x80)
Table 5.25. Coadministration of benzofuran and inducing agents. Effects upon 
hepatic distribution of glucose-6-phosphatase and 5 ’-nucleotidase
Pretreatment Glucose-6-
phosphatase
5 '-Nucleotidase
Corn oil Distributed throughout, 
but slightly more 
intense PP and MZ
Plasma membranes stain, 
most.intense in immediate 
PT and CL areas
Benzofuran Pronounced loss of CL 
activity
Possibly slight, diffuse 
decrease in staining
Phenobarbitone Moderate loss of CL 
activity
As corn oil
Phenobarbitone +
benzofuran
Extensive loss, mainly 
CL
Slight increase in CL 
reaction in one rat, more 
marked in second, with 
increased CL reaction
3-Methylcholanthrene Slight CL loss Intensification of staining 
in immediate CL area, p Z u A  
scattered, diffuse increase 
throughout parenchymal 
plasma membranes
3-Methylcholanthrene + 
benzofuran
Extensive CL loss. Most 
activity remaining is 
intense, and immediate 
to PT
Major increase in activity 
in immediate CL area, with 
intense staining into MZ 
area
Rats were pretreated with corn oil (2.5ml/kg i.p. for 6 days) o k benzofuran (5.0 
mmol/kg i.p. in corn oil for 3 days) o k phenobarbitone sodium (0.3mmol/kg i.p. 
in saline for 6 days) o k phenobarbitone sodium (0.3mmol/kg i.p. in saline for 
5 days with coadministration of benzofuran, 5.0mmol/kg in corn oil for the last 
2 days) o k 3-methylcholanthrene (0.075mmol/kg i.p. in corn oil for 6 days) o k  
3-methylcholanthrene (0.075mmol/kg i.p. in corn oil for 6 days with coadministration 
of benzofuran, 5.0mmol/kg for the last 3 days)
'As corn oil' indicates that the reaction did not differ significantly from that 
in sections of liver from corn oil-pretreated rats.
Staining methods were as described in 2.17.4. and 2.17.5.
Abbreviations: PT = portal tract PP = periportally MZ = midzonal CL = centri-
lobular
Plate 5.32. Distribution of 5 ’-nucleotidase activity in section of 
liver from a rat pretreated with corn oil (2.5ml/kg x 
3 days). Fresh, frozen tissue, 10ym, 5 '-AMP substrate, 
trapping agent calcium (x80)
Plate 5.33. Distribution of 5 ’-nucleotidase activity in section of 
liver from a rat pretreated with benzofuran (5.0mmol/kg 
x 3 days). Fresh, frozen tissue, 10ym, 5 ’-AMP substrate, 
trapping agent calcium (x80)
Plate 5.3^. Intense staining for 5'-nucleotidase activity in
section of liver from a rat pretreated with 3-methyl­
cholanthrene (0.075mmol/kg x 6 days). Fresh, frozen 
tissue, 10ym, 5 '-AMP substrate, trapping agent calcium 
(x80)
Plate 5-35. Increased 5 '-nucleotidase activity in section of
liver from a rat pretreated with 3-methylcholanthrene 
(0.075mmol/kg x 6 days), with coadministration of 
benzofuran (5.0mmol/kg) for the last 3 days. Fresh, frozen 
tissue, 10ym, 5 '-AMP substrate, trapping agent calcium (x80)
5.2.10. Effects of benzofuran on microsomal components
in vitko
The influence of a range of concentrations of 
benzofuran on some rat liver microsomal enzyme activities 
in vitko is shown graphically in Figure 5.7. Ethoxycoumarin 
0-deethylase activity was the most severely affected, 
being depressed to 17$ of the control value in the presence 
of 500yM benzofuran, when the microsomes were preincubated 
with benzofuran and the reaction started with NADPH.
Residual activity as a percentage of control activity 
was logarithmically related to concentration of benzofuran 
over the range used. When an NADPH-generating system was 
employed, and the reaction initiated by the addition of 
ethoxycoumarin, inhibition was greater in the presence of 
1OyM and 100yM benzofuran than under the conditions described 
above, but the enzyme activities in the presence of 500yM 
benzofuran were identical.
Ethoxycoumarin 0-deethylase activity in microsomes 
obtained from the livers of corn oil-pretreated rats 
was linear up to a protein concentration of at least 1mg/ml 
in the incubation mixture. When microsomes obtained from 
animals receiving 5.0mmol benzofuran/kg daily for 3 days 
were used, the activity fell from 0.37nmol 7-hydroxycoumarin 
formed/min/mg protein to 0.26nmol/min/mg protein as the 
protein concentration increased from 0.2 to 1.Omg/ml.
If microsomes obtained from rats pretreated with corn oil 
and those from rats pretreated with benzofuran (5.0mmol/kg 
x 3 days) were mixed in equal proportions up to a maximum 
combined protein concentration of 1.5mg/ml, the resulting 
ethoxycoumarin 0-deethylase activity was consistently 
85-89$ of that expected by addition of the activities 
measured in the two sources of protein separately.
The effects of benzofuran on ethoxyresorufin 
0-deethylase activity in vitko were broadly similar whether
Figure 5.7.
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Liver microsomes from untreated rats were employed. Benzofuran was added 
dissolved in 66mM Tris-HCl, pH 7.4, for ethoxyresorufin and ethoxycoumarin 
0-deethylase assays, in acetonitrile for epoxide hydrolase, and in 
dimethylformamide for the aminopyrine W-demethylase assay. Preincubation 
was carried out with benzofuran and substrate at 37 for 5 minutes, 
except in the case of epoxide hydrolase, where, after 3 minutes’ 
preincubation with benzofuran, the reaction was started with styrene oxide.
v— v Ethoxycoumarin 0-deethylase a— ▲ Ethoxyresorufin 0-deethylase
O— O Aminopyrine W-demethylase •— • Epoxide hydrolase
the reaction was initiated with NADPH, or preincubation 
was carried out with an NADPH-regenerating system, and
the reaction started with substrate. The degree of inhibition
was slightly reduced in the latter case.
Aminopyrine W-demethylase activity was less affected
by benzofuran In vZtsio, a concentration of 100yM producing 
only 16% inhibition. A concentration of 1.OmM caused 45% 
inhibition, but at concentrations of benzofuran higher 
than this, the compound began to precipitate from solution.
Epoxide hydrolase activity remained practically 
unaffected even in the presence of 1 . OmM benzofuran, the 
greatest degree of inhibition observed being about 9%
(Figure 5.7.).
Before examining the effects of benzofuran upon 
cytochrome P-450 Xn vXVio the former was checked for its 
ability to produce carbon monoxide by lipoperoxidation.
After preincubation of rat liver microsomes in the presence 
of 500yM benzofuran for 20 minutes at 37°, the dithionite- 
reduced v&AAuA oxidised spectrum showed a peak at 450nm 
that did not represent more than 1-2% of the subsequently 
estimated cytochrome P-450 concentration. Similar results 
were obtained after preincubation with 250yM NADPH pZuA 
500yM benzofuran. When microsomes were preincubated at 
37° with 250yM NADPH alone, the dithionite-reduced 
oxidised.spectrum.possessed a peak at 450nm that accounted 
for up to 8% of the total cytochrome P-450 present.
Incubation of microsomes from a corn oil-pretreated 
rat with benzofuran alone had little effect on cytochrome 
P-450 concentration, the maximum depression being about 
10% in the presence of 10yM benzofuran (Figure 5.8.).
In the presence of 500yM benzofuran, the cytochrome P-450 
concentration was practically identical to that in control 
microsomes. When preincubation was carried out with both 
NADPH and benzofuran present, the cytochrome P-450 level 
apparently rose with respect to the control (pZu^ S NADPH)
Figure 5.8.
Effects of benzofuran on cytochrome P-450 Zn viVio
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Liver microsomes from untreated rats were employed, and benzofuran 
(0-500yM) was added dissolved in dimethylformamide. Measurements were 
carried out in 66mM Tris-HCl, pH 7.4, containing EDTA (1.0mM).
a — a  After incubation for 20 min in the presence of benzofuran alone.
O — O After incubation for 20 min in the presence of benzofuran and
NADPH (250pM), expressed as a percentage of the specific content
of cytochrome P-450 in microsomes incubated in the presence of 
NADPH alone.
□— □ After incubation for 20 min in the presence of benzofuran and
NADPH (250yM), expressed as a percentage of the specific content
of cytochrome P-450 in microsomes incubated in the absence of 
both NADPH and benzofuran.
value, until it was 122% of the control value in the 
presence of 500yM benzofuran (Figure 5 .8 .). If the concentration 
of cytochrome P-450 in both test and control incubations 
in the presence of NADPH is expressed as a percentage of 
the concentration of cytochrome P-450 in control microsomes 
in the absence of NADPH, then the third plot of Figure 5.8. 
is obtained. In this case, the cytochrome P-450 concentration 
after incubation with 500yM benzofuran apparently returns 
to almost the control {mZnU'i NADPH) value.
When an NADPH-regenerating system was employed, 
during the preincubation of microsomes with benzofuran, 
the depression in' cytochrome P-450 concentration with time 
was similar for benzofuran concentrations from 0 to 500yM, 
the degree of apparent cytochrome P-450 loss after 20 minutes 
being about 15% (Figure 5.9.).
5.2.11. Spectral studies
Ligand binding spectra
Characteristics of the spectral interactions of 
benzofuran (at 25°) with microsomes prepared from animals 
pretreated with various inducing agents are shown in 
Table 5.26.
With control microsomes, benzofuran gave an
abnormal spectrum with X = 390nm, X . = 420nm, but^ max ’ m m  ’
with no definable isosbestic point (Figure 5.10.). A^ max
and Kg could not be measured reliably.
Benzofuran added to microsomes prepared from
rats pretreated with phenobarbitone produced a typical
type I spectrum (Xmax = 390nm, Xmin = 420nm), with Am&x =
0.0127 and K = 82.7yM (Figure 5.11.). Addition of NADPH s
resulted in the appearance of a trough at 424nm, which 
became less pronounced with time (Figure 5.12.).
Microsomes prepared from rats pretreated with
3-methylcholanthrene interacted with benzofuran to yield a
Figure 5.9.
Effects of benzofuran on. cytochrome P-450 -in V4.&LO with 
regeneration of NADPH
100
90-
80-
7'0 -
30-
20 -
100 20
Time of incubation (min)
Liver microsomes from untreated rats were used and benzofuran was added 
dissolved in dimethylformamide. An NADPH-regenerating system consisting 
of 250TJM NADPH, 4.OmM glucose-6-phosphate and 2units/ml glucose-6- 
phosphate dehydrogenase was included. Results are expressed as percentage 
of specific content of cytochrome P-450 in each preparation at t = 0.
□— □ Control a — A 10yM Benzofuran O— O 100yM Benzofuran
• — • 500yM Benzofuran
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Figure 5.10.
Spectral changes produced by the addition of benzofuran 
to microsomes prepared from the liver of a rat pretreated 
with corn oil
0.05A
< i i i i i i i i i i i i i i  
360 380 400 420 440 460 480 500
nm
Microsomes (1mg protein/ml), prepared from the liver of a rat 
pretreated with corn oil (2.5ml/kg i.p. daily for 3 days) were 
suspended in 66mM Tris-HCl, pH 7.^, and divided equally between two 
cuvettes. After incubation at 25° for 5 minutes, a baseline of equal 
light absorbance was established, and benzofuran (25yM) was added to 
the sample cuvette. The spectrum was recorded between 350 and 500nm 
(1). Successively higher concentrations of benzofuran (100, 200, 500, 
900, 1700yM) were added to the sample cuvette, and the spectra 
produced were recorded (2-6).
Figure 5.11.
Spectral changes produced by the addition of benzofuran 
to microsomes prepared from the liver of a rat pretreated 
with phenobarbitone
0.01A
i i i i i i i t i i  i i i i i i  
360 380 400 420 440 460 480 500
Microsomes (1mg protein/ml), prepared from the liver of a rat pretreated 
with phenobarbitone sodium (0.3nunol/kg i.p. daily for 6 days), were 
suspended in 66mM Tris-HCl, pH 7.4, and divided equally between two 
cuvettes. After incubation at 25° for 5 minutes, a baseline of equal 
light absorbance was established, and benzofuran (10pM) was added to 
the sample cuvette. The spectrum between 350 and 500nm was recorded 
(1). Successively higher concentrations of benzofuran (50, 100, 200,
500, 900, 1300yM) were added to the sample cuvette, and the resulting 
spectra were recorded.
Figure 5.12.
Spectral changes produced by the addition of benzofuran 
to rat liver microsomes in both the reduced and oxidised 
state
0.01A
360 380 400 420 440 460 480 500
nm
Microsomes (1 mg protein/ml) were suspended in 66mM Tris-HCl, 
pH 7.4, and divided equally between two cuvettes. After incubation 
at 37° for 5 minutes, a baseline of equal light absorbance was 
established, • and benzofuran (250yM) was added to the sample 
cuvette (•-— • ). NADPH was added to both cuvettes, and the spectrum 
was recorded after 30 seconds, 2, 5 and 8 minutes.
typical type I spectrum similar to that seen with
phenobarbitone-induced microsomes, but with a lower A7 max
and a higher affinity constant (Table 5.26.).
With microsomes from rats pretreated with isosafrole,
benzofuran gave a spectrum similar in shape to the typical
type I, but with Amax = 394nm and Amin = 436nm, and an
isosbestic point at about 4l5nm (Figure 5-13.)- The K wass
similar to that obtained with phenobarbitone-induced
microsomes, but the A value was much higher. After the 7 max - o
treatment of isosafrole-induced microsomes with 2n-heptyl-
benzimidazole, the spectrum obtained in the presence of
benzofuran was much reduced in displacement, but had
L  v = 390nm, X . - 420nm, and an isosbestic point atmax min
401nm (Figure 5.1*1.).
Benzofuran added to microsomes prepared from rats 
induced with tsianA-stilbene oxide yielded a typical type I 
spectrum at 37°, whose characteristics are described in 
Table 5.26.
Displacement o-f methylenedioxyphenyl metabolites with 
2fl-heptylbenzimidazole and benzofuran
Characteristics of the dithionite-reduced 
oxidised spectra derived from microsomes prepared from 
safrole- and isosafrole-pretreated rats are shown before 
and after displacement (37°, 30 minutes) with either 
250yM 2n-heptylbenzimidazole or 250yM benzofuran, in Table 
5.27. For both safrole- and isosafrole-induced microsomes, 
the measurable increase in cytochrome P-450 concentration 
after displacement was similar whichever agent was used, 
but the value was consistently significantly lower
after displacement with benzofuran (Table 5.27.). Dithionite- 
reduced vtsiAtiA oxidised spectra obtained before and after 
incubation of isosafrole-induced microsomes with either 
2jt-heptylbenzimidazole (Figure 5.15.) or benzofuran (Figure 
5.16.) are illustrated.
Figure 5.13.
Spectral changes produced by the addition of benzofuran 
to liver microsomes prepared from rats pretreated with 
isosafrole
5
0.01A
360 300 400 420 440 460 480 500
Liver microsomes (1mg protein/ml), prepared from rats pretreated 
with isosafrole (3.75mmol/kg i.p. daily for 3 days), were suspended 
in 66mM Tris-HCl, pH 7.*4, and divided equally between two cuvettes. 
After incubation at 25° for 5 minutes, a baseline of equal light 
absorbance was established, and benzofuran (60yM) added to the 
sample cuvette. A spectrum was recorded between 350 and 500nm,(1). 
Successively higher concentrations of benzofuran (100, 160, 240 and 
300yM) were added to the sample cuvette, and the spectra recorded.
Figure 5.14.
Spectral changes produced by the addition of benzofuran to 
liver microsomes prepared from rats pretreated with 
isosafrole, following displacement with 2tt-heptylbenz- 
imidazole
0.005A
5I
360 380 400 420 440 460 480 500
Microsomes (1mg protein/ml), prepared from rats pretreated 
with isosafrole (3.75mmol/kg i.p. daily for 3 days) were incubated with 
2tt-heptylbenzimidazole (250yM), as described in the legend to 
Figure 5.15. The microsomes were divided equally between two cuvettes, 
and a baseline of equal light absorbance was established at 25°.
Benzofuran (25yM) was added to the sample cuvette, and the spectrum 
was recorded between 350 and 500nm (1). Successively higher concentrations 
of benzofuran (100, 250, 1000, 2000yM) were added to the sample 
cuvette, and the spectra recorded.
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Figure 5.15.
Reduced mZnuA oxidised spectra of liver microsomes prepared from rats 
pretreated with isosafrole, before and after incubation with 
2n-heptylbenzimidazole
0.02A
I
500
I
480
I
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I
420400
. nm
Microsomes prepared from rats pretreated with isosafrole were diluted 
with 66mM Tris-HCl, pH 7.4, to give a protein concentration of 1mg/ml. 
The suspension was either incubated at 37 for 5 min, followed by the 
addition of 2ft-heptylbenzimidazole (250jjM) and further incubation for 30 
min, or the reduced minuA oxidised spectrum was measured immediately.
The suspensions were divided equally between two cuvettes and a baseline 
of equal light absorbance was established. Solid sodium dithionite (1mg) 
was added to the sample cuvette, and the spectrum was recorded. Spectra 
are shown pre-displacement (--- ) and after displacement (---).
Figure 5.16.
Reduced mZncU oxidised spectra of liver microsomes prepared from rats 
pretreated with isosafrole, before and after incubation with benzofuran
i \i \
0.02A
400 420 440 460 480 500
nm
Microsomes prepared from rats pretreated with isosafrole were diluted 
with 66mM Tris-HCl, pH 7.4, to give a protein concentration of 1mg/ml. 
The suspension was either incubated at 37° for 5 min, followed by the 
addition of benzofuran (250jjM) and further incubation for 30 min, or 
the reduced mivuiA oxidised spectrum was measured immediately. The 
suspensions were divided equally between two cuvettes and a baseline of 
equal light absorbance was established. Solid sodium dithionite (1mg) 
was added to the sample cuvette, and the spectrum recorded. Spectra are 
shown pre-displacement (--- ) and after displacement (--- ).
5.3. Discussion
5.3.T. Non-specific markers of toxicity
An acute toxic response to many of the compounds 
examined was evident from the diminished food and water 
consumption, and weight loss, among treated rats, and some 
immediate ’clinical signs* occurred, presumably indieating 
a direct effect upon the central nervous system. These 
varied from the violent convulsions and rapid death resulting 
from the administration of large amounts of indole, to 
temporary tremors or loss of coordination. Sometimes the 
response was bizarre, as in the excessive salivation and 
’digging' behaviour exhibited by rats on a more prolonged 
course of benzofuran treatment. It is possible that the 
structure of benzofuran, and other agents among those 
tested, is sufficiently analogous to molecules such as 
serotonin as to evoke a neuronal reaction. Alternatively, 
some or all of these effects may be non-specific, and related 
to considerable proportions of the relatively large doses 
of the compounds administered rapidly reaching the nervous 
system.
It is apparent that many of the compounds produced 
toxic changes in the liver and, in some cases, also in the 
kidney. No consistent or gross pathological alterations 
were observed in other tissues, except for the reduction 
or absence of splenic erythropoiesis. This is particularly 
significant in the case of the furans, since the most widely 
described lesions following the administration of various 
substituted furans to several mammalian species occur in 
lung tissue (e.g. see Boyd, 1980a,b).
Relative liver weight was increased most markedly 
after the pretreatment of rats with furan, benzofuran, 
dibenzofuran, isosafrole or X'ta.R^-stilbene oxide, and to 
a lesser extent after treatment with dihydrobenzofuran, 
safrole or benzodioxole. Phenobarbitone also elicited a
considerable increase in liver weight:body weight ratio, 
but 3-methylcholanthrene did not. This is in accordance 
with the many reports that administration of phenobarbitone 
to rats and other species increases liver weight more 
effectively than does the administration of 3-methylcholan- 
threne (e.g. Dent zt at., 1980). However, whereas the increase 
in relative liver weight seen after the administration 
of phenobarbitone ptuA benzofuran is approximately additive 
with respect to the two compounds individually, the 
corresponding increase following pretreatment with 3-methyl- 
cholanthrene p£iu benzofuran is the greatest of all. This 
may be explained if the liver enlargement results primarily 
from the action of a metabolite of benzofuran, whose production 
may be catalysed preferentially by cytochrome P-448, rather 
than by cytochrome P-450. Observations during dosing, and 
the results of various liver parameter estimations, indicate 
that the toxic response evoked by benzofuran in rats pretreated 
with inducing agents is also most severe when 3-methyl- 
cholanthrene is employed.
Changes in hepatic protein yield do not correlate 
well with relative liver weights. Although phenobarbitone 
(and 3-methylcholanthrene, despite its failure to increase 
the relative liver weight), and also safrole and isosafrole 
increased preferentially the yield of microsomal protein, 
benzodioxole and benzofuran elevated both whole homogenate 
and microsomal protein yields by a similar factor.
Pretreatment with dihydrofuran or dihydrobenzofuran increased 
selectively the whole homogenate protein yield, and 
coadministration of 3-methylcholanthrene and benzofuran, 
although causing gross hepatomegaly, diminished the protein 
recovery per g liver whether whole homogenate or microsomes 
were considered. In some instances, an elevated whole 
homogenate protein yield may be explained in part by loss 
of hepatic glycogen as food intake falls, since fasted 
animals exhibit an apparent increase in protein concentration
in liver when expressed per g of tissue. Further reference
to these results is made below in the discussion of
cholestasis.
Nor did cytochrome P-450 levels in liver associate 
with liver weight:body weight ratio following the administration 
of the series of compounds investigated. Increased relative 
liver weight occurred simultaneously with either increased 
or decreased hepatic cytochrome P-450 concentration (measured 
either spectrally or by SDS-polyacrylamide disc gel 
electrophoresis).
5.3.2. Chemically induced changes in the electrophoretic
pattern of hepatic microsomal proteins
Alterations in the electrophoretically demonstrable 
distribution of microsomal proteins occurred after the 
administration of several of the compounds used. One of 
the most consistent changes was an increase in the intensity 
of staining of a polypeptide of 48000 MW, which was seen 
in SDS-solubilised hepatic microsomes after the treatment 
of rats with various furan derivatives, safrole or 
phenobarbitone, but not 3-methylcholanthrene. The molecular 
weight was comparable with that of 49000 reported by Bentley 
and Oesch (1975) for purified epoxide hydrolase, and the 
polypeptide also co-migrated with purified epoxide hydrolase 
in the present study. TAan^-Stilbene oxide, which has 
previously been shown to induce mammalian microsomal epoxide 
hydrolase (Schmassmann and Oesch, 1978), also increased 
this band. The ability of various.chemicals described in 
this and the previous chapter, when administered 
intraperitoneally to rats, to increase the staining intensity 
of this polypeptide on electrophoresis correlates well with 
increases in the capacity of hepatic microsomes to hydrate 
styrene oxide. These data strongly support the contention 
that the polypeptide band of 48000 MW described represents 
epoxide hydrolase, and that this protein is susceptible to
induction by the administration to rats of various foreign 
compounds. That the increase in activity is the result of 
an increased rate of protein synthesis, and not activation 
of existing enzyme (Oesch zt at., 1971c; Ganu and Alworth, 
1978; Seidegard and DePierre, 1980), is suggested both by 
the results of SDS-polyacrylamide disc gel electrophoresis, 
and, in the case of benzofuran (the only chemical in the 
present study evaluated so far in such a manner), by the 
failure of this compound to increase epoxide hydrolase 
activity when added to hepatic microsomes tn vZVio. 
Structure-activity relationships, and the significance of 
epoxide hydrolase induction, are discussed below.
Polypeptides in the molecular weight region • 
49000-55000 were also affected by pretreatment of rats with 
heterocyclic and other compounds. Phenobarbitone induced 
a band of 50000 MW, whereas 3-methylcholanthrene increased 
predominantly band 5 (55000 MW), and shifted the absorbance 
maximum of the carbon monoxide-complexed, dithionite- 
reduced VZA.AU.A dithionite-reduced spectrum to 448nm. These 
results are in accordance with those published by other 
workers (e.g. Alvares zt at., 1967; Alvares and Siekevitz, 
1973; Welton and Aust, 1974), and appear to represent the 
major haemoproteins induced by these two agents. The pattern 
of induction described following the administration of 
methylenedioxyphenyl compounds to rats is comparable with 
that reported by Dickins zt at. (1978), isosafrole inducing 
a protein with a molecular weight between those of the major 
bands induced by phenobarbitone and by 3-methylcholanthrene. 
Only the methylenedioxyphenyl compounds of the various 
chemicals examined formed a metabolite complex tn vtvo.
This is not unexpected, as formation of a carbene, which 
may be involved in the generation of the 427/455nm spectrum, 
is believed to require the presence of two hetero-atoms to 
stabilise the structure (Werringloer and Estabrook, 1978; 
Fennell, 1980). The formation of a stable 455nm complex
In vivo seems to be associated with the induction of the 
53000 MW band, which in turn requires i) the presence of 
a dioxole ring, ii) metabolism of the methylene group of 
the dioxole ring to form a stable adduct with cytochrome 
P-450, iii) the absence of alternative sites of metabolism 
that undergo preferential attack and iv) possession of a 
lipophilic side chain, which enhances inducing ability.
Alterations by the administration to rats of 
other compounds of the 50000-52000 MW region in hepatic 
microsomes are more difficult to interpret. Ptan^-Stilbene 
oxide generally caused an increase in band 3, which is 
consistent with the observations of Bucker z£ at. (1979), 
employing inhibition studies with a-naphthoflavone, 
tetrahydrofuran and metyrapone, that the induced cytochrome 
P-450 resembled the species of this cytochrome induced by 
phenobarbitone. However, there is evidence that Vian*- 
stilbene oxide also induces a polypeptide band of slightly 
higher molecular weight (51500-52000), which is not detectable 
in microsomes from untreated rats. A band of apparently 
the same molecular weight is induced also by benzofuran, 
and, to a lesser extent, by dibenzofuran or dihydrobenzofuran. 
Its appearance is presumably not an obligatory response 
to the furan ring, since furan itself provokes the phenomenon 
only weakly, if at all. Nor is it an artefactual result 
of residual chemical present in the liver, since benzofuran 
mixed with control microsomes does not elicit its presence. 
Pretreatment with benzofuran decreases band 3, and the 
amount of spectrally measurable cytochrome P-450. This band 
is broad in SDS-polyacrylamide disc gel electrophoresis 
tracks from control microsomes, and may be composed of more 
than one polypeptide. It is impossible to state unequivocally 
at present that the 51500-52000 MW band represents a new 
protein, since it may instead represent a refractory component 
of band 3, revealed when the 50000 MW component (inducible 
with phenobarbitone pretreatment) is diminished. However,
arguing against this is the sequence of cytochrome P-450 
changes seen when a range of doses of benzofuran is given 
to rats. In this instance, the concentration of spectrally 
determinable cytochrome P-450 falls when a dosing regimen 
of up to 1.25mmol benzofuran/kg bodyweight per day for 3 
days is used , but begins to rise again as the dose is increased 
up to 5.0mmol/kg. Enhanced intensity of the 51500-52000 MW 
polypeptide band correlates with this renascence of cytochrome 
P-450 in a dose-dependent manner. However, the hypolipidaemic 
drug, Clofibrate (Heady, 1973), increases rat liver cytochrome 
P-450 concentration (Lewis zt at., 1974; Orton and Parker, 
1982), the main form of the induced haemoprotein having a 
molecular weight of 52000 by SDS-polyacrylamide disc gel 
electrophoresis,- and a ferrous-carbon monoxide complex 
absorbance maximum of 451.8nm (Gibson zt at., 1982). Benzofuran 
pretreatment also appears to shift the corresponding 
absorbance maximum to 451-452nm. In addition, the poor rates 
of ethoxycoumarin and ethoxyresorufin 0-deethylation supported 
by the Clofibrate-induced cytochrome P-450 (Orton and Parker, 
1982) are consistent with the failure of these activities 
to rise as cytochrome P-450 concentration recovers with 
increasingly higher doses of benzofuran in the dose-response 
study. However, whereas Clofibrate administration causes a 
large and selective induction of laurate w-hydroxylase 
activity in mammalian liver (Gibson zt at. , 1982; Orton and 
Parker, 1982), benzofuran reduced the total laurate 00- 
ptuA (a)-1)-hydroxylase activity to 39$ of the control level 
when expressed per nmol of cytochrome P-450. Neither did 
benzofuran nor tKan^s-stilbene oxide increase the staining 
intensity of a higher molecular weight (70000-80000) band 
seen after Clofibrate administration, both in the present 
study and by others (Reddy zt at., 1982).
Chemically inducible diabetes in rats has also been 
reported to produce a cytochrome P-450 band of slightly 
higher molecular weight than the phenobarbitone-induced
cytochrome upon SDS-polyacrylamide disc gel electrophoresis 
(Past and Cook, 1980, 1982a,b), but the former has a 
reduced-carbon monoxide complex absorbance maximum of 450nm, 
in contrast to the shift seen after the administration to 
rats of benzofuran. Starvation may move the absorbance 
maximum towards higher wavelengths (Kato zt at., 1970;
Ellin and Orrenius, 1975), but both starvation and diabetes 
enhance the rate of hepatic co-oxidation (Mitsuhashi and 
Imai, 1967; Bjorkhem, 1973). Hence, it appears unlikely 
that the induction of the 51500-52000 MW polypeptide band 
resulting from the pretreatment of rats with benzofuran is 
related to the phenomena described above.
The possibility must be considered that the 
electrophoretic band of 51500-52000 MW is not a haemoprotein. 
Haemoproteins are difficult to identify reliably after 
SDS-polyacrylamide disc gel electrophoresis, because haem 
may be lost from proteins during sample preparation, or free 
haem may become associated with other proteins. Moreover, 
stearoyl CoA desaturase has been reported to have a molecular 
weight of 53000 (Strittmatter zt at., 1974), while UDP- 
glucuronyltransf erase has been recorded as possessing 
multiple forms of molecular weights 48000, 52000 and 56000 
(Bock zt at., 1977). Microsomal studies showed that benzofuran 
increased UDP-glucuronyltransferase, activity, whereas 
stilbene oxide did not, in contrast to the results of 
Elmamlouk and Mukhtar (1979), who described an enhanced 
activity with 4-nitrophenol as substrate. However, phenobarb- 
itone has also been reported to induce rat liver microsomal 
UDP-glucuronyltransferase (Dutton zt at,, 1970; Burchell 
zt at., 1972), but did not appear to increase a polypeptide 
band of 51500-52000 MW in the present study. Glutathione 
S-transferases of rat liver have molecular weights of about 
46000 (Habig zt at., 1974), but the major ones are 
cytosolic proteins.
5.3*3. Spectral interactions of benzofuran with
cytochrome P-450
Spectral evidence of interaction of benzofuran and
cytochrome P-450 is provided by the generation of typical
type I spectra (^max = 390nm, Am^n = 420nm) when benzofuran
is titrated against hepatic microsomes prepared from rats
pretreated with phenobarbitone, 3-methylcholanthrene or
tAanA-stllbene oxide. Calculation of K values indicates
that the highest binding affinity is for phenobarbitone-
inducible cytochrome P-450. Addition of NADPH to a cuvette
containing phenobarbitone-induced microsomes ptuA benzofuran
produces with time a decrease in the absorbance at 424nm,
which is probably due to oxidation of cytochrome 6^ in the
sample cuvette. Mixing benzofuran with control microsomes
generates a ’binding1 spectrum which is badly distorted
and atypical, although peak and trough wavelengths are
representative of a type I interaction. If benzofuran is
added to microsomes prepared from rats pretreated with
isosafrole, a spectrum is generated at 25° which is normal
in shape, but has L  = 394nm and \ . = 436nm, with an.max min
isosbestic point at 4l5nm. When microsomes from isosafrole-
pretreated rats were preincubated with 2n-heptylbenzimidazole
(250yM) at 37° for 30 minutes, the subsequent binding spectrum
showed a markedly diminished A and increased K value,J max s ’
but had wavelength characteristics typical of a type I 
spectrum. The distorted spectrum obtained with benzofuran 
under the first described conditions may be due to the 
ability of benzofuran to displace the isosafrole metabolite 
from its complex with cytochrome P-450. At 37°, the incubation 
of isosafrole-induced microsomes with benzofuran (250yM) was 
as effective as incubation of the microsomes with the same 
concentration of 2*i-heptylbenzimidazole in abolishing 
absorbance at 455nm, and increasing the amount of cytochrome 
P-450 spectrally determinable by reaction with carbon
monoxide. This requires further investigation, as the 
2n-alkylberizimidazoles have previously been reported to 
be the most effective displacers of the complex; their 
ability to do so is related to the presence of a side 
chain, with an optimum length of 7 carbon atoms (Dickins 
zt clZ., 1979). The apparent ineffectiveness of benzofuran 
in competing with 2ft-heptylbenzimidazole for cytochrome 
P-450 binding after displacement of the methylenedioxy- 
phenyl metabolite with the latter compound is also notable.
It is surprising to find an agent which behaves as a good 
displacer, apparently.from an active site, while itself 
being a poor substrate.
Some benzodioxole derivatives administered to 
animals result in an initial decrease in spectrally measurable 
cytochrome P-450, and inhibition of drug metabolism-(Philpot 
and Hodgson, 1971a,b; Franklin, 1976; Dickins, 1978), lasting 
up to 24 hours. Dickins (1978) reported that it is difficult 
to detect an early metabolite-cytochrome P-450 complex 
tn vtvo; since the results reported in Chapter 3 of this 
work indicate that the complex may be shown microspectro- 
photometrically in frozen liver sections, this may prove to 
be a valuable approach in looking for the early stages of 
formation of the complex, with minimal disturbance of 
tissue organisation. In any case, if such a complex is the 
cause of the initial inhibition of monooxygenation seen 
after the administration of methylenedioxyphenyl compounds, 
it is apparent that irreversible inactivation of cytochrome 
P-450 does not occur, as substrate-elicited dissociation of 
the complex restores a metabolically competent cytochrome 
(Elcombe zt aZ., 1977). By analogy with the data for safrole 
and isosafrole, it appears to be unlikely that an inhibitory 
benzofuran metabolite-cytochrome P-450 complex is responsible 
for the observed loss of this cytochrome. (N.B. A further 
test of this would be to examine the effect of incubation 
of microsomes from benzofuran-pretreated rats with 
2n-heptylbenzimidazole.)
5.3.4. Is the loss of hepatic microsomal cytochrome P-450
a primary effect of benzofuran or its metabolite(s )?
It is evident from both the spectral and the 
electrophoretic data that the overall specific content of 
rat hepatic cytochrome P-450 falls after pretreatment of 
the animals with either furan or benzofuran. The loss of 
cytochrome after the administration of furan was more severe, 
and was similar in extent whichever of the two dosing 
regimens was employed. Hence, either 1.5 or 3.7mmol furan/kg 
bodyweight/day for 3 days resulted in practically identical 
hepatic microsomal specific contents of cytochrome P-450, 
suggesting tentatively that there may be destruction of a 
particular labile fraction of the cytochrome. The same 
situation was obtained when total content of cytochrome P-450 
per liver was calculated, and similar losses of cytochrome 
6^, or induction of epoxide hydrolase activity, occurred 
after either dose, when the concentrations of these proteins 
were calculated on the same bases. Curiously, the lower furan 
dose elicited the greater inhibition of ethoxyresorufin' 
0-deethylase activity, and increased haem oxygenase activity, 
but resulted in the smaller depression of glucose-6-phosphatase 
activity.
Many toxic chemicals effect changes in the hepatic 
endoplasmic reticulum of pretreated animals. Frequently, 
as seen with several agents used during this study, evidence 
of concomitant greater or lesser generalised tissue damage 
can be demonstrated either biochemically or histologically. 
Hence, a major problem is to segregate primary effects upon 
proteins of the endoplasmic reticulum (including the destruction 
of cytochrome P-450) from those which are secondary to that 
damage, or arise from non-specific hepatocellular destruction. 
Often, a chemical’s action does appear to involve a direct 
and/or selective attack upon the microsomal components of 
the cell, since, as shown here, the degree of disturbance
of these components is not necessarily related to (i.e. 
exceeds) the extent of histologically demonstrable liver 
cell damage. When examined by haematoxylin and eosin staining, 
liver sections from rats pretreated with benzofuran exhibit 
relatively little cellular destruction when compared with 
those from furan-pretreated rats, whereas some microsomal 
enzymes, including epoxide hydrolase and glucose-6-phosphatase, 
are affected more severely by the former compound. The 
lesser degree of generalised hepatic cell damage after 
pretreatment with benzofuran, coupled with a considerable 
loss of microsomal cytochrome P-450, is also useful in the 
consideration of specific means of cytochrome P-450 
destruction.
There are several possible mechanisms that could 
account for an apparent loss of hepatic microsomal cytochrome 
P-450. Firstly, there may be direct feedback inhibition 
of pituitary function by an administered chemical. The half- 
life of constitutive rat hepatic cytochrome P-450 has been 
estimated as 11-12 hours for the apocytochrome, and about
4-5 hours for the haem prosthetic group (Kumar zt at.,
1980). Thus, partial repression of synthesis could easily 
account for the effects seen after 3 days’ dosing with 
benzofuran, or for the time course of cytochrome P-450 loss 
after a single injection of benzofuran, but the enhanced 
depression of cytochrome P-450 levels when benzofuran is 
administered after pretreatment with either phenobarbitone 
or 3-niethylcholanthrene argues that benzofuran (or more 
likely, a metabolite) exerts its action by a direct or indirect 
intrahepatic mechanism.
A large number of agents known to be toxic to the 
endoplasmic reticulum are not themselves directly responsible 
for the damage, but are converted by the cytochrome P-450 
monooxygenation system to reactive metabolites. Several have 
been observed to be activated by isolated microsomes tn vttko 
in the presence of NADPH, and to subsequently exert toxic 
effects. Benzofuran presents a problem in this respect.
When administered at 5.0mmol/kg each day for 3 days, the 
resulting loss of hepatic cytochrome P-450, if expressed 
per mg protein, could be partly accounted for by dilution 
caused by proliferation of endoplasmic reticulum deficient 
in cytochrome P-450, since the change in total amount of 
cytochrome P-450 per liver is relatively small. It is 
notable in this regard that the presence of ’hypertrophic, 
hypoactive endoplasmic reticulum' is a feature of cholestasis 
(Denk zt at., 1971; Schaffner zt at., 1971), and, indeed, 
pretreatment of rats with benzofuran elicits several 
biochemical and structural disturbances indicative of 
cholestasis, which are discussed below. However, the results 
of SDS-polyacrylamide disc gel electrophoresis, and of 
dose-response studies, suggest a destruction of cytochrome 
P-450, albeit possibly accompanied by induction of another 
species of the cytochrome. (N.B. Other pointers to 
cholestasis are very evident at dose levels where the 
specific content of hepatic cytochrome P-450 seems to be 
recovering.) It must be emphasised that the proliferation 
of a cytochrome P-450-poor endoplasmic reticulum is 
insufficient alone to account for the maximum loss of this 
haemoprotein seen when 1.25mmol benzofuran/kg were given 
per day for 3 days, or for the profound effects produced 
by pretreatment with phenobarbitone ptu* benzofuran or 
3-methylcholanthrene ptuA benzofuran. Despite this evidence 
of cytochrome P-450 destruction, the data obtained from 
incubation studies with benzofuran and hepatic microsomes 
tn vttAo indicate that, even in the presence of NADPH, 
there is.no destruction of cytochrome P-450 that cannot be 
attributed to the lipoperoxidative properties of NADPH 
alone [notwithstanding the presence of EDTA, which has been 
reported to inhibit lipoperoxidation (Jacobson zt at., 1973; 
Levin zt at., 1973a,b)]. This implies that the conversion 
of benzofuran to an active metabolite, if it occurs, may 
require enzymes other than those of the endoplasmic reticulum,
or operate by an indirect mechanism e.g. by induction of 
microsomal haem oxygenase (see below). As high concentrations 
of benzofuran appear to protect against NADPH-mediated 
destruction of cytochrome P-450 tn vtVio, it is possible 
that either the microsomal system depletes NADPH by slow 
production of an inactive metabolite (which may or may not 
be the precursor of an active species), or the effect is 
in some way non-specific.
The effects of benzofuran upon the monooxygenase 
activities, ethoxycoumarin 0-deethylation, ethoxyresorufin 
0-deethylation and aminopyrine W-demethylation tvi vtVio 
are probably due to direct inhibition, considering the lack 
of destruction of cytochrome P-450, and the failure of 
preincubation with an NADPH-regenerating system to exacerbate 
the loss of activity. That'residual benzofuran or metabolite 
remains in microsomes is implied by the non-linearity of 
ethoxycoumarin 0-deethylation activity with protein 
concentration, when a suspension prepared from high-dose 
animals was used, and by the effects of mixing microsomes 
from treated and untreated animals. Ethoxycoumarin 0-deethylase 
activity is sensitive to inhibition by many organic solvents, 
including the commonly used dimethylformamide and dimethyl- 
sulphoxide, and such inhibition in the presence of benzofuran 
might be expected.
However, more than one mechanism may be operative 
during the inhibition of aminopyrine W-demethylase tn vtvo 
and invtVio. Studies tn vtVio showed only 16$ and 45$ 
inhibition of activity in the presence of 100yM and 1.OmM 
benzofuran respectively, whereas a single dose of 1.25mmol/kg 
bodyweight a  u-ti/o caused 45$ inhibition within 2 hours of. 
administration. If a simple inhibitory action of benzofuran 
is solely responsible, a large proportion of the dose would 
have to be translocated to, and accumulate in, the liver to 
account for these observations, and a more pronounced effect 
on ethoxycoumarin 0-deethylase and ethoxyresorufin
0-deethylase activities would be predicted. It is more 
likely that aminopyrine W-demethylation is inhibited at 
least partly as a consequence of the specific action of 
benzofuran or its metabolite(s) tn vtvo.
5.3.5. Models of cytochrome P-450 loss
Many chemicals cause a loss of hepatic microsomal 
cytochrome P-450 tn vtvo, and among these are a number that 
perturb haem oxygenase and A-aminolaevulinic acid 
synthetase activities. Members of one class of such compounds 
contain a terminal acetylenic or olefinic double bond, 
and are represented by allylisopropylacetamide (AIA, 
2-isopropyl-4-pentenamide), first recorded by Wada zt at.
(1968) and Waterfield zt at. (1969), and largely defined 
by De Matteis (De Matteis, 1970, 1971, 1978a). These 
terminally unsaturated compounds attack the haem moiety of 
cytochrome P-450 (De Matteis, 1978a; Ortiz de Montellano 
zt at., 1978; Correia zt at., 1979), producing haem catabolites 
termed ’green pigments’ (De Matteis, 1973; Unseld and 
De Matteis, 1976; Ortiz de Montellano zt at., 1980).
Destruction of cytochrome P-450 haem appears to follow 
catalytic activation of the compounds by cytochrome P-450 
(De Matteis, 1971; Levin zt at., 1972b; Ivanetich zt at.,
1980), and subsequent alkylation of the haem moiety (Ortiz 
de Montellano zt at., 1979, 1981).
Both carbon disulphide (Dalvi zt at., 1974, 1975;
De Matteis, 1974) and parathion (De Matteis, 1974; Halpert 
and Neal, 1981) are metabolised by hepatic microsomes to 
reactive sulphur species, which attack cytochrome P-450 
vta the apocytochrome (Kamataki and Neal, 1976; Jarvisalo 
and De Matteis, 1977; Savolainen zt at., 1977). Pretreatment 
of animals with certain metals, including iron (De Matteis 
and Sparks, 1973), cobalt (Tephly and Hibbeln, 1971) and 
cadmium (Hadley zt at., 1974), has also been reported to
decrease hepatic cytochrome P-450 levels.
None of these models fits entirely satisfactorily 
the pattern of biochemical and histological changes observed 
when benzofuran is administered to rats. Like AIA (see 
De Matteis, 1978b), benzofuran elicits a decrease in the 
cytochrome P-450- content of the liver at a dose level at 
which there is little or no histologically demonstrable 
damage to hepatocytes, although degenerative changes and 
focal hepatocellular necrosis occur after the injection of 
greater amounts. Phenobarbitone pretreatment of rats greatly 
increases the extent of loss of cytochrome P-450 caused by 
AIA (De Matteis, 1971); pretreatment with either pheno­
barbitone or 3-niethylcholanthrene exerts a similar influence 
upon the depression of cytochrome P-450 provoked by benzofuran, 
but also leads to extensive degenerative and necrotic 
changes. In addition, examination of microsomes .for the 
presence of green pigments after benzofuran administration 
was negative, as reported for several other internally 
unsaturated compounds that destroy cytochrome P-450 (Menard 
zt at., 1979; Ortiz de Montellano and Kunze, 1980a,b).
AIA added to microsomes tn vlVio destroys 
cytochrome P-450 haem (De Matteis, 1971; Unseld and De 
Matteis, 1976), whereas benzofuran does not. Despite evidence 
for AIA-mediated depletion of glutathione tn vivo (Maines, 
1981), glutathione added to microsomes ptuA AIA In vltKo 
does not appear to attenuate the loss of cytochrome P-450 
(Ortiz de Montellano and Mico, 1981), and no induction of 
glutathione S-transferase is observed In vivo (Maines,
1981). Benzofuran administration causes an increase in both 
glutathione and glutathione S-transferase levels. The 
significance of the former is unclear; it may represent 
an overcompensation for an initial depression of hepatic 
glutathione concentration, and earlier time point studies 
are required to investigate this. AIA stimulates 
A-aminolaevulinic acid synthetase activity (De Matteis, 1975),
but does not have a marked effect on haem oxygenase (Maines,
1981). Benzofuran increases the activity of both enzymes.
In contrast to the results of Kato zt at. (1970) 
and the present study, starvation has been claimed by some 
workers to cause a loss of cytochrome P-450 (Bock zt at.,
1973), and to increase the activities of both haem oxygenase 
and A-aminolaevulinic acid synthetase (Bakken zt at., 1972;
De Matteis and Sparks, 1973). In the present work, fasting 
elevated A-aminolaevulinic acid synthetase activity, but 
to a much lesser extent than that seen after the administration 
of benzofuran, and had no effect upon haem oxygenase activity. 
Even if these discrepancies are ignored, lack of food intake 
alone could not account for the biochemical changes resulting 
from the administration of benzofuran to rats.
Carbon disulphide and some other sulphur-containing 
compounds produce hepatocellular lesions in animals 
pre-induced with phenobarbitone, including centrilobular 
degeneration and dilatation of rough endoplasmic reticulum 
(Bond zt at., 1969; see De Matteis, 1978b). Haem oxygenase 
activity is elevated following carbon disulphide pretreatment 
(Jarvisalo zt at., 1978), but A-aminolaevulinic acid 
synthetase activity is slightly decreased (Kikuchi zt at.,
1981). Carbon tetrachloride causes a marked loss of hepatic 
microsomal cytochrome P-450 (Greene zt at., 1969; Levin zt 
at., 1972a), apparently as a result of lipoperoxidation 
(Uehleke zt at., 1973; Glende zt at., 1976). A lipoperox- 
idative mechanism cannot be ruled out as a partial reason 
for the decrease in cytochrome P-450 concentration elicited 
by benzofuran, but both the severity and type of the 
histologically demonstrable lesions attributable to benzofuran 
or to carbon tetrachloride administration differ distinctly.
Studies by Kikuchi zt at. (1981) indicate that 
there may be two different mechanisms by which haem oxygenase 
is inducible in the liver, one of them dependent upon an 
increased concentration of haem, and the other haem-independent.
These authors found that haemin or carbon disulphide 
administration caused a small to moderate elevation in haem 
oxygenase activity in rat liver, .a diminished A-aminolaevu­
linic acid synthetase activity, and increased saturation of 
tryptophan pyrrolase with haem. Carbon disulphide evoked a 
rapid drop in cytochrome P-450 levels; haemin had no 
significant effect. Cobaltous chloride (single dose of 
250ymol/kg), cadmium2* (75ymol/kg) or bromobenzene (5.0 
mmol/kg) elicited a much greater increase in haem oxygenase 
activity (45- to 75-fold), a fall in hepatic cytochrome 
P-450 concentration, and a markedly decreased saturation of 
tryptophan pyrrolase with haem. Cobalt pretreatment also 
greatly elevated A-aminolaevulinic acid synthetase activity, 
whereas cadmium and bromobenzene had practically no effect 
on this enzyme (Kikuchi zt at., 1981)..It is claimed by 
these authors that haemin and carbon disulphide operate via, 
a haem-mediated mechanism to stimulate the activity of 
haem oxygenase, the latter possibly by liberation of haem 
from cytochrome P-450, whereas bromobenzene and cobalt act 
via a mechanism independent of haem. This postulate is 
supported by the work of Kappas and colleagues (Maines and 
Kappas, 1975; Drummond zt at., 1982), who showed that 
SKF525A administered concurrently with various metals 
and metalloporphyrins protected against cytochrome P-450 
destruction in the presence of high haem oxygenase activities.
Of the classes of compounds described above, 
benzofuran appears to most closely resemble cobalt in the 
consequences of its action, when the response of enzyme 
parameters is considered. The measured increase in rat 
hepatic microsomal haem oxygenase activity (28-fold with 
respect to controls) is of an order corresponding to the 
haem-independent mechanism of Kikuchi zt at. (1981).
However, single-dose time-course studies of haem oxygenase, 
A-aminolaevulinic acid synthetase, ferrochelatase, tryptophan 
pyrrolase saturation and cytochrome P-450 concentration
should be carried out to confirm the comparability of 
effects. In the study of K i k u c h i ztat. (1981), haem oxygenase 
activity was falling from its maximum induced activity 
24.hours after administration of 250ymol cobaltous chloride/ 
kg, as was A-aminolaevulinic acid synthetase activity.
The latter parameter generally exhibits initial inhibition, 
followed by a rebound increase in activity before returning 
to normal values, after the pretreatment of animals with 
cobaltous salts (Maines and Kappas, 1975; De Matteis and 
Gibbs, 1976). Thus, it is difficult to compare these results 
with the effects of a 3-day benzofuran dosing study, in 
which animals were killed and examined 24 hours after the 
final injection. Differences in routes of administration 
should also be considered. Another feature that requires 
further investigation is the increase in haem oxygenase 
activity after pretreatment of rats with tAanA-stilbene 
oxide, which in one instance was of the same order as the 
effect produced by pretreatment with benzofuran. Taclvla- 
stilbene oxide has been variously reported to have no 
influence on cytochrome P-450 concentration (Schmassmann and 
Oesch, 1978), and to act as an inducer (Seidegard zt at.,
1979; present study). In no case has a loss of cytochrome 
P-450 been reported. Furan, while causing the greatest 
depression of cytochrome P-450 concentration, presumably 
acts via a mechanism independent of haem oxygenase, since 
the maximum increase in haem oxygenase activity was about 
4.5-times the control value. Hepatocellular necrosis is 
extensive after high doses of furan, and there may be sufficient 
non-specific destruction of protein to account for the fact 
that the lower dose used in this study apparently produced 
a higher haem oxygenase activity than did the higher dose.
The only other chemical to elicit a significant change in 
this enzyme activity was dihydrobenzofuran, which caused a 
9-fold increase at a dose level of 7.5mmol/kg. The methylene- 
dioxyphenyl compounds, which initially inhibit microsomal
monooxygenation and decrease cytochrome P-450 levels (Fine 
and Molloy, 1964; Matthews and Casida, 1970; Matthews zt at., 
1970), caused no significant increase in haem oxygenase 
activity.
Examination of splenic haem oxygenase activity 
may be interesting, in view of the observation that 
erythropoiesis is inhibited by several of the compounds used 
in this study, including benzodioxole. The potency of 
benzofuran in the induction of hepatic haem oxygenase 
activity, in conjunction with its ability to depress splenic 
erythropoiesis, may also be significant, considering that 
haem oxygenase of spleen has previously been reported to 
be refractory to induction (Maines and Kappas, 1975).
5.3.6. Is benzofuran-induced cholestasis responsible for
the loss of hepatic -cytochrome P-450?
Another possible explanation for the action of 
benzofuran is that this compound causes intrahepatic 
cholestasis in the rat. Decreased hepatic rates of drug 
metabolism have been observed after bile duct ligation in 
rabbits and rats (McLuen and Fouts, 1961; Leonard zt at.,
1981a). Some biochemical changes observed in vivo (Denk 
ztat., 1971; Schaffner zt at., 1971) could be reproduced 
In vltK0 (Hutterer zt at., 1970a,b) by the addition of bile 
salts to microsomes, and it has been suggested that pertur­
bation of the endoplasmic reticulum in cholestasis is a 
result of the detergent properties of bile salts, and their 
behaviour as competitive inhibitors of drug metabolism 
(Denk zt at., 1971). However, bile duct ligation has been 
reported to not increase the rate of turnover of either haem 
or apocytochrome P-450 (Denk zt at., 1973; Mackinnon and 
Simon, 1974), and it has been claimed that the loss of 
cytochrome P-450 seen in cholestasis is due to the proliferation 
of ’hypertrophic, hypoactive endoplasmic reticulum’ described
by Popper and coworkers, and referred to above. A 
primary lesion of the endoplasmic reticulum has, nonetheless, 
been considered as a cause of intrahepatic cholestasis 
(Schaffner and Popper, 1969). A£pA<z-Naphthylisothiocyanate 
(ANIT) is a biliary toxin (Eliakim zt a,Z., 1959), which 
causes acute cholestasis in the rat (Goldfarb zt at., 1962; 
Krstulovic zt at., 1968; Plaa, 1969; Indacochea-Redmond 
and Plaa, 1971), with histological changes resembling those 
of human intrahepatic cholestasis (Goldfarb zt at., 1962).
In addition, this compound decreases hepatic cytochrome 
P-450 levels and associated monooxygenase activities (Buxton 
zt at., 1973; Drew and Priestly, 1976). Although the literature 
is not entirely in agreement, there are indications that the 
appearance of hypertrophic, hypoactive endoplasmic reticulum 
after the administration of ANIT is not an important 
precursor to ANIT-induced cholestasis (Drew and Priestly,
1976, 1978).
There are several factors that point to at least 
partial cholestasis being a result of the administration to 
rats of benzofuran, and to*this compound’s major effects 
being different from those elicited by pretreatment with 
furan. Cholestasis is difficult to define precisely, or 
to diagnose accurately when the lesion is intrahepatic 
(see Section 1.3.). Certain histological, ultrastructural 
and serological phenomena are, however, associated, with 
cholestasis, and the changes produced by benzofuran are 
generally consistent with these. Small necrotic hepato­
cellular foci are seen after intoxication with benzofuran, 
and with ANIT (Eliakim zt at., 1959). These foci may be the 
result of the detergent action of bile salts in areas of 
breakdown of the tight junctions between liver cells, which 
would explain the difficulty of demonstrating such breakdown 
under the electron microscope. Bile duct ligation (Hinton 
zt aZ.y unpublished observations), and the administration 
of benzofuran, produce necrotic foci scattered throughout
the parenchyma, indicating that bile leakage occurs 
parenchymally, and not from bile ductules.
Dilatation of bile canaliculi and distortion of 
microvilli, with hypertrophy of the Golgi apparatus of the 
pericanalicular region, all observed after the pretreatment 
of rats with benzofuran, are also features of cholestasis 
(see Section 1.3-), although similar changes may be induced 
by choleretic infusions of dehydrocholate (Nemchausky zt aZ.,
1977). Canalicular changes produced by the administration 
of benzofuran were not consistent, with normal and altered 
canaliculi seen adjacent to each other, another phenomenon 
reported in human and experimental cholestasis (Desmet,
1972). Benzofuran causes hypertrophy of the smooth endoplasmic 
reticulum, a feature recorded in ANIT-induced cholestasis 
(Schaffner zt aZ., 1973). In contrast, the light microscopic 
picture of extensive necrosis and fatty infiltration seen 
in the liver after the administration to rats of furan is 
more typical of generalised hepatocellular toxicity.
Despite the more extensive hepatocellular damage 
caused by the injection of furan, compared even with higher 
doses of benzofuran (characterised by the histological 
picture, and by the more profoundly elevated aspartate 
aminotransferase and sorbitol dehydrogenase activities), 
serum bilirubin levels were increased to a much greater 
extent by the administration of benzofuran than by the 
administration of furan. Furthermore, the increase produced 
by benzofuran was primarily of conjugated bilirubin, whereas : 
practically all of the increase attributable to furan 
pretreatment was of the unconjugated form. Benzofuran 
elicited a marked rise in alanine aminotransferase activity; 
this enzyme also rises to high levels in serum after the 
administration of ANIT, commencing during the pre-cholestatic 
phase (Gallenkamp and Richter, 1974; El-Hawari and Plaa,
1979). The most striking difference among the results of 
serum enzyme estimations was the 8.4- and 2.3-fold increases
in y-glutamyltransferase activity caused by the 
administration of benzofuran and furan respectively.
Hepatic y-glutamyltransferase is located mainly in the 
bile ductular cells (Ronchi and Desmet, 1973a), and its 
activity is increased in sections of liver after the 
pretreatment of rats with benzofuran. Bile ductular 
changes are a feature of both mechanically and chemically 
induced cholestasis (McLean and Rees, 1958; Leonard z.t at . , 
1981a), and serum y-glutamyltransferase activity is 
frequently most markedly elevated in cholestasis (Schmidt, 
1977), being present in high concentrations in bile 
(Rosalki, 1975). Secretory Immunoglobulin A and IgA Free 
Secretory Component, which are major components of rat 
bile, but not normal serum (LeMaitre-Coelho zt at.,
1977), were also present in relatively large quantities 
in serum obtained from rats pretreated with benzofuran.
These two proteins were also elevated in the serum of 
rats receiving 1.25mmol benzofuran/kg each day for 21 
days, in which other markers of cholestasis were slightly, 
but not significantly, increased. Such results indicate
a reflux of bile into serum, since the components described 
reach bile in distinctly different ways. Free Secretory 
Component, normally absent from serum, appears to be 
manufactured in the liver and discharged into bile (Mullock 
and Hinton,'1979), whereas y-glutamyltransferase is 
suggested to derive from bile duct lining cells (Rosalki,
1975; Moss, 1977). Biliary Immunoglobulin A is transported 
across hepatocytes into bile from serum (Orlans zt at.,
1978). Considering their separate origins, leakage of 
bile, in which they are found together, is the most 
likely explanation of their presence in blood. The same 
phenomenon would account for the profound (almost 10-fold) 
increase of total bilirubin concentration in serum. One 
anomaly is the failure of 5 1-nucleotidase levels to rise, 
although a slight decrease in the histochemically demonstrable
bile canalicular reaction for 5 1-nucleotidase, a common 
feature of cholestasis (see Section 1.3.), was noted.
Bile contains a high 5'-nucleotidase activity (Mullock 
zt at., 1977), and the biliary form of the enzyme is 
believed to appear in serum during cholestasis via 
solubilisation by bile salts of the plasma membrane of 
the hepatocyte canalicular face (Coleman zt aZ.t 1977). 
Reflux into blood of bilirubin, 5 ’-nucleotidase, 
Immunoglobulin A and IgA Free Secretory Component has been 
described for ANIT-induced cholestasis (Woolley zt aZ.,
1979). The administration of furan to rats also elevated 
Immunoglobulin A and IgA Free Secretory Component levels 
in serum during the present study; concentrations of the 
latter protein remained markedly below those seen after 
the administration of benzofuran, which suggests either 
that the primary effect of furan pretreatment is not 
cholestatic, or that the ability of the liver to manufacture 
Free Secretory Component may be compromised. Despite the 
lack of supporting haematological evidence, the increased 
concentration of unconjugated bilirubin in serum following 
furan pretreatment is more typical of a haemolytic process 
than of cholestasis. That a degree of cholestasis should be 
part of the hepatotoxic consequence of furan administration 
is not, however, surprising; indeed, such a phenomenon is 
a recognised feature of toxic hepatitis of various origins 
(see Schaffner and Popper, 1979).
The converse is also true. Benzofuran appears 
to cause some generalised hepatocellular dysfunction, 
as evidenced by a decreased serum protein concentration 
and some elevated serum ’liver function enzyme’ activities, 
and thus furan and benzofuran apparently share some toxic 
properties. More difficult to explain are the.biochemical 
and histochemical changes produced in rats by the 
administration of tAanA-stilbene oxide. Haematoxylin and 
eosin-stained sections of liver showed a degree of
hepatocellular eosinophilia and necrosis, but this was 
relatively slight, as confirmed by the unchanged serum 
sorbitol dehydrogenase activity, although serum aspartate 
aminotransferase activity was raised significantly. 
G&mma-Glutamyltransferase and 5 ’-nucleotidase activities 
were increased both in stained liver sections and in serum. 
Serum Immunoglobulin A and IgA Free Secretory Component 
levels were elevated, but a rise in serum bilirubin 
concentration was moderate in one animal and absent in the 
others. Serum total protein and albumin were both decreased. 
Hence, this compound exerts signs of early cholestatic 
change, which are not seen with phenobarbitone, 3-niethyl- 
cholanthrene, safrole or isosafrole. All act as inducers 
of cytochrome P-450, and of associated monooxygenase 
activities, suggesting that the properties of tAanA-stllbene 
oxide are worthy of further attention.
Although it is probable that increasing intrahepatic 
bile concentrations resulting from the administration of 
ANIT to rats contributes to the loss of cytochrome P-450 
(Leonard zt at., 1981a), a single intraperitoneal injection 
of 150mg ANIT/kg bodyweight has been reported to lower 
aniline hydroxylase and aminopyrine W-demethylase activities 
significantly during the pre-cholestatic phase, and to 
cause a considerable loss of spectrally measurable cytochrome 
P-450 In vltAo in the presence of NADPH (De Matteis, 1974; 
El-Hawari and Plaa, 1979). Aminopyrine N-demethylase 
activity also appears to be rapidly susceptible In vivo 
to the action of benzofuran administration. The metabolism 
of type II substrates (including aniline) is reported to 
be more labile than the metabolism of type I substrates 
to the early action of ANIT, which is the converse of the 
effects of bile duct ligation (Hutterer zt at., 1970b; 
El-Hawari and Plaa, 1979). Be^ta-Naphthylisothiocyanate 
(BNIT) parallels the effects of ANIT on microsomal 
monooxygenation in the liver In vivo, yet is non-cholestatic
(El-Hawari and Plaa, 1977). The loss of cytochrome P-450 
observed In vltKo in the presence of both ANIT and BNIT is 
accompanied by very little formation of cytochrome P-420 
(El-Hawari and Plaa, 1979); in contrast, benzofuran does 
not appear to decrease hepatic microsomal cytochrome P-450 
levels In vltxo, but the loss In vivo is also not paralleled 
by an increase in absorbance at 420nm. However, the effects 
of these isothiocyanate isomers appear to vary according 
to the route or duration of administration, since continuous 
feeding of BNIT increases hepatic cytochrome P-450 
concentrations in the rat (Leonard et at. , 1981b), and 
continuous feeding of ANIT causes an initial fall in cytochrome 
P-450 levels, followed by a return to control values 
(Leonard zt at., 1981a), or even a net increase after 10 
weeks’ feeding (Breschi zt at., 1975). It would be useful 
to examine the possibility that benzofuran feeding parallels 
any of these phenomena, particularly in view of the results 
of the dose-response study reported here.
Studies by El-Hawari and Plaa (1979), using 
1'’C-A-aminolaevulinic acid, suggest that ANIT increases 
the rate of degradation of cytochrome P-450. Haem oxygenase 
activity was not measured, but this observation is not 
incompatible with an increase in activity. Bile duct 
ligation, ANIT administration (Leonard zt at., 1981a) 
and benzofuran administration all provoke a marked elevation 
of hepatic microsomal epoxide hydrolase activity. This is 
apparently not a result of activation of the enzyme due 
to the presence of bile constituents, since bile added 
to microsomes In vltJio does not increase epoxide hydrolase 
activity (Leonard zt at., 1981a). The significance of 
induction of epoxide hydrolase activity is discussed below.
5-3.7. ’Cholestasis’ without cessation of bile flow?
Several approaches to the definition and diagnosis
of cholestasis have been discussed in Section 1.3.1.
The administration of benzofuran to rats produced a syndrome 
that was clinically, histologically and ultrastructurally 
identifiable with cholestasis, but, although biliary 
parameters had changed in value, there was no evidence 
in this study for either the reduction or cessation of 
bile flow after 3 days’ treatment with benzofuran. Indeed, 
the rate of bile flow immediately after biliary cannulation 
appeared to be very rapid, which might be expected if there 
was an obstructive lesion at or near the opening of the common 
bile duct, but no such lesion has as yet been demonstrated.
The median time-to-cholestatic effect of ANIT has 
been reported to be about 15 hours (Lock zt at., 1982), and 
before this point there is no.gradual effect on bile flow 
or upon erythritol clearance (Fukumoto zt at., 1980; Lock 
zt at., 1982). It is possible that the time-to-cholestatic 
effect for benzofuran is very prolonged if cessation of 
bile flow pzA &z is taken as the end-point, but there is 
no evidence at present in favour of such a phenomenon.
However, there may be a lesion at the level of 
the microstructure of hepatocytes, leading to a leakage of 
bile into blood, with either no, or partial, biliary stasis, 
or with such stasis being apparent only after a long 
period of time. One possibility is that benzofuran and/or 
its metabolite(s) damages the hepatic cytoskeleton (see 
Section 1.3-3. )• Microfilaments have been suggested to 
have a regulatory role in the paracellular pathway (Dubin 
zt at., 1978; Elias zt at., 1980), and compounds interfering 
with their normal function appear to increase the leakiness 
of the tight junctions. This mechanism has been proposed 
to explain the cholestatic action of oestrogens (Forker,
1969). Colchicine, which interferes with microtubular 
structure, does not affect basal bile flow, but impairs 
the ability of the hepatocyte to handle a bile acid load 
(Erlinger zt al., 1980). The establishment of the presence
of cytoskeletal damage following the administration of 
benzofuran to rats will require considerably more extensive 
electron microscopic examination of liver sections, especially 
if the lesion is zonally, rather than generally, distributed.
5.3*8. Effects of pre-induction on the hepatic and renal
toxicity of benzofuran
Phenobarbitone administered before, and then 
concurrently with, benzofuran, enhances the degree of 
ultrastructural evidence of cholestasis and hepatocellular 
disorganisation provoked by pretreatment with benzofuran 
alone, and either phenobarbitone or 3-methylcholanthrene 
pretreatment markedly increases the values of serum parameters 
of cholestasis affected by dosing with benzofuran. The 
coadministration of benzofuran and 3-methylcholanthrene 
causes a particularly great increase in serum bilirubin 
concentration.
Either inducer given with benzofuran resulted in 
pronounced histochemically and histologically demonstrable 
hepatocellular damage. Whereas such damage caused by the 
coadministration of phenobarbitone and benzofuran was 
predominantly centrilobular in distribution, that caused 
by 3-methylcholanthrene ptuA benzofuran did not exhibit a 
pattern immediately explicable in terms of lobular structure. 
However, a ’ring’ of affected tissue around the portal 
tracts, and encompassing central veins, is representative 
of the perivenular lesion described by Rappaport (1976), in 
which damage occurs to the parts of zone 3 most remote from 
the terminal afferent vessels of complex acini occupying 
parts of several adjacent hexagonal fields.
Of interest also are the observations that the 
fatty infiltration of liver resulting from the coadministration 
of phenobarbitone and benzofuran spreads from the periportal 
region towards the midzone, whereas the corresponding 
lesion accompanying the coadministration of 3-methylchol-
anthrene and benzofuran appears to be initially centrilobular. 
The areas of least fatty change thus correspond in each 
case with those areas in which the species of cytochrome 
P-450 induced by either phenobarbitone or 3-methylcholanthrene 
is most concentrated (see Chapter 3). These phenomena 
require further investigation; however, two possible 
explanations are that cytochrome P-450 may be involved 
with the detoxication of benzofuran, and thus exert a 
regio-selective hepatoprotective influence, or that enzymes 
responsible for the metabolism of fats are selectively 
induced.
Benzofuran pZu* 3-methylcholanthrene, particularly, 
caused a high degree of renal toxicity, with gross histological 
change, and elevation of blood urea nitrogen concentration.
The bilirubinuria and proteinuria detected after pretreatment 
with benzofuran alone was exacerbated, although there was 
still no evidence for the presence of urinary glucose.
Massive proteinuria without glycosuria implies usually 
a lesion of the glomerular apparatus (see e.g. Zilva and 
Pannall,' 1978). However, the histological picture, coupled, 
with observation of the living animals, suggests profound 
oligouria, and a strong possibility for the origin of the 
urinary protein is breakdown of the renal tubules themselves. 
Certainly, loss of protein in the urine due to failure of 
the renal filtration apparatus is unlikely to account 
simply for the decreased serum protein concentration, since 
glomerular dysfunction leads generally to a rather selective 
albumin loss, and the percentage fall in serum globulin 
level is comparable with the fall in serum albumin level 
in the present study, whether produced by the administration 
of benzofuran alone or of benzofuran pZu* 3-methylcholanthrene.
5.3.9. Metabolic activation of benzofuran
The behaviour of benzofuran when given to rats in
conjunction with inducing agents, and other factors discussed 
previously, suggest that benzofuran may be metabolically 
activated In vivo. Also, a metabolite(s) rather than, or 
as well as, the parent compound, may be responsible for the 
observed toxicity. The results discussed in Section 5.3.8. 
indicate that the species of cytochrome P-450 induced by 
phenobarbitone or by 3-methylcholanthrene may be capable 
of activating benzofuran; whether metabolism by these 
cytochromes results in metabolites of the same nature 
and relative distribution is unknown. Nonetheless, it is 
interesting to speculate about some possibilities.
Several compounds whose toxicity has been described 
in the literature are suggested to be activated by the 
epoxidation of a furanic double bond. A nucleophilic 
metabolite of aflatoxin (Garner zt at., 1972; Essigmann 
zt at., 1977; Martin and Garner, 1977; Swenson zt al.,
1977), whose binding to DNA is diminished in the presence 
of glutathione (Raj zt at., 1975; Allen-Hoffmann and 
Campbell, 1977), is apparently a 2,3-epoxide (Swenson et ,
1973; Campbell and Hayes, 1976). Furosemide (Mitchell zt at., 
1974; McMurtry and Mitchell, 1977) and 4-ipomeanol (see 
Boyd, 1980a,b) show species- and tissue-dependent toxicity, 
which is mediated by activation of their furan ring (see 
also Section 1.8.2.). McMurtry and Mitchell (1977) also 
reported that benzofuran provoked renal necrosis in mice, 
accompanied by hepatic necrosis only when the kidney lesion 
was severe. Phenobarbitone or piperonyl butoxide pretreatment 
abolished the effect, suggesting that benzofuran is 
converted to a reactive metabolite in mice. Furan caused 
marked hepatic and renal toxicity in mice, in contrast to 
its selectively hepatic effects seen in the present study 
in rats. Investigation of species differences in the action 
of benzofuran would be useful, in view of this, and with 
regard to the observations that ANIT shows species selectivity 
in its cholestatic action. Hamsters are resistant to ANIT,
and rabbits appear to be non-susceptible (Phillips and 
Steiner, 1964; Capizzo and Roberts, 1971; Indacochea- 
Redmond and Plaa, 1971; Plaa and El-Hawari, 1976).
An active metabolite of benzofuran corresponding 
to the metabolites postulated to be formed by furosemide 
or 3-methylfuran would be benzofuran 2,3-epoxide. If this 
chemical species is generated by cytochrome P-450, it is 
presumably not itself responsible for a subsequent loss of 
the cytochrome, as there is no effect In vltKO with NADPH 
present, although a benzofuran epoxide might be responsible 
for other biochemical changes, or for inflicting tissue 
damage. Possibly intrahepatic bile salt accumulation is 
the cause of cytochrome P-450 loss in this case, and 
comparison of the progress of cholestasis and depression 
of cytochrome P-450 concentration may be helpful. Alternatively, 
induction of haem oxygenase activity by benzofuran or its -
metabolite(s) could trigger the drop in cytochrome P-450 
concentration; in this instance, early time-course studies 
should reveal haem oxygenase induction prior to a significant 
fall in cytochrome P-450 levels.
Pretreatment with benzofuran increases the activity 
of some phase II enzymes, notably UDP-glucuronyltransferase 
and glutathione S-transferase. Glutathione levels are also 
increased, perhaps in response to an initial depression.
It is feasible that the metabolite ultimately responsible 
for the cholestatic action of benzofuran is a conjugated 
species or its metabolic product (s.), possibly a cysteine 
conjugate derived ultimately from the reaction of benzofuran 
with glutathione (see Section 1-.6.2.). Such a cysteine 
conjugate would probably have a relatively low solubility 
in bile, but, if the cholestatic manifestations of benzofuran 
pretreatment are due to such a chemical species, they are 
probably the result of subtle canalicular or tight junctional 
changes, rather than frank obstruction due to a precipitate, 
in view of the undiminished bile flow observed.
Bile canalicular changes due to the toxicity of 
an epoxide of benzofuran, or saturation of the canalicular 
clearance mechanism for bilirubin conjugates would both 
explain the rather sharp dose-response to benzofuran, 
and some of the effects of inducing agents. A combination 
of the suggested phenomena may be involved. Prolonged 
dosing of benzofuran may lead to tolerance, which appears 
likely, too, in the case of ANIT, although whether cytochrome 
P-450 loss would slow the rate of active metabolite production 
depends on whether or not there is destruction of a specific 
species of the cytochrome, and increased capacity for 
bilirubin clearance depends upon the induction of the 
appropriate glucuronyltransferase.
Some possible routes to jaundice, enzyme induction 
and the destruction of cytochrome P-450 after the administration 
of benzofuran to rats are summarised in Figure,5.17.
The pretreatment of various mammalian species with 
phenobarbitone potentiates ANIT-dependent cholestasis, 
whereas SKF525A and cycloheximide diminish or abolish the 
cholestatic response (Roberts and Plaa, 1965; Indacochea- 
Redmond zt at. , 1973). Radiolabelling studies also suggest 
the importance of metabolism of ANIT (Capizzo and Roberts,
1970; Roberts, 1973). In contrast to many other compounds, 
including furosemide (Mitchell zt aZ., 1976b) and bromobenzene 
(Reid zt glZ. , 1971), the irreversible binding of ANIT 
to tissue macromolecules does not correlate well with its 
toxicity (El-Hawari and Plaa, 1977). Macromolecular 
binding studies using radiolabelled benzofuran might be 
valuable in characterising the relationship between such 
binding and toxicity in comparison with ANIT. ‘Pta.f'U-stilbene 
oxide might also be examined in a similar manner.
Figure 5.17.
Some possible routes to jaundice following the administration 
of benzofuran to rats
A-Aminolaevulinic acid
Haetn Cytochrome P-450*.
^Other metabolites*
Haem *—
oxygenate ^
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5.3.10. Epoxide hydrolase - introductory remarks
It should be noted during the following discussion 
of epoxide hydrolase induction that, although there is 
conflicting evidence regarding the existence of multiple . 
forms of microsomal epoxide hydrolase (see Lu and Miwa,
1980), the rate of hydration of epoxides may vary considerably 
according to the substrate employed, and pretreatment with 
inducing agents. Most of the data referred to below are 
based on the metabolism of styrene oxide to its dihydrodiol, 
which is generally accepted as a useful criterion of 
microsomal epoxide hydrolase activity.
Many organic compounds increase the activity of 
hepatic microsomal epoxide hydrolase when administered by 
various routes to rodents or to other mammalian species.
These compounds include ones examined during the present 
study (Table 4.7.) and others (Table 5.28.). An attempt 
is made here to rationalise some characteristics of their 
structure, and their ability to provoke acute or chronic 
changes in the livers of experimental species.
5.3.11. Chemical.structure and the induction of epoxide
hydrolase activity
Of the compounds considered in the structure- 
activity study reported in Chapter 4, the two most potent 
inducers of rat hepatic microsomal epoxide hydrolase were
2,3-benzofuran and dibenzofuran (309 and 291 percent of 
the control value respectively), when the degree of induction 
was considered in relation to the dose level used. Absence 
of the 2,3-double bond, as in the case of dihydrobenzofuran, 
decreased the extent of the induction. A parallel situation 
was seen for furan and dihydrofuran, where reduction of one 
of the double bonds of furan resulted in a greater than 50$ 
loss of ability to induce epoxide hydrolase activity.
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Conversely, the presence of a furanic double bond in 
a position available for metabolic attack does not of 
itself appear to ensure a greater capacity of the 
compound to induce epoxide, hydrolase activity, since
a) such a bond is not exposed in dibenzofuran, 
which is one of the most potent inducers examined here, 
and,
b) dihydrobenzofuran appears to be about as effective 
an inducer of epoxide hydrolase activity as is 
dihydrofuran.
When the 2,3-double bond is eliminated, and 
an oxo- group occupies the 2-position of benzofuran, 
the resulting compound, 2-coumaranone, is a poor inducer 
of hepatic microsomal epoxide hydrolase activity, and 
coumarin (unsaturated at the 3,4-positions) is even 
less effective (Table 4.7.). Indole, the hi analogue of 
benzofuran, does not increase epoxide hydrolase activity 
at the dose level used in the present study, despite 
a considerable similarity of physicochemical properties 
of these 0- and AJ- heterocyclic structures. The ’ring- 
opened’ species, o-hydroxyphenylacetic acid, which is 
a metabolite of coumarin in rat liver (Van Sumere and 
Teuchy, 1971), and a plausible candidate as a metabolite 
of benzofuran, is similarly without effect.
Of the methylenedioxyphenyl compounds examined, 
safrole, possessing a side-chain double bond at the 
2 ’,3’-position, and isosafrole, unsaturated at the 
1’,2’-position, yielded an approximately dose/extent 
of hepatic microsomal epoxide hydrolase induction ratio 
when administered to rats, and were only marginally 
better inducers than benzodioxole, which lacks a side 
chain. Ptcm4-Stilbene oxide was included in the study 
primarily as a positive control for epoxide hydrolase 
induction (Schmassmann and Oesch, 1978; Biicker at at., 
1979; Oesch and Schmassmann,•1979), and was an effective
inducer at both of the dose levels utilised.
There are no structural features evident that 
are common to-all of the compounds listed in Table 5.28. 
that would correlate immediately with their ability to 
increase the activity of hepatic microsomal epoxide 
hydrolase when administered to rats. However, some relevant 
observations may be made.
One feature typical of several of the compounds 
in Table 5.28. is their possession, of two unsaturated 
rings linked directly, or \jta a 1- or 2-carbon bridge. 
Compounds having this structure have been shown to be 
produced as metabolites of both ct*- and tkaYi.6-stilbene 
in mammalian liver (Watabe and Akamatsu, 1975). Some 
of the pathways leading to their formation are shown in 
Figure 5.18.
The stilbenes, and all of the unconjugated 
metabolites except benzoic acid, induced epoxide hydrolase 
to 242-513% of the control activity in the livers of rats 
pretreated with these compounds (Seidegard zt at., 1981). 
‘pttf.ft'6-Stilbene oxide was found to be a better inducer of 
epoxide hydrolase than either its parent stilbene or its 
diol metabolite. In contrast, c^-stilbene was as effective 
as its epoxide in inducing epoxide hydrolase, and the 
c^-isomer of the epoxide has been reported to be converted 
to the diol 700 ttmZA faster than the Vian.6-isomer (Watabe 
zt at., 1971). Curiously, benzoin and benzil, not expected 
to be substrates for epoxide hydrolase, were very 
effective inducers of the enzyme. Observation of the 
behaviour of these compounds, and of related chemicals, 
including diphenylmethane and chalcone derivatives, led 
Seidegard and colleagues (1981) to conclude that for optimal 
induction of epoxide hydrolase, the compounds required 
both phenyl rings, and, preferably, a 2-carbon bridge bearing 
either one oxo- and one hydroxyl-, or two oxo- groups.
If both carbon atoms were replaced by nitrogen atoms, the
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extent of induction was lessened.
Despite this last observation, phenobarbitone, 
containing one phenyl ring and one saturated nitrogenous 
ring, has been shown in this study and others (Bresnick 
at at., 1977; Van Cantfort at at., 1979) to be a fairly 
effective inducer of epoxide hydrolase tn vtvo. Several 
other compounds shown in Table 5.28., and including 
£-a-acetylmethadol (Bellward at at., 1977; Gontovnick and 
Bellward, 1980) and DDT (Parkki at at., 1977), possess two 
phenyl rings linked by a 1-carbon bridge. According to 
Seidegard at at. (1981) these compounds should be relatively 
weak inducers of epoxide hydrolase, whereas, in fact, 
£-a-acetylmethadol has a potency equal to approximately 
that of benzoin, when results from treated animals are 
expressed as a percentage of control activity.
Two other points of interest arise from the study 
of Seidegard and coworkers (1981). The first is that, since 
c-c4-stilbene oxide is both an effective inducer and a good 
substrate for epoxide hydrolase, the hypothesis that potent 
inducers of drug-metabolising enzymes are poor substrates for 
these same systems is questionable, at least in this case. 
Secondly, the apparent unsuitability of benzoin and benzil 
as substrates for epoxide hydrolase raises a doubt as to 
whether inducers of drug-metabolising systems must be 
substrates for these systems at all.
5.3.12. Steric considerations in the induction of epoxide
hydrolase
When the evidence arising from the present study 
and other reported data are considered, the conclusion must 
be that the deductions of Seidegard at at. (1981) regarding 
structural requirements for the induction of epoxide 
hydrolase hold only for a restricted series of closely 
related compounds. It could be claimed that the inducing 
properties of benzoin and benzil reside in their degree of
steric similarity to the stilbene oxides. However, dibenzo- 
furan, although possessing two phenyl rings, linked in this 
instance directly, and vta an oxygen bridge, is essentially 
a planar molecule, while the stilbenes and their metabolites 
are out-of-plane structures. It is unlikely that the 0 
atom in dibenzofuran would mimic spatially the oxirane ring 
of an epoxide, which is out-of-plane, strained and polarised. 
Nor is the oxygen atom of the furan moiety in benzofuran, 
even though adjacent to the n-bonded system of the benzene 
ring and the unsaturated 2,3-bond in the furan ring, 
postulated to be a sufficiently close analogue of an 
aromatic epoxide for benzofuran to bind strongly to, or 
to induce, epoxide hydrolase. On purely steric considerations, 
the more strained rings of dihydrofuran and dihydrobenzofuran 
might be predicted to mimic epoxides more closely, and 
hence be better inducers of epoxide hydrolase activity, 
than furan or benzofuran respectively, but this is not the 
case.
5.3.13. Planarity, epoxide hydrolase and cytochrome P-450
In view of the observations of Schmassmann et a£. 
(1978) that substituents on the phenyl rings of structural 
analogues of stilbene result in a diminution of inducing 
ability for epoxide hydrolase, the behaviour of certain 
chloro-substituted compounds is interesting. Biphenyl itself 
is a relatively poor inducer of hepatic epoxide hydrolase 
and of cytochrome P-450 when administered i.p. to adult male 
Sprague-Dawley rats (Seidegard at at., 1981). In contrast, 
mixtures of polychlorinated biphenyls have been shown to 
induce both epoxide hydrolase activity (Parkki at at. ,
1977) and cytochrome P-450-associated monooxygenases in 
rodent liver, exhibiting properties of 3-methylcholanthrene 
and of phenobarbitone (Litterst at at., 1972; Alvares at at., 
1973; Goldstein at at., 1977). Biphenyls chlorinated in the
o- and p- positions, e.g. 2,4,5,2’,41,5f-hexachlorobiphenyl, 
induce cytochrome P-450 (Goldstein at at., 1977) and 
epoxide hydrolase activity (Kohli at at., 1979) tn vivo, 
whereas those chlorinated symmetrically m- and p-, e.g.
3,4,5,3’ ,4’,5'-hexachlorobiphenyl, induce cytochrome P-448 
(Goldstein at at., 1977), but not epoxide hydrolase (Kohli 
at at., 1979). Since 3, 4 -, 5 , 3 ’ , 4 ’, 5 1 -hexachlorobiphenyl 
exhibits toxic and pathological effects similar to those 
caused by the essentially coplanar molecules 2,3,7,8- 
tetrachlorodibenzo-p-dioxin and 2,3,7,8-tetrachlorodibenzo- 
furan, and since chlorination at the o- position would not 
favour planarity, a planar structure may be favourable for 
the induction of cytochrome P-448, as opposed to cytochrome 
P-450. The results of Kohli at at. (1979) corroborate an 
earlier report (Bresnick at at., 1977) that phenobarbitone- 
type inducers cause an increase in hepatic epoxide hydrolase 
activity, whereas 3-methylcholanthrene-like compounds do so 
poorly or not at all.
If only those compounds inducing cytochrome P-450 
or cytochrome P-448 are considered, the results of the present 
study are also generally in agreement with those of Bresnick 
and colleagues (1977). Phenobarbitone (which increased 
epoxide hydrolase to 310% of control activity) was a far 
more effective inducer of hepatic microsomal epoxide 
hydrolase in Wistar rats than was 3-methylcholanthrene 
(155% of control) at the dose levels used, and phenobarbitone 
given in conjunction with benzofuran produced a greater 
increase in epoxide hydrolase activity than did 
3-methylcholanthrene ptuA benzofuran. ‘Ptai'i.a-Stilbene oxide, 
which appears to induce a pattern of hepatic monooxygenase 
activity more closely resembling that induced by phenobarbi­
tone than the pattern resulting from 3-methylcholanthrene 
pretreatment, is a good inducer also of epoxide hydrolase. 
Safrole and isosafrole, while apparently inducing a novel 
species of cytochrome P-450 (see Fennell, 1980), increase
the activities of some 'phenobarbitone-type1 monooxygenases, 
and are both reasonably good inducers of hepatic epoxide 
hydrolase. However, other (essentially planar) compounds, 
which either have no significant effect upon cytochrome 
P-450 levels (dibenzofuran), or reduce them (e.g. benzofuran), 
are also good inducers of epoxide hydrolase. Thus, it is 
evident that the theory of Bresnick and coworkers (1977) 
cannot be extended to show that the induction of cytochrome 
P-450 and of epoxide hydrolase are necessarily associated.
Dibenzofuran has been shown in the present study to 
be a good inducer of hepatic epoxide hydrolase. No data 
appear to be available on the ability of 2,3,7,8-tetra- 
chlorodibenzofuran to increase epoxide hydrolase activity 
when administered to rats, but such data do exist for 
2,3,7,8-tetrachlorodibenzo-p-dioxin, which has several 
known properties in common with the furan derivative. Both 
are potent inducers of cytochrome P-448 and associated 
monooxygenase activities in rodent hepatic microsomes 
(Poland and Glover, 1974; Poland at at., 1974), whereas 
dibenzo-p-dioxin itself is not (Poland at at., 1976). 
Tetrachlorodibenzo-p-dioxin has been reported to not induce 
epoxide hydrolase in rodent hepatic and extrahepatic tissues 
(Ryan at at., 1976; Kouri at at., 1978; DiGiovanni at at.,
1980; Lee and Suzuki, 1980). It may be surmised that 
tetrachlorodibenzofuran would behave in a similar manner.
The failure of inducers of cytochrome P-448 and 
of aryl hydrocarbon hydroxylase activity to induce epoxide 
hydrolase activity is interesting in the respect that 
polycyclic aromatic hydrocarbons are associated with the 
induction of cytochrome P-448, which may mediate their 
conversion to epoxides that are frequently carcinogenic 
(see Garner, 1976). It is surprising, therefore, that 
where such association of induction of the two proteins 
exists, it is between epoxide hydrolase and the phenobarbitone- 
inducible cytochrome P-450.
5.3.14. How important are epoxides in the induction of
epoxide hydrolase?
The data of Seidegard at at. (1981) imply that a 
high likelihood of a compound forming an epoxide is not 
necessarily a prerequisite for an ability to induce epoxide 
hydrolase. Nonetheless, it is notable that many of the 
compounds listed in Table 5.28. are epoxides, are known to 
form epoxides In vivo, or epoxide formation is a strong 
possibility.
Aflatoxin (Swenson a t a t ., 1977), chlordane 
(Schwemmer at at., 1970; Tashiro and Matsumara, 1977),
1.2-dibromo-3-chloropropane (Lee and Suzuki, 1979; Suzuki 
and Lee, 1981), the pyrrolizidine alkaloids (Schoental, 1970) 
and the polychlorinated biphenyls (Hsu at aZ., 1975; Norback 
at at. , 1976) have all been demonstrated or proposed to
be metabolised via an epoxide.
Of compounds examined in the present study, 
phenobarbitone (Harvey at aZ., 1972), safrole and isosafrole 
(Janiaud at at., 1976; Wislocki at at., 1976) produce 
epoxides In vtvo. The epoxidation of furans has already been 
discussed. Other good inducers of epoxide hydrolase examined 
during the present study, however, are furans in which the
2.3-position is not available for metabolism to an epoxide.
An epoxide might be formed in the 6-membered aromatic ring, 
but dibenzofuran, for instance, has been reported to be 
largely inert to metabolic attack (Lu at aZ., 1978).
Some chemicals that induce epoxide hydrolase e.g. 
safrole and isosafrole, are converted to epoxides by rat 
liver cells at a very slow rate (Phillips at aZ., 1981; 
Swanson at at., 1981). Hence, it would be valuable to know 
the subsequent rate of turnover of the epoxides, to ascertain 
whether or not the cell actually requires an increased 
capacity for epoxide hydration to deactivate these reactive 
species. Alternatively, although evidence for this is lacking
at present, the induced epoxide hydrolase may possess 
properties different from those of the constitutive enzyme 
i.e. be more selective for the metabolism of methylene- 
dioxyphenyl epoxides.
5.3.15. Is there a relationship between epoxide hydrolase
induction and carcinogenicity?
Another aspect of epoxide hydrolase induction to 
be considered is whether such induction is a hepatocellular 
response to challenge by a molecule of carcinogenic potential 
(or perhaps of selectively toxic potential, associated with 
hypertrophy or hyperplasia), irrespective of whether or 
not the pathway of chemical activation of the molecule 
involves the production of an epoxide moiety. Furthermore, 
is the tissue in which the compound exerts its effects the 
same one as that in which epoxide hydrolase activity is 
increased?
Of the compounds examined in the present study, 
safrole and isosafrole have been reported to cause an 
increased incidence of hepatocellular carcinoma in both rat 
and mouse (Hagan at at., 1965, 1967; Borchert at at., 1973). 
Phenobarbitone produces hepatocyte tumours in rodents in 
long feeding studies (Thorpe and Walker, 1973; Rossi at at., 
1977). Coumarin at high doses causes bile duct carcinoma, 
in rats (Griepentrog, 1973), but not hepatocyte carcinoma, 
and does not induce hepatocellular epoxide hydrolase.
Although 1-hydroxymethylcholanthrene-9,10-dihydrodiol is a 
liver carcinogen in mice (Levin at at., 1979), administration 
of 3-methylcholanthrene to rats or mice appears generally to 
result in extrahepatic tumour formation, and does not induce 
hepatic epoxide hydrolase activity.
It is notable that safrole, isosafrole and 
phenobarbitone pretreatment increased the relative liver 
weight of rats, and that 3-methylcholanthrene did not. An
increased liver weight, whether due to hypertrophy of 
hepatocytes, which appears to be the major causative factor 
following the administration of benzofuran, safrole or 
isosafrole, or to the hyperplasia reported to follow 
pretreatment with ^tan^-stilbene oxide (Suzuki a t  a t . ,
1980), correlated generally with an increased hepatic epoxide 
hydrolase activity. However, the extent of induction of 
this enzyme suggests that it is not simply a marker of an 
increased hepatic concentration of endoplasmic reticulum 
protein, unless, by extension of an argument presented above, 
the proliferated membrane is relatively rich in epoxide 
hydrolase, as well as deficient in cytochrome P-450 or other 
proteins. Furthermore, in the livers of rats pretreated 
with benzofuran, hypertrophy of hepatocytes was predominantly 
centrilobular, whereas the inducible epoxide hydrolase 
activity (at least following the administration of tA .a n A -  
stilbene oxide) has been reported to be located in the 
periportal hepatocytes of rat liver (Bentley a t  a t . , 1979). 
However, it must be emphasised that the lobular site of 
induction of epoxide hydrolase after benzofuran pretreatment 
has not yet been demonstrated.
Many inducers of epoxide hydrolase (Table 5.28.) 
are initiators of hepatocellular carcinoma in rodents.
Such chemicals include aflatoxin B,j (Wogan and Newberne,
1967)i chlordane (Epstein, 1976), DDT (Deichmann a t  a t . ,
1967), diethylnitrosamine (Takayama a t  a t . , 1975),
3 ’-methyl-N,W-dimethyl-4-aminoazobenzene (Druckrey, 1967) 
and 2-acetamidofluorene (Farber and Cameron, 1980). Some, 
such as aflatoxin B ^ , probably mediate their carcinogenicity 
and/or toxicity through the production of an epoxide 
metabolite, but the potent diethylnitrosamine and 2-acetamido- 
fluorene have not been reported to be metabolised by 
epoxidation. Diethylnitrosamine is activated by oxidative 
W-deethylation (Magee and Barnes, 1967), and the carcinogenic 
metabolite of 2-acetamidofluorene is believed to be an
N ,0-sulphate ester (Brouns at at., 1981). Nonetheless, these 
two compounds are among the most potent inducers of epoxide 
hydrolase (Table 5.28.). It remains to be established 
whether furan, benzofuran or dibenzofuran are carcinogenic 
in rats. Benzofuran has been reported to be non-mutagenic 
in a SaZmonaZZa/microsome assay (Weill-Thevenet at aZ.,
1-981)-, but has not been administered In vivo over long 
periods to rodents.
Is an increase in hepatic epoxide hydrolase activity 
then a response to a hepatocarcinogen? Epoxide hydrolase 
has been identified with a preneoplastic antigen (Levin 
at at., 1975; see Section 1.7.5.), and of considerable 
interest in this context is the observation (Astrom at aZ.f 
1981) that short-term (1-3 weeks) administration of
2-acetamidofluorene to rats elevated 5- to 6-fold the 
hepatic microsomal rate of hydration of styrene oxide, well 
before the appearance of preneoplastic nodules. Early 
elevation of epoxide hydrolase activity following the 
administration to rats of W-nitrosomorpholine (Kuhlmann at 
aZ. , 1981), diethylnitrosamine , 3 ' -methyl-A/, W-dimethyl-4- 
aminoazobenzene, aflatoxin B^ and safrole (Sharma at aZ.,
1981) has been reported.
Thus, there is evidence that hepatocarcinogenic 
agents may often cause an increase in hepatic epoxide 
hydrolase activity at an early stage, preceding the 
occurrence of either preneoplastic nodules or of hepatocellular 
carcinoma. If so, this has obvious implications in testing 
for the ability of compounds to produce hepatic tumours.
Also, since epoxide hydrolase seems to be ubiquitous in 
rat tissues (Oesch at aZ., 1977), it would be interesting 
to investigate the possibility that other organ-selective 
carcinogens increase the activity of this enzyme at their 
sites of action.
It has been claimed that several hepatocarcinogens 
may induce epoxide hydrolase activity via a common mechanism
(Dent and Graichen, 1982). Significantly, diethylnitrosamine 
did not fit the observed pattern, whereas 2-acetamidofluorene 
did, and the response of epoxide hydrolase to the latter 
compound was used by these authors as their datum line.
Hence, no clear association between routes of metabolism 
and induction of epoxide hydrolase activity emerged from 
this study. Dent and Graichen (1982) therefore suggested 
that the correspondence between carcinogenic potency and 
an ability to induce epoxide hydrolase was a result of the 
initial toxicity of the carcinogens, leading to an increased 
concentration of bile components in the liver. They quote 
Farber and Cameron (1980); ’an almost constant feature of 
liver carcinogenesis is the appearance of proliferating 
ductular cells early in the process’. This mechanism is 
supported by the ability of bile duct ligation to increase 
epoxide hydrolase activity in hepatic microsomes. However, 
further studies should concentrate on showing whether 
retention of bile is a result of the administration of 
carcinogens, and whether there is at least some degree of 
correlation among compounds that cause hepatocarcinogenesis, 
bile retention and the induction of epoxide hydrolase. Also, 
it would be relevant to determine whether non-carcinogenic 
hepatotoxins generally induce epoxide hydrolase, and if 
not, in what manner their toxicity differs from the early 
toxicity of the classical hepatocarcinogens considered by 
Dent and Graichen-(1982).
Some compounds, including the polychlorinated 
biphenyls (Makiura at at., 1974), butylated hydroxytoluene 
(Slaga and Bracken, 1977) and ethoxyquin (Wattenberg, 1972), 
protect against the tumorigenicity of other compounds in 
rodent liver. Their effects are usually ascribed to induction 
or inhibition of cytochrome P-450, but induction of epoxide 
hydrolase, suggested by Leonard at at. (1981a) to play a 
role in the anticarcinogenic properties of ANIT, might 
alternatively be responsible. However, since the carcinogens
are frequently better inducers of epoxide hydrolase than is 
ANIT, studies should be carried out to ascertain whether 
administration of carcinogen pZu* other inducer produces 
an additive or synergistic increase in epoxide hydrolase 
activity, or whether ANIT, for example, induces a different 
form of this enzyme. The ability of benzofuran (which induces 
epoxide hydrolase effectively at a dose that causes no 
histologically identifiable liver lesion) to protect against 
hepatocarcinogenicity might be worth investigating. 
Dibenzofuran is also promising, because it appears at present 
to have little effect on hepatic cytochrome P-450 
concentration.
5.3.16. Is the induction of epoxide hydrolase related to
the induction of other enzymes involved in drug
metabolism or carcinogenesis?
The physiological and biochemical significance of 
the elevated epoxide hydrolase activity caused in liver, 
hyperplastic nodules and hepatomas by hepatocarcinogens 
is unknown. However, one suggestion is that epoxide hydrolase 
is induced in no more than fortuitous association with one 
or more other proteins that may have a role in hepato- 
carcinogenesis.
The results of the present study, and of others 
(Oesch, 1976; Thomas et clZ., 1981), indicate that control of 
the induction of epoxide hydrolase and of cytochrome P-450 
are independent. Cytochrome P-450 also appears to be spatially 
independent of phase II metabolising enzymes in the liver 
(Stasiecki at at., 1979). Hepatic microsomal UDP-glucuronyl- 
transferase activity is induced by several epoxide hydrolase 
inducers (this study; Chadwick at at., 1971a,b; Burchell at 
at., 1972; Griffin and Walston, 1979), but also by 
3-methylcholanthrene (Bock at at., 1979), and it was not 
induced by tKa.vi&-stilbene oxide in the present study.
Similarly, the results of the present work and 
those reported in the literature (e.g. Clifton and Kaplowitz, 
1978; Chasseaud, 1979) show no clear relationship between 
the induction of epoxide hydrolase and of glutathione 
S-transferase. However, both 2-acetamidofluorene (Astrom at 
at., 1981) and ^ta^-stilbene oxide (Guthenberg at aZ., 1980), 
while elevating the levels of all cytosolic species of 
glutathione S-transferase, apparently cause the greatest 
increase in the activity of glutathione S-transferase B 
(ligandin). Ligandin, although possessing enzymic activity, 
has traditionally been regarded as a binding protein (see 
Chasseaud, 1979), and has been suggested by Astrom at aZ. 
(1981) to bind metabolites of 2-acetamidofluorene. It would 
be worth investigating the possibility that in hepato- 
carcinogenesis, epoxide hydrolase functions as a binding 
or transport protein of greater or lesser specificity.
5.3.17. Other protein markers in carcinogenesis
Among several other suggested positive markers for 
hepatocellular carcinogenesis (Farber, 1976) are glucose-6- 
phosphate dehydrogenase (Kojima at aZ., 1979) and y- 
glutamyltransferase (Cameron at aZ., 1978; Jalanko and 
Ruoslahti, 1979), both of which may be elevated early after 
the administration to rats of chemical hepatocarcinogens 
(Kojima ataZ., 1981). A very large increase in glucose-6- 
phosphate dehydrogenase activity was observed histochemically 
after the pretreatment of rats with benzofuran, although it 
may be useful to repeat the assay in the absence of 
phenazine methosulphate, since it has been suggested 
(Altman, 1972; Chayen at aZ., 1972) that hydrogen from NADPH 
passed through the NADPH-diaphorase system may be related 
to the microsomal respiratory chain. Either benzofuran or 
tA.ant-stilbene oxide (3 days’ pretreatment) markedly increased 
the staining of liver sections for y-glutamyltransferase. The 
specificity of these markers for carcinogenesis, and the 
carcinogenic potential of benzofuran and tAan^-stilbene oxide, 
remain to be investigated.
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6. SOME STUDIES OF THE DISTRIBUTION AND EXCRETION
OF RADIOLABELLED BENZOFURAN IN THE MALE RAT
6.1. Introduction
Many compounds exhibiting biological activity 
become localised or concentrated in their target organs 
following their administration to experimental species 
(e.g. Karim, 1978).
The results described in previous chapters have 
indicated that benzofuran exerts toxic effects in the liver 
(clinical and histological evidence of cholestasis), the 
spleen (diminution or abolition of erythropoietic activity) 
and the kidney (swelling and necrosis of proximal convoluted 
tubules, compression of Bowmanfs capsules) of rats, when 
administered by intraperitoneal injection. One question 
that has not been answered is whether or not benzofuran 
or its metabolite(s ) become Selectively located, or 
retained, in any of these tissues. Also, in view of the 
apparently cholestatic damage caused by benzofuran, one 
would perhaps expect a considerable degree of biliary 
excretion of benzofuran-related material.
Accordingly, rats were injected intraperitoneally 
with [2-3H]-benzofuran, and studies undertaken of the 
excretion of radiolabelled material, ranging from a short 
time period examination of the biliary route, to a 7-day 
collection of faeces and urine. Excreted material was 
subjected to thin-layer chromatography, in an attempt to 
demonstrate the conversion of benzofuran to other products. 
The relative distribution of radiolabel in tissues and 
blood was also determined, to identify sites of possible 
accumulation of benzofuran or metabolites.
6.2. Results
6.2.1. Biliary cannulation following the administration
of [2-3H]-benzofuran
Rats cannulated v^ ta the common bile duct one 
hour after the administration of [2-3H]-benzofuran 
(typically 5.Ommol/kg; 13*4]jCi/kg i.p. in corn oil) showed 
a greater biliary flow rate, especially during the first 
15 minutes following cannulation, than rats cannulated 
24 hours after injection (Table 6.1.). Relatively large 
amounts of radiolabelled material (benzofuran and/or its 
metabolites) were excreted in the bile during the period 
of examination when rats were cannulated one hour after 
dosing. Thus rat B excreted in the bile 1.33% of the total 
count administered during the first 10 minutes following 
cannulation (=l87yg benzofuran/min), and rat C (given 
2.0mmol [2-3H]-benzofuran/kg; 5.4yCi/kg) excreted 8.67% of 
the total count in 104 minutes (=67*5yg benzofuran/min). 
Twenty-four hours after dosing, the rate of biliary elimination 
of label, and biliary flow rate, had fallen considerably 
in comparison with the values of these parameters in rats 
cannulated one hour after dosing. Bile collected over a 
period of 181 minutes from rat D contained 2.11 of the total 
radioactivity administered (=17.3yg benzofuran/min).
6:2.2. Urinary and faecal excretion of radiolabelled
material
The administration of [2-3H]-benzofuran (5.Ommol/kg; 
1.22yCi/kg) i.p. in corn oil resulted in a large proportion 
(21.8%) of the total radioactivity administered being 
excreted in the urine during the first 24 hours, and 33*41 
of the amount given was eliminated this route in 7 days
(Table 6.2.). Plotting mid-point of collection period 
v. 1/(dpm/ml urine) yielded a straight line, indicating
Table 6.1. Biliary excretion of radioactive material after the intraperitoneal
injection of rats with [2-3H]-benzofuran
Animal Time of Sample No./ Bile flow Percentage of
cannulation period of (yl/min/kg total radioactivity
(h after dosing) collection (min) bodyweight) excreted/min
A 1 i), 77 0.09
B 1 i), 10 85 0.13
C 1 i), 20 . 93 0.12
ii), 84 83 0.07
D 24 i), 25 62 0.013
ii), 23 67 0.012
iii), 33 65 0.012
iv), 54 65 0.011
v), 46 59 0.010
E 24 i), 21 66 • 0.009
ii), 73 62 0.008
■ iii), 86 55 0.008
F 24 i), 10 64 0.009
ii), 21 61 0.009
Male rats were administered [2-3H]-benzofuran (5.Ommol/kg; 13.4yCi/kg) by injection 
i.p., except for animal C, which received 2.0mmol [2-3H]-benzofuran/kg (5.4yCi/kg). 
The animals were anaesthetised and cannulated at the times indicated. Samples of bile 
were collected, and the volume was measured during timed intervals. Few samples could 
be collected from rats cannulated one hour after dosing, because of early death, due 
probably to the combination of benzofuran toxicity and operative shock.
Table 6.2. Urinary and faecal excretion of radioactive material after the
intraperitoneal injection of rats with [2-3H]-benzofuran
Interval after Faecal weight/ Percent total Urine volume/ Percent total
dosing (h) 24h (g) radioactivity/ 24h (ml) radioactivity/
g faeces ml urine
0 - 2 4  1.75 0.53 14.5 1.50
24 - 48 Nonea  - 14.0 0.30
48 - 72 0.78 19.6 14.0 0.13
72 - 96 2.76 3.0 17.0 0.11
96 - 120 9.42 0.06 7.3 0.09
120-144 6.25 0.19 23.0 0.13
144 - 168 6.77 ND 11.9 0.03
A single rat housed in a metabolism cage- (University of Surrey manufactured) was injected 
i.p. with [2-3H]-benzofuran (5.Ommol/kg; 1.22yCi/kg) in corn oil. Faeces and urine were 
collected over timed 24-hour periods following injection, and the excretion of radio­
labelled material determined. 25.1 and 33.4 percent of the total count administered 
was recovered in faeces and urine respectively during the 7-day period of collection.
aNo faeces were collected in the metabolism cage trap during the period 24 - 48 hours 
after dosing.
ND = none detected (count not significantly different from background)
that the elimination probably followed second-order 
kinetics. A diuresis occurred on day 6, but it is impossible 
to say at present whether or not this was related to 
pretreatment with benzofuran. Faecal production was decreased 
after benzofuran dosing, and was absent during the second 
24-hour period. The 48- to 72-hour collection was small, 
but contained 15-3% of the total count injected. Of the 
administered radioactivity, 2 5 -1 % was excreted in the faeces 
over 7 days i.e. at the dose level and route used, urinary 
and faecal elimination of label were of similar prominence.
6.2.3* Thin-layer chromatography of bile, serum and urine
obtained from rats given [2-3H]-benzofuran
When bile obtained from rats pretreated with 
[2-3H]-benzofuran (typically 5.Ommol/kg; 13*4yCi/kg in corn 
oil by injection i.p.) was subjected to thin-layer 
chromatography on silica gel plates developed in butanol/acetic 
acid/ water (4:1:2, v/v), three major radioactive spots 
were detected, of Rf values 0.24, 0.40 and 0.62. The most 
intense of these (and yielding the highest.radioactive 
count) was at Rf = 0.40 (Figure 6.1.), whether bile was 
collected from animals dosed one hour or 24 hours prior to 
cannulation. In the former case, a fourth spot of Rf = 0.10 
was located, which had disappeared in the 24-hour treated 
animals. No radioactivity was detected in this spot.
However, a rather low total count was applied to the plate, 
and, sinae this spot was of slight intensity, any radio­
activity present may have been below the threshold of 
detection. The low number of counts applied suggests further 
that dpm figures for the chromatographic spots are at best 
indicators of the relative amount of benzofuran-related 
material present, and should not be interpreted as absolute 
values.
Chromatographic analysis of urine samples showed
Figure 6.1.
Thin-layer chromatographic analysis of bile and urine from rats pretreated with 
[2-3H]-benzofuran
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All rats were given [2-3H]-benzofuran (5.Ommol/kg; 13.4pCi/kg) by injection i.p., 
except rat C, which received 2.0mmol [2-3H]-benzofuran/kg (5.4yCi/kg).
Animals B and C were cannulated 1 hour after injection of benzofuran.
Animals D, E and F were biliary cannulated 24 hours after injection of benzofuran.
Key:
Track 1 Rat D, initial bile sample, 10pl
2 Rat E, initial bile sample, 10yl
3 Rat B, initial bile sample, 10pl
4 Rat C, initial bile sample, 10pl
5 Rat B, serum from vena cava blood,
6 Rat F, serum from vena cava blood,
7 Rat C, bladder urine collected at post-mortem,
8 Rat D, bladder urine collected at post-mortem,
obtained immediately post-mortem, 10yl 
obtained immediately post-mortem, 10pl 
10yl 
10pl
For spots:
I = intense, M = moderate, W = weak.
First figure is Rf. For radioactive spots, second figure is approximate 
percentage of total radioactivity applied to that track located in the spot,
BF = authentic benzofuran
oHPAA = o-hydroxyphenylacetic acid
Chromatography was on Silica Gel, G, developed in butanol/acetic acid/water (4:1:2, v/v) 
Visualisation of spots was by fluorescence quenching.
radioactive spots at Rf =0.25, 0.42 and 0.68. The percentage 
of total radioactivity applied comprised by the first of 
these rose from 17 to 36 over 24 hours, whereas the 
corresponding value for Rf = 0.42 fell markedly. This change 
may be related only to time, or to a difference in the 
distribution of benzofuran-related material due to the 
different dose levels employed in the two animals examined 
(see Figure 6.1.). A similar percentage of total radio­
activity was obtained at both time points for the spot of 
Rf = 0.68. No unchanged benzofuran (which runs in this system 
with Rf = 0.82) was detected. The Rf value for o-hydroxy- 
phenylacetic acid, a possible metabolite of benzofuran, 
in the butanol/acetic acid/water system was 0.68, and 
coincident with one of the radioactive spots found.
Serum samples remained at the origin in butanol/ 
acetic acid/water developer. No movement of the radioactive 
material in bile, serum or urine was observed using 
chloroform only.
When successive 24-hour urine samples were collected 
from a rat given [2-3H]-benzofuran (5.Ommol/kg; 1.22yCi/kg 
i.p. in corn oil), and subjected to thin-layer chromatography 
in the butanol-containing solvent, a definite pattern of 
change emerged (Figure 6.2.). Radioactivity could not be 
satisfactorily determined because of the low total number 
of radioactive counts applied, but a series of spots 
correlating plosely with those described in the urine samples 
above was seen. Spots of Rf values 0.22 and 0.28 (possibly 
corresponding to the tailed spot previously measured as 
Rf = 0.25) became less intense, and had disappeared altogether 
by day 7. Spots of Rf = 0.42 and Rf = 0.69 were also very 
faint by day 5 of urine collection. In contrast, an area of 
Rf = 0.56, which was present, but non-radioactive in the plate 
drawn in Figure 6.1.,. increased in intensity with time after 
dosing, especially after the fourth day. A further spot 
(Rf = 0.36), of unknown significance, appeared during the
Figure 6.2.
Thin-layer chromatographic analysis of 24-hour urine collections from a rat 
pretreated with [2-3H]-benzofuran
o
0.82
O O o O o o #0
m 0.69 -Di m w w m w
O  O  O  •••-' 0  0  0
w 0.56 w w w/m i i i
C '■ - U  ' . U  A  A
‘O  O  O 0
m 0.41 m m ra w w w
! »
W O.36 w w
m^ 28 °  
o  0 o
m 0.22 m m
BF 1 .2 3 4 5 6 7 OHPAA
A single' rat housed in a metabolisim cage (University of Surrey manufactured) was 
injected i.p. with [2-3H]-benzofuran (5.Ommol/kg; 1.22yCi/kg) in corn oil. Urine 
samples were collected over 24-hour time periods, and 10yl aliquots were subjected 
to thin-layer chromatography.
K e y :
Track 1 Urine collected 0 - 2 4  hours after dosing
2 Urirte collected 24 - 48 hours after dosing '
3 Urine collected 48 - 72 hours after dosing
4 Urine collected 72 - 96 hours after dosing
5 Urine'collected 96 - 120 hours after dosing
6 Urine collected 120 - 144 hours after dosing
7 Urine collected 144 - 168 hours after dosing
For spots:
I = intense, M r  moderate, W = weak.
Figures are Rf values.
BF r authentic benzofuran
oHPAA = authentic o-hydroxyphenylacetic acid
Chromatography was on Silica Gel, G, developed in butanol/acetic acid/water (4:1:2, 
Visualisation of spots was by fluorescence quenching.
v/v)
first 3 days of sampling.
6.2.4. Blood and tissue radioactivity after the
administration to rats of [2-3H]-benzofuran
Of tissues digested and counted 28 hours after the 
administration to a male rat of [2-3H]-benzofuran (5.0 
mmol/kg; 1.22yCi/kg i.p. in corn oil), most radioactivity 
was detected in whole liver (Table 6.3.), with smaller 
amounts in kidney, spleen and lung. A lower dose of 
[2-3H]-benzofuran (3•75mmol/kg; 0.92yCi/kg) resulted in a 
lower percentage of total count administered remaining in 
the liver, and a greater amount in the spleen, at the same 
time point after injection. When expressed per g tissue,., 
the highest amount of radioactivity was generally located 
in the spleen; significantly, in the rat killed 7 days after 
dosing, a similar proportion of the label was retained in 
the spleen as was measured in the spleen of rats killed 
28 hours after dosing as described above. In contrast, the 
amount of radioactivity detected in liver, kidney and lung 
was much reduced.
Thin-layer chromatography of solvent-extracted 
untreated or hydrolysed tissue provided little information.
In butanol/acetic acid/water, a single, weakly radioactive 
spot of Rf = 0.79-0.84 was detected, and, in chloroform, 
a single spot of Rf =0.63-0.67. As the Rf values for 
benzofuran in butanol/acetic acid/water and in chloroform 
were 0.82 and 0.65 respectively, these areas probably 
represent the unchanged compound.
The analysis of sequential samples of blood collected 
from a rat cannulated in the right external jugular vein 
showed a practically steady-state serum concentration of 
radiolabel over the first 4 hours, but this concentration 
was much reduced in the terminal sample obtained from the 
vena cava 28 hours after dosing (Table 6.4.). Assuming that 
a rat of 400g bodyweight has a total blood volume of about
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)
30ml, and that the radioactive material is located 
predominantly in plasma, some 5- to 6-percent of the dose 
remains in the circulation during the first 4 hours. If 
the tissue:serum concentration ratio is expressed as total 
3H concentration (dpm/g) in tissue/total 3H concentration 
(dpm/ml) in serum, which is a means of defining the degree 
of accumulation of radioactivity in the respective tissue, 
the values for the liver:serum ratio are 2.3, 3.0 and 3.2 
respectively, and those for the kidney:serum ratio are 
1.3, 1.3 and 4.0 respectively, for each of the three rats 
killed 28 hours after dosing. The corresponding spleen:serum 
concentration ratios are 4.0, 1.7 and 13.0 (rats 1, 2 and 
3, Tables 6.3* and 6.4.). In the rat killed 7 days after 
dosing, the spleen:serum concentration ratio for 3H was still 
as high as 11.5, suggesting that benzofuran-related material 
may remain bound in some manner in this tissue.
6.3* Discussion
The administration of [2-3H]-benzofuran (5.Ommol/kg;
1.22yCi/kg) to rats shows that an accumulation of radiolabelled 
material occurs in liver and spleen relative to blood serum 
after 28 hours. A slightly lower dose (3•75mmol/kg; 0.92pCi/kg) 
resulted in a shift towards spleen and, slightly, towards 
kidney, at the expense of the hepatic radioactivity. The 
concentration of radiolabelled material in liver correlates 
with the previous evidence that this organ is a target site 
for benzofuran. Although the liver is the major site of 
foreign compound metabolism in the adult rat, a chemical 
toxic to extrahepatic tissues is generally found intra- 
hepatically in considerable quantities only at early time 
points after administration.
It is not known at present whether the label in 
liver is located in hepatocytes or in biliary tract components, 
or in both. Certainly, biliary excretion appears to play an 
important role in the removal of benzofuran, considering the 
amount of radiolabelled material present in the bile shortly 
after the intraperitoneal injection of [2-3H]-benzofuran.
The results in fact suggest that the peak concentration in 
bile may be past before the biliary cannulation of rats 
one hour after dosing.
The rate of bile flow in rats cannulated one hour 
after dosing with benzofuran was greater than that in rats 
cannulated 24 hours after injection, and greater than that 
normally encountered in control untreated Wistar rats of 
the University of Surrey strain. Such an initial increase 
in bile flow is not inconsistent with later cholestasis; if 
early perturbations of bile transport mechanisms or of the 
metabolism of biliary components lead to the intrahepatic 
accumulation of bile acids, the first effect is likely to 
be a choleresis (Paumgartner, 1977). However, reference 
should be made to the comments in Section 5.3*7. regarding
bile flow after the pretreatment of rats with benzofuran 
for 3 days.
The considerable amount of radiolabelled material 
appearing in faeces also correlates with the observation of 
biliary excretion. Furthermore, the relatively low overall 
rate of excretion of benzofuran-related material indicates 
that enterohepatic recirculation may take place. When this 
occurs, the amount of compound eliminated in the faeces 
may be as great as that appearing in the urine, which is 
generally the predominant route of excretion for relatively 
low molecular weight compounds (see Goldstein zt a,Z., 1974).
In the 7 days following the administration of [2-3H]-benzofuran, 
33*4$ and 25.1% of the total count was recovered in urine 
and faeces respectively. Enterohepatic recirculation may 
also cause greater or lesser proportions of the administered 
compound to remain in the body for a considerable period of. 
time.
There was little concentration of radioactivity 
in the kidneys. However, a striking feature was the high 
activity per g spleen remaining after 7 days, when the 
concentration of label in the other tissues examined had 
fallen markedly. This may be related to the diminished or 
absent erythropoiesis observed in the spleen after 
pretreatment with benzofuran, and may involve covalent 
binding of benzofuran or its metabolites to splenic 
macromolecules. This requires-further investigation, as do 
any possible effects of benzofuran upon haem oxygenase 
activity in the spleen, since this organ is a major site of 
haem degradation.
It must be emphasised that no evidence of unchanged 
benzofuran was found when bile or urine from rats injected 
with [2-3H]-benzofuran were subjected to thin-layer 
chromatographic separation in butanol/acetic acid/water 
(4:1:2, v/v), suggesting that benzofuran is extensively 
metabolised by the rat. Three radioactive spots were detected
in bile, two of which appeared to be common also to the 
urine of the same animals. A third radioactive substance 
in urine had an Rf value slightly higher than the fastest 
running material in bile, and ran coincidentally with 
o-hydroxyphenylacetic acid. This last compound is a metabolite 
of coumarin (van Sumere and Teuchy, 1971), and is analogous 
to the o-aminophenylacetic acid postulated to be an inter­
mediate in the metabolism of [11+C]-indole in the rat (King 
<Lt at., 1966). The intensity of the Rf = 0.68 spot suggests 
that benzofuran may undergo ring-opening to a considerable 
extent. If lysis of the furan ring does occur, other 
metabolic intermediates may be formed Zn vZvo, notably 
o-hydroxyphenylacetaldehyde or, once more by analogy with 
indole, o-hydroxybenzoic acid or o-hydroxybenzaldehyde.
Several unsaturated organic aldehydes are known to cause 
the destruction of cytochrome P-450 in rats (Marinello e.t at.-, 
1978; Patel, 1979). Alternatively, benzofuran may be postulated 
to undergo 5-hydroxylation in a manner similar to one of 
the pathways of indole metabolism (King Q.t at., 1966).
If ring cleavage and subsequent formation of the phenylacetic 
acid moiety occurred, the resulting compound would be 
capable of existence as a p-quinone. Such compounds are 
potentially very toxic e.g. the p-quinoneimine metabolite 
reported to be responsible for paracetamol-induced 
nephropathy (Mitchell zt at., 1977). The metabolism of 
benzofuran in the rat thus remains in need of much more 
extensive characterisation, but some evident or postulated 
metabolites are shown in Figure 6 .3 .
It must be noted, with respect to the above discussion, 
that the necessity for long digestion procedures before 
radioactive counting of tissues and excretion products 
caused thin-layer chromatography to be performed before 
the results of this counting became available. Consequently, 
low total counts were applied, to the silica gel plates, and, 
in some cases, it transpired that considerable concentration
Figure 6.3.
Some possible routes of benzofuran metabolism in the rat liver
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of urine or bile samples would have been required before 
the addition of a reasonable quantity of radiolabelled 
material to the plate would contain sufficient counts for 
statistically accurate determination. Further, benzofuran 
(and possibly some of its metabolites) is relatively volatile, 
and some radioactivity may have been lost by evaporation. 
However, relatively little loss of tritium by exchange with 
body water should have occurred, since the specifically 
labelled [2-3H]-benzofuran is stable in this respect.
Ideally, further studies should be carried out, 
using higher doses of the radiolabelled benzofuran, and with 
special precautions being taken both during sample collection 
and during thin-layer chromatography. It may also prove 
valuable to examine tissue distribution and biliary excretion 
of the labelled material at very early (<1 hour) time 
points.
CHAPTER ?
FINAL SUMMARY AND DISCUSSION
7. FINAL SUMMARY AND DISCUSSION
7.1. Intrahepatic Distribution of Cytochrome P-450
In recent years considerable emphasis has been 
placed upon the differential distribution of foreign 
compound metabolising enzymes in the liver, and their 
relationship to regional manifestations of toxicity.
Probably the most important initial reaction in this 
metabolism is cytochrome P-450-catalysed monooxygenation.
Three recognised inducers of cytochrome P-450 - 
phenobarbitone, 3-methylcholanthrene and isosafrole - 
have been examined for their ability to increase some 
spectrally distinguishable subpopulations of this cytochrome 
in different regions of the liver lobule (Chapter 3).
The microspectrophotometric approach used yielded results 
generally in agreement with those of existing immuno- 
cytochemical studies (e.g. Baron zt.aJL., 1978b), indicating 
that phenobarbitone increases the concentration of 
cytochrome P—450 predominantly in the centrilobular region 
of the hepatic lobule, whereas the administration of 
3-methylcholanthrene causes primarily a periportal and 
midzonal increase. The lobular distribution of isosafrole- 
inducible cytochrome P-450 has not previously been reported, 
and was found in the present study to resemble qualitatively 
the pattern of induction resulting from pretreatment with 
phenobarbitone. Furthermore, it was demonstrated that 
the Zeiss UMSPI instrument employed was capable of resolving 
clearly the spectral maxima of the reduced, carbon monoxide- 
complexed cytochromes ’P-450’ and TP-448’, and the 455nm 
peak of the isosafrole metabolite-reduced cytochrome P-450 
complex. The last observation is also significant in 
that, whereas spectral evidence of the 455nm complex had 
been demonstrated both i.n vZ&io, and in microsomes prepared 
from animals pretreated with several of the methylene-
dioxyphenyl compounds (see Dickins, 1978), it had not 
yet been shown in preparations in which cells were 
maintained in a relatively normal relationship with 
one another.
The extent of induction of cytochrome P-450 
by isosafrole as measured by microspectrophotometry in 
liver sections remains to be determined. Although it is 
possible to demonstrate an increased concentration of 
cytochrome P-450 in microsomes prepared from the same 
livers from which sections were obtained, the amount 
of cytochrome P-450 present in the sections cannot be 
calculated from the approach used in this study. Such 
estimations will require the careful investigation o f : 
the displacement of the isosafrole metabolite complex 
in hepatic frozen sections, and subsequent measurement 
of the reduced-carbon monoxide complex with cytochrome 
P-450.
In addition to the implications of a non-uniform 
intralobular distribution of xenobiotic-metabolising 
enzymes, discussed in Chapter 3, differences in interlobar 
metabolism also highlight two important points:
i) variations in the specific content of cytochrome 
P-450 and of monooxygenase activity among rat liver lobes 
indicates that there may be differences in the susceptibility 
of the lobes to some toxins. Such differences may also be 
important after partial hepatectomy i.e. the drug- 
metabolising capabilities of the residual or regenerating 
tissue may vary according to the portion of liver 
removed. However, since pretreatment of the rats with
3-methylcholanthrene appears to largely abolish differences 
in concentrations of cytochromes P-450 and 6^, and 
ethoxycoumarin 0-deethylase activity, this suggests that 
a maximum Z2.VQ.Z of induction is attained (for a given 
dose of 3-methylcholanthrene), rather than that these 
components in each lobe are increased by a common amount.
ii) The converse of the last point discussed above 
lies in the discrepancy between the 3-methylcholanthrene- 
induced concentration of cytochrome P-448, and the 
measured ethoxyresorufin 0-deethylase activity, in the 
left lobe, when compared with the other lobes. The induced 
specific' contents of cytochrome P-448 were comparable in 
left and median lobes, but the induced ethoxyresorufin 
0-deethylase activity in the left lobe was only about half 
of that in the median lobe. Since cytochrome P-448 and 
ethoxyresorufin 0-deethylation are specifically associated 
(Burke and Mayer, 1975), it may be that not all 
spectrally measurable cytochrome P-448 (or, indeed, 
cytochrome P-450) is metabolically active, at least 
towards certain substrates.
The present study has confirmed the value of 
the microspectrophotometric technique for cytochrome P-450 
measurement as applied by Chayen and associates (Gooding 
at clZ. , 1978). However, it is hoped to facilitate more 
rapid and specific measurement of lobar and lobular 
distributions of cytochrome P-450 by the synthesis of 
specific, histochemically useful substrates, and several 
promising compounds are currently being evaluated.
7.2. Oxygen Heterocycle Toxicity
Histological findings illustrated two clearly 
differing patterns of hepatotoxicity following the 
administration to rats of various furans or methylene- 
dioxyphenyl compounds (Chapters 4 and 5). The latter 
group of chemicals produced features of a classical 
hepatotoxic response, in which the accumulation of lipids 
in hepatocytes precedes cellular degeneration and 
necrosis. These effects were reflected in changes in 
the values of several serum parameters. Furan itself, 
and some furan derivatives, elicited a similar effect.
In contrast, the pretreatment of rats with benzofuran 
caused little fatty infiltration, but produced several 
structural and biochemical changes associated with 
cholestasis.
There are several difficulties in the inter­
pretation of the findings of serum analyses performed 
in this study. One of the major of these is the lack of 
an extensive data base for the University of Surrey 
Wistar rats, correlating serum changes with tissue 
pathology, whether originating from treatment of the rats 
with chemical toxins, or from infection. Consequently, 
some deductions are based on serum markers recognised in 
human disease. However, profound increases in serum 
bilirubin concentration are very rare in the Wistar rat, 
and the presence of this, and other components of bile, 
in blood, coupled with hepatocyte and canalicular 
derangements that are characteristic of cholestasis in 
both rodents and humans, is strongly suggestive of such 
a syndrome.
Although pretreatment with furan may provoke a 
degree of cholestasis, as indicated by the rise in serum 
IgA and IgA Free Secretory Component concentrations, 
the ability to produce a cholestatic, as opposed to a 
classical hepatotoxic, syndrome, does not appear to be 
simply a property of furans on the one hand, and 
methylenedioxyphenyl compounds on the other (Chapters 
4 and 5). Also, various patterns of alteration of other 
he.patic or serum components were caused by chemicals 
used in the present study, particularly among the furan 
derivatives. Three important considerations hence emerge:
i) Can some effects of the chemicals examined, 
especially those involving the endoplasmic reticulum, 
be correlated with the physicochemical properties of the 
particular chemicals producing them, or with their metabolic 
fate i.e. are there precise structure-activity relation­
ships?
ii) What are the special structural or other features 
of benzofuran that determine its comparatively high 
potency as a hyperbilirubinaemic agent? Is the parent 
compound directly responsible, or does it act vZa a 
metabolite? How can the clinical and ultrastructural 
evidence of cholestasis be rationalised in view of the 
failure to demonstrate stagnation of bile flow?
iii) To what extent are the individual manifestations 
of benzofuranfs toxicity dissociated from each other by 
mechanism, or, alternatively, are they interdependent?
The administration to rats of any of the 
methylenedioxyphenyl compounds used in this study resulted 
in the induction of cytochrome P-450, associated with 
an absorbance maximum in the reduced spectrum at 455nm, 
and the increase in the staining intensity of a 
polypeptide band o f -53000 MW upon SDS-polyacrylamide disc 
gel electrophoresis. The pretreatment of rats with one of 
several furans caused a fall in the specific content of 
hepatic microsomal cytochrome P-450, provided that the 
furan possessed a free furanic double bond. That is, 
furan and benzofuran produced a marked fall in cytochrome 
P-450 concentration, whereas dihydrobenzofuran and 
dibenzofuran did not. However, dihydrofuran also had 
no significant effect upon the level of hepatic cytochrome 
P-450. This suggests that, if activation of the furan 
double bond is a prerequisite for cytochrome P-450 loss, 
such activation might be preceded by an oxidative attack 
on the ’opposite end’ of the molecule. Hence, a toxic 
metabolite might possess a quinone type of structure 
rather than, for example, an oxirane ring (see discussion 
to Chapter 6). If this is the case, activation of the 
molecule would presumably have to follow an obligatory 
sequence, since 2-coumaranone (which possesses a 2-oxo 
substituent) did not lower cytochrome P-450 levels. 
Alternatively, a combination of molecular planarity and
an accessible furan double bond may favour cytochrome 
P-450 loss.
While the diminished hepatic cytochrome P-450 
content is associated with a fall in staining intensity 
of a 50000 MW polypeptide upon SDS-polyacrylamide disc 
gel electrophoresis, the significance of the 51500-52000 
MW polypeptide induced by pretreatment with some furans, 
and discussed in Chapters 4 and 5, is unclear, and it 
has not yet been identified definitely as a haemoprotein. 
The circumstances in which this band appears are of 
considerable interest. It is hoped to learn more about 
its nature by dose-response studies utilising e.g. 
benzofuran, dibenzofuran and V iclvia-stilbene oxide, and 
monitoring alterations in hepatic cytochrome P-450 
concentration, monooxygenase and conjugating enzyme 
activities, and polypeptide distribution on SDS- 
polyacrylamide disc gel electrophoresis plates. 
Measurement of change of- specific subpopulations of 
cytochrome P-450, using antibody techniques, may also be 
undertaken.
The possibility that a reduction in hepatic 
cytochrome P-450 concentration is an indirect effect of 
the chemicals examined cannot be discounted.
However, potency for the induction of haem 
oxygenase, for instance, does not correlate with the 
extent of cytochrome P-450 loss, and nor do the 
concentrations of serum markers of cholestasis. Although 
the administration of either furan or benzofuran resulted 
in a rise in serum levels of IgA and IgA Free Secretory 
Component, so too did the pretreatment of rats with 
Vi&vi'6-stilbene oxide, which acted as an inducer of 
cytochrome P-450. More extensive investigation of the 
prerequisite conditions for a loss of cytochrome P-450 is 
hence required.
In particular, the characteristics of the
putative metabolites of benzofuran should be determined.
One approach that might yield useful information is the 
pretreatment of rats with 5-substituted benzofurans or 
3-substituted furans, or with benzofuran analogues 
containing groups tending to favour or inhibit metabolism 
at the 5-position. In addition, further studies with 
inducers and inhibitors of cytochrome P-450, or with 
inhibitors of epoxide hydrolase, may be helpful.
Evidence presented during this study suggests 
strongly that a polypeptide band of 48000 MW visualised 
upon SDS-polyacrylamide disc gel electrophoresis of hepatic 
microsomes is epoxide hydrolase, and that this enzyme 
is susceptible to induction Zn vZvo by the pretreatment 
of rats with compounds of various chemical characteristics. 
The relationship of molecular structure to ability to 
increase epoxide hydrolase activity Zn vZv,o has already 
been extensively discussed (Chapter 5), but it has not 
been possible as yet to establish a conclusive structure- 
activity relationship for epoxide hydrolase induction.
It thus appears probable that the alteration in activity 
of this enzyme is at least in part an indirect consequence 
of the action of the compounds responsible. The initiating 
factor(s) is unknown; the work of Leonard at clZ. (1981a) 
indicates that intrahepatic bile retention may cause an 
increase in hepatic epoxide hydrolase activity, but 
disturbances of bile flow.have not been demonstrated to 
be a concurrent result of the administration of all of 
the compounds in the present study that increased epoxide 
hydrolase activity. For example, dibenzofuran was a better 
inducer of hepatic epoxide hydrolase activity than was 
furan, whereas the latter compound was the only one of 
the two to increase serum IgA and IgA Free Secretory 
Component concentrations.
Possibly, retention of specific biliary components 
such as bile salts, as suggested by Leonard and coworkers,
may be responsible for the rise in epoxide hydrolase 
activity, and an elevation of bile salt concentration 
is, indeed, accepted as a sensitive early marker of 
cholestasis in rats. If epoxide hydrolase were susceptible 
to an inductive process mediated by the presence of an 
increased intrahepatic concentration of bile salts, then 
its induction by dibenzofuran might be explained by early 
cholestatic changes not advanced enough to be reflected 
in serum bilirubin, IgA or IgA Free Secretory Component 
concentrations. However, one might also expect a more 
marked increase in hepatic epoxide hydrolase activity 
following the administration to rats of furan, since 
the elevated serum IgA and IgA Free Secretory Component 
concentrations presumably indicate a further developed 
cholestasis. Furthermore, Leonard and coworkers (1981a) 
have shown that bile duct ligation in rats results not 
only in an increased epoxide hydrolase activity, but also 
in a decrease in the specific content of cytochrome 
P-450 in liver microsomes. This is incompatible with 
results obtained in the present study after the 
administration to rats of VianA-stllbene oxide, which 
induced cytochrome P-450, increased epoxide hydrolase 
activity, and elevated serum concentrations of IgA and 
IgA Free Secretory Component.
In summary, the increased epoxide hydrolase 
activity seen after the administration of several furans 
or methylenedioxyphenyls to rats may be a secondary 
consequence of those compounds1 actions (although it 
cannot be confidently concluded that components of bile 
are responsible for the effect), whereas cytochrome P-450 
may be attacked directly by certain furans or their 
metabolites. The nature of such metabolites requires 
elucidation, however; they are not necessarily simply 
active species generated by cytochrome P-450-catalysed 
monooxygenation, as suggested by the failure of benzofuran
to lower cytochrome P-450 levels in hepatic microsomes 
Zn v<LVio in the presence of NADPH.
Further investigation of structure-activity 
relationships for oxygen-containing heterocycles and 
epoxide hydrolase induction, and of the principal toxic 
syndromes accompanying the pretreatment of rats with 
these chemicals, is required before a satisfactory correlation 
between their characteristics and their effects on 
endoplasmic reticulum, or other cellular components, can 
be reached.
It is evident from the data presented that 
clinical signs of cholestasis are more pronounced after 
the administration of benzofuran to rats, than 
following pretreatment with several other furans. The 
nature of some possible metabolites of benzofuran, and 
some physicochemical and steric considerations in relation 
to this, have been discussed (Chapters 5 and 6). The 
use of hepatocyte culture may be valuable in determining 
if organelles other than endoplasmic reticulum membranes, 
or cytosolic factors, are involved in the metabolism 
of benzofuran. Also, it may prove possible to culture 
cells of bile duct walls, and hence determine their 
possible role in the activation of benzofuran.
A major problem is the number of potentially 
discrete effects caused by the pretreatment of rats with 
benzofuran. These may be the result of more than one toxic 
metabolite, or they may be secondary or tertiary responses 
to an initial lesion, or parallel events, ascribable 
to a single reactive species. A valuable approach would 
be an early time course study correlating serum chemistry 
and histochemical/ultrastructural changes in the liver 
with alterations in protein parameters of the endoplasmic 
reticulum, in an attempt to characterise the sequence of 
toxic events. This would best be carried out as far as 
is possible by continuous monitoring of the same group
of animals. Ideally the techniques used would include a 
non-invasi’ve approach, and research in progress in 
conjunction with the Physics Department of the University 
of Surrey may lead to the application of whole body 
nuclear magnetic resonance imaging to this problem. 
Concurrent withdrawal of serial blood samples and their 
examination for biliary components could be carried out, 
and the practicability of liver biopsy samples for electron 
microscopy should be considered.
Stagnation of bile flow had not occurred after 
three days’ pretreatment of rats with benzofuran, despite 
strong evidence for the presence of biliary components 
in blood. This argues for either a specific lesion of 
the transport apparatus for some components of bile, 
resulting in a massive overflow of bile into blood 
without cholestasis pdA Ad, or a related lesion of the 
cellular cytoskeleton, as discussed in Chapter 5 . The 
role of microfilaments and microtubules in bile secretion 
and flow are poorly defined, but the observation that 
a microtubular lesion can impair the ability of the 
hepatocyte to handle a bile load (Erlinger dt at., 1980) 
may be significant. However, even if a bilirubin load 
was provided by the destruction of cytochrome P-450 
haem, such a mechanism presumes both an attack on cytochrome 
P-450 and on cytoskeletal elements as the results of 
pretreatment with benzofuran. Further electron microscope 
studies, and the use of hepatocytes in culture, may help 
to elucidate these processes.
A possible link between carcinogenicity and 
early induction of hepatic epoxide hydrolase activity 
has been discussed in Chapter 5. Dent and Graichen (1982) 
have suggested that the rise in epoxide hydrolase activity 
is due to a carcinogen-mediated retention of bile salts.
It therefore would be appropriate-to compare the effects 
of hepatocarcinogens, classical hepatotoxins and inducers
of intrahepatic cholestasis on the levels of proteins 
suggested as markers of hepatocarcinogenesis, primarily 
epoxide hydrolase, y-glutamyltransferase, ATPase and 
glucose-6-phosphate dehydrogenase, and to determine the 
degree of cholestasis caused by the two former classes 
of compounds.
Organ and species selectivity is particularly 
apparent in the toxicity of furans (e.g. see Boyd, 1980a,b). 
Comparison of the hepatotoxicity of benzofuran in rats 
with the previously small amount of information available 
regarding its effect on mice (McMurtry and Mitchell,
1977) indicates that different toxic metabolites may be 
formed in the two species. Evidence has also been presented 
in the present study that benzofuran and furan can cause 
kidney lesions, and that the action of the former is 
potentiated by pretreatment with inducers of cytochrome 
P-450.
In view of these observations, it would be 
interesting to determine the patterns of tissue damage 
caused in different species by benzofuran in particular, 
with emphasis on its ability to produce a lesion resembling 
cholestasis in those species. Among species to be considered 
should be those possessing a gall bladder e.g. mice, and 
those such as the ferret, which resemble man in that they 
release bile intermittently into the intestine.
Benzofuran pretreatment also diminished or 
abolished splenic erythropoiesis in the rat, and the 
amount of radiolabelled compound located in the spleen 
after the intraperitoneal injection of [3H]-benzofuran 
remained elevated when the amount detectable in other 
tissues was falling (Chapter 6). The reason for this is 
at present unknown, but attempts are being made to identify 
a splenic lesion, and subsequently to determine whether 
involvement of the spleen is unique to the rat.
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